Details of Disease

General Information of Disease (ID: DIS5Y6R9)

• Disease Name: Non-small-cell lung cancer
• Synonyms: NSCLC; non-small cell carcinoma of lung; non-small cell lung cancer; non-small cell cancer of lung; non-small cell carcinoma of the lung; NSCLC - non-small cell lung cancer; non-small cell cancer of the lung; non-small cell lung carcinoma; non-small cell lung carcinoma (disease)
• Disease Class: 2C25: Lung cancer
• Definition: A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.
• Disease Hierarchy:
  DIS0167R: Metastatic lung cancer
  DIS5Y6R9: Non-small-cell lung cancer
• ICD Code:
  ICD-11: ICD-11: 2C25.Y
  ICD-9: ICD-9: 162
  Expand ICD-9: 162
• Disease Identifiers:
  MONDO ID: MONDO_0005233
  MESH ID: D002289
  UMLS CUI: C0007131
  MedGen ID: 40104
  HPO ID: HP:0030358
  Orphanet ID: 488201
  SNOMED CT ID: 254637007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 49 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adagrasib	DMDV4EP	Approved	Small molecular drug	[1]
Alectinib	DMP1I6Y	Approved	Small molecular drug	[2]
Aminophylline	DML2NIB	Approved	Small molecular drug	[3]
Amivantamab	DMZ7AMY	Approved	Antibody	[4]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[5]
BIBW 2992	DMTKD7Q	Approved	Small molecular drug	[6]
Brigatinib	DM7W94S	Approved	Small molecular drug	[7]
Capmatinib	DMYCXKL	Approved	Small molecular drug	[8]
Carboplatin	DMG281S	Approved	Small molecular drug	[9]
Ceritinib	DMB920Z	Approved	Small molecular drug	[10]
Cisplatin	DMRHGI9	Approved	Small molecular drug	[11]
Crizotinib	DM4F29C	Approved	Small molecular drug	[12]
Dacomitinib	DMOH8VY	Approved	Small molecular drug	[13]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[14]
Denileukin diftitox	DMMHR1U	Approved	NA	[15]
Docetaxel	DMDI269	Approved	Small molecular drug	[16]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[17]
Etoposide	DMNH3PG	Approved	Small molecular drug	[18]
Gefitinib	DM15F0X	Approved	Small molecular drug	[19]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[20]
Intedanib	DMSTA36	Approved	Small molecular drug	[21]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[22]
Levoleucovorin	DMH5LME	Approved	Small molecular drug	[23]
Lonafarnib	DMGM2Z6	Approved	Small molecular drug	[24]
Lorlatinib	DMICDLV	Approved	NA	[13]
Nedaplatin	DMD6UKO	Approved	Small molecular drug	[25]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[26]
Olaratumab	DMNYOIX	Approved	Monoclonal antibody	[27]
Osimertinib	DMRJLAT	Approved	Small molecular drug	[28]
Ozanimod	DMT6AM2	Approved	NA	[29]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[30]
Panobinostat	DM58WKG	Approved	Small molecular drug	[31]
Pegfilgrastim	DM7UP8X	Approved	Small molecular drug	[32]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[33]
Pemetrexed	DMMX2E6	Approved	Small molecular drug	[34]
Porfimer Sodium	DM7ZWNY	Approved	Small molecular drug	[25]
Pralsetinib	DMWU0I2	Approved	NA	[35]
Ramucirumab	DMWUFQ4	Approved	Monoclonal antibody	[22]
Retifanlimab	DMRKTCP	Approved	Antibody	[36]
RG7853	DM17URL	Approved	NA	[37]
Selpercatinib	DMZR15V	Approved	NA	[38]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[39]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[40]
Sotorasib	DMLSV74	Approved	Small molecular drug	[41]
Sunitinib	DMCBJSR	Approved	Small molecular drug	[42]
Theophylline	DMRJFN9	Approved	Small molecular drug	[43]
Vinorelbine	DMVXFYE	Approved	Small molecular drug	[44]
HBI-8000	DMDWYUN	Registered	Small molecular drug	[22]
Icotinib hydrochloride	DM5GFIK	Registered	Small molecular drug	[45]

This Disease is Treated as An Indication in 164 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-888	DM4HYMS	Phase 3	Small molecular drug	[22]
AC0010	DMQRL2Y	Phase 3	NA	[46]
Almonertinib	DMCHA27	Phase 3	Small molecular drug	[47]
AM0010	DMGMNUE	Phase 3	NA	[48]
Astuprotimut-R	DMLY0H5	Phase 3	NA	[49]
Avastin+/-Tarceva	DMA86FL	Phase 3	Small molecular drug	[50]
Bavituximab	DMCGW5R	Phase 3	Monoclonal antibody	[51]
Belagenpumatucel-L	DMQG7ZM	Phase 3	Vaccine	[52]
BI 695502	DM4XT5D	Phase 3	Antibody	[53]
CO-1686	DMWZ2TU	Phase 3	Small molecular drug	[54]
CRL-8131	DMCIY7N	Phase 3	Small molecular drug	[55]
DE-766	DM0GUV2	Phase 3	NA	[56]
EGF816	DMCMJRA	Phase 3	NA	[22]
Ensartinib	DMIKDCQ	Phase 3	NA	[22]
Farletuzumab	DMFLWX1	Phase 3	Monoclonal antibody	[48]
FKB238	DM6R2XF	Phase 3	Antibody	[57]
Ganetespib	DM625WM	Phase 3	Small molecular drug	[58]
KN046	DMSDBPG	Phase 3	Antibody	[59]
MAGE-A3 immunotherapeutic	DMI0GZT	Phase 3	NA	[60]
Ociperlimab	DMEDSVJ	Phase 3	Antibody	[61]
OSE2101	DM4ORRQ	Phase 3	NA	[62]
Pelareorep	DM4WCF9	Phase 3	NA	[48]
PF-06439535	DMVHZDP	Phase 3	Antibody	[48]
Plinabulin	DMD7L48	Phase 3	Small molecular drug	[22]
RBP-7000	DMPJTZ1	Phase 3	NA	[63]
RG3638	DMTQJE0	Phase 3	NA	[64]
RRx-001	DMQM2FH	Phase 3	Small molecular drug	[22]
SAR408701	DMXGE3O	Phase 3	Antibody drug conjugate	[65]
Selumetinib	DMC7W6R	Phase 3	Small molecular drug	[66]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[22]
SYM-004	DMOVEDH	Phase 3	Antibody	[48]
Xilonix	DMK34MZ	Phase 3	NA	[48]
Imetelstat	DMONWJ4	Phase 2/3	Small molecular drug	[67]
LY2157299	DMP8HW1	Phase 2/3	Small molecular drug	[22]
MGCD516	DM752PU	Phase 2/3	NA	[22]
TG-4010	DMWE3GB	Phase 2/3	NA	[68]
TG4010	DM15VFJ	Phase 2/3	Vaccine	[69]
Turgenpumatucel-L	DM45EKP	Phase 2/3	NA	[70]
ABT-RTA-408	DM9Y1XB	Phase 2	NA	[71]
Alacizumab pegol	DM3P91Z	Phase 2	Antibody	[72]
ALT-803	DMK3U1X	Phase 2	NA	[48]
Anti-LAG3	DMJO402	Phase 2	NA	[48]
Antroquinonol	DMRGQVZ	Phase 2	NA	[73]
ASP8273	DMHLXUY	Phase 2	NA	[74]
Bemcentinib	DM0YCPL	Phase 2	Small molecular drug	[75]
BI 1361849	DMXDMFE	Phase 2	NA	[68]
BIO-11006	DM6N05H	Phase 2	NA	[22]
Cantuzumab mertansine	DMHHP50	Phase 2	Monoclonal antibody	[76]
CD40LGVAX	DMDXKA9	Phase 2	NA	[22]
Cixutumumab	DMNRYPF	Phase 2	Monoclonal antibody	[77]
CLR1404-I-124	DMIAEGX	Phase 2	NA	[78]
CP-547632	DMX054A	Phase 2	Small molecular drug	[79]
CRLX101	DMQUWXY	Phase 2	NA	[22]
CV-301	DMSJZB9	Phase 2	NA	[68]
DPV-001	DMMC3XR	Phase 2	NA	[80]
DS-8201	DMYCAN7	Phase 2	NA	[22]
Efatutazone	DM0M71T	Phase 2	Small molecular drug	[81]
Eftilagimod alpha	DML4BT1	Phase 2	Recombinant?protein	[82]
Emepepimut-S	DMCLT2F	Phase 2	Vaccine	[83]
Ficlatuzumab	DMG65WH	Phase 2	Monoclonal antibody	[84]
G1T38	DMQO2IT	Phase 2	NA	[22]
GRN 1201	DMEF5UT	Phase 2	Vaccine	[85]
GRN-1201	DMXOYIH	Phase 2	NA	[86]
GSK-2302032A	DML99RA	Phase 2	NA	[87]
HM-78136B	DMZ3BER	Phase 2	Small molecular drug	[22]
HS-110	DML4RCG	Phase 2	Vaccine	[88]
INCB039110	DMD9RV3	Phase 2	Small molecular drug	[22]
ISIS-EIF4E	DMRN543	Phase 2	Antisense drug	[89]
JTX-4014	DMOT0M7	Phase 2	Antibody	[90]
KD019	DMEFW3G	Phase 2	Small molecular drug	[91]
L-DOS47	DMIEZUB	Phase 2	NA	[22]
LYC-55716	DMV8WU9	Phase 2	NA	[22]
Mapatumumab	DMGQ175	Phase 2	Monoclonal antibody	[92]
MEGF0444A	DM2C1YN	Phase 2	NA	[93]
MGCD-0103	DM726HX	Phase 2	Small molecular drug	[22]
MGCD265	DMRPCF2	Phase 2	Small molecular drug	[94]
MK-5890	DM0XV88	Phase 2	NA	[95]
MM-121	DMDJRU1	Phase 2	NA	[22]
MV-NIS	DMGOLCU	Phase 2	Oncolytic virus therapy	[22]
Oncoprex	DMQ2N8Y	Phase 2	NA	[22]
PDT with Photofrin	DMR9H2B	Phase 2	NA	[22]
PEGPH20	DM26YJ1	Phase 2	NA	[22]
PF-06463922	DMKM7EW	Phase 2	Small molecular drug	[62]
PT-107	DMX1H4I	Phase 2	NA	[68]
R-roscovitine	DMSH108	Phase 2	Small molecular drug	[97]
Salirasib	DMRSU4X	Phase 2	Small molecular drug	[98]
Seribantumab	DMYT470	Phase 2	NA	[48]
Tarloxotinib	DMA7ISF	Phase 2	Small molecular drug	[99]
TAS-114	DM3D52L	Phase 2	NA	[22]
Tc-99m ethylenedicysteine glucosamine	DM7KSRL	Phase 2	NA	[100]
Telisotuzumab vedotin	DM8UCNK	Phase 2	Antibody	[101]
TT-100	DMZE6Y9	Phase 2	NA	[102]
U3-1402	DMLPFPE	Phase 2	NA	[22]
UCN-01	DMUNJZB	Phase 2	Small molecular drug	[103]
Viagenpumatucel-L	DMTT27W	Phase 2	Vaccine	[104]
Volociximab	DMNQG24	Phase 2	Antibody	[105]
VX-15	DMLWM4G	Phase 2	Antibody	[22]
WST11	DMWL50Z	Phase 2	NA	[106]
131I-radretumab	DMT17XU	Phase 1/2	Antibody	[107]
ADXS-503	DM9H5QG	Phase 1/2	NA	[108]
AMG888/U3-1287	DMEF4L5	Phase 1/2	NA	[109]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[110]
CEP-9722	DMY8NUF	Phase 1/2	NA	[111]
CK-101	DMMVWSY	Phase 1/2	NA	[22]
CLR1404-I-131	DMN9MVU	Phase 1/2	NA	[112]
CNVN-202	DMWZOD7	Phase 1/2	NA	[113]
CV-9201	DMCPZYT	Phase 1/2	Vaccine	[114]
Fus-1 tumor suppressor gene therapy	DMXV6YP	Phase 1/2	NA	[113]
GLR2007	DM7DWLY	Phase 1/2	NA	[115]
HS-10296	DMSZ849	Phase 1/2	NA	[22]
JNJ-64041757	DMVCJHO	Phase 1/2	NA	[68]
MP0250	DMR3VCY	Phase 1/2	NA	[22]
P2045	DMM2M1L	Phase 1/2	NA	[116]
PBF509	DMGFPQ0	Phase 1/2	NA	[22]
Quaratusugene ozeplasmid	DMZD7OA	Phase 1/2	Gene therapy	[117]
RG7802	DM3KOVX	Phase 1/2	Antibody	[118]
RGX-104	DM5AIKR	Phase 1/2	NA	[119]
SN-32793	DMEJT5Z	Phase 1/2	NA	[120]
SNK-01	DMB03SV	Phase 1/2	Cell therapy	[121]
SNX-5422	DMIU0VP	Phase 1/2	Small molecular drug	[22]
TSR-011	DMFOR9Y	Phase 1/2	NA	[122]
TUSC2/FUS1 gene therapy	DMBL285	Phase 1/2	NA	[113]
XMT-1592	DMU6TG7	Phase 1/2	Antibody drug conjugate	[123]
ZN-e4	DMLV4U1	Phase 1/2	Small molecular drug	[124]
A-337	DMRWTFG	Phase 1	Antibody	[125]
ABBV-184	DM71Q69	Phase 1	TCR-T cell therapy	[126]
ADXS-NEO	DMFJ1OW	Phase 1	Vaccine	[22]
Anti-EGFL7	DM0ZDJ5	Phase 1	Antibody	[127]
AP32788	DMGDARN	Phase 1	NA	[22]
AST-VAC2	DM6NXLV	Phase 1	Vaccine	[128]
BIIB 022	DMZ1V0E	Phase 1	NA	[129]
BMS214662	DM5M48F	Phase 1	Small molecular drug	[130]
CAN04	DM1FLXD	Phase 1	Antibody	[131]
CLN-081	DM05R4C	Phase 1	Small molecular drug	[132]
CMP-001	DMGMI8P	Phase 1	NA	[22]
DS-1062	DMRQ0WD	Phase 1	NA	[22]
DS-1205	DMXST9F	Phase 1	NA	[22]
DV281	DMJ0Y86	Phase 1	NA	[22]
GT103	DMX2J57	Phase 1	Antibody	[133]
IC 1001	DMD5Z7N	Phase 1	NA	[134]
IMA201	DMKLMV9	Phase 1	NA	[22]
IMU-201	DME35SA	Phase 1	Vaccine	[135]
IRX4204	DM9SCME	Phase 1	Small molecular drug	[22]
JCAR024	DMQ1TK0	Phase 1	NA	[48]
JNJ-26854165	DMNSJ3C	Phase 1	Small molecular drug	[136]
JNJ-61186372	DMM1TE6	Phase 1	NA	[22]
JNJ-73841937	DMK9IPF	Phase 1	Small molecular drug	[137]
LP-300	DMIOS7N	Phase 1	Small molecular drug	[138]
LV305	DMP0TQA	Phase 1	NA	[139]
LXH254	DMQE9PS	Phase 1	NA	[22]
mRNA-5671	DMWO3KW	Phase 1	Vaccine	[140]
NBF-006	DMG0SWE	Phase 1	Small interfering RNA	[141]
Neovastat	DMXTYWJ	Phase 1	NA	[142]
ONC-392	DM8B40M	Phase 1	Antibody	[143]
Patritumab	DMFSMCB	Phase 1	Antibody	[144]
PBF-1129	DMOPGXM	Phase 1	NA	[22]
Pegdinetanib	DM0E37K	Phase 1	NA	[145]
PRAME antigen-specific cancer immunotherapeutic	DMXRJ1N	Phase 1	NA	[146]
REGN5093	DM3720L	Phase 1	Antibody	[147]
S-17092-1	DMYR1K8	Phase 1	Small molecular drug	[148]
XMT-1522	DMPVP4D	Phase 1	NA	[22]
BMS-986192	DMG9U1E	Clinical trial	NA	[48]
KU-60019	DMWA5XP	Clinical trial	Small molecular drug	[149]
L-cysteine	DMCMOS8	Clinical trial	Small molecular drug	[150]

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nintedanib	DMMQ2OW	Phase 2 Trial	Small molecular drug	[96]

This Disease is Treated as An Indication in 8 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS 275291	DMKSFPE	Discontinued in Phase 3	Small molecular drug	[151]
CBT-1	DM097UP	Discontinued in Phase 3	NA	[152]
Motesanib	DMZAL8C	Discontinued in Phase 3	Small molecular drug	[153]
Apricoxib	DMR3Q82	Discontinued in Phase 2	Small molecular drug	[154]
Retaspimycin	DMBBIA7	Discontinued in Phase 2	Small molecular drug	[155]
RG7414	DMCQRS2	Discontinued in Phase 2	NA	[156]
ABT-839	DM4UN9A	Terminated	Small molecular drug	[158]
Nimesulide	DMR1NMD	Terminated	Small molecular drug	[127]

This Disease is Treated as An Indication in 4 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABP 215	DMGG6CO	Application submitted	NA	[48]
Pemfexy	DMKJ393	Application submitted	NA	[22]
GL21.T	DMZC91G	Preclinical	Oligonucleotide	[157]
YW327.6S2	DMH0I9N	Preclinical	Antibody	[157]

This Disease is Treated as An Indication in 5 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CAPTAT-414	DMNJT90	Investigative	NA	[28]
GI-3000	DMU92RC	Investigative	Vaccine	[159]
KIN-4044	DMO8JQM	Investigative	NA	[160]
RP-3035	DM661LX	Investigative	NA	[28]
XB-387	DMBN7UX	Investigative	Antibody	[161]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 940 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCG1	TTMWDGU	Limited	Biomarker	[164]
ADAM10	TTVXEGU	Limited	Altered Expression	[165]
AKT2	TTH24WI	Limited	Altered Expression	[166]
AKT3	TTO6SGY	Limited	Biomarker	[167]
ALCAM	TT2AFT6	Limited	Biomarker	[168]
ANGPT1	TTWNQ1T	Limited	Altered Expression	[169]
ATF4	TTQCKWT	Limited	Altered Expression	[170]
ATP7B	TTOPO51	Limited	Biomarker	[171]
BAGE	TTS5GLJ	Limited	Altered Expression	[172]
BCL6	TTC9YX5	Limited	Genetic Variation	[173]
BIRC7	TTHZ8TA	Limited	Biomarker	[174]
BRD2	TTDP48B	Limited	Biomarker	[175]
BRS3	TTKYEPM	Limited	Biomarker	[176]
BTK	TTGM6VW	Limited	Biomarker	[177]
BUB1	TT78309	Limited	Genetic Variation	[178]
CCNE1	TTCEJ4F	Limited	Altered Expression	[179]
CDC25C	TTESBNC	Limited	Biomarker	[180]
CDK1	TTH6V3D	Limited	Genetic Variation	[181]
CDK5	TTL4Q97	Limited	Altered Expression	[182]
CHEK2	TT9ABMF	Limited	Biomarker	[183]
CIT	TT3BKTU	Limited	Biomarker	[184]
CMA1	TT8VUE0	Limited	Altered Expression	[185]
COL7A1	TTBCOKN	Limited	Biomarker	[186]
CRTC2	TTFWETR	Limited	Altered Expression	[187]
CXCR2	TT30C9G	Limited	Genetic Variation	[188]
CYP2B6	TTMH124	Limited	Altered Expression	[189]
DEK	TT1NMGV	Limited	Altered Expression	[190]
DLK1	TTF4AVB	Limited	Biomarker	[191]
DLL1	TT9CFQD	Limited	Altered Expression	[192]
DSG3	TTEO4P8	Limited	Altered Expression	[193]
EGLN2	TTMHFRY	Limited	Posttranslational Modification	[194]
ENPEP	TT9PBIL	Limited	Biomarker	[195]
ETS2	TT9AH0M	Limited	Biomarker	[196]
FASLG	TTO7014	Limited	Biomarker	[197]
FOLR2	TTT54CI	Limited	Altered Expression	[198]
GALNS	TTT9YPO	Limited	Altered Expression	[199]
GLRA1	TTF45NW	Limited	Genetic Variation	[200]
GRIK2	TT0K5RG	Limited	Biomarker	[201]
GRPR	TTC1MVT	Limited	Biomarker	[202]
GSN	TTUH7OM	Limited	Biomarker	[203]
HMGB2	TTA78JQ	Limited	Biomarker	[204]
HNRNPA1	TTPJ9XK	Limited	Biomarker	[205]
IFNB1	TT4TZ8J	Limited	Biomarker	[206]
IGFBP1	TTCJTWF	Limited	Altered Expression	[207]
IKBKB	TTJ3E9X	Limited	Biomarker	[208]
IL16	TTW4R0B	Limited	Genetic Variation	[209]
IL9	TT0JTFD	Limited	Altered Expression	[210]
ITGA5	TTHIZP9	Limited	Biomarker	[211]
ITGAE	TTH0Z37	Limited	Altered Expression	[212]
JUN	TTS7IR5	Limited	Genetic Variation	[213]
KCNA5	TTW0CMT	Limited	Altered Expression	[214]
KCNJ3	TTGM19J	Limited	Altered Expression	[214]
KDM6B	TTDIJUQ	Limited	Biomarker	[215]
KITLG	TTDJ51N	Limited	Genetic Variation	[216]
KLK14	TTDA81R	Limited	Biomarker	[217]
KMT5A	TTGC95K	Limited	Biomarker	[218]
LAMB3	TT2WOUQ	Limited	Altered Expression	[219]
LAPTM4B	TTEJQT0	Limited	Altered Expression	[220]
LDHA	TTW76JE	Limited	Biomarker	[221]
LILRB2	TTHC6XU	Limited	Biomarker	[222]
LOXL2	TTFSUHX	Limited	Biomarker	[223]
MAGEA4	TT9EQUY	Limited	Altered Expression	[224]
MAGEC1	TT9M6NA	Limited	Altered Expression	[225]
MAP3K10	TT9FN4J	Limited	Biomarker	[226]
MAP4K3	TTI0AHJ	Limited	Biomarker	[227]
MCM7	TT1RM3F	Limited	Biomarker	[228]
MSMB	TTYH1ZK	Limited	Biomarker	[229]
NCAM1	TTVXPHT	Limited	Biomarker	[230]
NECTIN4	TTPO9EG	Limited	Altered Expression	[231]
NR0B2	TT25A9Q	Limited	Posttranslational Modification	[232]
NR1H2	TTXA6PH	Limited	Genetic Variation	[233]
NR1I2	TT7LCTF	Limited	Biomarker	[234]
NRAS	TTW2R9X	Limited	Altered Expression	[235]
OXTR	TTSCIUP	Limited	Biomarker	[236]
PAH	TTGSVH2	Limited	Altered Expression	[237]
PAK4	TT7Y3BZ	Limited	Biomarker	[238]
PDCD2	TTYOVWN	Limited	Altered Expression	[239]
PDXK	TTXI3KF	Limited	Biomarker	[240]
PEBP1	TT1BGU8	Limited	Biomarker	[241]
PLA2G2A	TTO8QRU	Limited	Biomarker	[242]
PPARD	TT2JWF6	Limited	Biomarker	[243]
PRMT1	TTVOJAI	Limited	Biomarker	[244]
PRMT5	TTR1D7X	Limited	Biomarker	[245]
PSMB6	TT8EPLT	Limited	Altered Expression	[192]
PTGER2	TT1ZAVI	Limited	Posttranslational Modification	[246]
PTP4A3	TT7YM8D	Limited	Biomarker	[247]
PTPN13	TT405FP	Limited	Biomarker	[248]
PTPN6	TT369M5	Limited	Posttranslational Modification	[232]
RACK1	TTJ10AL	Limited	Biomarker	[249]
RASA1	TTPNZ1F	Limited	Genetic Variation	[250]
RIPK1	TTVJHX8	Limited	Biomarker	[251]
ROBO1	TTND1YP	Limited	Biomarker	[252]
RSF1	TTMP86V	Limited	Altered Expression	[253]
SCGB1A1	TTONPVW	Limited	Biomarker	[254]
SERPINB3	TT6QLPX	Limited	Biomarker	[255]
SFTPD	TTGLMU7	Limited	Altered Expression	[256]
SGO1	TTBPKGD	Limited	Altered Expression	[257]
SIRT2	TTLKF5M	Limited	Altered Expression	[258]
SLC16A1	TTN1J82	Limited	Altered Expression	[185]
SLC3A2	TT5CZSM	Limited	Biomarker	[259]
SOCS1	TT8COJM	Limited	Biomarker	[260]
STMN1	TT7W5OT	Limited	Altered Expression	[261]
SYK	TT2HUPM	Limited	Biomarker	[262]
TACC3	TTQ4UFD	Limited	Biomarker	[263]
TAP1	TT7JZI8	Limited	Biomarker	[264]
TERF1	TT1Y6J2	Limited	Biomarker	[265]
TGFB2	TTI0KH6	Limited	Genetic Variation	[266]
TLR9	TTSHG0T	Limited	Biomarker	[267]
TMEM97	TT9NXW4	Limited	Altered Expression	[268]
TNC	TTUCPMY	Limited	Biomarker	[269]
TNKS	TTVUSO7	Limited	Biomarker	[270]
ULK1	TT4D7MJ	Limited	Posttranslational Modification	[271]
VDAC1	TTAMKGB	Limited	Altered Expression	[272]
VWF	TT3SZBT	Limited	Genetic Variation	[273]
CXCL11	TTWG0RE	Disputed	Biomarker	[274]
DCN	TTB3XAN	Disputed	Biomarker	[275]
GCLM	TTNFESW	Disputed	Altered Expression	[276]
HOXA11	TTEX4ZA	Disputed	Posttranslational Modification	[277]
KDM5B	TTCLI75	Disputed	Biomarker	[278]
MTNR1A	TT0WAIE	Disputed	Altered Expression	[279]
PBK	TTMY6BZ	Disputed	Genetic Variation	[280]
PRDX5	TTLPJWH	Disputed	Biomarker	[281]
TACSTD2	TTP2HE5	Disputed	Biomarker	[282]
TNFRSF1B	TT63WSF	Disputed	Genetic Variation	[283]
TNNC1	TT8RDXP	Disputed	Altered Expression	[284]
TTK	TTP7EGM	Disputed	Biomarker	[285]
ACKR3	TTRQJTC	moderate	Altered Expression	[286]
ADAM9	TTTYQNS	moderate	Altered Expression	[287]
ARG1	TT7ZQEV	moderate	Altered Expression	[288]
BMP4	TTD3BSX	moderate	Genetic Variation	[289]
CTSL	TT36ETB	moderate	Altered Expression	[290]
DLL4	TTV23LH	moderate	Biomarker	[291]
DNMT3A	TTJUALD	moderate	Biomarker	[292]
DYRK1B	TTYGQ8A	moderate	Altered Expression	[293]
EGFL7	TT7WD0H	moderate	Biomarker	[294]
EZR	TTE47YC	moderate	Altered Expression	[295]
FOXC1	TTNT3YA	moderate	Biomarker	[296]
FOXC2	TTLBAP1	moderate	Altered Expression	[297]
FOXQ1	TTEJZOL	moderate	Biomarker	[298]
GDF5	TT37XV9	moderate	Altered Expression	[299]
GRB2	TTEYRJ9	moderate	Biomarker	[300]
HDAC2	TTSHTOI	moderate	Genetic Variation	[301]
HNF4A	TT2F3CD	moderate	Genetic Variation	[181]
HTATIP2	TTC6IX5	moderate	Biomarker	[302]
IL17D	TTC5LTG	moderate	Biomarker	[303]
IL7	TT8FRMO	moderate	Biomarker	[304]
ILK	TT7ALZG	moderate	Biomarker	[305]
IRS1	TTAJSQ0	moderate	Genetic Variation	[306]
ITGA11	TTANXZ7	moderate	Altered Expression	[307]
ITGB3	TTJA1ZO	moderate	Biomarker	[308]
L1CAM	TTC9D3K	moderate	Biomarker	[309]
LAG3	TTNVXAW	moderate	Biomarker	[310]
MAP3K14	TT4LIAC	moderate	Genetic Variation	[280]
MERTK	TTO7LKR	moderate	Biomarker	[311]
MKI67	TTB4UNG	moderate	Biomarker	[312]
MMP12	TTXZ0KQ	moderate	Altered Expression	[313]
MMP14	TTJ4QE7	moderate	Biomarker	[314]
MRC1	TTKV8W5	moderate	Biomarker	[315]
NR5A2	TTAU3SY	moderate	Biomarker	[316]
NTN1	TT0AH4L	moderate	Biomarker	[317]
PGF	TT48I1Y	moderate	Biomarker	[318]
PLG	TTP86E2	moderate	Biomarker	[319]
PLP2	TTK5OG6	moderate	Genetic Variation	[320]
RPS6KB1	TTG0U4H	moderate	Biomarker	[198]
SGK1	TTTV8EJ	moderate	Biomarker	[321]
STEAP1	TT9E64S	moderate	Biomarker	[322]
STYK1	TTRMCYJ	moderate	Altered Expression	[323]
SULF2	TTLQTHB	moderate	Altered Expression	[324]
TBK1	TTMP03S	moderate	Biomarker	[308]
TLR3	TTD24Y0	moderate	Biomarker	[325]
TXNIP	TTTLDZK	moderate	Biomarker	[326]
USP14	TTVSYP9	moderate	Biomarker	[327]
VCAM1	TTHCEF6	moderate	Biomarker	[328]
VCP	TTHNLSB	moderate	Biomarker	[329]
ABCA4	TTLB52K	Strong	Genetic Variation	[330]
ABCC2	TTFLHJV	Strong	Genetic Variation	[331]
ABCC3	TTVLG21	Strong	Biomarker	[332]
ABCC4	TTUEAFL	Strong	Genetic Variation	[333]
ABCC8	TTP835K	Strong	Biomarker	[334]
ABL1	TT6B75U	Strong	Genetic Variation	[335]
ACE2	TTUI5H7	Strong	Biomarker	[336]
ACHE	TT1RS9F	Strong	Biomarker	[337]
ACLY	TT0Z6Y2	Strong	Altered Expression	[338]
ACTG1	TTGAZF9	Strong	Biomarker	[339]
ACVRL1	TTGYPTC	Strong	Biomarker	[340]
ADAM17	TT6AZXG	Strong	Biomarker	[341]
ADAMTS1	TTS2TEI	Strong	Altered Expression	[342]
ADAMTS5	TTXSU2Y	Strong	Biomarker	[343]
ADCYAP1	TTW4LYC	Strong	Biomarker	[344]
ADCYAP1R1	TT5OREU	Strong	Biomarker	[345]
ADIPOQ	TTXKA7D	Strong	Biomarker	[346]
ADRA1A	TTNGILX	Strong	Biomarker	[176]
ADRA2B	TTWM4TY	Strong	Biomarker	[176]
AGER	TTMO9HF	Strong	Biomarker	[347]
AGR2	TT9K86S	Strong	Altered Expression	[348]
AHSG	TTKF4WV	Strong	Biomarker	[349]
AIMP2	TTXWHGF	Strong	Biomarker	[350]
ALDH3A2	TTB6UM0	Strong	Biomarker	[351]
ALKBH5	TTOHB1M	Strong	Biomarker	[352]
ANGPT2	TTKLQTJ	Strong	Biomarker	[353]
ANGPTL4	TTWALY5	Strong	Altered Expression	[354]
ANK1	TTKFPMH	Strong	Posttranslational Modification	[355]
ANO1	TTOJI4S	Strong	Altered Expression	[356]
ANPEP	TTPHMWB	Strong	Biomarker	[357]
ANXA10	TT0NL6U	Strong	Altered Expression	[358]
ANXA2	TT4YANI	Strong	Biomarker	[359]
ANXA5	TT2Z83I	Strong	Altered Expression	[360]
APC2	TTSMK36	Strong	Biomarker	[361]
APEX1	TTHGL48	Strong	Altered Expression	[362]
AQP3	TTLDNMQ	Strong	Biomarker	[363]
ARAF	TT5TURO	Strong	Genetic Variation	[364]
AREG	TT76B3W	Strong	Altered Expression	[365]
ARRB1	TTMVD4A	Strong	Biomarker	[366]
ASAP3	TTB4ZEN	Strong	Biomarker	[367]
ASPA	TT6TLZP	Strong	Genetic Variation	[368]
ATF3	TTCE793	Strong	Biomarker	[369]
ATG2B	TTG6KCU	Strong	Biomarker	[370]
ATRAID	TTFLIKM	Strong	Genetic Variation	[371]
AURKB	TT9RTBL	Strong	Biomarker	[372]
AVPR2	TTK8R02	Strong	Biomarker	[373]
AXL	TTZPY6J	Strong	Biomarker	[374]
BACE1	TTJUNZF	Strong	Biomarker	[375]
BAK1	TTFM7V0	Strong	Biomarker	[376]
BAP1	TT47RXJ	Strong	Altered Expression	[377]
BBC3	TT7JUKC	Strong	Altered Expression	[378]
BCAT2	TTF9OQ6	Strong	Biomarker	[379]
BCL2A1	TTGT9C7	Strong	Biomarker	[380]
BCL2L2	TTQ79W8	Strong	Biomarker	[381]
BECN1	TT5M7LN	Strong	Biomarker	[382]
BIRC2	TTQ5LRD	Strong	Genetic Variation	[383]
BIRC3	TTAIWZN	Strong	Biomarker	[384]
BIRC5	TTTPU1G	Strong	Genetic Variation	[285]
BMP1	TT0L58T	Strong	Altered Expression	[385]
BMP2	TTP3IGX	Strong	Biomarker	[386]
BMP6	TT07RIB	Strong	Altered Expression	[387]
BMP7	TTKOBRA	Strong	Biomarker	[388]
BMX	TTN2I9E	Strong	Altered Expression	[389]
BPI	TTXCSDR	Strong	Genetic Variation	[390]
BRAF	TT0EOB8	Strong	Genetic Variation	[280]
BRD4	TTSRAOU	Strong	Biomarker	[391]
BRD7	TT07ZS1	Strong	Altered Expression	[392]
BSG	TT5UJWD	Strong	Altered Expression	[393]
BTG1	TTL7N2W	Strong	Altered Expression	[394]
C3	TTJGY7A	Strong	Genetic Variation	[368]
C5AR1	TTHXFA1	Strong	Altered Expression	[395]
CA1	TTHQPL7	Strong	Biomarker	[396]
CA4	TTZHA0O	Strong	Altered Expression	[397]
CA9	TT2LVK8	Strong	Altered Expression	[398]
CACNA1B	TT4FDG6	Strong	Biomarker	[399]
CACNA2D2	TTU8P3M	Strong	Altered Expression	[400]
CALCR	TTLWS2O	Strong	Genetic Variation	[401]
CALR	TTUZ7OA	Strong	Genetic Variation	[401]
CARM1	TTIZQFJ	Strong	Biomarker	[402]
CASP10	TTX5HEK	Strong	Genetic Variation	[403]
CASP2	TT12VNG	Strong	Biomarker	[404]
CASP4	TT6KIOT	Strong	Biomarker	[405]
CASP7	TTM7Y45	Strong	Genetic Variation	[406]
CASP8	TT6SZNG	Strong	Altered Expression	[407]
CASP9	TTB6T7O	Strong	Biomarker	[408]
CAT	TTPS279	Strong	Biomarker	[409]
CBL	TT7QT13	Strong	Genetic Variation	[410]
CBLB	TTHRAIJ	Strong	Genetic Variation	[411]
CBR1	TTVG0SN	Strong	Altered Expression	[412]
CBX7	TTBN3HC	Strong	Biomarker	[413]
CCK	TT90CMU	Strong	Biomarker	[414]
CCL17	TTMPHAE	Strong	Altered Expression	[415]
CCL20	TT2XAZY	Strong	Altered Expression	[416]
CCL21	TTLZK1U	Strong	Biomarker	[417]
CCL22	TTBTWI1	Strong	Altered Expression	[415]
CCN1	TTPK79J	Strong	Biomarker	[418]
CCNB1	TT9P6OW	Strong	Altered Expression	[419]
CCND3	TT1JXNR	Strong	Biomarker	[420]
CCNE2	TTLDRGX	Strong	Biomarker	[421]
CCR1	TTC24WT	Strong	Biomarker	[422]
CCR4	TT7HQD0	Strong	Biomarker	[423]
CCR7	TT2GIDQ	Strong	Altered Expression	[424]
CCR9	TTIPS8B	Strong	Biomarker	[425]
CD163	TTTZ9DE	Strong	Biomarker	[426]
CD200	TT0BE68	Strong	Genetic Variation	[427]
CD27	TTDO1MV	Strong	Altered Expression	[428]
CD28	TTQ13FT	Strong	Biomarker	[429]
CD300A	TTI2YFK	Strong	Altered Expression	[430]
CD34	TTZAVYN	Strong	Biomarker	[431]
CD40	TT1ERKL	Strong	Biomarker	[432]
CD47	TT28S46	Strong	Biomarker	[433]
CD55	TT5Z9WY	Strong	Altered Expression	[434]
CD69	TTPQE9F	Strong	Altered Expression	[212]
CD70	TTNCIE0	Strong	Biomarker	[435]
CD74	TTCMYP9	Strong	Biomarker	[436]
CD80	TT89Z17	Strong	Altered Expression	[437]
CD83	TTT9MRQ	Strong	Biomarker	[438]
CD9	TTZEIBV	Strong	Biomarker	[236]
CDC25A	TTLZS4Q	Strong	Biomarker	[439]
CDC25B	TTR0SWN	Strong	Genetic Variation	[371]
CDH2	TT1WS0T	Strong	Altered Expression	[440]
CDH5	TTXLCFO	Strong	Altered Expression	[441]
CDK8	TTBJR4L	Strong	Biomarker	[442]
CDK9	TT1LVF2	Strong	Biomarker	[443]
CDKN1A	TT9GUW0	Strong	Altered Expression	[444]
CDKN1C	TTBSUAR	Strong	Altered Expression	[445]
CDKN2C	TTBRUGA	Strong	Genetic Variation	[371]
CEACAM1	TTA9CK4	Strong	Biomarker	[446]
CEBPB	TTUI35N	Strong	Altered Expression	[447]
CENPE	TTZD5QR	Strong	Biomarker	[448]
CFH	TTUW6OP	Strong	Altered Expression	[449]
CFI	TT6ATLX	Strong	Genetic Variation	[450]
CHEK1	TTTU902	Strong	Altered Expression	[451]
CHKA	TT10AWB	Strong	Biomarker	[452]
CHPF	TTAZB7S	Strong	Altered Expression	[453]
CHRM3	TTQ13Z5	Strong	Biomarker	[454]
CHRNA4	TT4H1MQ	Strong	Biomarker	[455]
CHRNA5	TTH2QRX	Strong	Genetic Variation	[456]
CHRNA9	TTQACP9	Strong	Genetic Variation	[457]
CHRNB4	TTTVAFQ	Strong	Biomarker	[458]
CHUK	TT1F8OQ	Strong	Biomarker	[459]
CLDN4	TTMTS9H	Strong	Altered Expression	[460]
CMKLR1	TT4UGZL	Strong	Genetic Variation	[461]
CNTN1	TTPR8FK	Strong	Altered Expression	[462]
CNTN2	TT2Z1WB	Strong	Genetic Variation	[463]
COPS5	TTSTNJR	Strong	Biomarker	[464]
COX17	TT0F26C	Strong	Altered Expression	[465]
CPS1	TT42M75	Strong	Altered Expression	[466]
CR1	TTEA8OW	Strong	Genetic Variation	[289]
CRK	TTFEUYR	Strong	Biomarker	[350]
CRYZ	TTP6UO8	Strong	Biomarker	[467]
CSF1R	TT7MRDV	Strong	Genetic Variation	[468]
CSF3	TT5TQ2W	Strong	Biomarker	[469]
CSK	TTX6F0Q	Strong	Biomarker	[470]
CTAG1A	TTE5ITK	Strong	Genetic Variation	[471]
CTSB	TTF2LRI	Strong	Altered Expression	[360]
CTSD	TTPT2QI	Strong	Altered Expression	[360]
CTSS	TTUMQVO	Strong	Biomarker	[472]
CUL3	TTPCU0Q	Strong	Altered Expression	[473]
CXCL12	TT4UGTF	Strong	Biomarker	[474]
CXCL13	TT0NIZ1	Strong	Genetic Variation	[475]
CXCL9	TTWE5PB	Strong	Biomarker	[476]
CXCR1	TTMWT8Z	Strong	Biomarker	[477]
CXCR6	TT2BVUA	Strong	Biomarker	[176]
CYP19A1	TTSZLWK	Strong	Biomarker	[478]
CYP1A2	TTS1DTU	Strong	Biomarker	[479]
CYP1B1	TTI84H7	Strong	Genetic Variation	[480]
CYP24A1	TT82UI1	Strong	Genetic Variation	[481]
CYP2A6	TTAQ6ZW	Strong	Genetic Variation	[456]
CYP2C9	TTR40YJ	Strong	Biomarker	[482]
CYP2D6	TTVG215	Strong	Genetic Variation	[483]
CYP2E1	TTWVHQ5	Strong	Genetic Variation	[484]
CYP3A4	TTWP7HQ	Strong	Biomarker	[479]
DAPK3	TTERVQN	Strong	Biomarker	[485]
DCK	TTJOCE4	Strong	Biomarker	[486]
DCLK1	TTOHTCY	Strong	Altered Expression	[487]
DDIT4	TTVEOY6	Strong	Biomarker	[488]
DDR1	TTI1FPZ	Strong	Biomarker	[489]
DDR2	TTU98HG	Strong	Biomarker	[490]
DDX5	TTZKPVC	Strong	Altered Expression	[491]
DDX58	TTVB0O3	Strong	Altered Expression	[492]
DHCR24	TTTK0NH	Strong	Biomarker	[493]
DHFR	TTYZVDJ	Strong	Altered Expression	[494]
DIABLO	TTN74LE	Strong	Biomarker	[495]
DICER1	TTTEOPU	Strong	Biomarker	[496]
DKK3	TTY2ZV6	Strong	Biomarker	[497]
DLL3	TT1C9K6	Strong	Altered Expression	[498]
DNAJB1	TTPXAWS	Strong	Biomarker	[499]
DNMT3B	TT6VZ78	Strong	Biomarker	[500]
DPP10	TTOVUPC	Strong	Genetic Variation	[501]
DPP9	TTNDUL7	Strong	Altered Expression	[502]
DPYD	TTZPS91	Strong	Altered Expression	[503]
DPYSL2	TTZCW3T	Strong	Biomarker	[504]
DUSP1	TTG8HIM	Strong	Altered Expression	[505]
DUSP3	TTIFAYS	Strong	Altered Expression	[506]
DUT	TTH6MBO	Strong	Biomarker	[507]
DYRK1A	TTSBVFO	Strong	Biomarker	[508]
DYRK2	TT84OS6	Strong	Altered Expression	[509]
E2F2	TT5FYX0	Strong	Altered Expression	[510]
EBI3	TTJF68X	Strong	Biomarker	[511]
EEF2K	TT1QFLA	Strong	Biomarker	[512]
EGR1	TTE8LGD	Strong	Biomarker	[290]
EHMT2	TTS6RZT	Strong	Altered Expression	[513]
EIF2AK2	TTXEZJ4	Strong	Altered Expression	[514]
EIF2AK3	TT79U1M	Strong	Altered Expression	[515]
EIF4E2	TT2ZSKV	Strong	Genetic Variation	[516]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[517]
EIF5A	TTIVCNR	Strong	Biomarker	[518]
EIF5A2	TTH53G9	Strong	Biomarker	[519]
ELAVL1	TTPC9D0	Strong	Biomarker	[520]
ENTPD1	TTYM8DJ	Strong	Biomarker	[521]
EPHA2	TTRJB2G	Strong	Biomarker	[522]
EPHA7	TTAHTVG	Strong	Altered Expression	[523]
EPHB2	TTKPV6O	Strong	Biomarker	[350]
EPHB3	TT5LM7U	Strong	Biomarker	[524]
EPHB4	TTI4ZX2	Strong	Altered Expression	[525]
EPHB6	TTZEMUY	Strong	Biomarker	[526]
EPOR	TTAUX24	Strong	Biomarker	[527]
ERAP1	TT60XFL	Strong	Genetic Variation	[528]
ERBB3	TTSINU2	Strong	Biomarker	[529]
ERBB4	TTWALCO	Strong	Biomarker	[529]
ERN1	TTKIAT3	Strong	Altered Expression	[530]
ESR1	TTZAYWL	Strong	Biomarker	[531]
ESRRA	TTPNQAC	Strong	Altered Expression	[532]
ESRRB	TTKF0XS	Strong	Biomarker	[533]
ESRRG	TT9ZRHB	Strong	Biomarker	[532]
EYA2	TTUY9C6	Strong	Altered Expression	[534]
EZH1	TTNJA0C	Strong	Biomarker	[535]
EZH2	TT9MZCQ	Strong	Altered Expression	[414]
F11R	TT3C8EG	Strong	Biomarker	[536]
F3	TT38MDJ	Strong	Altered Expression	[537]
FAF1	TTSKL3G	Strong	Biomarker	[538]
FAM83B	TT1Q347	Strong	Biomarker	[539]
FASN	TT7AOUD	Strong	Biomarker	[540]
FBXW7	TT29KY7	Strong	Biomarker	[541]
FCGRT	TTKLPHO	Strong	Altered Expression	[542]
FGF18	TT6ICRA	Strong	Biomarker	[543]
FGF2	TTGKIED	Strong	Biomarker	[544]
FGFR2	TTGJVQM	Strong	Biomarker	[545]
FGFR4	TT1KX2S	Strong	Genetic Variation	[545]
FGG	TTR31L7	Strong	Biomarker	[319]
FHIT	TTMS54D	Strong	Biomarker	[546]
FHL1	TTI7ENL	Strong	Biomarker	[547]
FLT1	TT1VAUK	Strong	Biomarker	[548]
FMNL1	TTW20PQ	Strong	Altered Expression	[549]
FOLH1	TT9G4N0	Strong	Altered Expression	[550]
FOLR1	TTVC37M	Strong	Biomarker	[551]
FOSL2	TT689IR	Strong	Biomarker	[552]
FOXJ2	TTV1FDA	Strong	Biomarker	[553]
FOXM1	TTD3KOX	Strong	Altered Expression	[554]
FOXO1	TTLRVIA	Strong	Biomarker	[300]
FPR2	TTOJ1NF	Strong	Biomarker	[382]
FSCN1	TTTRS9B	Strong	Biomarker	[555]
FURIN	TTH9WF6	Strong	Altered Expression	[556]
FUS	TTKGYZ9	Strong	Altered Expression	[557]
FUT4	TTNV1KZ	Strong	Biomarker	[558]
G3BP1	TTG0R8Z	Strong	Altered Expression	[559]
GADD45B	TTMDW9L	Strong	Biomarker	[560]
GALC	TT5IZRB	Strong	Altered Expression	[561]
GAP43	TTSGLN5	Strong	Biomarker	[562]
GAPDH	TTUGSWA	Strong	Biomarker	[382]
GAS6	TT69QD2	Strong	Biomarker	[563]
GHSR	TTWDC17	Strong	Biomarker	[564]
GIPR	TTYMKBE	Strong	Altered Expression	[565]
GJB1	TTSJIRP	Strong	Altered Expression	[566]
GLI1	TTJOMH6	Strong	Biomarker	[567]
GLIPR1	TTEQF1O	Strong	Biomarker	[568]
GLUL	TTURQ2G	Strong	Biomarker	[569]
GOT1	TTU507L	Strong	Biomarker	[570]
GPBAR1	TTSDVTR	Strong	Altered Expression	[571]
GPC3	TTJTSX4	Strong	Biomarker	[490]
GPER1	TTDSB34	Strong	Biomarker	[572]
GPR35	TT254XD	Strong	Altered Expression	[573]
GPR55	TTNET8J	Strong	Altered Expression	[574]
GPRC6A	TTI1PRE	Strong	Biomarker	[575]
GRHL2	TTUGH4C	Strong	Biomarker	[576]
GRIA2	TTWM461	Strong	Biomarker	[577]
GRIA3	TT82EZV	Strong	Biomarker	[578]
GRIN2B	TTN9D8E	Strong	Posttranslational Modification	[579]
GRK5	TTTCXO0	Strong	Biomarker	[580]
GRM1	TTVBPDM	Strong	Altered Expression	[581]
GSK3B	TTRSMW9	Strong	Biomarker	[582]
GSR	TTEP6RV	Strong	Biomarker	[409]
GSTP1	TT40K12	Strong	Genetic Variation	[583]
GZMB	TTKEPHX	Strong	Biomarker	[584]
HBEGF	TT15SL0	Strong	Biomarker	[585]
HDAC1	TT6R7JZ	Strong	Biomarker	[586]
HDAC6	TT5ZKDI	Strong	Altered Expression	[587]
HDAC7	TTMUEK1	Strong	Biomarker	[588]
HDAC9	TT8M4E1	Strong	Altered Expression	[589]
HDGF	TTKGV26	Strong	Biomarker	[590]
HIPK2	TTOB49C	Strong	Altered Expression	[591]
HK2	TTK02H8	Strong	Altered Expression	[592]
HLA-A	TTHONFT	Strong	Genetic Variation	[456]
HLA-G	TTLKFB3	Strong	Genetic Variation	[593]
HMGA1	TTBA219	Strong	Biomarker	[594]
HMGA2	TTSTVM0	Strong	Altered Expression	[595]
HMGB1	TTWQYB7	Strong	Biomarker	[274]
HNRNPA2B1	TT8UPW6	Strong	Biomarker	[596]
HOXA13	TTN26OM	Strong	Biomarker	[597]
HOXA5	TTXSVQP	Strong	Biomarker	[598]
HPD	TT8DSFC	Strong	Biomarker	[599]
HPGDS	TTCYE56	Strong	Biomarker	[600]
HRH4	TTXJ178	Strong	Genetic Variation	[601]
HSD11B2	TT9H85R	Strong	Biomarker	[602]
HSD17B1	TTIWB6L	Strong	Altered Expression	[603]
HSP90AB1	TTH5YN2	Strong	Biomarker	[604]
HSP90B1	TTFPKXQ	Strong	Biomarker	[604]
HSPA12B	TTAI9ZQ	Strong	Altered Expression	[605]
HSPA5	TTW26OG	Strong	Biomarker	[606]
HSPA9	TTMTPG3	Strong	Altered Expression	[607]
ICOS	TTE5VP6	Strong	Biomarker	[584]
ID1	TTBXVDE	Strong	Biomarker	[608]
IDO1	TTZJYKH	Strong	Altered Expression	[609]
IFNL1	TTM624L	Strong	Genetic Variation	[610]
IGF2	TTE8WGO	Strong	Biomarker	[611]
IGF2R	TTPNE41	Strong	Altered Expression	[612]
IGFBP2	TTU4QSN	Strong	Altered Expression	[613]
IGFBP3	TTZHNQA	Strong	Biomarker	[614]
IGFBP6	TTLAYV8	Strong	Biomarker	[615]
IGFBP7	TTUQ01B	Strong	Biomarker	[616]
IL10	TTT0Q1F	Strong	Biomarker	[617]
IL12A	TTRTK6Y	Strong	Biomarker	[209]
IL17A	TTG0MT6	Strong	Altered Expression	[618]
IL17F	TT2B6PS	Strong	Biomarker	[619]
IL20	TTNZMY2	Strong	Altered Expression	[620]
IL21R	TTZO9B0	Strong	Biomarker	[621]
IL22	TTLDX4N	Strong	Biomarker	[621]
IL24	TT1EPXZ	Strong	Biomarker	[622]
IL25	TTVMO5W	Strong	Biomarker	[619]
IL2RA	TT10Y9E	Strong	Biomarker	[623]
IL31	TT1RJXK	Strong	Genetic Variation	[624]
IL37	TTQTX98	Strong	Altered Expression	[625]
IL7R	TTAWI51	Strong	Altered Expression	[626]
IMP3	TTEJA2R	Strong	Biomarker	[627]
INHBA	TTVB30D	Strong	Biomarker	[628]
INPP5D	TTTP2Z1	Strong	Altered Expression	[629]
INSR	TTCBFJO	Strong	Biomarker	[630]
IRF1	TT4TU3L	Strong	Biomarker	[631]
IRF3	TTYR7OH	Strong	Biomarker	[632]
IRF8	TTHUBNK	Strong	Biomarker	[633]
IRS2	TTF95B8	Strong	Altered Expression	[634]
ISG15	TTVOH3T	Strong	Altered Expression	[635]
ITCH	TT5SEWD	Strong	Biomarker	[636]
ITGA1	TTPERWV	Strong	Altered Expression	[212]
ITGA2	TTSJ542	Strong	Altered Expression	[637]
ITGAV	TTT1R2L	Strong	Biomarker	[211]
ITGB1	TTBVIQC	Strong	Biomarker	[638]
ITPR3	TTH1769	Strong	Biomarker	[639]
JAK1	TT6DM01	Strong	Altered Expression	[640]
KCNK3	TTGR91N	Strong	Biomarker	[641]
KCNN4	TT7M9I6	Strong	Genetic Variation	[642]
KDM1A	TTNR0UQ	Strong	Biomarker	[643]
KDM2A	TT8XTY2	Strong	Biomarker	[644]
KDM4A	TTZHPB8	Strong	Altered Expression	[645]
KDM5A	TTIG67W	Strong	Biomarker	[646]
KEAP1	TT3Z6Y9	Strong	Biomarker	[647]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[648]
KHK	TTPAFR9	Strong	Biomarker	[649]
KIF11	TTBGTCW	Strong	Biomarker	[650]
KIR2DL2	TTU0P73	Strong	Genetic Variation	[651]
KIR2DS1	TTVWAGF	Strong	Genetic Variation	[652]
KIR3DL2	TTQH3N0	Strong	Genetic Variation	[652]
KISS1	TTU2O6T	Strong	Altered Expression	[653]
KISS1R	TT3KBZY	Strong	Altered Expression	[653]
KIT	TTX41N9	Strong	Altered Expression	[654]
KLB	TTARBVH	Strong	Altered Expression	[655]
KLF4	TTTI53X	Strong	Altered Expression	[334]
KLK5	TTULSEW	Strong	Biomarker	[656]
KLK8	TTH5MRS	Strong	Biomarker	[657]
KLRK1	TTLRN4A	Strong	Altered Expression	[658]
KRT17	TTKV0EC	Strong	Altered Expression	[659]
LAMC2	TTNS7H3	Strong	Biomarker	[186]
LANCL1	TTZW8NS	Strong	Biomarker	[660]
LARP1	TTSN1YP	Strong	Altered Expression	[661]
LASP1	TTZJA87	Strong	Biomarker	[662]
LCK	TT860QF	Strong	Altered Expression	[663]
LGALS3	TTFPQV7	Strong	Biomarker	[664]
LGR4	TTY6C71	Strong	Biomarker	[665]
LGR5	TTTSGRH	Strong	Altered Expression	[666]
LILRB1	TTC0QRJ	Strong	Posttranslational Modification	[667]
LIMK1	TTWL9TY	Strong	Biomarker	[668]
LIMK2	TTASMD8	Strong	Biomarker	[669]
LIN28A	TTO50LN	Strong	Biomarker	[670]
LONP1	TTM1VPZ	Strong	Biomarker	[671]
LOX	TTQHNAM	Strong	Biomarker	[672]
LPAR2	TTB7Y8I	Strong	Biomarker	[176]
LPAR3	TTE2YJR	Strong	Biomarker	[575]
LPL	TTOF3WZ	Strong	Altered Expression	[673]
LRP1	TTF2V7I	Strong	Biomarker	[674]
LRP5	TT7VMG4	Strong	Biomarker	[675]
LRP6	TTSXOWE	Strong	Biomarker	[675]
LTBR	TTFO0PM	Strong	Biomarker	[432]
LY6K	TT5GKHN	Strong	Altered Expression	[676]
LYN	TT1RWNJ	Strong	Altered Expression	[663]
LYVE1	TTG8DNU	Strong	Altered Expression	[677]
MAGEA1	TT63M7Q	Strong	Biomarker	[678]
MAGEA10	TT1VNVM	Strong	Altered Expression	[679]
MAGEA3	TTWSKHD	Strong	Altered Expression	[680]
MAGEC2	TTKGUEB	Strong	Altered Expression	[681]
MAOB	TTGP7BY	Strong	Altered Expression	[682]
MAP2K1	TTIDAPM	Strong	Biomarker	[630]
MAP2K2	TT8H9GB	Strong	Biomarker	[683]
MAP3K11	TTETX6Q	Strong	Biomarker	[684]
MAP3K2	TTIX0ZU	Strong	Biomarker	[685]
MAP3K3	TTJZNIG	Strong	Biomarker	[686]
MAP4K1	TTSHWUP	Strong	Biomarker	[687]
MAP4K4	TT6NI13	Strong	Altered Expression	[688]
MAPK7	TTU6FSC	Strong	Biomarker	[689]
MAPK8	TT0K6EO	Strong	Biomarker	[690]
MAPK9	TT3IVG2	Strong	Biomarker	[691]
MAPKAP1	TTWDKCL	Strong	Biomarker	[692]
MAPKAPK2	TTMUG9D	Strong	Biomarker	[693]
MARK2	TTAJ45Y	Strong	Biomarker	[234]
MCAM	TTHRE05	Strong	Biomarker	[694]
MCM6	TTQGKSD	Strong	Altered Expression	[228]
MCOLN1	TT9XBVO	Strong	Biomarker	[695]
MDK	TTV8UE7	Strong	Biomarker	[696]
MDM2	TT9TE0O	Strong	Genetic Variation	[697]
METAP2	TTZL0OI	Strong	Altered Expression	[698]
MIF	TT6804T	Strong	Biomarker	[699]
MKNK2	TTRECN3	Strong	Biomarker	[700]
MLH1	TTISG27	Strong	Posttranslational Modification	[701]
MMP10	TTXLEG7	Strong	Posttranslational Modification	[702]
MMP11	TTZW4MV	Strong	Altered Expression	[703]
MMP15	TTNSTO3	Strong	Biomarker	[704]
MMP16	TTNP4CU	Strong	Altered Expression	[705]
MRGPRX1	TTIX6PK	Strong	Biomarker	[575]
MRM2	TTUQ7WN	Strong	Biomarker	[706]
MSH2	TTCAWRT	Strong	Biomarker	[707]
MSI1	TTSM4BA	Strong	Biomarker	[708]
MSLN	TT4RXME	Strong	Biomarker	[709]
MSR1	TT2TDH9	Strong	Biomarker	[710]
MST1R	TTBQ3OC	Strong	Altered Expression	[711]
MTA1	TTO4HUS	Strong	Biomarker	[712]
MTAP	TTDBX7N	Strong	Biomarker	[713]
MTDH	TTH6SA5	Strong	Altered Expression	[714]
MTOR	TTCJG29	Strong	Altered Expression	[715]
MUC1	TTBHFYQ	Strong	Altered Expression	[471]
MUC16	TTC1PS3	Strong	Biomarker	[716]
MUC5AC	TTEL90S	Strong	Biomarker	[717]
MUTYH	TTNB0ZK	Strong	Genetic Variation	[718]
MYB	TT8V13P	Strong	Biomarker	[719]
MYCBP	TTVW4XU	Strong	Biomarker	[720]
MYLK	TT18ETS	Strong	Biomarker	[721]
NAMPT	TTD1WIG	Strong	Altered Expression	[722]
NCL	TTK1V5Q	Strong	Altered Expression	[723]
NCOA3	TT124R0	Strong	Genetic Variation	[724]
NCOA4	TT8OY02	Strong	Biomarker	[725]
NCR1	TTQNRJM	Strong	Altered Expression	[726]
NEDD4	TT1QU6G	Strong	Altered Expression	[727]
NEDD9	TT1UREA	Strong	Biomarker	[728]
NEK2	TT3VZ24	Strong	Biomarker	[729]
NES	TTHZ752	Strong	Biomarker	[730]
NFKB2	TTKLNRV	Strong	Genetic Variation	[289]
NLRP1	TTQX29T	Strong	Biomarker	[731]
NME1	TTDY8JH	Strong	Biomarker	[732]
NNT	TTKIH76	Strong	Biomarker	[733]
NOTCH4	TTXDIK2	Strong	Altered Expression	[734]
NOX4	TTQRBSJ	Strong	Altered Expression	[735]
NQO1	TT8XK6L	Strong	Biomarker	[736]
NR1H3	TTECBXN	Strong	Biomarker	[737]
NR4A1	TTMXE2Q	Strong	Biomarker	[738]
NR4A3	TTJQB49	Strong	Biomarker	[739]
NRG1	TTEH395	Strong	Biomarker	[740]
NRN1	TTS05MJ	Strong	Altered Expression	[741]
NRP1	TTIPJCB	Strong	Altered Expression	[742]
NT5E	TTK0O6Y	Strong	Biomarker	[743]
NTF3	TTZHKV9	Strong	Genetic Variation	[744]
NTRK1	TTTDVOJ	Strong	Biomarker	[745]
NTSR1	TTTUMEP	Strong	Altered Expression	[746]
NUAK1	TT65FL0	Strong	Biomarker	[747]
NUF2	TTIXBFP	Strong	Biomarker	[748]
OAT	TTTSCQ2	Strong	Biomarker	[749]
ODC1	TTUMGNO	Strong	Biomarker	[750]
OLFM4	TTK1CX7	Strong	Biomarker	[751]
OPRK1	TTQW87Y	Strong	Biomarker	[752]
OPRL1	TTNT7K8	Strong	Altered Expression	[753]
OPRM1	TTKWM86	Strong	Biomarker	[754]
ORAI1	TTE76YK	Strong	Altered Expression	[755]
OSMR	TTAH0KM	Strong	Biomarker	[756]
OXER1	TT7WBSV	Strong	Biomarker	[575]
PADI4	TTQHAXM	Strong	Altered Expression	[757]
PAGE5	TTNWOIT	Strong	Biomarker	[758]
PAK1	TTFN95D	Strong	Biomarker	[759]
PAK2	TT279WO	Strong	Biomarker	[760]
PAOX	TTNQ760	Strong	Genetic Variation	[761]
PARP1	TTVDSZ0	Strong	Biomarker	[762]
PAWR	TT3I4WV	Strong	Biomarker	[763]
PAX5	TTA4REJ	Strong	Biomarker	[764]
PCNA	TTLG1PD	Strong	Altered Expression	[765]
PCSK4	TTK3VYC	Strong	Altered Expression	[766]
PCSK9	TTNIZ2B	Strong	Biomarker	[767]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[768]
PDE10A	TTJW4LU	Strong	Altered Expression	[769]
PDE4D	TTSKMI8	Strong	Altered Expression	[770]
PDE5A	TTJ0IQB	Strong	Biomarker	[771]
PDK1	TTCZOF2	Strong	Biomarker	[772]
PDPK1	TTYMGWX	Strong	Biomarker	[772]
PECAM1	TT4EZB2	Strong	Biomarker	[773]
PFKFB3	TTTHMQJ	Strong	Biomarker	[774]
PGR	TTUV8G9	Strong	Biomarker	[775]
PHF8	TT81PFE	Strong	Altered Expression	[776]
PHGDH	TT8DRCK	Strong	Altered Expression	[777]
PIM1	TTTN5QW	Strong	Biomarker	[778]
PIN1	TTJNTSI	Strong	Altered Expression	[779]
PINX1	TT4FJ3A	Strong	Altered Expression	[780]
PKM	TT4LOT8	Strong	Altered Expression	[781]
PLA2G4A	TTT1JVS	Strong	Altered Expression	[782]
PLAC1	TTM18HX	Strong	Biomarker	[783]
PLOD2	TT8MEUD	Strong	Biomarker	[784]
PML	TTLH9NY	Strong	Biomarker	[785]
POSTN	TT8ALTZ	Strong	Biomarker	[786]
PPIA	TTL2ADK	Strong	Biomarker	[787]
PPIB	TT6ZFQ4	Strong	Biomarker	[788]
PPM1D	TTENJAB	Strong	Biomarker	[789]
PPP5C	TTTW7FJ	Strong	Biomarker	[790]
PPT1	TTSQC14	Strong	Biomarker	[790]
PRAME	TTPH7T0	Strong	Altered Expression	[791]
PRKCA	TTFJ8Q1	Strong	Biomarker	[792]
PRKCB	TTYPXQF	Strong	Altered Expression	[793]
PRKCD	TT7A1BO	Strong	Biomarker	[794]
PRKCI	TTWJTHX	Strong	Altered Expression	[793]
PRKD1	TTSLUMT	Strong	Altered Expression	[795]
PRKDC	TTK3PY9	Strong	Altered Expression	[796]
PRMT7	TTAR2P0	Strong	Biomarker	[797]
PROM1	TTXMZ81	Strong	Altered Expression	[798]
PRSS8	TTT4N0Q	Strong	Biomarker	[799]
PRTN3	TT5MLC4	Strong	Biomarker	[800]
PSCA	TT9T4AV	Strong	Biomarker	[801]
PSMD10	TT2H4LN	Strong	Altered Expression	[802]
PTAFR	TTQL5VC	Strong	Altered Expression	[803]
PTBP1	TTWMX0U	Strong	Altered Expression	[804]
PTEN	TTXJ3W7	Strong	Biomarker	[805]
PTGDR	TTNVEIR	Strong	Biomarker	[806]
PTGER4	TT79WV3	Strong	Altered Expression	[807]
PTGES	TTYLQ8V	Strong	Altered Expression	[808]
PTGIS	TTLXKZR	Strong	Biomarker	[809]
PTK2	TTON5IT	Strong	Posttranslational Modification	[810]
PTK7	TTXH2ZN	Strong	Altered Expression	[811]
PTN	TTA9EJK	Strong	Altered Expression	[812]
QPCT	TTJ7YTV	Strong	Biomarker	[813]
RAB22A	TTAJ746	Strong	Altered Expression	[814]
RABL3	TTYGK57	Strong	Altered Expression	[815]
RAC1	TT2M9CG	Strong	Biomarker	[792]
RAF1	TTAN5W2	Strong	Altered Expression	[816]
RALBP1	TTVSRUA	Strong	Altered Expression	[817]
RARA	TTW38KT	Strong	Altered Expression	[818]
RARB	TTISP28	Strong	Genetic Variation	[819]
RBPJ	TT72D4Z	Strong	Biomarker	[820]
RECK	TTRZBW7	Strong	Biomarker	[821]
RET	TT4DXQT	Strong	Genetic Variation	[822]
RGS4	TTGTKX9	Strong	Altered Expression	[823]
RGS6	TTJ96M8	Strong	Biomarker	[824]
RHOB	TT6LPFO	Strong	Altered Expression	[825]
RICTOR	TT143WL	Strong	Genetic Variation	[826]
ROBO4	TT3S9TY	Strong	Genetic Variation	[827]
ROCK1	TTZN7RP	Strong	Biomarker	[828]
ROCK2	TTGWKQJ	Strong	Altered Expression	[829]
ROR1	TTDEJAU	Strong	Biomarker	[830]
ROR2	TTUDPCI	Strong	Biomarker	[831]
RORA	TT1TYN7	Strong	Genetic Variation	[832]
RORB	TTGB2LZ	Strong	Genetic Variation	[832]
RORC	TTGV6LY	Strong	Biomarker	[833]
RPE65	TTBOH16	Strong	Biomarker	[834]
RPS6KA1	TTIXKA4	Strong	Biomarker	[835]
RPS6KB2	TTMVQXO	Strong	Biomarker	[836]
RPSA	TTLUW5B	Strong	Biomarker	[660]
RRM2	TT1S4LJ	Strong	Altered Expression	[837]
RTN4	TT7GXMU	Strong	Genetic Variation	[838]
RTN4R	TTVRZUO	Strong	Biomarker	[839]
RUNX2	TTD6SZ8	Strong	Altered Expression	[840]
RUNX3	TTKCVO7	Strong	Biomarker	[841]
RXRG	TTH029C	Strong	Genetic Variation	[842]
S100A4	TTPR5SX	Strong	Altered Expression	[843]
S100A8	TT4AF6N	Strong	Altered Expression	[844]
S100B	TTQ0V86	Strong	Biomarker	[845]
SAA1	TTY0DN9	Strong	Biomarker	[846]
SATB1	TTLFRIC	Strong	Altered Expression	[847]
SCUBE2	TTWREQP	Strong	Altered Expression	[848]
SELE	TT1PL7M	Strong	Biomarker	[849]
SEMA3A	TTVKD3S	Strong	Altered Expression	[850]
SEMA4D	TT5UT28	Strong	Biomarker	[851]
SENP1	TTW9HY5	Strong	Altered Expression	[852]
SERPINB5	TT1KW50	Strong	Biomarker	[853]
SETD7	TTJ0FSU	Strong	Altered Expression	[854]
SHCBP1	TTZ9WGL	Strong	Altered Expression	[855]
SIK1	TT1H6LC	Strong	Biomarker	[856]
SIK3	TTW6L4V	Strong	Biomarker	[856]
SIRT1	TTUF2HO	Strong	Altered Expression	[857]
SIRT3	TTVZLIJ	Strong	Altered Expression	[858]
SIRT5	TTH0IOD	Strong	Altered Expression	[859]
SIRT6	TTUXYWF	Strong	Biomarker	[860]
SKP2	TT5B2EO	Strong	Altered Expression	[861]
SLAMF7	TT7ILZ1	Strong	Biomarker	[862]
SLC10A2	TTPI1M5	Strong	Altered Expression	[863]
SLC11A2	TT2IS7P	Strong	Biomarker	[864]
SLC12A3	TTP362L	Strong	Biomarker	[357]
SLC15A1	TT5LF3C	Strong	Altered Expression	[865]
SLC16A3	TTG6VD5	Strong	Altered Expression	[866]
SLC17A5	TTFSUIA	Strong	Genetic Variation	[867]
SLC19A1	TT09I7D	Strong	Genetic Variation	[868]
SLC1A2	TT2F078	Strong	Altered Expression	[869]
SLC1A5	TTF7WRM	Strong	Biomarker	[870]
SLC22A16	TTITAVR	Strong	Biomarker	[871]
SLC25A1	TTTD730	Strong	Biomarker	[872]
SLC29A1	TTLXAKE	Strong	Genetic Variation	[873]
SLC34A2	TTQPZTM	Strong	Biomarker	[874]
SLC38A3	TTMAVJQ	Strong	Altered Expression	[875]
SLC39A6	TTZN1CF	Strong	Altered Expression	[876]
SLC44A4	TT0NYDG	Strong	Biomarker	[877]
SLC46A1	TTY8Z2E	Strong	Biomarker	[878]
SLC52A2	TT6TKEN	Strong	Biomarker	[234]
SLC5A1	TT2UE56	Strong	Altered Expression	[879]
SLC5A2	TTF8JAT	Strong	Altered Expression	[879]
SLC5A5	TTW7HI9	Strong	Altered Expression	[880]
SLC6A5	TTI0138	Strong	Biomarker	[881]
SLC6A8	TTYUHB5	Strong	Genetic Variation	[401]
SLC7A11	TTBZMIO	Strong	Biomarker	[882]
SLC7A5	TTPH2JB	Strong	Biomarker	[870]
SLCO1B3	TTU86P0	Strong	Genetic Variation	[883]
SLIT2	TTDWK85	Strong	Altered Expression	[884]
SMAD6	TTON5JB	Strong	Genetic Variation	[885]
SMAD7	TT0J32Z	Strong	Altered Expression	[886]
SMARCA4	TTVQEZS	Strong	Biomarker	[887]
SMPD1	TTJTM88	Strong	Biomarker	[888]
SMYD2	TT7YJFO	Strong	Biomarker	[889]
SOCS3	TTI0ME6	Strong	Biomarker	[890]
SOD2	TT9O4C5	Strong	Biomarker	[409]
SOX2	TTCNOT6	Strong	Biomarker	[891]
SOX5	TTXHSZK	Strong	Altered Expression	[892]
SP1	TTZEP6S	Strong	Altered Expression	[893]
SPAG6	TTDAKTW	Strong	Altered Expression	[894]
SPARC	TTBQFM7	Strong	Altered Expression	[895]
SPHK1	TTOHFIY	Strong	Altered Expression	[896]
SPHK2	TTCN0M9	Strong	Altered Expression	[897]
SPN	TTOZAX0	Strong	Altered Expression	[898]
SPOCK1	TTF23RE	Strong	Biomarker	[703]
SQSTM1	TTOT2RY	Strong	Altered Expression	[648]
SRC	TT6PKBN	Strong	Biomarker	[899]
SREBF2	TTRQ4AP	Strong	Altered Expression	[900]
SRGN	TTCHB06	Strong	Altered Expression	[901]
SRPK1	TTU3WV6	Strong	Altered Expression	[902]
SRPK2	TTCZEJ9	Strong	Biomarker	[903]
SSRP1	TTETDKQ	Strong	Biomarker	[904]
SSTR2	TTZ6T9E	Strong	Altered Expression	[905]
SSTR4	TTAE1BR	Strong	Biomarker	[176]
STAT1	TTN7R6K	Strong	Biomarker	[617]
STAT3	TTHJT3X	Strong	Biomarker	[906]
STAT6	TTWOE1T	Strong	Biomarker	[907]
STC1	TTDLUER	Strong	Altered Expression	[908]
STK33	TTP34DQ	Strong	Biomarker	[909]
STK39	TTYQTIU	Strong	Biomarker	[910]
STOML2	TTOI329	Strong	Biomarker	[911]
SYVN1	TT8XKYM	Strong	Biomarker	[912]
TARDBP	TT9RZ03	Strong	Biomarker	[913]
TBL1XR1	TTYXT16	Strong	Biomarker	[914]
TBX21	TTNF9PH	Strong	Altered Expression	[915]
TDP2	TTYF26D	Strong	Biomarker	[916]
TEK	TT9VGXW	Strong	Biomarker	[917]
TERF2	TT5XSLT	Strong	Biomarker	[918]
TFPI	TT068JH	Strong	Biomarker	[919]
TGFB3	TTWOMY8	Strong	Biomarker	[920]
TGFBR1	TTP4520	Strong	Biomarker	[921]
THBD	TTAPV67	Strong	Biomarker	[922]
THBS1	TTKI0H1	Strong	Altered Expression	[923]
TIAM1	TTNU6I5	Strong	Biomarker	[924]
TIE1	TTT4236	Strong	Biomarker	[738]
TK1	TTP3QRF	Strong	Altered Expression	[925]
TLR1	TTW14D0	Strong	Biomarker	[926]
TLR5	TTCXP8J	Strong	Biomarker	[927]
TMPRSS11D	TTWHYC8	Strong	Biomarker	[928]
TMSB4X	TTMVAIU	Strong	Biomarker	[929]
TNFRSF11A	TT3K9S2	Strong	Biomarker	[432]
TNFRSF12A	TTKPS7V	Strong	Biomarker	[930]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[432]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[931]
TNFRSF4	TTL31H0	Strong	Biomarker	[932]
TNFSF10	TTA5MS9	Strong	Biomarker	[933]
TNFSF11	TT9E8HR	Strong	Biomarker	[934]
TNFSF12	TTBTDM1	Strong	Biomarker	[935]
TNFSF13	TTOI1RM	Strong	Altered Expression	[931]
TNFSF14	TTKVENM	Strong	Altered Expression	[936]
TNFSF4	TTBW580	Strong	Biomarker	[932]
TNK2	TTIET93	Strong	Biomarker	[937]
TNKS2	TTFQI4H	Strong	Genetic Variation	[938]
TOP1	TTGTQHC	Strong	Biomarker	[939]
TOP2A	TTCGY2K	Strong	Genetic Variation	[940]
TOP2B	TT4NVEM	Strong	Altered Expression	[941]
TP53BP1	TTX4UE9	Strong	Biomarker	[201]
TPO	TT52XDZ	Strong	Biomarker	[880]
TPX2	TT0PHL4	Strong	Biomarker	[942]
TRAF6	TTCDR6M	Strong	Biomarker	[943]
TREM1	TTHZQP0	Strong	Biomarker	[944]
TRIM24	TT9Q7AE	Strong	Biomarker	[945]
TRIM27	TTTO3QN	Strong	Biomarker	[382]
TRIM28	TTQ2BKV	Strong	Biomarker	[946]
TRIM37	TTAMCSL	Strong	Biomarker	[947]
TRIP10	TTKHTGE	Strong	Altered Expression	[948]
TRPV3	TT946IA	Strong	Biomarker	[949]
TRPV6	TTBK14N	Strong	Altered Expression	[950]
TSPAN7	TTMT6VE	Strong	Biomarker	[951]
TUSC2	TTJ8O14	Strong	Altered Expression	[952]
TWIST1	TTX1MY7	Strong	Biomarker	[953]
TXNRD1	TTR7UJ3	Strong	Altered Expression	[954]
TYMP	TTO0IB8	Strong	Altered Expression	[955]
UBC	TTBP3XA	Strong	Biomarker	[956]
UBE3A	TTUZX6V	Strong	Biomarker	[957]
UCHL1	TTX9IFP	Strong	Altered Expression	[958]
UCHL5	TTSX29Z	Strong	Biomarker	[959]
UCP1	TTI12YJ	Strong	Altered Expression	[960]
UCP3	TT12RJK	Strong	Altered Expression	[960]
UGCG	TTPHEX3	Strong	Altered Expression	[961]
UGT1A1	TT34ZAF	Strong	Biomarker	[962]
UMPS	TTAFJUD	Strong	Biomarker	[963]
USP1	TTG9MT5	Strong	Biomarker	[964]
USP10	TT5IH09	Strong	Altered Expression	[707]
USP13	TTVJIO2	Strong	Biomarker	[965]
USP44	TTJLTNM	Strong	Biomarker	[966]
USP5	TTGYTMA	Strong	Altered Expression	[967]
USP7	TTXU3EQ	Strong	Altered Expression	[968]
USP8	TT1J07C	Strong	Altered Expression	[969]
UTS2R	TTW5UDX	Strong	Biomarker	[724]
VDR	TTK59TV	Strong	Biomarker	[970]
VEGFB	TTPJQHE	Strong	Altered Expression	[971]
VEGFD	TTOM5H4	Strong	Biomarker	[972]
VIP	TTGTWLF	Strong	Biomarker	[973]
VSIR	TT51SK8	Strong	Altered Expression	[974]
WEE1	TTJFOAL	Strong	Biomarker	[391]
WNK1	TTJ9UMX	Strong	Altered Expression	[975]
WNT5A	TTKG7F8	Strong	Biomarker	[976]
WNT7A	TT8NARC	Strong	Posttranslational Modification	[977]
XPA	TTGT87E	Strong	Genetic Variation	[978]
XRCC5	TTCB9KW	Strong	Altered Expression	[979]
YAP1	TT8UN2D	Strong	Altered Expression	[980]
YES1	TT0SQ8J	Strong	Altered Expression	[981]
YOD1	TTFSH0K	Strong	Altered Expression	[982]
ZEB2	TTT2WK4	Strong	Altered Expression	[983]
AMACR	TTLN1AP	Definitive	Biomarker	[984]
CD33	TTJVYO3	Definitive	Biomarker	[558]
CLDN18	TT6PKBX	Definitive	Altered Expression	[985]
CLDN6	TTKSV48	Definitive	Altered Expression	[985]
CSNK2A2	TT7GR5W	Definitive	Altered Expression	[986]
CUL7	TTI8R0P	Definitive	Altered Expression	[987]
CXCR5	TTIW59R	Definitive	Altered Expression	[988]
CYP3A5	TTHS0OK	Definitive	Genetic Variation	[989]
DRD4	TTE0A2F	Definitive	Genetic Variation	[990]
EGFR	TTZ04AF	Definitive	Autosomal dominant	[991]
EREG	TTYSB89	Definitive	Biomarker	[992]
GART	TTEXB9Z	Definitive	Altered Expression	[993]
GFRA3	TT63XRS	Definitive	Altered Expression	[994]
KIR2DL1	TT4UXPE	Definitive	Biomarker	[995]
LAMP1	TTC214J	Definitive	Biomarker	[996]
LTF	TTSZDQU	Definitive	Altered Expression	[997]
MYCN	TT9JBY5	Definitive	Biomarker	[998]
NTRK3	TTXABCW	Definitive	Genetic Variation	[999]
PKMYT1	TTB4PAZ	Definitive	Altered Expression	[1000]
S100A6	TT716MY	Definitive	Biomarker	[1001]
SLC22A1	TTM5Q4V	Definitive	Altered Expression	[1002]
SLC38A7	TTEARWC	Definitive	Biomarker	[1003]
SLCO1B1	TTFGXEB	Definitive	Genetic Variation	[1004]
STS	TTHM0R1	Definitive	Biomarker	[1005]
TDP1	TT64IHJ	Definitive	Altered Expression	[1006]
TF	TT8WXAV	Definitive	Altered Expression	[1007]
TNFRSF18	TTG6LA7	Definitive	Altered Expression	[1008]
TNNI3	TTNLDK6	Definitive	Biomarker	[1009]

This Disease Is Related to 21 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC10	DTPS120	Limited	Biomarker	[1010]
ATP7A	DT0LT17	Limited	Genetic Variation	[1011]
SLC26A2	DTFSLX5	Limited	Biomarker	[1012]
SLC28A1	DT0EQPW	Limited	Genetic Variation	[1013]
SLC4A7	DT03V27	Limited	Biomarker	[1014]
ABCA3	DT2T6VQ	Strong	Altered Expression	[1015]
ABCB9	DT68UV2	Strong	Biomarker	[1016]
ABCC11	DTWN7FC	Strong	Biomarker	[1017]
ABCC5	DTYVM24	Strong	Altered Expression	[1018]
SLC11A1	DT650XW	Strong	Biomarker	[1019]
SLC12A2	DTHKL3Q	Strong	Altered Expression	[1020]
SLC14A2	DT8QC7K	Strong	Biomarker	[724]
SLC16A7	DTLT3UG	Strong	Genetic Variation	[1021]
SLC25A11	DT0YAUQ	Strong	Biomarker	[1022]
SLC25A16	DTNU9EW	Strong	Biomarker	[1023]
SLC25A5	DTL1TRY	Strong	Biomarker	[1024]
SLC29A3	DTZAWTH	Strong	Biomarker	[1025]
SLC2A3	DT9SQ3L	Strong	Genetic Variation	[1026]
SLC2A5	DTOR02F	Strong	Biomarker	[1027]
SLC31A1	DTP8L4F	Strong	Biomarker	[864]
SLC39A4	DTEZCUM	Strong	Biomarker	[1028]

This Disease Is Related to 57 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ALDH1A1	DE2JP1Y	Limited	Altered Expression	[1029]
BAAT	DERA3OF	Limited	Genetic Variation	[1030]
CHKB	DEHWR6V	Limited	Biomarker	[1031]
CYP2A13	DEXZA9U	Limited	Biomarker	[1032]
GPT	DER5HFI	Limited	Genetic Variation	[1033]
HK1	DEDMAGE	Limited	Biomarker	[1034]
HPRT1	DEVXTP5	Limited	Altered Expression	[1035]
NAT2	DER7TA0	Limited	Genetic Variation	[1036]
SAT1	DEMWO83	Limited	Biomarker	[1037]
LDHC	DEQG7F9	Disputed	Altered Expression	[1038]
MT1A	DE5ME8A	Disputed	Altered Expression	[279]
ACSS2	DEE76VW	Strong	Biomarker	[649]
AKR1B10	DEP6GT1	Strong	Biomarker	[1039]
AKR1C1	DE7P2FB	Strong	Biomarker	[1040]
AKR1C2	DEOY5ZM	Strong	Altered Expression	[1041]
ALDH1A2	DEKN1H4	Strong	Altered Expression	[1042]
ALDH1B1	DEXI4UQ	Strong	Altered Expression	[1042]
APRT	DE2MV1R	Strong	Altered Expression	[1043]
ASNS	DEXISVQ	Strong	Biomarker	[1044]
CMPK1	DEMPH4I	Strong	Genetic Variation	[1045]
CPA4	DEXKD7J	Strong	Altered Expression	[1046]
CRMP1	DE0EUXB	Strong	Altered Expression	[1047]
CYP1A1	DE6OQ3W	Strong	Genetic Variation	[1048]
CYP27A1	DEBS639	Strong	Altered Expression	[1049]
CYP27B1	DE3FYEM	Strong	Genetic Variation	[1050]
CYP2C8	DES5XRU	Strong	Altered Expression	[1051]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[1052]
EGLN3	DEMQTKH	Strong	Altered Expression	[1053]
EPHX1	DELB4KP	Strong	Biomarker	[1054]
FAAH	DEUM1EX	Strong	Altered Expression	[1055]
GCLC	DESYL1F	Strong	Altered Expression	[1056]
GFPT2	DERQCJM	Strong	Altered Expression	[1057]
GLDC	DEIN8FB	Strong	Altered Expression	[1058]
GLS	DE3E0VT	Strong	Biomarker	[1059]
HAGH	DE05IKP	Strong	Biomarker	[1060]
HINT1	DEWJATF	Strong	Altered Expression	[1061]
INPP4A	DEBJ2NL	Strong	Biomarker	[1062]
LARS2	DEP7BTH	Strong	Biomarker	[1063]
MARS1	DE0K52I	Strong	Biomarker	[1064]
ME1	DE97WM8	Strong	Biomarker	[1065]
MSRA	DEU2ZBY	Strong	Biomarker	[1066]
MTRR	DE6NIY9	Strong	Genetic Variation	[1067]
NAT1	DE7OAB3	Strong	Genetic Variation	[1068]
NT5C2	DE1DOKJ	Strong	Biomarker	[1069]
OPLAH	DEJ1LMB	Strong	Biomarker	[1070]
PAPSS1	DEDG68B	Strong	Biomarker	[1071]
PARK7	DEPOVCH	Strong	Altered Expression	[1072]
PSAT1	DEBS17P	Strong	Biomarker	[1073]
PTGR1	DE4Q2OE	Strong	Altered Expression	[1074]
TGM5	DEW8QEH	Strong	Genetic Variation	[1075]
THOP1	DE95LJC	Strong	Altered Expression	[1076]
UGP2	DE4U39Y	Strong	Altered Expression	[1077]
CYP4F3	DEFCMPI	Definitive	Genetic Variation	[1078]
HPGD	DEHKSC6	Definitive	Altered Expression	[1079]
PER1	DE9HF0I	Definitive	Altered Expression	[1080]
UGT1A7	DEZO4N3	Definitive	Genetic Variation	[1081]
UGT1A9	DE85D2P	Definitive	Genetic Variation	[1081]

This Disease Is Related to 1642 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACACA	OT5CQPZY	Limited	Biomarker	[1082]
ACTN4	OTCNZAJ5	Limited	Biomarker	[1083]
ACY1	OT9WU7X3	Limited	Altered Expression	[1084]
ADAMTS8	OT2KFY1S	Limited	Altered Expression	[1085]
ALDH3A1	OTAYZZE6	Limited	Altered Expression	[1086]
ALKBH3	OTS1CD9Z	Limited	Biomarker	[1087]
AMFR	OTQRX7LC	Limited	Altered Expression	[1088]
APAF1	OTJWIVY0	Limited	Biomarker	[1089]
ARHGEF2	OTBQTFRT	Limited	Biomarker	[660]
ARSF	OTC0L12N	Limited	Biomarker	[205]
ASCC1	OTH4VAP9	Limited	Altered Expression	[1090]
ASCL1	OTI4X44G	Limited	Altered Expression	[1091]
ATG3	OT28VBVK	Limited	Altered Expression	[1092]
BPIFA1	OTQFD2J5	Limited	Altered Expression	[1093]
BTG2	OTZF6K1H	Limited	Biomarker	[1094]
BTG3	OT9ANHVT	Limited	Biomarker	[1095]
CA11	OT8RX3AJ	Limited	Altered Expression	[1096]
CA8	OT9Y8GA8	Limited	Altered Expression	[1096]
CABLES1	OTMN4XSX	Limited	Altered Expression	[1097]
CAMK1	OTRN55RE	Limited	Biomarker	[1098]
CAP1	OTYM8A2N	Limited	Altered Expression	[1099]
CARD18	OTBMLB80	Limited	Biomarker	[1100]
CCNH	OTKDU3SR	Limited	Biomarker	[201]
CD151	OTF3UZS7	Limited	Altered Expression	[1101]
CDK14	OT385ZH1	Limited	Altered Expression	[1102]
CHD1L	OT7CZK7C	Limited	Biomarker	[1103]
CKS1B	OTNUPLUJ	Limited	Altered Expression	[1104]
CLPTM1	OT14QP7N	Limited	Genetic Variation	[1105]
COTL1	OT6YCNLF	Limited	Altered Expression	[1106]
COX5A	OTP0961M	Limited	Biomarker	[1107]
CPEB4	OTW1SCZW	Limited	Biomarker	[1108]
CPNE3	OTCR3WG2	Limited	Biomarker	[249]
CPOX	OTIAY121	Limited	Biomarker	[1107]
CRISP2	OT8HLTV5	Limited	Altered Expression	[1109]
CST6	OTZVHJTF	Limited	Biomarker	[236]
CUX1	OTU1LCNJ	Limited	Genetic Variation	[1110]
CXADR	OT9ZP02A	Limited	Biomarker	[709]
CXCL16	OTD49T9R	Limited	Biomarker	[1111]
CYLD	OT37FKH0	Limited	Biomarker	[236]
DDIAS	OTTGG2PM	Limited	Biomarker	[1112]
DECR1	OTCDIR6X	Limited	Biomarker	[1113]
DEUP1	OTXLM86J	Limited	Biomarker	[201]
DHDH	OTKA2AL6	Limited	Altered Expression	[1114]
DMBT1	OTVNU9D9	Limited	Altered Expression	[1115]
DNAJB4	OTUD01BK	Limited	Altered Expression	[1116]
DTD1	OT63V2KK	Limited	Biomarker	[1012]
DVL1	OTD67RF1	Limited	Altered Expression	[1117]
E2F5	OT1XWING	Limited	Biomarker	[1118]
ECT2	OTQDUCT6	Limited	Biomarker	[1119]
EFNA3	OTJGOUMZ	Limited	Biomarker	[1120]
EIF3A	OTFABY9G	Limited	Biomarker	[1121]
EIF3E	OTI0WG98	Limited	Altered Expression	[1122]
EIF4A1	OTMTBX6N	Limited	Genetic Variation	[1123]
EIF4A2	OT08H03R	Limited	Biomarker	[1124]
EIF4G1	OT2CF1E6	Limited	Biomarker	[1124]
ELF3	OTUTLEQO	Limited	Altered Expression	[1125]
EPB41L3	OTS6CHG2	Limited	Biomarker	[1126]
EXTL3	OT2BRUBN	Limited	Biomarker	[1127]
FAM83A	OTBI16V7	Limited	Biomarker	[1128]
FBXW11	OT2A6RLR	Limited	Genetic Variation	[1129]
FEZF2	OTU4TXIW	Limited	Biomarker	[1130]
FOXA1	OTEBY0TD	Limited	Biomarker	[1131]
FZD4	OTGLZIE0	Limited	Biomarker	[1132]
GADD45A	OTDRV63V	Limited	Genetic Variation	[1133]
GATA6	OTO2BC0F	Limited	Altered Expression	[1134]
GOLM1	OTOZSV6O	Limited	Altered Expression	[1135]
GPRC5A	OTPOCWR7	Limited	Biomarker	[1136]
HELLS	OTVVV668	Limited	Biomarker	[1019]
HES1	OT8P19W2	Limited	Biomarker	[1137]
HHLA2	OTYBTVQS	Limited	Biomarker	[1138]
HIP1	OT7AKCFQ	Limited	Altered Expression	[1139]
HMMR	OT4M0JTZ	Limited	Biomarker	[1140]
HOPX	OTBSR6C9	Limited	Biomarker	[1141]
HOXA1	OTMSOJ7D	Limited	Altered Expression	[1142]
HOXB5	OTU74TB8	Limited	Biomarker	[1143]
HOXB7	OTC7WYU8	Limited	Biomarker	[1144]
HYAL1	OT2SJN0X	Limited	Altered Expression	[1145]
IFNA17	OTHXRYG3	Limited	Genetic Variation	[1146]
IGFBP4	OT2HZRBD	Limited	Biomarker	[1147]
IKBKE	OT5VYOSM	Limited	Altered Expression	[1148]
IL6ST	OT1N9C70	Limited	Altered Expression	[1149]
ING1	OTEZBRKW	Limited	Biomarker	[1150]
ING2	OT6H0EWF	Limited	Biomarker	[1151]
ING4	OT0VVG4V	Limited	Biomarker	[1152]
INTS6	OT6GDV46	Limited	Biomarker	[1153]
KLK10	OTD573EL	Limited	Biomarker	[1154]
KLK11	OT5PKX7Y	Limited	Biomarker	[1155]
KRT14	OTUVZ1DW	Limited	Biomarker	[1156]
KRT18	OTVLQFIP	Limited	Biomarker	[1157]
KRT5	OTVGI9HT	Limited	Genetic Variation	[1158]
LATS1	OTOOCG4R	Limited	Altered Expression	[1159]
LDHB	OT9B1CT3	Limited	Biomarker	[1160]
LRPPRC	OTXSK5LP	Limited	Altered Expression	[1149]
LRRC59	OT6BQJ5E	Limited	Biomarker	[201]
MACIR	OTPSW8Y8	Limited	Biomarker	[201]
MAGED4B	OTO37U7W	Limited	Biomarker	[1161]
MAP2K4	OTZPZX11	Limited	Biomarker	[1162]
MB	OTYWYL2D	Limited	Biomarker	[1163]
MBD3	OTRL76H5	Limited	Altered Expression	[1164]
MBD4	OTWR9YXE	Limited	Biomarker	[1164]
MCAT	OTH07FIW	Limited	Altered Expression	[185]
MCC	OTQVI1EM	Limited	Biomarker	[1165]
MCRS1	OT8K2X8P	Limited	Altered Expression	[1166]
MCTS1	OT7SAOJP	Limited	Altered Expression	[185]
MEST	OT8Q4U8Y	Limited	Biomarker	[1167]
MPG	OTAHW80B	Limited	Biomarker	[1168]
MPST	OTCDPH5D	Limited	Biomarker	[226]
MSTO1	OT37XCNP	Limited	Biomarker	[226]
MXI1	OTUQ9E0D	Limited	Biomarker	[1169]
NAE1	OTMC6F3Y	Limited	Biomarker	[1170]
NANOG	OTUEY1FM	Limited	Altered Expression	[1171]
NDRG1	OTVO66BO	Limited	Biomarker	[1172]
NGB	OTW0SIUY	Limited	Posttranslational Modification	[1163]
NLK	OT2LETFS	Limited	Altered Expression	[1173]
NLRP2	OTJA81JU	Limited	Genetic Variation	[1174]
NMBR	OTBJEGPN	Limited	Altered Expression	[1175]
NME2	OTCYGLHV	Limited	Altered Expression	[1176]
OCA2	OTDWIGBF	Limited	Biomarker	[1177]
OPN1LW	OTFNUZ7O	Limited	Altered Expression	[1178]
PAG1	OTFOJUIQ	Limited	Altered Expression	[1178]
PAGR1	OTXR5PQ8	Limited	Altered Expression	[199]
PCLAF	OTMVIOUU	Limited	Altered Expression	[1179]
PEA15	OTKCKTSX	Limited	Altered Expression	[1177]
PHLPP2	OTXB1OUI	Limited	Biomarker	[1180]
PIAS3	OT3TWH9R	Limited	Altered Expression	[1181]
PIK3R1	OT5BZ1J9	Limited	Biomarker	[1182]
PINK1	OT50NR57	Limited	Biomarker	[1183]
PPIP5K1	OT06HYH8	Limited	Biomarker	[1184]
PRDX6	OTS8KC8A	Limited	Biomarker	[1185]
PRPF31	OTSJ0Z1Y	Limited	Biomarker	[1186]
PRSS50	OTC5JAVO	Limited	Altered Expression	[1187]
PRSS55	OTXXWI5Y	Limited	Altered Expression	[1109]
PSMD4	OTH1VZTM	Limited	Biomarker	[205]
PTPRA	OTZA82J1	Limited	Altered Expression	[1188]
RAB5A	OTFR2KM4	Limited	Altered Expression	[1189]
RABGEF1	OTWC3Z3R	Limited	Biomarker	[1190]
RAD17	OT1I93DT	Limited	Altered Expression	[1191]
RALA	OT734R7X	Limited	Biomarker	[1192]
RASGRF1	OTNWJ7EN	Limited	Biomarker	[1193]
RPL14	OTZZW7TK	Limited	Genetic Variation	[1194]
RPL22	OTVCN8K0	Limited	Biomarker	[195]
S100A2	OTTGHJ1H	Limited	Biomarker	[1195]
SBNO1	OTNX3RL0	Limited	Biomarker	[1196]
SBNO2	OT1C6J3K	Limited	Biomarker	[1196]
SCGB3A1	OTIR98RB	Limited	Altered Expression	[1197]
SCYL1	OTQ0IN7P	Limited	Biomarker	[1198]
SEC14L2	OTJST64D	Limited	Biomarker	[1199]
SEMA4B	OT1Y3YZD	Limited	Biomarker	[1200]
SERINC1	OTF3UASX	Limited	Altered Expression	[1201]
SERINC2	OTZ039U0	Limited	Altered Expression	[1201]
SET	OTGYYQJO	Limited	Altered Expression	[1202]
SFTPC	OTIZJD09	Limited	Altered Expression	[1203]
SHMT2	OT5NCAZN	Limited	Biomarker	[1204]
SIVA1	OTDT0XZK	Limited	Biomarker	[1205]
SKIL	OTNBXH32	Limited	Biomarker	[1196]
SLC22A10	OTUVJI3H	Limited	Biomarker	[201]
SMS	OT8JYKNH	Limited	Biomarker	[1206]
SNAI2	OT7Y8EJ2	Limited	Altered Expression	[1207]
SOS1	OTTCWXC3	Limited	Altered Expression	[1208]
SOX7	OTOZOFAG	Limited	Altered Expression	[1209]
SPZ1	OTQH8HJ5	Limited	Altered Expression	[1109]
STMN3	OT20F289	Limited	Altered Expression	[1210]
SUB1	OTK71JYU	Limited	Biomarker	[1211]
TBX1	OTQLBPRA	Limited	Altered Expression	[1212]
TBX5	OT70PISV	Limited	Genetic Variation	[1129]
TCF19	OT7NKLF9	Limited	Biomarker	[1213]
TCHP	OTVDMHSY	Limited	Altered Expression	[358]
TERF2IP	OT3M5P3G	Limited	Biomarker	[1190]
TFAP2C	OTUDIW05	Limited	Biomarker	[560]
TIA1	OTGPN3P8	Limited	Biomarker	[1214]
TMEM100	OTRJ6OHY	Limited	Biomarker	[1215]
TMEM135	OT63ZT3X	Limited	Biomarker	[201]
TMPRSS13	OTMAOAP3	Limited	Biomarker	[229]
TMSB10	OTLVZ13T	Limited	Genetic Variation	[1216]
TNFAIP8	OT1G9297	Limited	Altered Expression	[1217]
TOPORS	OT1ERFFQ	Limited	Biomarker	[1218]
TREH	OTJE0NOY	Limited	Altered Expression	[199]
TRIM13	OTQIUACB	Limited	Biomarker	[709]
TRIM29	OT2DNESG	Limited	Altered Expression	[1219]
TRIM66	OT0VJCP6	Limited	Altered Expression	[1220]
TRMT11	OTRK0IOR	Limited	Biomarker	[201]
AKIP1	OT7XPG27	Disputed	Altered Expression	[1221]
ALG1	OTVXPA9E	Disputed	Altered Expression	[279]
ANLN	OTXJY54C	Disputed	Biomarker	[1222]
BIN1	OTK8O0X8	Disputed	Altered Expression	[1223]
BRINP1	OTEUVSCP	Disputed	Biomarker	[1224]
CCNY	OTK1KG5W	Disputed	Biomarker	[1225]
CDK16	OTUBXIIT	Disputed	Genetic Variation	[280]
CISD3	OT0MM1MW	Disputed	Genetic Variation	[1226]
DUS2	OTVBE313	Disputed	Altered Expression	[1227]
EFEMP2	OT0I2B4J	Disputed	Biomarker	[1228]
ELK1	OTH9MXD6	Disputed	Altered Expression	[1229]
EMD	OTR8ZANE	Disputed	Biomarker	[1230]
FANCG	OT7MC8TZ	Disputed	Genetic Variation	[1231]
FARP2	OTNRQIMK	Disputed	Biomarker	[1232]
FBN2	OT3KYJQL	Disputed	Posttranslational Modification	[1233]
FRAT1	OT1PS84E	Disputed	Altered Expression	[1234]
FZD5	OTXFFY56	Disputed	Altered Expression	[1235]
FZD9	OTTZ9MKK	Disputed	Biomarker	[1235]
GYPA	OTABU4YV	Disputed	Biomarker	[1236]
HABP2	OTAUIPW0	Disputed	Altered Expression	[1237]
HIPK3	OT4WYQM2	Disputed	Biomarker	[382]
HIVEP1	OT7CAG4A	Disputed	Biomarker	[1228]
HLA-C	OTV38BUJ	Disputed	Altered Expression	[1238]
KIF22	OTY6X6BL	Disputed	Altered Expression	[1239]
MT1B	OTUA4FFH	Disputed	Biomarker	[279]
MT1E	OTXJKU4Y	Disputed	Altered Expression	[279]
MT1F	OTZVUYG1	Disputed	Altered Expression	[279]
MT1G	OTAV1OCR	Disputed	Altered Expression	[279]
MT1H	OT0MVBM6	Disputed	Altered Expression	[279]
MT1M	OTVT8PLU	Disputed	Altered Expression	[279]
MT4	OTDBOZEN	Disputed	Altered Expression	[279]
NAPSA	OT6F8IAL	Disputed	Altered Expression	[1240]
NDC80	OTS7D306	Disputed	Biomarker	[1241]
NEDD4L	OT1B19RU	Disputed	Altered Expression	[1242]
OBP2A	OTBIJ5TI	Disputed	Altered Expression	[1239]
OSR1	OTB19LEQ	Disputed	Biomarker	[1243]
PEBP4	OTKDCVC6	Disputed	Biomarker	[1244]
PKP3	OTPL1HRB	Disputed	Altered Expression	[1245]
POLR2A	OTHJQ1DZ	Disputed	Altered Expression	[1246]
PRG2	OT0BCPQG	Disputed	Biomarker	[1228]
PTPRD	OTZPJ3GX	Disputed	Genetic Variation	[1247]
PUF60	OTG90DYF	Disputed	Biomarker	[1232]
SFTPB	OTOHS07E	Disputed	Genetic Variation	[761]
SIX1	OT70YYWM	Disputed	Biomarker	[1248]
SIX2	OTYOVGSC	Disputed	Biomarker	[1249]
SPEN	OT37A2MD	Disputed	Genetic Variation	[1226]
SRCIN1	OTQZNQQ5	Disputed	Biomarker	[1250]
ADAM28	OT3GBVHL	moderate	Biomarker	[1251]
AIM2	OT86QUI8	moderate	Biomarker	[1252]
ARMC8	OTNAXGM7	moderate	Biomarker	[1253]
BRF2	OT2C6TH2	moderate	Altered Expression	[1254]
CLDN1	OT27KV99	moderate	Altered Expression	[1255]
CLDN7	OTNE0XHQ	moderate	Biomarker	[1256]
COL11A1	OTB0DRMS	moderate	Biomarker	[1257]
COX8A	OTU0NR39	moderate	Biomarker	[1107]
CUL4A	OTTBV70J	moderate	Altered Expression	[1258]
CUL4B	OT2QX4DO	moderate	Altered Expression	[1259]
CXCL5	OTZOUPCA	moderate	Biomarker	[1260]
DACH1	OTMKNAGG	moderate	Biomarker	[1261]
EPS15	OT7NPP8U	moderate	Biomarker	[1262]
ERRFI1	OT7VZ2IZ	moderate	Altered Expression	[1263]
FEN1	OT6QGG7O	moderate	Biomarker	[1264]
FUT8	OTJJCVG1	moderate	Altered Expression	[1265]
HMGB3	OTCJ2EZY	moderate	Biomarker	[1266]
IL27	OTIS3OF8	moderate	Biomarker	[303]
KLF5	OT1ABI9N	moderate	Posttranslational Modification	[1267]
LGALS9	OT7MF91K	moderate	Biomarker	[1268]
LMLN	OTQF0JPY	moderate	Biomarker	[1269]
LRIG1	OTY5HZN5	moderate	Biomarker	[1270]
MACC1	OTV3DLX0	moderate	Biomarker	[1271]
MAP1LC3B	OTUYHB84	moderate	Altered Expression	[382]
MEOX1	OTJEMT2D	moderate	Altered Expression	[1272]
METTL3	OTSXP1M3	moderate	Biomarker	[1273]
MOK	OTQK7M9V	moderate	Biomarker	[347]
NRSN2	OT4OS3M2	moderate	Biomarker	[1274]
NTS	OTPGDNQS	moderate	Biomarker	[746]
OTUD4	OT7U62SW	moderate	Biomarker	[1275]
PGK1	OT6V1ICH	moderate	Biomarker	[1276]
PIGR	OT6GLSUL	moderate	Altered Expression	[1277]
PLAAT4	OTI66SAJ	moderate	Biomarker	[1278]
PMAIP1	OTXEE550	moderate	Biomarker	[560]
PRRT2	OTCJUBDO	moderate	Altered Expression	[793]
PYGB	OT2ZTJT0	moderate	Altered Expression	[1279]
RPL36A	OT1LYV85	moderate	Altered Expression	[1263]
SEL1L	OTC0FB7T	moderate	Altered Expression	[1280]
SESN2	OT889IXY	moderate	Altered Expression	[1281]
SETDB1	OTWVUA1B	moderate	Altered Expression	[1282]
SFRP2	OT8GZ0CA	moderate	Biomarker	[1283]
SH2B1	OTJZO2CI	moderate	Biomarker	[1284]
SIX4	OTG2HFH0	moderate	Altered Expression	[1285]
SMARCA2	OTSGJ8SV	moderate	Biomarker	[1286]
SNX1	OTXQSJ1J	moderate	Biomarker	[1217]
STAT5B	OTZVPEBT	moderate	Altered Expression	[1287]
SUMO1	OTJFD4P5	moderate	Biomarker	[1288]
THY1	OTVONVTB	moderate	Altered Expression	[1289]
TIMM50	OTWJNUQL	moderate	Biomarker	[1290]
TRAT1	OTMPUNPD	moderate	Biomarker	[1291]
A1CF	OTJBKFA1	Strong	Genetic Variation	[368]
AAMP	OTZXBSS4	Strong	Biomarker	[1292]
ABCE1	OTH19LOA	Strong	Altered Expression	[1293]
ABCG4	OT2XJIOG	Strong	Altered Expression	[1294]
ACOT8	OTHY684G	Strong	Altered Expression	[1240]
ACSS1	OT6C1WQD	Strong	Altered Expression	[649]
ACTB	OT1MCP2F	Strong	Altered Expression	[1295]
ADA2	OTGCV24S	Strong	Genetic Variation	[1296]
ADAM15	OTZ7VLTP	Strong	Biomarker	[1297]
ADAM19	OTH88TXU	Strong	Biomarker	[1298]
ADAM22	OT452ZDC	Strong	Altered Expression	[1299]
ADAM23	OTVWT6JZ	Strong	Altered Expression	[1300]
ADARB1	OTGKSZEV	Strong	Genetic Variation	[1301]
ADD1	OTTF68DC	Strong	Biomarker	[1302]
ADD3	OTDRSHAZ	Strong	Biomarker	[1302]
ADGRA2	OTBT4W36	Strong	Biomarker	[1303]
ADGRF1	OTRAOBYH	Strong	Biomarker	[1304]
ADGRG6	OTY2UBXO	Strong	Genetic Variation	[1305]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[1306]
ADIPOR2	OT2HDTL8	Strong	Biomarker	[1306]
AFAP1	OTR473H8	Strong	Biomarker	[1307]
AFAP1L1	OTWNTNDB	Strong	Biomarker	[1308]
AGAP2	OTEYO9TM	Strong	Altered Expression	[1309]
AGFG1	OTI8ZKC4	Strong	Biomarker	[251]
AGL	OTWBM7WY	Strong	Biomarker	[1310]
AGO2	OT4JY32Q	Strong	Biomarker	[599]
AHSA1	OTC7AFHT	Strong	Biomarker	[350]
AKAP4	OTL4Z99V	Strong	Altered Expression	[1311]
AKT1S1	OT4JHN4Y	Strong	Biomarker	[1312]
ALG13	OTOH9PMY	Strong	Altered Expression	[982]
ALOX15B	OTWQQ08W	Strong	Genetic Variation	[1313]
ALPK2	OTWZZDQ9	Strong	Altered Expression	[1314]
AMELX	OTIN26MM	Strong	Biomarker	[1315]
AMMECR1	OTWMQ67T	Strong	Biomarker	[1316]
AMPH	OTWPGWZX	Strong	Biomarker	[1317]
ANAPC10	OTM03SME	Strong	Biomarker	[1318]
ANGPTL2	OTB6JG41	Strong	Biomarker	[1319]
ANGPTL5	OTC6AFVO	Strong	Altered Expression	[222]
ANKRD22	OT6CRQ67	Strong	Biomarker	[1320]
ANKRD6	OTM86B04	Strong	Altered Expression	[1321]
ANKRD7	OTBW7AR4	Strong	Genetic Variation	[1322]
ANP32B	OT3SQMLU	Strong	Biomarker	[931]
ANXA4	OTUCRYXL	Strong	Altered Expression	[1323]
APC	OTKV0TIK	Strong	Genetic Variation	[1324]
API5	OTYX9YCZ	Strong	Biomarker	[986]
APIP	OT8ZABOU	Strong	Biomarker	[869]
APOBEC3B	OTHLNI51	Strong	Genetic Variation	[1325]
APOM	OTI3FQQC	Strong	Altered Expression	[1326]
APPBP2	OTLNFV4J	Strong	Altered Expression	[789]
AQP4	OTA9MYD5	Strong	Biomarker	[1327]
ARAP2	OTBXYFRH	Strong	Biomarker	[1328]
ARHGAP10	OT84ATF5	Strong	Altered Expression	[1329]
ARHGAP24	OTCQCEZS	Strong	Biomarker	[1330]
ARHGAP5	OTOQELUN	Strong	Altered Expression	[1331]
ARHGEF19	OTKD9XY9	Strong	Biomarker	[1332]
ARHGEF39	OT9UKTQ5	Strong	Altered Expression	[1333]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[1334]
ARHGEF7	OT9BPJCL	Strong	Biomarker	[1335]
ARID2	OTIRJXWM	Strong	Genetic Variation	[1336]
ARIH1	OTO3XDR2	Strong	Biomarker	[1337]
ARMCX3	OTMG7RWW	Strong	Biomarker	[1338]
ARMH1	OTTJC0D6	Strong	Biomarker	[660]
ARNT2	OTAQD3YV	Strong	Biomarker	[1339]
ARTN	OTWIWGL6	Strong	Biomarker	[1340]
ASPM	OTKXQMNA	Strong	Genetic Variation	[368]
ASS1	OT4ZMG0Q	Strong	Biomarker	[1341]
ATF1	OT251CI0	Strong	Biomarker	[1342]
ATF6	OTAFHAVI	Strong	Biomarker	[515]
ATG10	OTVRPC5X	Strong	Altered Expression	[1343]
ATG12	OTJRO09Y	Strong	Biomarker	[1344]
ATG16L1	OTEOYC5D	Strong	Genetic Variation	[1345]
ATG16L2	OTJYU0W8	Strong	Genetic Variation	[1346]
ATG5	OT4T5SMS	Strong	Biomarker	[1347]
ATN1	OTNZFLKY	Strong	Biomarker	[1348]
ATOX1	OT05LF59	Strong	Biomarker	[1349]
ATP2C1	OTQN51T3	Strong	Biomarker	[1350]
ATP5F1A	OT3FZDLX	Strong	Biomarker	[1351]
ATP6V1E1	OT76J5R9	Strong	Biomarker	[1352]
ATP8A1	OT2B7XBT	Strong	Altered Expression	[1353]
ATRNL1	OTY5JUX2	Strong	Biomarker	[1354]
ATXN7	OTL3YF1H	Strong	Altered Expression	[1355]
AVEN	OTGIN5YK	Strong	Biomarker	[756]
AXIN1	OTRGZGZ5	Strong	Altered Expression	[1356]
AZI2	OT61Q7Q8	Strong	Altered Expression	[1240]
AZIN1	OTX5W77I	Strong	Biomarker	[1357]
B3GALNT1	OT8GFSQL	Strong	Biomarker	[1358]
B3GAT1	OTXFP98E	Strong	Biomarker	[584]
B3GNT3	OTVT1Q25	Strong	Biomarker	[1359]
BABAM2	OTOY7FNT	Strong	Genetic Variation	[739]
BAD	OT63ERYM	Strong	Posttranslational Modification	[1360]
BAG1	OTRQNIA4	Strong	Biomarker	[1361]
BAG4	OTUPX3M2	Strong	Genetic Variation	[545]
BAG6	OT4Z0S2U	Strong	Genetic Variation	[1362]
BAMBI	OTCEJ8W5	Strong	Altered Expression	[1363]
BARD1	OTTC0Z9Y	Strong	Altered Expression	[1364]
BARHL2	OTASKG2P	Strong	Altered Expression	[1365]
BARX2	OT0R3QD3	Strong	Biomarker	[1366]
BATF	OT9VSD2D	Strong	Altered Expression	[1367]
BATF2	OT4XBZC9	Strong	Altered Expression	[1368]
BAZ1A	OTWHOVZS	Strong	Genetic Variation	[456]
BCAR1	OTKT2C2N	Strong	Altered Expression	[1369]
BCL10	OT47MCLI	Strong	Biomarker	[1370]
BCL3	OT1M5B95	Strong	Altered Expression	[688]
BCS1L	OT5PY5CY	Strong	Biomarker	[1371]
BHLHE22	OTZUQY5L	Strong	Altered Expression	[1372]
BHLHE40	OTITX14U	Strong	Biomarker	[1373]
BICD2	OTVJ03NZ	Strong	Biomarker	[1374]
BID	OTOSHSHU	Strong	Genetic Variation	[1375]
BIRC6	OTCQJAB0	Strong	Biomarker	[1376]
BLID	OT479VJV	Strong	Altered Expression	[1377]
BMF	OT90NSLI	Strong	Biomarker	[1378]
BMS1	OTEGQ8ZO	Strong	Biomarker	[1379]
BNIP3	OT4SO7J4	Strong	Altered Expression	[1380]
BOK	OTDQPDIX	Strong	Altered Expression	[1381]
BPTF	OTD1RZAD	Strong	Altered Expression	[1382]
BRK1	OTTUB5KS	Strong	Altered Expression	[893]
BRMS1	OTV5A6LL	Strong	Biomarker	[1383]
BRMS1L	OTJIW47U	Strong	Altered Expression	[1383]
BTBD7	OTNUV6MQ	Strong	Biomarker	[1384]
BZW1	OT4GUFIG	Strong	Altered Expression	[1385]
C10orf90	OT6DNZC4	Strong	Altered Expression	[1386]
C12orf54	OTOMJVVB	Strong	Biomarker	[1387]
C15orf48	OT85J32K	Strong	Biomarker	[1388]
CACUL1	OT6P1ZVP	Strong	Altered Expression	[1389]
CADM1	OTRWG9QS	Strong	Biomarker	[1390]
CALB1	OTM7IXDG	Strong	Biomarker	[1391]
CAMK2D	OTJ5XLVU	Strong	Genetic Variation	[1392]
CAND1	OTGB6NU0	Strong	Altered Expression	[1393]
CAPNS1	OT95EBBD	Strong	Biomarker	[1394]
CARD10	OT2RPM4I	Strong	Altered Expression	[1395]
CARD16	OT4NUHWB	Strong	Biomarker	[1396]
CASS4	OTGPIPUS	Strong	Altered Expression	[1397]
CASZ1	OTWJ2OR8	Strong	Altered Expression	[1398]
CAVIN1	OTFO915U	Strong	Altered Expression	[1399]
CAVIN2	OTFHHDRU	Strong	Biomarker	[1400]
CBFA2T2	OTNOIB23	Strong	Biomarker	[1335]
CBLC	OT3RKZI9	Strong	Biomarker	[1401]
CBLL1	OTZUQBYX	Strong	Altered Expression	[1402]
CBLL2	OTB4AD3V	Strong	Biomarker	[1403]
CBX3	OTOP9RLD	Strong	Altered Expression	[1404]
CBX4	OT4XVRRF	Strong	Biomarker	[1405]
CBX5	OT8VYY84	Strong	Biomarker	[361]
CCDC106	OTWUTA1W	Strong	Biomarker	[1406]
CCDC54	OTW5WCX9	Strong	Biomarker	[1407]
CCDC6	OTXRQDYG	Strong	Biomarker	[1408]
CCDC8	OTO295IH	Strong	Biomarker	[1409]
CCDC85B	OTKEQLNK	Strong	Biomarker	[1410]
CCDC88A	OT3SSYYC	Strong	Biomarker	[1411]
CCL18	OT7JYSK9	Strong	Biomarker	[1412]
CCL19	OTQ2UJMH	Strong	Altered Expression	[424]
CCL25	OTLWJ8CJ	Strong	Biomarker	[425]
CCL7	OTDIS99H	Strong	Altered Expression	[1293]
CCL8	OTCTWYN8	Strong	Genetic Variation	[476]
CCN4	OT69BER9	Strong	Genetic Variation	[1413]
CCN6	OTRFHQ2Z	Strong	Biomarker	[599]
CCNB2	OTIEXTDK	Strong	Altered Expression	[1414]
CCND2	OTDULQF9	Strong	Biomarker	[924]
CCNJ	OTCR4WVV	Strong	Biomarker	[1415]
CCT4	OT5D452X	Strong	Biomarker	[1416]
CCT5	OTPZ38BT	Strong	Biomarker	[1417]
CD177	OTS79FNF	Strong	Altered Expression	[1418]
CD1D	OT3ROU4J	Strong	Altered Expression	[1419]
CD63	OT2UGZA9	Strong	Biomarker	[1420]
CD68	OTOYEY3J	Strong	Biomarker	[619]
CD82	OTH8MC64	Strong	Biomarker	[1421]
CD93	OT6HZT6H	Strong	Biomarker	[1422]
CD99	OTPUZ5DE	Strong	Biomarker	[1423]
CDC42	OT5QBC5M	Strong	Biomarker	[1424]
CDC45	OT6NNLOD	Strong	Altered Expression	[1425]
CDCA3	OTUI8QK3	Strong	Altered Expression	[1426]
CDCA5	OTZLCQ5U	Strong	Biomarker	[1427]
CDH13	OTD2CYM5	Strong	Posttranslational Modification	[1428]
CDK15	OT8S67QS	Strong	Genetic Variation	[280]
CDKN2B	OTAG24N1	Strong	Posttranslational Modification	[1429]
CDKN3	OTBE3H07	Strong	Biomarker	[1430]
CDX2	OTCG4TSY	Strong	Genetic Variation	[970]
CELF1	OT6JQ5RS	Strong	Biomarker	[1431]
CELF2	OTLJJ4VT	Strong	Biomarker	[1432]
CEMIP	OTK80FYN	Strong	Altered Expression	[1433]
CENPU	OTQ4TZRS	Strong	Altered Expression	[1434]
CEP55	OTGSG2PA	Strong	Altered Expression	[1435]
CEP72	OTVYNPNL	Strong	Biomarker	[1436]
CERS6	OTOP4GV1	Strong	Biomarker	[1437]
CERT1	OTNUCNHX	Strong	Biomarker	[756]
CETN1	OTGQ8JOZ	Strong	Altered Expression	[844]
CFAP97	OT0RSQO4	Strong	Biomarker	[1438]
CFHR1	OT72R16T	Strong	Biomarker	[1439]
CFL1	OTT6D5MH	Strong	Altered Expression	[1440]
CHAF1A	OTXSSY4H	Strong	Biomarker	[1441]
CHAF1B	OTOMK4KH	Strong	Altered Expression	[1442]
CHAMP1	OTBGWU86	Strong	Biomarker	[1443]
CHCHD2	OTL5PA3Y	Strong	Biomarker	[1444]
CHD5	OTS5EVHH	Strong	Biomarker	[1445]
CHGA	OTXYX5JH	Strong	Biomarker	[1446]
CHL1	OT6E6E8P	Strong	Altered Expression	[1447]
CHMP2B	OTZA7RJB	Strong	Biomarker	[864]
CHMP4C	OT5X8A3O	Strong	Biomarker	[1448]
CHODL	OTVCNOUQ	Strong	Biomarker	[1449]
CHPT1	OT4FJ0K3	Strong	Biomarker	[1450]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[458]
CHRNB3	OTE5XENW	Strong	Genetic Variation	[1451]
CIAPIN1	OTWS90F9	Strong	Altered Expression	[1452]
CIB1	OT4BVCRU	Strong	Biomarker	[1453]
CIB2	OT9ZJX1I	Strong	Altered Expression	[445]
CILK1	OTWOYEYP	Strong	Genetic Variation	[280]
CIP2A	OTVS2GXA	Strong	Altered Expression	[1454]
CKAP4	OTDUC9ME	Strong	Biomarker	[834]
CKAP5	OTEMFY7X	Strong	Biomarker	[1455]
CKLF	OTHLPHA0	Strong	Biomarker	[1456]
CLDN2	OTRF3D6Y	Strong	Altered Expression	[1457]
CLDN5	OTUX60YO	Strong	Altered Expression	[1255]
CLEC2D	OTVRLKPM	Strong	Altered Expression	[1458]
CLEC4M	OT2WUIIP	Strong	Biomarker	[1459]
CLOCK	OTNEOJY7	Strong	Biomarker	[1460]
CLSTN1	OTQN35G2	Strong	Biomarker	[862]
CMTM1	OTKN7E89	Strong	Altered Expression	[1461]
CMTM6	OT70T27A	Strong	Altered Expression	[1462]
CMTM7	OTI7Q2JW	Strong	Biomarker	[1463]
CMYA5	OTYV0RME	Strong	Altered Expression	[1464]
CNDP2	OTJR9436	Strong	Biomarker	[1069]
CNKSR3	OTXP4QH8	Strong	Biomarker	[591]
CNOT3	OT4D5Z9L	Strong	Altered Expression	[444]
CNPY2	OTGY8ESX	Strong	Biomarker	[1465]
COIL	OTP4I4DL	Strong	Altered Expression	[1466]
COL10A1	OTC4G2YC	Strong	Altered Expression	[1467]
COL11A2	OT3BQUBH	Strong	Biomarker	[762]
COL17A1	OTID5AH2	Strong	Altered Expression	[1468]
COL4A3	OT6SB8X5	Strong	Altered Expression	[1469]
COMMD3	OT1UTJH4	Strong	Altered Expression	[1470]
COMMD4	OTOOYSHW	Strong	Altered Expression	[1470]
COMMD5	OT6R7DXN	Strong	Altered Expression	[1470]
COMMD6	OTRZQJFW	Strong	Altered Expression	[1470]
COMMD8	OTRMN4EU	Strong	Altered Expression	[1471]
COMMD9	OT3IZ61B	Strong	Biomarker	[1470]
CORO1C	OTXDF9T3	Strong	Biomarker	[756]
COX1	OTG3O9BN	Strong	Altered Expression	[1472]
COX7A1	OTHV25GG	Strong	Biomarker	[1473]
CPEB1	OTLCXC6H	Strong	Altered Expression	[1474]
CPNE1	OTH5YKSL	Strong	Biomarker	[1475]
CPQ	OTTNZNLD	Strong	Altered Expression	[698]
CPSF3	OTS3KSNG	Strong	Biomarker	[1476]
CRABP2	OTY01V9G	Strong	Altered Expression	[1477]
CRACD	OTII2U6L	Strong	Biomarker	[1367]
CRAMP1	OT0X95YA	Strong	Biomarker	[1478]
CREBZF	OTO3TOEU	Strong	Genetic Variation	[1479]
CRISPLD2	OTVSFHTL	Strong	Altered Expression	[1480]
CRLS1	OT7XNL0K	Strong	Biomarker	[1481]
CRYBG3	OTHXQCX7	Strong	Altered Expression	[1482]
CSH1	OT33HTRR	Strong	Biomarker	[862]
CSH2	OTW8JVAN	Strong	Biomarker	[862]
CST1	OTE4I83Q	Strong	Altered Expression	[1483]
CSTA	OT1K68KE	Strong	Altered Expression	[1484]
CSTF2	OTR6G4II	Strong	Biomarker	[1485]
CT45A2	OT9X9KTC	Strong	Biomarker	[1486]
CT83	OTQEGHAB	Strong	Altered Expression	[1487]
CTAG1B	OTIQGW6U	Strong	Genetic Variation	[471]
CTBP2	OTGZGT87	Strong	Biomarker	[1488]
CTC1	OTRJY7QD	Strong	Biomarker	[1489]
CTDSPL	OTZJ0CZK	Strong	Biomarker	[1490]
CTHRC1	OTV88X2G	Strong	Altered Expression	[1491]
CTNND1	OTUMPSHR	Strong	Biomarker	[1492]
CTNND2	OTYKE30Y	Strong	Altered Expression	[1493]
CTTN	OTJRG4ES	Strong	Biomarker	[1494]
CXCL14	OTM189TA	Strong	Altered Expression	[1495]
CXCL6	OTFTCQ4O	Strong	Biomarker	[1496]
CYGB	OTX153DQ	Strong	Altered Expression	[1497]
DAB1	OTPL9MA3	Strong	Genetic Variation	[1498]
DAB2	OTRMQTMZ	Strong	Posttranslational Modification	[1499]
DAB2IP	OTF456VC	Strong	Altered Expression	[1500]
DAND5	OTWNWQDJ	Strong	Altered Expression	[1501]
DAP	OT5YLL7E	Strong	Genetic Variation	[1502]
DBN1	OTZVKG8A	Strong	Biomarker	[1503]
DCAF1	OT3ZDVOE	Strong	Biomarker	[251]
DCBLD1	OTA702JK	Strong	Genetic Variation	[456]
DCC	OT2C1SHW	Strong	Altered Expression	[1504]
DCDC2	OTSUFH1H	Strong	Biomarker	[1505]
DCTN4	OTM7C943	Strong	Altered Expression	[648]
DCTN6	OTI8PIN9	Strong	Biomarker	[1506]
DCUN1D1	OT8UJLZU	Strong	Biomarker	[1389]
DDB1	OTTR2L3Z	Strong	Altered Expression	[1507]
DDB2	OTO8HVVB	Strong	Altered Expression	[1508]
DDT	OTF5HTYL	Strong	Biomarker	[1509]
DDX17	OTXRMMBP	Strong	Altered Expression	[1510]
DDX23	OTBJHS8C	Strong	Altered Expression	[1511]
DDX3X	OTDO4TRX	Strong	Biomarker	[1512]
DDX43	OTK1RYSK	Strong	Biomarker	[1513]
DDX51	OTLMA7AH	Strong	Biomarker	[1514]
DDX53	OTHK3EGZ	Strong	Biomarker	[678]
DDX56	OTGURA53	Strong	Biomarker	[1514]
DEFB1	OT5SV0E4	Strong	Biomarker	[1515]
DENND2D	OTXEFJWM	Strong	Biomarker	[1516]
DENR	OTXP9HOY	Strong	Biomarker	[1517]
DEPDC1B	OTMVFOT1	Strong	Biomarker	[1518]
DERL1	OTJUS74N	Strong	Altered Expression	[1519]
DHDDS	OTVLYBUS	Strong	Biomarker	[1450]
DHX15	OT4F98TK	Strong	Biomarker	[1520]
DHX29	OT0NDSOE	Strong	Biomarker	[1521]
DHX9	OT5AAOQI	Strong	Biomarker	[1522]
DIP2A	OTXPTR8R	Strong	Biomarker	[1523]
DISC1	OT43AW4H	Strong	Biomarker	[1524]
DISP1	OTLDFZSY	Strong	Altered Expression	[1525]
DKK4	OTWCCVF6	Strong	Biomarker	[1526]
DLC1	OTP8LMCR	Strong	Altered Expression	[1527]
DLEC1	OTMKKBUW	Strong	Biomarker	[1528]
DLG3	OTH591WK	Strong	Biomarker	[311]
DLGAP5	OTWCN39U	Strong	Altered Expression	[1529]
DLX6	OT0FIJHY	Strong	Altered Expression	[1530]
DMRT1	OT5PU9U1	Strong	Biomarker	[864]
DNAH8	OTGES2OU	Strong	Biomarker	[1531]
DNAJA3	OT61924T	Strong	Biomarker	[1532]
DNASE2	OT6RC1BL	Strong	Biomarker	[1533]
DNM1L	OTXK1Q1G	Strong	Biomarker	[1534]
DNTTIP1	OTAP29SS	Strong	Altered Expression	[1535]
DOCK3	OTF3YS2W	Strong	Altered Expression	[1536]
DPPA4	OTAEOACS	Strong	Altered Expression	[1160]
DRAM2	OTBOCZH8	Strong	Altered Expression	[1537]
DROSHA	OTCE68KZ	Strong	Altered Expression	[1538]
DSC2	OTODVH8K	Strong	Biomarker	[1539]
DSC3	OTYG47F8	Strong	Biomarker	[1539]
DSG2	OTJPB2TO	Strong	Altered Expression	[1540]
DSP	OTB2MOP8	Strong	Altered Expression	[1541]
DSPP	OT1TYNDN	Strong	Biomarker	[1542]
DSTN	OTMXO4YB	Strong	Biomarker	[203]
DTX1	OTYX91DX	Strong	Genetic Variation	[1543]
DTX3	OTSUUV9N	Strong	Biomarker	[1544]
DUSP2	OTH54FMR	Strong	Biomarker	[345]
DUSP4	OT6WAO12	Strong	Altered Expression	[1545]
DVL3	OTPRROHJ	Strong	Altered Expression	[1546]
DYNLL1	OTR69LHT	Strong	Altered Expression	[1547]
DYNLL2	OTLIT58K	Strong	Altered Expression	[1548]
DYNLRB1	OTWVKOFB	Strong	Altered Expression	[1549]
E2F6	OT2PN28R	Strong	Biomarker	[1550]
E2F7	OTWW358N	Strong	Biomarker	[1551]
E2F8	OTQKZGFP	Strong	Biomarker	[1552]
EBAG9	OTTQLQCP	Strong	Biomarker	[1553]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[660]
ECM1	OT1K65VW	Strong	Biomarker	[349]
ECSCR	OT9L72MD	Strong	Altered Expression	[827]
EDARADD	OT0G52MC	Strong	Posttranslational Modification	[1554]
EDIL3	OTDVVNS0	Strong	Altered Expression	[1555]
EEF1A2	OT9Z23K5	Strong	Posttranslational Modification	[1556]
EEF1E1	OTRA6XOB	Strong	Genetic Variation	[371]
EFEMP1	OTZVUOOB	Strong	Biomarker	[1557]
EFNA1	OTU2NUA2	Strong	Biomarker	[1558]
EFNB3	OT12WTXQ	Strong	Altered Expression	[1558]
EGR2	OTAVQ78J	Strong	Biomarker	[1559]
EGR3	OTGPJIRA	Strong	Altered Expression	[1560]
EGR4	OT4R3ECK	Strong	Biomarker	[1561]
EHD1	OTDMEKLV	Strong	Biomarker	[1562]
EI24	OTD4NOYS	Strong	Altered Expression	[1563]
EIF2S1	OTM0GDTP	Strong	Biomarker	[1564]
EIF2S2	OTXF0B09	Strong	Biomarker	[1564]
EIF2S3	OTARRES9	Strong	Biomarker	[1564]
EIF3B	OTF67VPH	Strong	Biomarker	[1565]
EIF3C	OTR8RF9X	Strong	Biomarker	[1566]
EIF3D	OTDOMP80	Strong	Biomarker	[1567]
EIF3J	OTJ4TAWK	Strong	Genetic Variation	[1568]
EIF4A3	OTYYFE7K	Strong	Altered Expression	[1569]
EIF6	OTEXMUED	Strong	Biomarker	[1570]
ELAC2	OTY3BOF6	Strong	Biomarker	[1405]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[1571]
ELMO3	OTQHO9VM	Strong	Altered Expression	[1572]
ELP1	OTYEWBF7	Strong	Genetic Variation	[283]
ELP3	OTT5UKSZ	Strong	Biomarker	[800]
EMP1	OTSZHUHQ	Strong	Biomarker	[394]
EMP3	OTODMJ1D	Strong	Biomarker	[1573]
EN2	OT7EZCM2	Strong	Altered Expression	[1574]
ENO1	OTB1KWJS	Strong	Biomarker	[1575]
ENO2	OTRODL0T	Strong	Genetic Variation	[1576]
EOMES	OTB9VQFA	Strong	Altered Expression	[1577]
EPG5	OT3P5HQD	Strong	Biomarker	[1578]
EPN3	OTNNYDT6	Strong	Altered Expression	[1579]
EPS8	OTZ6ES6V	Strong	Altered Expression	[1580]
ERCC4	OTFIOPG1	Strong	Genetic Variation	[1581]
ERCC5	OTQAKFJM	Strong	Genetic Variation	[1582]
ERGIC3	OT8RWHN3	Strong	Biomarker	[1583]
ERO1A	OTVKOQWM	Strong	Altered Expression	[1584]
ESD	OTUSIBPS	Strong	Altered Expression	[1585]
ESM1	OT331Y8V	Strong	Altered Expression	[1586]
ESRP1	OTNCS4SL	Strong	Biomarker	[1587]
ESYT1	OTA8NSJF	Strong	Posttranslational Modification	[1588]
ETFA	OTXX61VZ	Strong	Biomarker	[1589]
ETV4	OT8C98UZ	Strong	Biomarker	[1590]
EXO1	OTI87RS5	Strong	Genetic Variation	[1591]
EYA4	OTINGR3Z	Strong	Biomarker	[1592]
FADD	OTV7GFHH	Strong	Altered Expression	[1593]
FAIM2	OT6QINVO	Strong	Altered Expression	[1594]
FAM107A	OTBG61YZ	Strong	Biomarker	[1595]
FAM13A	OTZ6GN0Q	Strong	Biomarker	[1596]
FAM83F	OTGGJRO7	Strong	Altered Expression	[1597]
FAM98A	OTBLMZXO	Strong	Altered Expression	[1598]
FASTK	OTTHFZMP	Strong	Biomarker	[1599]
FBLIM1	OTFHXMON	Strong	Biomarker	[1600]
FBLN5	OTLVNZ8U	Strong	Genetic Variation	[1601]
FBRS	OTUVH446	Strong	Biomarker	[1602]
FBXL19	OTGDHPOE	Strong	Biomarker	[1603]
FBXL3	OTDQ1QKV	Strong	Biomarker	[1604]
FBXO17	OTDSRA7P	Strong	Altered Expression	[1605]
FBXO6	OT58MKP3	Strong	Biomarker	[451]
FBXO7	OTGTN8TJ	Strong	Biomarker	[1072]
FBXO8	OTZNGJGW	Strong	Biomarker	[1602]
FBXW4	OTEGSZOX	Strong	Altered Expression	[1606]
FBXW5	OT5TQK3H	Strong	Biomarker	[1507]
FCGBP	OT63T6XQ	Strong	Genetic Variation	[1498]
FCHSD2	OTKXLIJ6	Strong	Altered Expression	[1607]
FDX1	OT7I3DN0	Strong	Genetic Variation	[1608]
FEZF1	OTRX4NOT	Strong	Altered Expression	[1609]
FGF13	OTHNNVSG	Strong	Biomarker	[1610]
FGF5	OTQXGHBY	Strong	Altered Expression	[1611]
FGF9	OT2SKDGM	Strong	Biomarker	[1612]
FKBP3	OT7ETKPE	Strong	Biomarker	[1613]
FLOT1	OT0JPPJZ	Strong	Biomarker	[1614]
FLOT2	OTZ0QR5L	Strong	Altered Expression	[1615]
FLVCR1	OT9XCFOC	Strong	Genetic Variation	[1616]
FNDC5	OT5CSK9X	Strong	Altered Expression	[1617]
FOSB	OTW6C05J	Strong	Biomarker	[1618]
FOXA2	OTJOCVOY	Strong	Altered Expression	[1619]
FOXD1	OT80PRHS	Strong	Biomarker	[1620]
FOXD2	OTAF63YV	Strong	Biomarker	[1621]
FOXD3	OTXYV6GO	Strong	Altered Expression	[1622]
FOXE1	OT5IR5IT	Strong	Biomarker	[1623]
FOXF2	OTV20NGX	Strong	Genetic Variation	[1624]
FOXG1	OTAW57J4	Strong	Biomarker	[1625]
FOXJ3	OTXAUJ47	Strong	Biomarker	[1626]
FOXK2	OTFXDZ3R	Strong	Biomarker	[1627]
FOXN1	OTE80D6I	Strong	Altered Expression	[1628]
FOXO3	OTHXQG4P	Strong	Biomarker	[1580]
FOXO4	OT90X9LN	Strong	Altered Expression	[1629]
FOXP2	OTVX6A59	Strong	Altered Expression	[1630]
FOXP4	OTHCGIEZ	Strong	Altered Expression	[1631]
FRK	OTEKV1SC	Strong	Biomarker	[1632]
FRS2	OTDMD800	Strong	Biomarker	[1633]
FRS3	OTTNP6H7	Strong	Biomarker	[1634]
FRZB	OTTO3DPY	Strong	Altered Expression	[1635]
FSD1	OT8P6PT3	Strong	Biomarker	[1636]
FSD1L	OTBQ48RF	Strong	Biomarker	[1636]
FSIP1	OTYLL6GM	Strong	Biomarker	[1637]
FUZ	OTC427QQ	Strong	Altered Expression	[1638]
FXR1	OTEMQ1SR	Strong	Biomarker	[591]
FZD1	OTZATHVS	Strong	Biomarker	[1639]
FZD8	OTZ9IRFL	Strong	Altered Expression	[1640]
G0S2	OT8FL49L	Strong	Altered Expression	[1641]
GAB1	OTQKE6V4	Strong	Altered Expression	[1642]
GAB2	OTBFN705	Strong	Biomarker	[1643]
GADD45G	OT8V1J4M	Strong	Genetic Variation	[1644]
GAGE1	OT53E50E	Strong	Biomarker	[1645]
GALNT14	OT9BSDDQ	Strong	Biomarker	[1646]
GATA2	OTBP2QQ2	Strong	Altered Expression	[1647]
GCA	OTAJ7ZHG	Strong	Genetic Variation	[1648]
GCNT3	OTQ9ALTR	Strong	Altered Expression	[1649]
GCSAM	OTZNOPYK	Strong	Biomarker	[1650]
GDE1	OTU6FSBF	Strong	Biomarker	[1651]
GDF10	OTEVXGJ7	Strong	Biomarker	[1652]
GDI2	OTGLY3I7	Strong	Biomarker	[1653]
GEMIN2	OT4L6TLL	Strong	Biomarker	[1654]
GHRH	OT94U6MO	Strong	Altered Expression	[1655]
GINS1	OTVQZMMQ	Strong	Biomarker	[264]
GINS2	OT974IYI	Strong	Altered Expression	[1656]
GINS4	OTCVOO3S	Strong	Biomarker	[1019]
GK5	OT65U8L1	Strong	Biomarker	[1657]
GMEB1	OT4F8RFH	Strong	Altered Expression	[407]
GML	OTHKIB62	Strong	Altered Expression	[1658]
GNA12	OT3IRZH3	Strong	Biomarker	[1659]
GORASP1	OTQS91S7	Strong	Altered Expression	[975]
GPC5	OT8NR7GC	Strong	Biomarker	[1660]
GPKOW	OTGS3H0M	Strong	Biomarker	[1661]
GPR151	OT7EACU6	Strong	Biomarker	[575]
GPR42	OTEB0ROY	Strong	Biomarker	[176]
GPX3	OT6PK94R	Strong	Altered Expression	[1662]
GPX4	OTRAFFX2	Strong	Altered Expression	[1663]
GRAP2	OTS5NIZ3	Strong	Biomarker	[350]
GREB1	OTU6ZA26	Strong	Biomarker	[1633]
GRP	OT8JDFNI	Strong	Altered Expression	[1664]
GSDMD	OTH39BKI	Strong	Altered Expression	[1665]
GSPT1	OT18H1B0	Strong	Altered Expression	[1530]
GSTM2	OTG4WT05	Strong	Genetic Variation	[1666]
GTF2B	OTAH5NSO	Strong	Biomarker	[1254]
GTF2H1	OTCRXC6B	Strong	Altered Expression	[648]
GZMA	OT43R33L	Strong	Altered Expression	[1667]
H2AX	OT18UX57	Strong	Biomarker	[1668]
H2AZ1	OT3KJJNQ	Strong	Biomarker	[1669]
H3-4	OTY6ITYF	Strong	Posttranslational Modification	[1670]
HAS2	OTTD3PAL	Strong	Altered Expression	[1310]
HAS3	OTPM8IL8	Strong	Altered Expression	[1671]
HAVCR2	OTOL603T	Strong	Biomarker	[1672]
HBE1	OTJPKMX4	Strong	Altered Expression	[1673]
HBP1	OTDPGGDV	Strong	Biomarker	[1674]
HEATR1	OTOWIB9Z	Strong	Altered Expression	[1675]
HEATR6	OTD3MYS0	Strong	Biomarker	[1676]
HEPACAM	OT1MJ51D	Strong	Biomarker	[1677]
HERC2	OTNQYKOB	Strong	Altered Expression	[1678]
HERC4	OTU4DSDE	Strong	Biomarker	[1679]
HERC5	OTZ5PR39	Strong	Posttranslational Modification	[1680]
HES3	OTJ1J42N	Strong	Biomarker	[1681]
HES5	OTW7JEHV	Strong	Biomarker	[1682]
HEY2	OTU4J3ZI	Strong	Biomarker	[1683]
HEYL	OTN7BH79	Strong	Genetic Variation	[1624]
HHIP	OT77RQYS	Strong	Altered Expression	[1684]
HIC1	OTI9TWY4	Strong	Biomarker	[1685]
HIF3A	OTPWAAMC	Strong	Biomarker	[1686]
HINT2	OTW9GS0U	Strong	Altered Expression	[1687]
HJURP	OTWMV16B	Strong	Altered Expression	[1085]
HLA-DMB	OT17HGXJ	Strong	Biomarker	[1688]
HLA-DOA	OTZE5Q7R	Strong	Biomarker	[1689]
HLTF	OTRX2OSF	Strong	Altered Expression	[1690]
HMGB4	OT28OBR2	Strong	Altered Expression	[1691]
HMGN5	OTUUAHVQ	Strong	Biomarker	[1692]
HNRNPC	OT47AK4C	Strong	Posttranslational Modification	[1693]
HNRNPD	OT5UO1FA	Strong	Biomarker	[1694]
HNRNPDL	OTB3BFCV	Strong	Posttranslational Modification	[1693]
HNRNPK	OTNPRM8U	Strong	Altered Expression	[1695]
HOOK1	OTTTKV7V	Strong	Altered Expression	[1696]
HORMAD1	OT7DR5T2	Strong	Biomarker	[1697]
HORMAD2	OTL2ENWI	Strong	Genetic Variation	[1698]
HOXA10	OTB6GQ09	Strong	Altered Expression	[1699]
HOXA3	OTIX5XFB	Strong	Altered Expression	[1700]
HOXA4	OTNVTQDT	Strong	Biomarker	[1701]
HOXA9	OTKNK5H0	Strong	Biomarker	[1702]
HOXB9	OTMVHQOU	Strong	Biomarker	[1646]
HOXC11	OT8NMHM6	Strong	Biomarker	[1703]
HOXC6	OTBCRAZV	Strong	Altered Expression	[1704]
HOXC8	OTJUYU8J	Strong	Biomarker	[1705]
HOXD10	OT0NOWU2	Strong	Biomarker	[1706]
HOXD13	OTWSC8TF	Strong	Genetic Variation	[1707]
HOXD8	OTJ5H7AT	Strong	Biomarker	[1708]
HPS5	OTLO2374	Strong	Biomarker	[1505]
HRG	OTPLUFOG	Strong	Altered Expression	[1709]
HS3ST2	OTWFA0GJ	Strong	Biomarker	[1710]
HS3ST3B1	OTK53GUD	Strong	Altered Expression	[1711]
HSPA14	OTZCA5LK	Strong	Biomarker	[1712]
HSPA1A	OTKGIE76	Strong	Biomarker	[1713]
HSPA2	OTSDET7B	Strong	Biomarker	[1713]
HSPA4	OT5HR0AR	Strong	Biomarker	[1714]
HTRA2	OTC7616F	Strong	Biomarker	[1715]
HTRA3	OTXJ0H4X	Strong	Biomarker	[1716]
HUWE1	OTFH6BJS	Strong	Biomarker	[1717]
IARS1	OT9WXH5N	Strong	Biomarker	[1718]
IARS2	OTDX4SCA	Strong	Biomarker	[1719]
IFI27	OTI2XGIT	Strong	Biomarker	[1506]
IFI44	OTOKSZVA	Strong	Altered Expression	[1720]
IFIT2	OTI4EOAR	Strong	Biomarker	[1721]
IFITM1	OTECO1G8	Strong	Biomarker	[1722]
IFNGR1	OTCTQBWW	Strong	Altered Expression	[1723]
IFRD1	OT4SQMLQ	Strong	Altered Expression	[766]
IGF2BP1	OT9G360P	Strong	Altered Expression	[1724]
IGF2BP2	OT4ZSEEE	Strong	Biomarker	[1725]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[1726]
IL17B	OTS86H50	Strong	Altered Expression	[620]
IL17RA	OTVVI8ER	Strong	Biomarker	[619]
IL17RB	OT0KDNSF	Strong	Altered Expression	[619]
IL17RC	OTEFOBSS	Strong	Biomarker	[619]
IL18R1	OT83XMPQ	Strong	Biomarker	[511]
IL1F10	OTJAASGC	Strong	Biomarker	[1727]
IL20RA	OTSIVBVS	Strong	Biomarker	[620]
IL20RB	OTHFXK95	Strong	Altered Expression	[620]
IL6R	OTCQL07Z	Strong	Biomarker	[382]
ILF2	OTWWVM9X	Strong	Altered Expression	[1728]
ILRUN	OTE8FHQD	Strong	Altered Expression	[1729]
IMPACT	OTQ923OB	Strong	Biomarker	[250]
INHBC	OT8SUTZR	Strong	Genetic Variation	[885]
INO80	OTJBMS8T	Strong	Altered Expression	[1730]
INO80D	OTY39R4P	Strong	Altered Expression	[1731]
INPPL1	OTCDAVBQ	Strong	Altered Expression	[1229]
INS-IGF2	OTZR74BO	Strong	Altered Expression	[1732]
INSL4	OTK9F0LX	Strong	Altered Expression	[1733]
INVS	OT8KPESR	Strong	Biomarker	[1269]
IPO8	OTBHGNKT	Strong	Biomarker	[1734]
IQGAP1	OTZRWTGA	Strong	Biomarker	[1735]
IRAK2	OT6Y1QZN	Strong	Genetic Variation	[1736]
IREB2	OT747D24	Strong	Biomarker	[1737]
IRF4	OT1DHQ1P	Strong	Biomarker	[1738]
IRF5	OT8SIIAP	Strong	Altered Expression	[1739]
IRF7	OTC1A2PQ	Strong	Altered Expression	[492]
IRX5	OT05J514	Strong	Biomarker	[1740]
ISG20	OTCWRJJW	Strong	Biomarker	[623]
ITGA2B	OT4Y17PY	Strong	Biomarker	[1741]
ITGA7	OTTBTAYW	Strong	Altered Expression	[1742]
ITGA9	OTHN1IKA	Strong	Biomarker	[1528]
ITGB4	OT28UK84	Strong	Biomarker	[357]
ITGBL1	OTJDHE17	Strong	Altered Expression	[1743]
ITIH5	OTP46PZM	Strong	Posttranslational Modification	[1744]
ITPRID2	OTO3JDX5	Strong	Biomarker	[862]
JAM2	OTHVJJRJ	Strong	Biomarker	[1745]
JAM3	OTX0F9QL	Strong	Biomarker	[1745]
JMJD6	OTILR7E4	Strong	Altered Expression	[1746]
JPT2	OTJGPA4T	Strong	Biomarker	[1478]
KARS1	OT0EU4SV	Strong	Biomarker	[1747]
KAT2A	OTN0W2SW	Strong	Biomarker	[1748]
KAT5	OTL7257A	Strong	Altered Expression	[1749]
KAT8	OT5LPQTR	Strong	Biomarker	[1750]
KCNH4	OTHJ8WTU	Strong	Genetic Variation	[1751]
KCNH8	OT3I5FLB	Strong	Genetic Variation	[1751]
KCTD20	OTJLEFX1	Strong	Altered Expression	[1752]
KDM4B	OT5P1UPY	Strong	Altered Expression	[645]
KHSRP	OTDHZARB	Strong	Biomarker	[1753]
KIAA1217	OTRMK3PU	Strong	Genetic Variation	[1754]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[1755]
KIF14	OTXHT4JM	Strong	Biomarker	[1756]
KIF16B	OTDWIFQ2	Strong	Genetic Variation	[1757]
KIF20A	OTXOQHE0	Strong	Biomarker	[690]
KIF2C	OTJ8G3NP	Strong	Biomarker	[1758]
KIF3A	OTMUBSSK	Strong	Biomarker	[1759]
KIF5B	OTT34MT8	Strong	Biomarker	[725]
KIFC1	OTNQDS00	Strong	Altered Expression	[1760]
KIN	OTB2DNQU	Strong	Altered Expression	[1761]
KIR2DL4	OTXN18OA	Strong	Genetic Variation	[1762]
KLC2	OTCTPFA5	Strong	Altered Expression	[1763]
KLC3	OT38HGDY	Strong	Altered Expression	[1763]
KLF17	OT5NWVP7	Strong	Biomarker	[1764]
KLF6	OTQY9S7F	Strong	Biomarker	[1765]
KLF7	OTS3YVA0	Strong	Altered Expression	[1766]
KLF8	OTUC5CDB	Strong	Biomarker	[1107]
KLK13	OT8LOD2U	Strong	Altered Expression	[1767]
KLLN	OTV3FPH0	Strong	Altered Expression	[1768]
KLRB1	OTQ2959Y	Strong	Altered Expression	[1458]
KLRD1	OTMYLOV4	Strong	Biomarker	[726]
KMT2B	OTMMAZQX	Strong	Genetic Variation	[1769]
KMT2D	OTTVHCLY	Strong	Genetic Variation	[1770]
KPNA2	OTU7FOE6	Strong	Altered Expression	[1771]
KRT16	OTGA0EQN	Strong	Biomarker	[1772]
KRT6B	OTBXJYHY	Strong	Altered Expression	[766]
KRT8	OTTM4X11	Strong	Altered Expression	[1773]
KRT81	OTMKIK2S	Strong	Genetic Variation	[1774]
L1TD1	OTB2W20Y	Strong	Biomarker	[894]
LAMTOR1	OTIBJBW9	Strong	Genetic Variation	[371]
LAMTOR5	OTER0U8L	Strong	Altered Expression	[1775]
LARS1	OT4557NF	Strong	Altered Expression	[1063]
LAT	OTZC1XZ1	Strong	Biomarker	[870]
LDOC1	OTWZH4O9	Strong	Biomarker	[1776]
LECT2	OTSFZ9JD	Strong	Biomarker	[1777]
LEMD3	OTILAM4I	Strong	Genetic Variation	[1778]
LETM1	OT8N4MRU	Strong	Biomarker	[1779]
LGI1	OTPS77HO	Strong	Altered Expression	[1062]
LGI3	OT0CZ85H	Strong	Genetic Variation	[1299]
LGR6	OTPZ1PWR	Strong	Biomarker	[1780]
LHX2	OTK61NP8	Strong	Biomarker	[1781]
LHX3	OTQ5BAJ9	Strong	Biomarker	[1782]
LHX6	OT47UQZ5	Strong	Altered Expression	[1783]
LIG1	OTEEQS43	Strong	Genetic Variation	[1784]
LIG4	OT40DNXU	Strong	Biomarker	[1785]
LIMCH1	OTYPC4XA	Strong	Altered Expression	[1786]
LIMD2	OTSIFTD8	Strong	Biomarker	[1787]
LIME1	OTJWUQSK	Strong	Altered Expression	[1788]
LIN28B	OTVWP0FN	Strong	Altered Expression	[235]
LIPC	OTZY5SC9	Strong	Altered Expression	[1789]
LLGL1	OTAIQSXZ	Strong	Altered Expression	[1480]
LMNB2	OTXRDUOS	Strong	Biomarker	[1790]
LMO1	OTB59SKB	Strong	Altered Expression	[1791]
LMO7	OTDLY6TC	Strong	Altered Expression	[1786]
LOXL1	OTA0NEJU	Strong	Biomarker	[1792]
LPCAT1	OTCV7AGV	Strong	Biomarker	[1793]
LPIN3	OTK1C2KL	Strong	Biomarker	[1794]
LRG1	OTLD0KWA	Strong	Biomarker	[1795]
LRIG2	OTDUBLIH	Strong	Biomarker	[1796]
LRP12	OTRT1UJ7	Strong	Posttranslational Modification	[1797]
LRP1B	OT4YZG2N	Strong	Genetic Variation	[1798]
LSM2	OTHL77NY	Strong	Biomarker	[1799]
LTO1	OTQ17ZDT	Strong	Genetic Variation	[383]
LYPD3	OTLR2PYX	Strong	Biomarker	[1800]
LYPD5	OTGP7UKA	Strong	Biomarker	[1801]
LYPLA1	OTENU47T	Strong	Altered Expression	[1802]
LZTS2	OTQFSQEE	Strong	Altered Expression	[1803]
LZTS3	OTFFMOJN	Strong	Altered Expression	[1804]
MAD2L1	OTXNGZCG	Strong	Biomarker	[650]
MAFK	OTZJUE4P	Strong	Genetic Variation	[371]
MAGED1	OT6EOLFC	Strong	Biomarker	[1805]
MAGI2	OTXDDKZS	Strong	Biomarker	[1806]
MAK16	OTD546E5	Strong	Altered Expression	[804]
MAP1LC3A	OTPMGIU4	Strong	Altered Expression	[1807]
MAP2K3	OTI2OREX	Strong	Altered Expression	[1808]
MAPK8IP2	OTDUHLN0	Strong	Biomarker	[1809]
MAPRE1	OTCVQD60	Strong	Altered Expression	[1810]
MARCHF1	OTI2EYO6	Strong	Biomarker	[1811]
MARCHF3	OT89V4N5	Strong	Biomarker	[1812]
MARCHF8	OTH7PNN2	Strong	Altered Expression	[1813]
MARCKSL1	OT13J2FM	Strong	Altered Expression	[1188]
MARCO	OT0NW2Q0	Strong	Altered Expression	[1814]
MARK1	OTP7KL47	Strong	Biomarker	[1815]
MARVELD1	OT5CPOJE	Strong	Biomarker	[1816]
MASTL	OTQ7YKK5	Strong	Altered Expression	[1817]
MBD2	OTUQPP0R	Strong	Altered Expression	[968]
MBD5	OTFHT4MO	Strong	Biomarker	[1818]
MCM2	OTGGORIQ	Strong	Biomarker	[1819]
MCM4	OT19PNNG	Strong	Altered Expression	[1820]
MCPH1	OTYT3TT5	Strong	Genetic Variation	[1021]
MDFI	OTIA6YUG	Strong	Posttranslational Modification	[1821]
MDH1	OTJEO4E8	Strong	Altered Expression	[777]
MDH2	OT7364GY	Strong	Biomarker	[1822]
ME2	OTO4LL76	Strong	Biomarker	[1823]
MED1	OTOO24C4	Strong	Biomarker	[1824]
MED12	OTQZ4D2X	Strong	Genetic Variation	[669]
MED19	OTT9RT5N	Strong	Altered Expression	[1825]
MED23	OTKZQT0R	Strong	Biomarker	[1826]
MED28	OTEDM1L5	Strong	Biomarker	[1827]
MEF2D	OT7CEIG0	Strong	Altered Expression	[1828]
MEOX2	OTKZCJCB	Strong	Biomarker	[1829]
MESP1	OTY5QDBN	Strong	Altered Expression	[1830]
MFAP1	OTZN4FT3	Strong	Altered Expression	[1043]
MFF	OTEVIXOM	Strong	Altered Expression	[272]
MGA	OTTLB216	Strong	Altered Expression	[1831]
MICA	OTPEIEAR	Strong	Altered Expression	[658]
MICB	OTS2DVDW	Strong	Altered Expression	[1832]
MIIP	OT79EXZ7	Strong	Biomarker	[1833]
MINDY3	OT6YZPWC	Strong	Genetic Variation	[1834]
MKS1	OT83W5PB	Strong	Biomarker	[1065]
MLC1	OTCNZLSP	Strong	Biomarker	[1835]
MLKL	OTDSLC81	Strong	Altered Expression	[1836]
MLXIP	OT30UNI7	Strong	Altered Expression	[1813]
MMD	OTB5I4OC	Strong	Biomarker	[1837]
MMP19	OTLSTT2B	Strong	Altered Expression	[1838]
MMP26	OT9O89KU	Strong	Altered Expression	[543]
MMRN1	OT7ZNYHT	Strong	Altered Expression	[186]
MMS19	OTAXB34N	Strong	Altered Expression	[1839]
MMUT	OTBBBV70	Strong	Biomarker	[228]
MORC2	OT52A8BJ	Strong	Altered Expression	[1840]
MOS	OTNMQPFJ	Strong	Biomarker	[1841]
MOV10L1	OTP978LK	Strong	Biomarker	[1443]
MPHOSPH8	OTYI2WNS	Strong	Altered Expression	[598]
MPRIP	OT5FV5NS	Strong	Altered Expression	[1836]
MPZL3	OTC4LRBU	Strong	Genetic Variation	[456]
MRGPRD	OTTMOJ8U	Strong	Altered Expression	[1842]
MRGPRX3	OTRKCCDS	Strong	Biomarker	[575]
MRGPRX4	OTOBHZVA	Strong	Biomarker	[575]
MRPL28	OT4LUTZU	Strong	Genetic Variation	[1843]
MRPL41	OTG5URO4	Strong	Biomarker	[1844]
MRPL58	OTPTWLZY	Strong	Biomarker	[1845]
MST1	OTOC4UNG	Strong	Genetic Variation	[1846]
MT1X	OT9AKFVS	Strong	Biomarker	[1847]
MT3	OTVCZ7HI	Strong	Altered Expression	[1848]
MTA2	OTCCYIQJ	Strong	Altered Expression	[1849]
MTA3	OTIA6C79	Strong	Altered Expression	[1850]
MTBP	OTWLCW9C	Strong	Biomarker	[1851]
MTERF1	OT3EIK39	Strong	Altered Expression	[1852]
MTERF2	OTYLCNCA	Strong	Altered Expression	[1852]
MTFMT	OT1OIVJL	Strong	Biomarker	[1853]
MTHFD1	OTMKHVWC	Strong	Biomarker	[1854]
MTHFD2	OT1LQSGX	Strong	Biomarker	[1855]
MTSS1	OT5DTDO2	Strong	Altered Expression	[1856]
MTUS1	OTBPALMU	Strong	Posttranslational Modification	[1857]
MUL1	OT2JC9YR	Strong	Biomarker	[1403]
MXRA5	OTXZBWCU	Strong	Biomarker	[1858]
MYBBP1A	OTIVEMIU	Strong	Biomarker	[1859]
MYDGF	OT9HRPL6	Strong	Biomarker	[303]
MYEOV	OTDC7UHL	Strong	Biomarker	[1860]
MYH11	OTVNVWY3	Strong	Biomarker	[448]
MYH9	OT94Z706	Strong	Altered Expression	[1861]
MYL9	OT6B22JB	Strong	Altered Expression	[721]
MYLIP	OTL0PFGV	Strong	Altered Expression	[1813]
MYO10	OTHB78ZQ	Strong	Altered Expression	[1862]
MYO6	OTJQYRC7	Strong	Altered Expression	[1863]
MYOZ2	OTMEIQJA	Strong	Biomarker	[862]
MZB1	OT071TET	Strong	Biomarker	[344]
NAA25	OTS3QVF1	Strong	Altered Expression	[1240]
NAA50	OTFJ8S47	Strong	Biomarker	[538]
NAIF1	OT0B3H72	Strong	Altered Expression	[1864]
NANOS3	OTGX9IQU	Strong	Biomarker	[1865]
NAP1L1	OTI7WBZV	Strong	Altered Expression	[1240]
NBL1	OTT37U4O	Strong	Biomarker	[1866]
NBN	OT73B5MD	Strong	Genetic Variation	[1174]
NCALD	OTJZ8UEL	Strong	Altered Expression	[1867]
NCBP1	OTYBR927	Strong	Biomarker	[1868]
NCKAP1	OTEZQXXJ	Strong	Altered Expression	[1240]
NCOR1	OT04XNOU	Strong	Biomarker	[191]
NCR3	OT20M764	Strong	Altered Expression	[1869]
NDC1	OTF2GQC1	Strong	Biomarker	[1870]
NDRG3	OTJTJCHD	Strong	Altered Expression	[1871]
NDUFA4L2	OTK0PG7R	Strong	Altered Expression	[1872]
NDUFS1	OTTIZDFR	Strong	Biomarker	[1873]
NDUFS8	OTMEAWKO	Strong	Biomarker	[1873]
NEBL	OT2WH1NC	Strong	Biomarker	[1874]
NECAB3	OTRASC9G	Strong	Biomarker	[1875]
NEIL1	OTHBU5DJ	Strong	Posttranslational Modification	[1876]
NEMF	OT9DK06P	Strong	Biomarker	[1877]
NET1	OTZHNMJV	Strong	Biomarker	[881]
NEU1	OTH9BY8Y	Strong	Biomarker	[1878]
NEU3	OTQ5PQOW	Strong	Altered Expression	[1879]
NEURL1	OT2C4P70	Strong	Biomarker	[1878]
NEUROD1	OTZQ7QJ2	Strong	Biomarker	[1880]
NFASC	OTBDUXZT	Strong	Biomarker	[1881]
NFAT5	OTKIE59S	Strong	Biomarker	[1882]
NFATC1	OT4TMERS	Strong	Altered Expression	[1883]
NFE2	OTLM94BI	Strong	Altered Expression	[1884]
NHLH1	OTXN5B9R	Strong	Biomarker	[1885]
NID1	OTKLBLS6	Strong	Biomarker	[472]
NID2	OTHC33FF	Strong	Biomarker	[1886]
NIPBL	OTF6OOLU	Strong	Altered Expression	[1887]
NIPSNAP2	OTG3B2QL	Strong	Genetic Variation	[1888]
NIT1	OT1KHPKJ	Strong	Genetic Variation	[1889]
NKD1	OTY3MO97	Strong	Biomarker	[1890]
NKTR	OTIADJNW	Strong	Biomarker	[1891]
NKX2-1	OTCMEJTA	Strong	Biomarker	[1892]
NKX2-8	OT6Q3DJ0	Strong	Genetic Variation	[1893]
NMB	OT4NLN6H	Strong	Biomarker	[1894]
NME4	OT2JTT42	Strong	Biomarker	[1895]
NMU	OTW9X7BQ	Strong	Biomarker	[1896]
NNAT	OTNRLO7G	Strong	Biomarker	[236]
NOB1	OTW0YNSL	Strong	Altered Expression	[1897]
NOCT	OTVSYP2D	Strong	Genetic Variation	[1898]
NOL3	OT1K0L0D	Strong	Altered Expression	[753]
NOLC1	OTKDZU0D	Strong	Biomarker	[1899]
NOVA1	OT6A9KHY	Strong	Biomarker	[1900]
NPAS2	OTMRT2TS	Strong	Genetic Variation	[832]
NPRL2	OTOB10MO	Strong	Biomarker	[1901]
NR2C2	OTDZWVOJ	Strong	Altered Expression	[1902]
NR2C2AP	OTNP4LEO	Strong	Biomarker	[533]
NR2F6	OTNVO2B6	Strong	Altered Expression	[1903]
NRARP	OTMYHUV2	Strong	Altered Expression	[1904]
NSD3	OT3677ZG	Strong	Biomarker	[1905]
NUMB	OTMB586Q	Strong	Altered Expression	[1906]
NUP62	OTMN63DH	Strong	Altered Expression	[648]
NUP98	OTNT12G2	Strong	Genetic Variation	[1301]
NUPR1	OT4FU8C0	Strong	Altered Expression	[1907]
NUS1	OT4DQ82L	Strong	Biomarker	[1908]
NUSAP1	OT85HIJ5	Strong	Biomarker	[1909]
NXT1	OT0VO6AY	Strong	Genetic Variation	[1843]
OAZ1	OTPT0PKZ	Strong	Biomarker	[1910]
ONECUT2	OTHUE5YY	Strong	Biomarker	[1911]
OPCML	OT93PQ6Y	Strong	Biomarker	[1154]
OR2J3	OTSOLZWA	Strong	Altered Expression	[1912]
ORAI3	OTUP3OH3	Strong	Biomarker	[1913]
ORM1	OTZKSBRE	Strong	Altered Expression	[1351]
OTUB2	OTZUMPH2	Strong	Altered Expression	[1914]
OTUD3	OTHUWQHP	Strong	Altered Expression	[982]
OTUD6B	OTNGMN6S	Strong	Biomarker	[1915]
OTUD7B	OTMVM8R7	Strong	Biomarker	[1916]
P2RX5	OTLBR20R	Strong	Biomarker	[1917]
P4HB	OTTYNYPF	Strong	Altered Expression	[1584]
PABPN1	OT3MC5SE	Strong	Altered Expression	[1474]
PADI1	OT13WAQX	Strong	Altered Expression	[1584]
PAEP	OTQA0NV4	Strong	Biomarker	[1918]
PAFAH1B1	OT9T2TCJ	Strong	Altered Expression	[1919]
PALB2	OT6DNDBG	Strong	Altered Expression	[1920]
PAQR3	OTTKJ9Y4	Strong	Biomarker	[1921]
PAQR4	OTNO659U	Strong	Altered Expression	[1922]
PARD6A	OTWLV3X1	Strong	Biomarker	[1923]
PARN	OTTG4PE3	Strong	Biomarker	[1866]
PAX6	OTOC9876	Strong	Altered Expression	[1924]
PAX8	OTRPD9MI	Strong	Altered Expression	[1925]
PBX1	OTORABGO	Strong	Biomarker	[1926]
PC	OT6O0V51	Strong	Biomarker	[1927]
PCBP4	OTDLL4NB	Strong	Altered Expression	[1928]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[1929]
PCDH7	OTP091X8	Strong	Biomarker	[1930]
PCDHB13	OTBZ53YK	Strong	Biomarker	[1618]
PCK2	OTJ8LX4N	Strong	Altered Expression	[1931]
PCNX3	OTOM3GHH	Strong	Biomarker	[1932]
PDC	OT1UUVYY	Strong	Altered Expression	[1933]
PDCD10	OTCHJTSF	Strong	Biomarker	[1934]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[1935]
PDCD6	OT2YA5M8	Strong	Genetic Variation	[1936]
PDCD6IP	OTS8T6A7	Strong	Genetic Variation	[1937]
PDIA2	OTC2WMXS	Strong	Altered Expression	[1584]
PDIA3	OTHPQ0Q3	Strong	Biomarker	[1938]
PDIA6	OT8YBR17	Strong	Biomarker	[687]
PDIK1L	OTISF4KG	Strong	Genetic Variation	[1939]
PDPN	OTBUV19I	Strong	Biomarker	[1940]
PDYN	OTEJ6430	Strong	Biomarker	[1941]
PELI3	OTCBUSKJ	Strong	Altered Expression	[1942]
PELP1	OTVXQNOT	Strong	Altered Expression	[1943]
PER2	OTU2B1DJ	Strong	Biomarker	[1944]
PER3	OTVKYVJA	Strong	Genetic Variation	[832]
PEX19	OTQIDE9Z	Strong	Biomarker	[1945]
PFN2	OT5SSSA7	Strong	Altered Expression	[1946]
PGAM1	OTZ5DB06	Strong	Biomarker	[1947]
PGAM5	OT6Q5M0C	Strong	Altered Expression	[1948]
PHACTR2	OTWMX2A8	Strong	Genetic Variation	[1949]
PHF20	OTCBVH5P	Strong	Biomarker	[1950]
PHF5A	OTS94JFM	Strong	Altered Expression	[1951]
PHLDA2	OTMV9DPP	Strong	Biomarker	[756]
PHLPP1	OTIFXW8D	Strong	Biomarker	[1952]
PHRF1	OT21KEGX	Strong	Altered Expression	[1953]
PIAS1	OTZVAHZI	Strong	Biomarker	[785]
PIAS4	OTB7SVMZ	Strong	Biomarker	[586]
PIDD1	OTWFM930	Strong	Altered Expression	[1954]
PIEZO2	OTQ7AT38	Strong	Genetic Variation	[1498]
PIK3C2B	OTY2PROB	Strong	Genetic Variation	[1955]
PIK3C3	OTLUM9L7	Strong	Biomarker	[1956]
PIK3R2	OTZSUQK5	Strong	Biomarker	[1957]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[836]
PITX1	OTA0UN4C	Strong	Biomarker	[1958]
PITX2	OTWMXAOY	Strong	Biomarker	[823]
PIWIL1	OT7CRGZ3	Strong	Altered Expression	[1959]
PIWIL4	OTDA9MY0	Strong	Altered Expression	[1959]
PJA2	OT45TMC4	Strong	Biomarker	[1960]
PKD1	OT5ALRZ5	Strong	Altered Expression	[795]
PKNOX1	OTUDMNHX	Strong	Altered Expression	[1961]
PKP2	OTJOVF68	Strong	Altered Expression	[1962]
PKP4	OTQHOF8L	Strong	Biomarker	[1963]
PLA2G10	OTRZ2L5A	Strong	Biomarker	[242]
PLAC8	OT3SYRUJ	Strong	Altered Expression	[1964]
PLB1	OTZ6TTYV	Strong	Genetic Variation	[1965]
PLBD1	OTHYEB4W	Strong	Biomarker	[756]
PLCB3	OT0OMDEM	Strong	Altered Expression	[1966]
PLEK2	OTUBWUUK	Strong	Altered Expression	[1229]
PLSCR4	OT2AMYLY	Strong	Altered Expression	[1967]
PMCH	OT3D9SA4	Strong	Altered Expression	[1968]
PNO1	OT010GIS	Strong	Altered Expression	[804]
PNOC	OTJEAADN	Strong	Altered Expression	[753]
POGLUT1	OTDX7GZD	Strong	Biomarker	[1969]
POLA2	OTTWQ73N	Strong	Genetic Variation	[1970]
POLDIP2	OT8SZSJ6	Strong	Biomarker	[350]
POLK	OTKZ38JH	Strong	Genetic Variation	[1971]
POTEF	OTV3WXYE	Strong	Altered Expression	[1972]
POU3F1	OTYARA94	Strong	Biomarker	[871]
POU5F1	OTDHHN7O	Strong	Altered Expression	[1973]
PPA1	OTHZK1QB	Strong	Biomarker	[1974]
PPBP	OT1FHGQS	Strong	Altered Expression	[1975]
PPDPF	OT4LO2GJ	Strong	Biomarker	[1271]
PPIG	OTZ8BTTM	Strong	Biomarker	[1976]
PPP1R11	OTSHYPPW	Strong	Biomarker	[1183]
PPP1R12C	OT9Q86JO	Strong	Biomarker	[1335]
PPP1R13B	OTC88VQO	Strong	Biomarker	[1335]
PPP1R13L	OTNCPLWE	Strong	Altered Expression	[1977]
PPP2R2A	OT9297OG	Strong	Biomarker	[1978]
PRAP1	OT48QD82	Strong	Altered Expression	[1979]
PRC1	OTHD0XS0	Strong	Altered Expression	[1980]
PRCC	OTJ0KRYX	Strong	Altered Expression	[1981]
PRDM1	OTQLSVBS	Strong	Biomarker	[1982]
PRDM14	OTWZKY4L	Strong	Biomarker	[1982]
PRDX1	OTZ3BEC4	Strong	Altered Expression	[1983]
PRDX2	OTLWCY9T	Strong	Biomarker	[1984]
PRIMA1	OT9ITT3P	Strong	Biomarker	[674]
PRKAA1	OT7TNF0L	Strong	Biomarker	[382]
PRKAA2	OTU1KZPV	Strong	Biomarker	[382]
PRKAB1	OT1OG4QZ	Strong	Biomarker	[382]
PRKACG	OTKOQYF8	Strong	Genetic Variation	[280]
PRKN	OTJBN41W	Strong	Biomarker	[1403]
PROP1	OT8GF6N8	Strong	Biomarker	[1985]
PRPF38B	OTQLH551	Strong	Biomarker	[881]
PRPF40A	OT6EXJZN	Strong	Biomarker	[1986]
PRR11	OT2JJ08Z	Strong	Altered Expression	[1987]
PRRX2	OT8UR4AU	Strong	Biomarker	[1984]
PSG1	OT1U4ZZW	Strong	Altered Expression	[1501]
PSMA4	OTAD2XXI	Strong	Biomarker	[1075]
PSMD7	OT7PZZ4K	Strong	Biomarker	[660]
PSMD8	OTY6X27P	Strong	Biomarker	[1352]
PSMD9	OT6Y5CC3	Strong	Biomarker	[1506]
PSME3	OTSTC4YY	Strong	Altered Expression	[1988]
PSMG1	OTZ5I6UM	Strong	Biomarker	[345]
PSPH	OTV1PVAX	Strong	Altered Expression	[1989]
PTGES3	OTPPQWI0	Strong	Altered Expression	[1990]
PTHLH	OTI1JF13	Strong	Biomarker	[1991]
PTMA	OT2W4T1M	Strong	Biomarker	[1992]
PTOV1	OT94WT5X	Strong	Altered Expression	[1993]
PTPN3	OTSLZBVY	Strong	Biomarker	[1994]
PTPN4	OT6SXU5Y	Strong	Biomarker	[1995]
PTPRF	OTH5KF2D	Strong	Biomarker	[1996]
PTPRH	OTDUHQGF	Strong	Altered Expression	[1997]
PTPRK	OTAP5AT3	Strong	Altered Expression	[1998]
PTPRT	OTV5TXNN	Strong	Posttranslational Modification	[1999]
PTRH2	OTBU39Q1	Strong	Biomarker	[2000]
PTTG1	OTIMYS4W	Strong	Altered Expression	[2001]
PTTG1IP	OTX21QTE	Strong	Biomarker	[2002]
PTTG2	OTXGZ8FV	Strong	Altered Expression	[2001]
PUM1	OTTMWP8L	Strong	Biomarker	[2003]
PXN	OTVMMUOF	Strong	Biomarker	[1590]
PYCARD	OT67RON3	Strong	Biomarker	[1005]
PYCR1	OTQHB52T	Strong	Altered Expression	[2004]
RAB11A	OTC4FW0J	Strong	Altered Expression	[2005]
RAB11FIP2	OTTX9RWE	Strong	Posttranslational Modification	[1276]
RAB14	OTF1J0TB	Strong	Biomarker	[2006]
RAB17	OT7NBUGQ	Strong	Biomarker	[2007]
RAB18	OTNMAQLS	Strong	Altered Expression	[2008]
RAB25	OTW0W6NP	Strong	Altered Expression	[2009]
RAB26	OTHMPRJK	Strong	Biomarker	[2010]
RAB27A	OT9SQRWY	Strong	Altered Expression	[2011]
RAB27B	OTPF9D0K	Strong	Altered Expression	[2011]
RAB38	OTU0NZU0	Strong	Biomarker	[2012]
RAB8A	OTPB54Y3	Strong	Biomarker	[2013]
RABEPK	OTCZSREH	Strong	Biomarker	[660]
RAC2	OTAOHFNH	Strong	Altered Expression	[2014]
RACGAP1	OTQE8IEH	Strong	Biomarker	[1990]
RAD23B	OT0PGOG3	Strong	Altered Expression	[924]
RAD50	OTYMU9G1	Strong	Biomarker	[2015]
RAD51AP1	OTXM7UTD	Strong	Biomarker	[2016]
RAD51B	OTCJVRMY	Strong	Biomarker	[2017]
RAD52	OT0OTDHI	Strong	Biomarker	[2018]
RAD9A	OTJ3AJQU	Strong	Biomarker	[2019]
RAG2	OTG9UYTW	Strong	Biomarker	[2020]
RALGPS2	OTOYS0SD	Strong	Biomarker	[1192]
RANBP9	OTM8COM5	Strong	Biomarker	[2021]
RAP1A	OT5RH6TI	Strong	Biomarker	[2022]
RAP1GDS1	OTH70UHD	Strong	Biomarker	[2023]
RAP2B	OTD2NDQP	Strong	Altered Expression	[2024]
RARRES2	OT1BJE8K	Strong	Biomarker	[346]
RASD1	OT2BAJHK	Strong	Biomarker	[2006]
RASIP1	OTCRY2AN	Strong	Biomarker	[2025]
RASSF2	OT2JHDO4	Strong	Posttranslational Modification	[2026]
RASSF3	OT4V9SRK	Strong	Biomarker	[2027]
RASSF4	OT7YLOFH	Strong	Altered Expression	[2028]
RASSF7	OT0V4EIZ	Strong	Biomarker	[2029]
RASSF8	OTXKGIB3	Strong	Biomarker	[2030]
RB1	OT9VMY7B	Strong	Biomarker	[2031]
RBAK	OTYJ6EAU	Strong	Biomarker	[2032]
RBM19	OT3Q6UIM	Strong	Biomarker	[1818]
RBM23	OTDNGLHY	Strong	Biomarker	[205]
RBM3	OTAJ7R31	Strong	Biomarker	[2033]
RBM38	OTPO8EXU	Strong	Biomarker	[2034]
RBM39	OTCMPTF9	Strong	Altered Expression	[2035]
RBM5	OTCBWHHV	Strong	Altered Expression	[2036]
RBM7	OTFIWTMF	Strong	Biomarker	[756]
RBM8A	OT5SR6G0	Strong	Biomarker	[2037]
RBMS3	OTFSC9MR	Strong	Altered Expression	[804]
RBP2	OTR8QG5V	Strong	Biomarker	[2038]
RBX1	OTYA1UIO	Strong	Biomarker	[2039]
RCCD1	OT60N06L	Strong	Biomarker	[2040]
RCN1	OT3JBGAG	Strong	Altered Expression	[2041]
RDM1	OTBSJEAG	Strong	Biomarker	[2018]
RECQL	OTPCH3JH	Strong	Altered Expression	[2042]
RFPL3	OTBMMY9Z	Strong	Altered Expression	[2043]
RFWD3	OTDUULBQ	Strong	Biomarker	[2044]
RFX5	OT73KJ5P	Strong	Altered Expression	[2045]
RGCC	OTYJMLWM	Strong	Genetic Variation	[2046]
RGMB	OT2DROYU	Strong	Genetic Variation	[2047]
RGN	OTD04KB1	Strong	Altered Expression	[2048]
RGS17	OT5RVUDS	Strong	Biomarker	[2049]
RGS3	OTYG5OXI	Strong	Altered Expression	[2050]
RHEB	OTFLTSEC	Strong	Biomarker	[2051]
RHOH	OT1J9SEB	Strong	Altered Expression	[288]
RHOJ	OTWI65OA	Strong	Altered Expression	[2052]
RHOV	OTW4N3QN	Strong	Altered Expression	[2053]
RIF1	OTPE49OE	Strong	Biomarker	[1920]
RIN1	OTPBROUD	Strong	Altered Expression	[2054]
RING1	OTCWTAX0	Strong	Biomarker	[2055]
RIOK2	OTQODJ7F	Strong	Altered Expression	[1897]
RITA1	OTUH8IPS	Strong	Biomarker	[2056]
RMDN1	OTE1NB6U	Strong	Altered Expression	[648]
RMDN2	OTK5WSFI	Strong	Altered Expression	[648]
RMDN3	OTKO7AUM	Strong	Altered Expression	[648]
RNASE3	OTVE2XD1	Strong	Altered Expression	[816]
RND3	OTXMXPIH	Strong	Altered Expression	[2057]
RNF111	OTO3QT6Q	Strong	Biomarker	[2058]
RNF146	OTE4CO7E	Strong	Biomarker	[2059]
RNF187	OTXTN1HP	Strong	Biomarker	[2060]
RNF19A	OTKWCV80	Strong	Biomarker	[350]
RNF25	OTQJSBEG	Strong	Biomarker	[2061]
RNF38	OTRLV4WZ	Strong	Altered Expression	[2062]
RNF8	OTRR43PZ	Strong	Biomarker	[2063]
RNPS1	OT7G4COD	Strong	Altered Expression	[2064]
ROBO3	OTPVG40S	Strong	Altered Expression	[492]
ROMO1	OTIEYVBW	Strong	Biomarker	[2065]
ROPN1L	OTRWZJ68	Strong	Genetic Variation	[368]
RPA1	OT76POLP	Strong	Genetic Variation	[1591]
RPAIN	OTBMXAYK	Strong	Biomarker	[251]
RPL13A	OTME3VXN	Strong	Altered Expression	[1972]
RPL32	OTKRQJT4	Strong	Biomarker	[1741]
RPL34	OT0U9VMQ	Strong	Biomarker	[2066]
RPLP0	OT3XKD6Y	Strong	Altered Expression	[1972]
RPS15A	OT0BUA12	Strong	Biomarker	[2067]
RPS27A	OTIIGGZ2	Strong	Biomarker	[956]
RPS3	OT0K3TMH	Strong	Biomarker	[699]
RPS6	OTT4D1LN	Strong	Biomarker	[2068]
RRAD	OTW2O4GD	Strong	Biomarker	[2069]
RTL10	OTHGB81W	Strong	Altered Expression	[2070]
RTRAF	OTJ6NVMW	Strong	Altered Expression	[2071]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[2072]
S100A1	OT1F2G4J	Strong	Biomarker	[2073]
S100A11	OTI57KDN	Strong	Biomarker	[2074]
S100A13	OT582SUS	Strong	Altered Expression	[2075]
S100A14	OTVFJJ91	Strong	Biomarker	[2076]
S100A7	OTJFVJRF	Strong	Biomarker	[1650]
S100A7A	OTNM8DCP	Strong	Biomarker	[2076]
SAA2	OTYAVJWG	Strong	Biomarker	[846]
SAGE1	OT4H6FFA	Strong	Biomarker	[2077]
SAMD9	OTDG48P0	Strong	Altered Expression	[2078]
SARDH	OTQ49Q27	Strong	Altered Expression	[2079]
SARNP	OTE0OVK5	Strong	Altered Expression	[2035]
SART3	OTC1AM7S	Strong	Biomarker	[2080]
SAXO1	OT7M6PLA	Strong	Genetic Variation	[2081]
SCAF1	OT16TM3N	Strong	Genetic Variation	[2082]
SCAF11	OTX59D0X	Strong	Biomarker	[1654]
SCO2	OTJQQDRS	Strong	Altered Expression	[955]
SDC4	OTKUVUGZ	Strong	Genetic Variation	[2083]
SDF4	OTQ7WFYW	Strong	Altered Expression	[844]
SDHA	OTOJ8QFF	Strong	Genetic Variation	[2084]
SDHAF2	OT0UG9H5	Strong	Altered Expression	[2085]
SDHC	OTC8G2MX	Strong	Altered Expression	[2086]
SEC31A	OT2U42AC	Strong	Altered Expression	[2087]
SEC61G	OT7MJRXY	Strong	Biomarker	[2088]
SEC62	OTCWEL5F	Strong	Biomarker	[2089]
SELENOS	OTUEWIU9	Strong	Biomarker	[2090]
SEMA3B	OTCZCPMS	Strong	Biomarker	[2091]
SEMA4C	OTF5JHQ0	Strong	Biomarker	[2092]
SEMA6A	OTDQ7QAW	Strong	Altered Expression	[1258]
SEPTIN7	OTJI08YX	Strong	Biomarker	[2093]
SERBP1	OTZVSU0X	Strong	Biomarker	[2094]
SERPINA3	OT9BP2S0	Strong	Biomarker	[2095]
SERPINB2	OT72QLZB	Strong	Altered Expression	[2096]
SERPINB4	OT88LHZ8	Strong	Altered Expression	[2097]
SESN3	OTJRY1Y5	Strong	Biomarker	[2098]
SETD5	OTRPAVEO	Strong	Biomarker	[2099]
SF3A3	OTHBGNXE	Strong	Biomarker	[1208]
SF3B3	OTAC9LZT	Strong	Biomarker	[2100]
SFN	OTLJCZ1U	Strong	Altered Expression	[1372]
SFRP1	OT0U9G41	Strong	Biomarker	[2101]
SFRP5	OTLCVVSH	Strong	Biomarker	[2102]
SFTPA1	OT87XL1U	Strong	Genetic Variation	[2103]
SFTPA2	OT6SFOMU	Strong	Genetic Variation	[2103]
SGSM3	OTIB1P8A	Strong	Genetic Variation	[2104]
SH3GL2	OTOE443G	Strong	Biomarker	[2105]
SHC1	OT1J5IRN	Strong	Biomarker	[855]
SHISA3	OTE8TPCP	Strong	Biomarker	[2106]
SHOC2	OTUNQ2CT	Strong	Biomarker	[2107]
SHOX2	OTLCZZJW	Strong	Biomarker	[2108]
SHQ1	OTFBXX2H	Strong	Altered Expression	[2109]
SHTN1	OTB07MOG	Strong	Genetic Variation	[545]
SIAH2	OTKED2XN	Strong	Biomarker	[2110]
SIGLEC9	OTZC7SIM	Strong	Altered Expression	[2111]
SIM2	OT0QWHK4	Strong	Altered Expression	[2112]
SIN3A	OTM8OZWV	Strong	Altered Expression	[2113]
SIPA1	OTXY5RXC	Strong	Genetic Variation	[2114]
SIRT4	OT5S0J23	Strong	Biomarker	[2115]
SIRT7	OT5M4OT4	Strong	Altered Expression	[2116]
SIX6	OTD1RD9D	Strong	Biomarker	[2117]
SKAP2	OTSF44KP	Strong	Biomarker	[2118]
SLC12A9	OTR7VRAK	Strong	Altered Expression	[445]
SLC16A4	OT1YXBKC	Strong	Altered Expression	[866]
SLC22A18	OT9C3KR4	Strong	Biomarker	[2119]
SLC2A4RG	OTW3LX8D	Strong	Biomarker	[1536]
SLC35F2	OTSAD4EQ	Strong	Altered Expression	[2120]
SLPI	OTUNFUU8	Strong	Biomarker	[340]
SMAD2	OTC6VB4K	Strong	Altered Expression	[2121]
SMAD4	OTWQWCKG	Strong	Genetic Variation	[2122]
SMAD5	OTQNSVCQ	Strong	Altered Expression	[1521]
SMARCA1	OT0Y6PTU	Strong	Biomarker	[1286]
SMARCA5	OT5GR4Z2	Strong	Biomarker	[2123]
SMARCD1	OTHFFT6G	Strong	Altered Expression	[2124]
SMARCE1	OTAX4ITH	Strong	Biomarker	[2125]
SMPX	OTLSHGBF	Strong	Genetic Variation	[2126]
SMR3B	OTL5HNM8	Strong	Altered Expression	[2127]
SNAI1	OTDPYAMC	Strong	Altered Expression	[1207]
SNAI3	OTG9DI66	Strong	Altered Expression	[2128]
SNAP47	OT1DE2QT	Strong	Altered Expression	[2094]
SND1	OTT734JN	Strong	Altered Expression	[2074]
SNIP1	OTL3RA91	Strong	Biomarker	[2129]
SNRPB	OT3UJ4ZU	Strong	Biomarker	[2130]
SNRPD3	OTZXBQ45	Strong	Biomarker	[1208]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[206]
SOCS2	OTBPNKJQ	Strong	Altered Expression	[2131]
SOCS6	OT2O5ZBK	Strong	Biomarker	[2132]
SOS2	OTV3XRE5	Strong	Biomarker	[2133]
SOSTDC1	OTAKDNSM	Strong	Biomarker	[2134]
SOX1	OTVI1RAR	Strong	Biomarker	[2135]
SOX13	OTCIF6KC	Strong	Altered Expression	[2136]
SOX17	OT9H4WWE	Strong	Posttranslational Modification	[2137]
SOX18	OTPUMHWA	Strong	Altered Expression	[2138]
SOX30	OTGT38E3	Strong	Altered Expression	[2139]
SOX4	OTSS40SS	Strong	Biomarker	[728]
SOX6	OTT0W0LE	Strong	Altered Expression	[2140]
SOX8	OTEJXYZM	Strong	Altered Expression	[2141]
SOX9	OTVDJFGN	Strong	Altered Expression	[2142]
SPA17	OT8J7T7U	Strong	Biomarker	[1407]
SPAAR	OTWXG2R8	Strong	Biomarker	[2143]
SPAG5	OTCLJ56M	Strong	Biomarker	[2144]
SPAG9	OT45AHMB	Strong	Biomarker	[2145]
SPC24	OT1HVYV4	Strong	Biomarker	[2146]
SPC25	OTCAS0OH	Strong	Biomarker	[2147]
SPIN1	OT69VAOX	Strong	Altered Expression	[2148]
SPINK1	OTSUVAL2	Strong	Biomarker	[2149]
SPINT1	OT1CLR5L	Strong	Altered Expression	[2150]
SPINT2	OTQV7BKQ	Strong	Altered Expression	[2151]
SPNS2	OTPODAPU	Strong	Altered Expression	[2152]
SPOP	OTP0107S	Strong	Biomarker	[2153]
SPRY4	OT2VK9N0	Strong	Altered Expression	[2154]
SPTB	OT1Q9ABM	Strong	Biomarker	[1614]
SRF	OTW18FQN	Strong	Biomarker	[2155]
SRL	OT7IEBWZ	Strong	Altered Expression	[2079]
SRRM2	OTSIMMC9	Strong	Altered Expression	[804]
SRSF1	OTF61HOV	Strong	Biomarker	[1223]
SRSF2	OTVDHO6U	Strong	Altered Expression	[903]
SRSF5	OTC5WP98	Strong	Biomarker	[781]
SRY	OT516T6D	Strong	Altered Expression	[904]
SSBP1	OTH2PZWH	Strong	Biomarker	[2156]
SSR1	OTQ6GDL2	Strong	Genetic Variation	[2157]
ST13	OTNML6UP	Strong	Genetic Variation	[2158]
ST6GAL1	OT7US3NO	Strong	Biomarker	[2159]
ST8SIA2	OTRBBBD8	Strong	Biomarker	[2160]
STARD13	OTB4U1HY	Strong	Altered Expression	[1548]
STAT2	OTO9G2RZ	Strong	Altered Expression	[907]
STAT5A	OTBSJGN3	Strong	Altered Expression	[1287]
STIM1	OT8CLQ1W	Strong	Biomarker	[2161]
STIP1	OT7TXLOX	Strong	Genetic Variation	[2158]
STOM	OTC8R6EH	Strong	Altered Expression	[2162]
STPG4	OT5K4UFL	Strong	Altered Expression	[1828]
STRN4	OTHK2ZN6	Strong	Biomarker	[2163]
STUB1	OTSUYI9A	Strong	Biomarker	[2164]
STXBP5	OTE3M7QB	Strong	Altered Expression	[2165]
SUSD6	OTZS4SKF	Strong	Biomarker	[2166]
SYBU	OT3FQV7N	Strong	Altered Expression	[648]
SYCP3	OTKOF54H	Strong	Biomarker	[2167]
SYF2	OTY2ZW1H	Strong	Altered Expression	[2168]
SYP	OTFJKMO4	Strong	Altered Expression	[2169]
SYT1	OTVTPOI6	Strong	Altered Expression	[975]
SYT7	OTBWAOWY	Strong	Altered Expression	[2170]
SYTL2	OTUIOWKL	Strong	Biomarker	[911]
TAB1	OTPM6F85	Strong	Altered Expression	[2171]
TAB3	OT1ECMDL	Strong	Altered Expression	[1240]
TADA3	OTNUAIO9	Strong	Altered Expression	[2172]
TAPBP	OTL81AVZ	Strong	Altered Expression	[2173]
TARBP1	OT14Z6RJ	Strong	Altered Expression	[2174]
TARBP2	OT1QQ8H3	Strong	Biomarker	[2037]
TAT	OT2CJ91O	Strong	Biomarker	[2175]
TATDN1	OTQ3S9AL	Strong	Biomarker	[1220]
TBP	OT6C0S52	Strong	Biomarker	[1734]
TBPL1	OT4I143E	Strong	Biomarker	[918]
TBX2	OTTOT7A9	Strong	Altered Expression	[2176]
TBX3	OTM64N7K	Strong	Altered Expression	[2177]
TCEAL7	OTNPDZCN	Strong	Altered Expression	[2178]
TCF21	OT393IMA	Strong	Posttranslational Modification	[2179]
TCF7	OT1ID822	Strong	Altered Expression	[2180]
TCN1	OTW6A49Y	Strong	Altered Expression	[2181]
TCTN1	OTG5KEV8	Strong	Biomarker	[2182]
TEAD1	OTK6971C	Strong	Altered Expression	[2183]
TENT5A	OTSYF511	Strong	Genetic Variation	[1362]
TES	OTL8PP6V	Strong	Biomarker	[2184]
TESC	OTI8C76M	Strong	Biomarker	[2185]
TESMIN	OTZ5UILU	Strong	Altered Expression	[2186]
TET1	OTZDHT1D	Strong	Posttranslational Modification	[2187]
TFAM	OTXXV5V7	Strong	Biomarker	[2188]
TFAP2B	OTR1T8E9	Strong	Biomarker	[2189]
TFDP1	OT6RZ7VT	Strong	Biomarker	[1470]
TFE3	OTM99ZWH	Strong	Altered Expression	[2190]
TFEB	OTJUJJQY	Strong	Altered Expression	[2191]
TFIP11	OT7NVSWU	Strong	Biomarker	[2192]
TFPI2	OTZCRWOR	Strong	Posttranslational Modification	[2193]
TG	OT3ELHIJ	Strong	Biomarker	[2194]
TGFBI	OTR443C5	Strong	Biomarker	[2195]
TGFBR3	OTQOOUC4	Strong	Biomarker	[2196]
TGIF1	OTN9VHAG	Strong	Altered Expression	[2197]
TGIF2	OTMKKE3W	Strong	Biomarker	[2198]
THBS2	OTXET551	Strong	Biomarker	[2199]
TIAM2	OTPYIPT6	Strong	Biomarker	[2200]
TICAM2	OTK7GIJ5	Strong	Biomarker	[1506]
TIGAR	OTR7NMRJ	Strong	Biomarker	[2201]
TIMD4	OTGGC20G	Strong	Biomarker	[2202]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[1334]
TIMM8A	OTDX9687	Strong	Altered Expression	[1248]
TIMP2	OT8S1RRP	Strong	Biomarker	[2203]
TIMP3	OTDGQAD1	Strong	Altered Expression	[2204]
TINAGL1	OTZZO56M	Strong	Biomarker	[2205]
TJP1	OTBDCUPK	Strong	Altered Expression	[2206]
TLK1	OTICTXI8	Strong	Genetic Variation	[280]
TM4SF1	OTY0ECQN	Strong	Biomarker	[2207]
TM4SF4	OTRI8EHN	Strong	Biomarker	[2208]
TM4SF5	OTPAV531	Strong	Altered Expression	[2209]
TM7SF2	OTILU5S7	Strong	Altered Expression	[169]
TMED7	OTONO8E6	Strong	Biomarker	[1506]
TMEFF2	OT1WZ2QO	Strong	Posttranslational Modification	[2210]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[2211]
TMEM14A	OTANQA6G	Strong	Biomarker	[2212]
TMEM158	OT0KUBBI	Strong	Biomarker	[1600]
TMEM17	OTEU00OH	Strong	Biomarker	[2213]
TMEM88	OTA96YEL	Strong	Biomarker	[2214]
TMPO	OTL68EL4	Strong	Biomarker	[2215]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[2216]
TMTC3	OTMTTDYG	Strong	Genetic Variation	[1479]
TNFAIP1	OT37EWR0	Strong	Biomarker	[2217]
TNFAIP8L3	OTHSBS1B	Strong	Altered Expression	[2218]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[496]
TNFSF9	OTV9L89D	Strong	Biomarker	[2219]
TNNI1	OT4GG8ED	Strong	Altered Expression	[2220]
TOB1	OTNW949D	Strong	Biomarker	[1544]
TOP3A	OT3CKUI9	Strong	Biomarker	[941]
TOPBP1	OT6UPZPD	Strong	Biomarker	[2221]
TP53AIP1	OT1XVNDP	Strong	Altered Expression	[2222]
TP53BP2	OTOWJ2Y4	Strong	Altered Expression	[2223]
TP53I3	OTSCM68G	Strong	Biomarker	[1844]
TP73	OT0LUO47	Strong	Biomarker	[1330]
TPD52L1	OTSA6U0I	Strong	Genetic Variation	[2224]
TPM3	OT5RU5G6	Strong	Biomarker	[2225]
TPPP2	OTI3WA6X	Strong	Genetic Variation	[371]
TPPP3	OTU8VUIG	Strong	Altered Expression	[2226]
TRA2B	OTZYQW52	Strong	Altered Expression	[2227]
TRAF1	OTTLM5RU	Strong	Biomarker	[2228]
TRAF2	OT1MEZZN	Strong	Altered Expression	[2229]
TRAF4	OTJLRVMC	Strong	Biomarker	[2230]
TRAP1	OTNG0L8J	Strong	Biomarker	[604]
TRERF1	OTA7UQF1	Strong	Biomarker	[2231]
TRIB1	OTPEO17G	Strong	Biomarker	[2232]
TRIB3	OTG5OS7X	Strong	Altered Expression	[2233]
TRIM14	OTLQKUG0	Strong	Altered Expression	[2234]
TRIM15	OTNYAKP6	Strong	Altered Expression	[1291]
TRIM16	OTLRXYOZ	Strong	Biomarker	[2235]
TRIM22	OTJBLG5R	Strong	Altered Expression	[2236]
TRIM25	OT35SG1R	Strong	Altered Expression	[2237]
TRIM32	OTJOV0PG	Strong	Altered Expression	[2238]
TRIM33	OT0KS4J7	Strong	Biomarker	[2239]
TRIM36	OT37JQ8Y	Strong	Posttranslational Modification	[2240]
TRIM4	OTLKQNKQ	Strong	Altered Expression	[1464]
TRIM45	OTFDQT4E	Strong	Altered Expression	[2241]
TRIM46	OTFE7WZW	Strong	Altered Expression	[1464]
TRIM47	OTM9DGUD	Strong	Biomarker	[2242]
TRIM54	OTI49DD6	Strong	Altered Expression	[1464]
TRIM65	OTSQTK3A	Strong	Altered Expression	[2243]
TRIM67	OTXRZN27	Strong	Altered Expression	[1464]
TRIM9	OTKYG33W	Strong	Altered Expression	[1464]
TRMO	OTNJ7K9K	Strong	Altered Expression	[1240]
TRPV5	OTWF4L0U	Strong	Biomarker	[373]
TSC22D1	OTN4GFWD	Strong	Biomarker	[2244]
TSN	OTOFAQ2Z	Strong	Altered Expression	[2074]
TSPAN1	OTZQPIYK	Strong	Biomarker	[881]
TSPAN12	OTF9I3CX	Strong	Biomarker	[2245]
TSPAN18	OTHSGPVB	Strong	Altered Expression	[2246]
TSPAN33	OTH6C0WU	Strong	Biomarker	[2247]
TSPAN8	OT1F68WQ	Strong	Biomarker	[2246]
TTF1	OT4K90WD	Strong	Biomarker	[1892]
ALDH1A3	OT1C9NKQ	Definitive	Biomarker	[2248]
AQP5	OT77GBY8	Definitive	Biomarker	[2249]
ARHGAP1	OT0H2ZBZ	Definitive	Biomarker	[1547]
ASH1L	OTUT5NLJ	Definitive	Genetic Variation	[2250]
C4BPA	OTHNH6Y8	Definitive	Biomarker	[2251]
C4BPB	OTJ70B0K	Definitive	Biomarker	[2251]
CRTAP	OT53H5U6	Definitive	Genetic Variation	[2252]
CSNK2A3	OTZP4KZK	Definitive	Altered Expression	[2253]
CYB561D2	OT1ZXC66	Definitive	Altered Expression	[2254]
CYTIP	OTRJ3ZC5	Definitive	Genetic Variation	[2252]
DMTF1	OTDKO9OO	Definitive	Biomarker	[2255]
DNTT	OTFSEF12	Definitive	Altered Expression	[2256]
DOK4	OTUEWLG8	Definitive	Biomarker	[2257]
EGFR	OTAPLO1S	Definitive	Autosomal dominant	[991]
EIF3H	OT61RBF5	Definitive	Biomarker	[2258]
ESPL1	OTMGEVOK	Definitive	Altered Expression	[2259]
FRMD3	OT0CD2GG	Definitive	Altered Expression	[2260]
GSTT2	OTANW3TJ	Definitive	Genetic Variation	[2261]
HNRNPAB	OTUKPFOK	Definitive	Altered Expression	[2262]
HOXB2	OTTD6HMV	Definitive	Biomarker	[2263]
HPR	OTXSC9UB	Definitive	Biomarker	[2264]
KIF4A	OT3UWL7D	Definitive	Biomarker	[2265]
KLHL1	OTAX6SAD	Definitive	Biomarker	[2266]
MOB1A	OTSPBZ4Z	Definitive	Altered Expression	[2267]
MOB4	OTOQRMAS	Definitive	Altered Expression	[2267]
MTHFS	OTZ39JNR	Definitive	Biomarker	[2268]
MUS81	OTVZ4E60	Definitive	Biomarker	[1006]
NEK4	OTOB8366	Definitive	Genetic Variation	[2269]
OGN	OTKP5S4L	Definitive	Biomarker	[2270]
OLIG1	OTIMFI31	Definitive	Altered Expression	[2271]
PAPPA	OTTTG9PG	Definitive	Genetic Variation	[2272]
PBX2	OTEBYCAW	Definitive	Altered Expression	[2273]
PCDH20	OTFSNRXK	Definitive	Genetic Variation	[2274]
PLCH1	OT6Z1L2E	Definitive	Genetic Variation	[2275]
POU2F1	OTK7ELJ0	Definitive	Altered Expression	[1002]
PRRX1	OTTZK5G8	Definitive	Altered Expression	[1983]
PRSS3	OTN3S5YB	Definitive	Biomarker	[2276]
RAB37	OTRL8IUO	Definitive	Posttranslational Modification	[2277]
RASGRF2	OT67DAGF	Definitive	Posttranslational Modification	[2278]
RBM14	OTO9GMBD	Definitive	Genetic Variation	[2279]
RBMX	OTFZN66E	Definitive	Altered Expression	[2280]
RDH10	OTL9FSGF	Definitive	Altered Expression	[2281]
RFC1	OT3L5PK3	Definitive	Altered Expression	[2282]
RPL19	OT33LM66	Definitive	Altered Expression	[2283]
RPN2	OTJ1SKOA	Definitive	Biomarker	[2284]
SELENOF	OT2JFB3S	Definitive	Biomarker	[2285]
SELENOP	OT02B8IR	Definitive	Altered Expression	[2285]
SEMA5A	OTUOIOJV	Definitive	Biomarker	[2286]
SEZ6L	OT5Z9CUA	Definitive	Altered Expression	[2287]
SGMS1	OTZQE7PW	Definitive	Altered Expression	[2267]
SPRY2	OTH0CRCZ	Definitive	Biomarker	[2288]
SYCE1L	OTXU44F3	Definitive	Biomarker	[2266]
TBC1D7	OT1ALJ63	Definitive	Altered Expression	[2289]
TFG	OT2KJENI	Definitive	Biomarker	[2290]
TMEM132D	OTV6I4Z0	Definitive	Biomarker	[2291]
TNFRSF10D	OTOSRDJT	Definitive	Altered Expression	[2292]
TRIM44	OT0B1T2B	Definitive	Biomarker	[2293]
TSPAN14	OT29167O	Definitive	Genetic Variation	[2281]

References

• [1] ClinicalTrials.gov (NCT04685135) Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12). U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7739).
• [3] Aminophylline FDA Label
• [4] ClinicalTrials.gov (NCT04538664) A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON). U.S. National Institutes of Health.
• [5] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Carboplatin FDA Label
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
• [11] Cisplatin FDA Label
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] Dasatinib FDA Label
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7044).
• [16] Docetaxel FDA Label
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
• [18] Etoposide FDA Label
• [19] Gefitinib FDA Label
• [20] Gemcitabine FDA Label
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936).
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Levoleucovorin FDA Label
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8024).
• [25] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [27] ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health.
• [28] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [29] ClinicalTrials.gov (NCT02294058) Phase 3 Study of RPC1063 in Relapsing MS. U.S. National Institutes of Health.
• [30] Paclitaxel FDA Label
• [31] Panobinostat FDA Label
• [32] Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2023 Nov 10;66:102303.
• [33] Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41(11):1992-1998.
• [34] Pemetrexed FDA Label
• [35] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [36] ClinicalTrials.gov (NCT04203511) INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301). U.S. National Institutes of Health.
• [37] Clinical pipeline report, company report or official report of Roche.
• [38] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [39] Sirolimus FDA Label
• [40] Sorafenib FDA Label
• [41] ClinicalTrials.gov (NCT04303780) Study to Compare AMG 510 Proposed INN Sotorasib With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).. U.S. National Institutes of Health.
• [42] Sunitinib FDA Label
• [43] Theophylline FDA Label
• [44] Vinorelbine FDA Label
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7641).
• [46] ClinicalTrials.gov (NCT03856697) Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation. U.S. National Institutes of Health.
• [47] ClinicalTrials.gov (NCT04870190) Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK). U.S. National Institutes of Health.
• [48] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [49] ClinicalTrials.gov (NCT00796445) A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor. U.S. National Institutes of Health.
• [50] Clinical pipeline report, company report or official report of Roche.
• [51] ClinicalTrials.gov (NCT01999673) Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE). U.S. National Institutes of Health.
• [52] ClinicalTrials.gov (NCT00676507) Phase III Lucanix Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy. U.S. National Institutes of Health.
• [53] ClinicalTrials.gov (NCT02272413) Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer. U.S. National Institutes of Health.
• [54] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7966).
• [55] ClinicalTrials.gov (NCT01737814) Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC). U.S. National Institutes of Health.
• [56] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [57] ClinicalTrials.gov (NCT02810457) Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA). U.S. National Institutes of Health.
• [58] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023735)
• [59] ClinicalTrials.gov (NCT04474119) KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [60] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [61] ClinicalTrials.gov (NCT04746924) A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer. U.S. National Institutes of Health.
• [62] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [63] ClinicalTrials.gov (NCT02109562) Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients. U.S. National Institutes of Health.
• [64] ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.
• [65] ClinicalTrials.gov (NCT04154956) SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03). U.S. National Institutes of Health.
• [66] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5665).
• [67] ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.
• [68] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [69] ClinicalTrials.gov (NCT01383148) Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME). U.S. National Institutes of Health.
• [70] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025022)
• [71] ClinicalTrials.gov (NCT02142959) RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE. U.S. National Institutes of Health.
• [72] ClinicalTrials.gov (NCT00152477) A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer. U.S. National Institutes of Health.
• [73] ClinicalTrials.gov (NCT02047344) Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC. U.S. National Institutes of Health.
• [74] ClinicalTrials.gov (NCT02500927) A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naive Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
• [75] ClinicalTrials.gov (NCT03184571) Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC. U.S. National Institutes of Health.
• [76] ClinicalTrials.gov (NCT00620607) huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas. U.S. National Institutes of Health.
• [77] ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [78] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034046)
• [79] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7881).
• [80] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038474)
• [81] ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
• [82] ClinicalTrials.gov (NCT03625323) Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002). U.S. National Institutes of Health.
• [83] ClinicalTrials.gov (NCT00828009) BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell LungCancer That Cannot Be Removed by Surgery. U.S. National Institutes of Health.
• [84] ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
• [85] ClinicalTrials.gov (NCT03417882) GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC. U.S. National Institutes of Health.
• [86] ClinicalTrials.gov (NCT03417882) GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC. U.S. National Institutes of Health.
• [87] ClinicalTrials.gov (NCT01149343) Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer. U.S. National Institutes of Health.
• [88] ClinicalTrials.gov (NCT02117024) A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [89] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [90] ClinicalTrials.gov (NCT04549025) Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT). U.S. National Institutes of Health.
• [91] ClinicalTrials.gov (NCT01487174) KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy. U.S. National Institutes of Health.
• [92] ClinicalTrials.gov (NCT00094848) Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
• [93] ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [94] ClinicalTrials.gov (NCT02544633) Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET.
• [95] ClinicalTrials.gov (NCT04165070) KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naive Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A). U.S. National Institutes of Health.
• [96] Nintedanib FDA Label
• [97] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6035).
• [98] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972)
• [99] ClinicalTrials.gov (NCT02454842) Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC (TH-4000). U.S. National Institutes of Health.
• [100] Clinical pipeline report, company report or official report of Cell Point Centennial.
• [101] ClinicalTrials.gov (NCT03539536) Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021633)
• [103] ClinicalTrials.gov (NCT00082017) UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas. U.S. National Institutes of Health.
• [104] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030166)
• [105] ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
• [106] ClinicalTrials.gov (NCT00975039) Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma. U.S. National Institutes of Health.
• [107] ClinicalTrials.gov (NCT01242943) Radioimmunotherapy With 131I-L19SIP in Patients With Cancer. U.S. National Institutes of Health.
• [108] ClinicalTrials.gov (NCT03847519) Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [109] ClinicalTrials.gov (NCT01211483) Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [110] ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
• [111] ClinicalTrials.gov (NCT01311713) Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [112] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011883)
• [113] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766)
• [114] ClinicalTrials.gov (NCT00923312) Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC). U.S. National Institutes of Health.
• [115] ClinicalTrials.gov (NCT04444427) Evaluation of GLR2007 for Advanced Solid Tumors. U.S. National Institutes of Health.
• [116] ClinicalTrials.gov (NCT02030184) Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas. U.S. National Institutes of Health.
• [117] ClinicalTrials.gov (NCT04486833) TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone. U.S. National Institutes of Health.
• [118] ClinicalTrials.gov (NCT03337698) A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung). U.S. National Institutes of Health.
• [119] Clinical pipeline report, company report or official report of Rgenix.
• [120] ClinicalTrials.gov (NCT01631279) A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors. U.S. National Institutes of Health.
• [121] ClinicalTrials.gov (NCT04872634) A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (SNK_ASTER). U.S. National Institutes of Health.
• [122] ClinicalTrials.gov (NCT02048488) A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas. U.S. National Institutes ofHealth.
• [123] ClinicalTrials.gov (NCT04396340) First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b. U.S. National Institutes of Health.
• [124] ClinicalTrials.gov (NCT03446417) A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [125] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [126] ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.
• [127] Clinical pipeline report, company report or official report of Genentech (2011).
• [128] ClinicalTrials.gov (NCT03371485) AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [129] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027382)
• [130] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8026).
• [131] ClinicalTrials.gov (NCT04452214) A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors. U.S. National Institutes of Health.
• [132] ClinicalTrials.gov (NCT04036682) A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [133] ClinicalTrials.gov (NCT04314089) Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902). U.S. National Institutes of Health.
• [134] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041112)
• [135] ClinicalTrials.gov (NCT04432207) A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [136] ClinicalTrials.gov (NCT00676910) A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.. U.S. National Institutes of Health.
• [137] ClinicalTrials.gov (NCT04077463) A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [138] Clinical pipeline report, company report or official report of Lantern Pharma.
• [139] ClinicalTrials.gov (NCT02122861) A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1. U.S. National Institutes of Health.
• [140] ClinicalTrials.gov (NCT03948763) A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001). U.S. National Institutes of Health.
• [141] ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
• [142] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [143] ClinicalTrials.gov (NCT04140526) Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001). U.S. National Institutes of Health.
• [144] ClinicalTrials.gov (NCT01957280) Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287). U.S. National Institutes of Health.
• [145] ClinicalTrials.gov (NCT01146171) Japanese Phase 1 Study of BMS-844203 (CT322). U.S. National Institutes of Health.
• [146] ClinicalTrials.gov (NCT01853878) A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor. U.S. National Institutes of Health.
• [147] ClinicalTrials.gov (NCT04077099) REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [148] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6565).
• [149] Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902.
• [150] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4782).
• [151] Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
• [152] ClinicalTrials.gov (NCT00437749) A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
• [153] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5660).
• [154] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026002)
• [155] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021934)
• [156] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030998)
• [157] AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.
• [158] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014561)
• [159] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [160] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [161] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804).
• [162] ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
• [163] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [164] ABCG1 as a potential oncogene in lung cancer. Exp Ther Med. 2017 Jun;13(6):3189-3194.
• [165] MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10.Onco Targets Ther. 2019 May 16;12:3829-3838. doi: 10.2147/OTT.S190282. eCollection 2019.
• [166] MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.Sci Rep. 2018 May 22;8(1):8007. doi: 10.1038/s41598-018-26381-w.
• [167] Abberent expression of oncogenic and tumor-suppressive microRNAs and their target genes in human adenocarcinoma alveolar basal epithelial cells.J Cancer Res Ther. 2016 Jan-Mar;12(1):395-400. doi: 10.4103/0973-1482.148673.
• [168] Novel triplepositive markers identified in human nonsmall cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics.Oncol Rep. 2018 Aug;40(2):669-681. doi: 10.3892/or.2018.6461. Epub 2018 May 24.
• [169] Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2.Chin J Nat Med. 2013 May;11(3):245-53. doi: 10.1016/S1875-5364(13)60023-0.
• [170] Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.Int J Oncol. 2016 May;48(5):2205-12. doi: 10.3892/ijo.2016.3441. Epub 2016 Mar 15.
• [171] Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients.J Cancer. 2018 Sep 8;9(19):3532-3539. doi: 10.7150/jca.26286. eCollection 2018.
• [172] BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.Immunity. 1995 Feb;2(2):167-75. doi: 10.1016/s1074-7613(95)80053-0.
• [173] Targeted DNA sequencing of non-small cell lung cancer identifies mutations associated with brain metastases.Oncotarget. 2018 May 25;9(40):25957-25970. doi: 10.18632/oncotarget.25409. eCollection 2018 May 25.
• [174] Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer.Lung Cancer. 2004 Dec;46(3):299-304. doi: 10.1016/j.lungcan.2004.05.002.
• [175] Neoantimycin F, a Streptomyces-Derived Natural Product Induces Mitochondria-Related Apoptotic Death in Human Non-Small Cell Lung Cancer Cells.Front Pharmacol. 2019 Sep 18;10:1042. doi: 10.3389/fphar.2019.01042. eCollection 2019.
• [176] Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.Am J Respir Crit Care Med. 2017 Mar 1;195(5):663-673. doi: 10.1164/rccm.201602-0300OC.
• [177] p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.J Exp Clin Cancer Res. 2019 Jun 14;38(1):260. doi: 10.1186/s13046-019-1199-7.
• [178] Genomic instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung cancer.Cancer Res. 2000 Aug 15;60(16):4349-52.
• [179] DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients.J Pathol. 2018 Aug;245(4):387-398. doi: 10.1002/path.5079. Epub 2018 Jun 20.
• [180] Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.Cancer Genet. 2019 Apr;233-234:67-74. doi: 10.1016/j.cancergen.2019.04.001. Epub 2019 Apr 9.
• [181] Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.J Biomed Inform. 2018 Oct;86:120-134. doi: 10.1016/j.jbi.2018.09.004. Epub 2018 Sep 6.
• [182] CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC.Cancer Cell Int. 2019 Sep 2;19:226. doi: 10.1186/s12935-019-0952-5. eCollection 2019.
• [183] Obtusilactone A and (-)-sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints.Cancer Sci. 2010 Dec;101(12):2612-20. doi: 10.1111/j.1349-7006.2010.01701.x.
• [184] Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study.Lung Cancer. 2004 Nov;46(2):197-204. doi: 10.1016/j.lungcan.2004.04.002.
• [185] Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status.Oncotarget. 2015 Mar 30;6(9):6708-21. doi: 10.18632/oncotarget.2862.
• [186] p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10869-E10878. doi: 10.1073/pnas.1808314115. Epub 2018 Oct 31.
• [187] The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non-small cell lung cancer.Sci Adv. 2019 Jul 24;5(7):eaaw6455. doi: 10.1126/sciadv.aaw6455. eCollection 2019 Jul.
• [188] C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC.Lung Cancer. 2013 Jul;81(1):123-9. doi: 10.1016/j.lungcan.2013.03.007. Epub 2013 Mar 30.
• [189] CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.Oncol Rep. 2017 Feb;37(2):921-928. doi: 10.3892/or.2016.5289. Epub 2016 Dec 2.
• [190] The miR-1204 regulates apoptosis in NSCLC cells by targeting DEK.Folia Histochem Cytobiol. 2019;57(2):64-73. doi: 10.5603/FHC.a2019.0009. Epub 2019 Jun 27.
• [191] Abnormally localized DLK1 interacts with NCOR1 in non-small cell lung cancer cell nuclear.Biosci Rep. 2019 Dec 20;39(12):BSR20192362. doi: 10.1042/BSR20192362.
• [192] Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta.J Biol Chem. 2005 Sep 30;280(39):33240-9. doi: 10.1074/jbc.M507617200. Epub 2005 Aug 1.
• [193] Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer.PLoS One. 2013 May 3;8(5):e62153. doi: 10.1371/journal.pone.0062153. Print 2013.
• [194] EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.Epigenetics. 2019 Feb;14(2):118-129. doi: 10.1080/15592294.2019.1573066. Epub 2019 Jan 31.
• [195] Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.
• [196] A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.Oncotarget. 2016 Mar 29;7(13):15948-58. doi: 10.18632/oncotarget.7433.
• [197] Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.Mol Cancer Ther. 2018 Jan;17(1):17-25. doi: 10.1158/1535-7163.MCT-17-0146. Epub 2017 Oct 27.
• [198] Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.Med Sci Monit. 2018 Nov 11;24:8064-8073. doi: 10.12659/MSM.911384.
• [199] Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins.Oncogene. 1998 Jun 11;16(23):3057-68. doi: 10.1038/sj.onc.1201845.
• [200] Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells.Oncogene. 2003 Aug 28;22(36):5636-45. doi: 10.1038/sj.onc.1206790.
• [201] Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
• [202] Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.Exp Cell Res. 2007 Apr 15;313(7):1361-72. doi: 10.1016/j.yexcr.2007.01.016. Epub 2007 Feb 3.
• [203] WDR1 Promotes Cell Growth and Migration and Contributes to Malignant Phenotypes of Non-small Cell Lung Cancer through ADF/cofilin-mediated Actin Dynamics.Int J Biol Sci. 2018 Jun 8;14(9):1067-1080. doi: 10.7150/ijbs.23845. eCollection 2018.
• [204] Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.Jpn J Cancer Res. 1999 Jan;90(1):108-15. doi: 10.1111/j.1349-7006.1999.tb00673.x.
• [205] HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells.PLoS One. 2013 Apr 29;8(4):e62729. doi: 10.1371/journal.pone.0062729. Print 2013.
• [206] JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.Cancer Gene Ther. 2019 Nov;26(11-12):411-418. doi: 10.1038/s41417-018-0074-6. Epub 2019 Jan 9.
• [207] Gene expression and prognosis of insulinlike growth factorbinding protein family members in nonsmall cell lung cancer.Oncol Rep. 2019 Nov;42(5):1981-1995. doi: 10.3892/or.2019.7314. Epub 2019 Sep 16.
• [208] Abietic acid suppresses non-small-cell lung cancer cell growth via blocking IKK/NF-B signaling.Onco Targets Ther. 2019 Jun 20;12:4825-4837. doi: 10.2147/OTT.S199161. eCollection 2019.
• [209] Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer.Pharmacogenet Genomics. 2017 Dec;27(12):438-444. doi: 10.1097/FPC.0000000000000307.
• [210] Interleukin-9 promotes tumorigenesis through augmenting angiogenesis in non-small cell lung cancer.Int Immunopharmacol. 2019 Oct;75:105766. doi: 10.1016/j.intimp.2019.105766. Epub 2019 Jul 25.
• [211] Integrin v promotes proliferation by activating ERK 1/2 in the human lung cancer cell line A549.Mol Med Rep. 2015 Feb;11(2):1266-71. doi: 10.3892/mmr.2014.2860. Epub 2014 Nov 4.
• [212] The Emerging Role of CD8(+) Tissue Resident Memory T (T(RM)) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin.Front Immunol. 2018 Aug 15;9:1904. doi: 10.3389/fimmu.2018.01904. eCollection 2018.
• [213] JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.Mol Cancer Ther. 2017 Aug;16(8):1645-1657. doi: 10.1158/1535-7163.MCT-16-0564. Epub 2017 May 31.
• [214] G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer.BMC Cancer. 2004 Nov 13;4:79. doi: 10.1186/1471-2407-4-79.
• [215] The diagnostic performance of lysine(K)-specific demethylase 6B (KDM6B) in non-small cell lung cancer.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2155-2160. doi: 10.1080/21691401.2019.1620758.
• [216] Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.Tumour Biol. 2016 Mar;37(3):3925-31. doi: 10.1007/s13277-015-4151-2. Epub 2015 Oct 19.
• [217] Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung.Biol Chem. 2008 Jun;389(6):781-6. doi: 10.1515/BC.2008.089.
• [218] miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer.Biomed Pharmacother. 2017 Feb;86:248-253. doi: 10.1016/j.biopha.2016.12.007. Epub 2016 Dec 19.
• [219] Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas.Biochem Biophys Res Commun. 2000 Aug 28;275(2):440-5. doi: 10.1006/bbrc.2000.3331.
• [220] Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.Oncotarget. 2016 Aug 30;7(35):56193-56199. doi: 10.18632/oncotarget.10907.
• [221] miR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation.Oncol Res. 2018 May 7;26(4):547-556. doi: 10.3727/096504017X15016337254605. Epub 2017 Aug 11.
• [222] Co-expression of immunoglobulin-like transcript 4 and angiopoietin-like proteins in human non-small cell lung cancer.Mol Med Rep. 2015 Apr;11(4):2789-96. doi: 10.3892/mmr.2014.3029. Epub 2014 Dec 2.
• [223] Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer.Clin Respir J. 2018 Feb;12(2):712-720. doi: 10.1111/crj.12584. Epub 2016 Dec 11.
• [224] Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.Int J Oncol. 2018 Aug;53(2):713-724. doi: 10.3892/ijo.2018.4425. Epub 2018 May 31.
• [225] CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues.Int J Cancer. 2002 Jun 20;99(6):839-45. doi: 10.1002/ijc.10416.
• [226] Non-surgical therapy for patients with advanced non-small cell lung cancer.Respirology. 1998 Sep;3(3):151-7. doi: 10.1111/j.1440-1843.1998.tb00114.x.
• [227] MicroRNA-98-5p regulates the proliferation and apoptosis of A549 cells by targeting MAP4K3.Oncol Lett. 2019 Oct;18(4):4288-4293. doi: 10.3892/ol.2019.10771. Epub 2019 Aug 22.
• [228] MCMs expression in lung cancer: implication of prognostic significance.J Cancer. 2017 Oct 9;8(18):3641-3647. doi: 10.7150/jca.20777. eCollection 2017.
• [229] Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population.Lung Cancer. 2007 Oct;58(1):1-6. doi: 10.1016/j.lungcan.2007.04.008. Epub 2007 May 25.
• [230] P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens.Ann Diagn Pathol. 2018 Apr;33:23-29. doi: 10.1016/j.anndiagpath.2017.11.008. Epub 2017 Nov 11.
• [231] A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.Oncotarget. 2015 Sep 22;6(28):24895-903. doi: 10.18632/oncotarget.4366.
• [232] SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).J Neurooncol. 2016 Sep;129(3):395-403. doi: 10.1007/s11060-016-2199-5. Epub 2016 Jul 11.
• [233] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.Mutat Res Rev Mutat Res. 2017 Jan-Mar;771:32-58. doi: 10.1016/j.mrrev.2016.11.003. Epub 2016 Nov 23.
• [234] Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.BMC Cancer. 2017 Feb 7;17(1):113. doi: 10.1186/s12885-017-3081-3.
• [235] MicroRNA?500 suppresses tumor progression in nonsmall cell lung cancer by regulating STAT3.Mol Med Rep. 2019 Dec;20(6):4973-4983. doi: 10.3892/mmr.2019.10737. Epub 2019 Oct 11.
• [236] Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.Oncogene. 2007 Apr 19;26(18):2621-34. doi: 10.1038/sj.onc.1210041. Epub 2006 Oct 9.
• [237] GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels.Eur J Cancer Prev. 1999 Aug;8(4):315-23. doi: 10.1097/00008469-199908000-00008.
• [238] PAK4 Phosphorylates Fumarase and Blocks TGF-Induced Cell Growth Arrest in Lung Cancer Cells.Cancer Res. 2019 Apr 1;79(7):1383-1397. doi: 10.1158/0008-5472.CAN-18-2575. Epub 2019 Jan 25.
• [239] Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.Virchows Arch. 2003 Jan;442(1):66-70. doi: 10.1007/s00428-002-0721-y. Epub 2002 Dec 5.
• [240] Prognostic value of LIPC in non-small cell lung carcinoma.Cell Cycle. 2013 Feb 15;12(4):647-54. doi: 10.4161/cc.23517. Epub 2013 Jan 23.
• [241] RKIP reduction enhances radioresistance by activating the Shh signaling pathway in non-small-cell lung cancer.Onco Targets Ther. 2017 Nov 23;10:5605-5619. doi: 10.2147/OTT.S149200. eCollection 2017.
• [242] Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.Int J Oncol. 2017 Jun;50(6):2113-2122. doi: 10.3892/ijo.2017.3964. Epub 2017 Apr 19.
• [243] Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha.Am J Respir Cell Mol Biol. 2009 Mar;40(3):325-31. doi: 10.1165/rcmb.2008-0197OC. Epub 2008 Sep 5.
• [244] PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.J Biol Chem. 2015 May 22;290(21):13479-89. doi: 10.1074/jbc.M114.636050. Epub 2015 Apr 6.
• [245] Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498.Gene. 2019 Dec 15;720:144099. doi: 10.1016/j.gene.2019.144099. Epub 2019 Aug 31.
• [246] Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.Cancer. 2008 Sep 15;113(6):1396-403. doi: 10.1002/cncr.23694.
• [247] Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.Oncotarget. 2016 Apr 19;7(16):21799-811. doi: 10.18632/oncotarget.7985.
• [248] Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.PLoS One. 2018 Feb 7;13(2):e0192157. doi: 10.1371/journal.pone.0192157. eCollection 2018.
• [249] CPNE3 promotes migration and invasion in non-small cell lung cancer by interacting with RACK1 via FAK signaling activation.J Cancer. 2018 Oct 20;9(22):4215-4222. doi: 10.7150/jca.25872. eCollection 2018.
• [250] RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10.
• [251] Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer.EBioMedicine. 2018 Nov;37:177-187. doi: 10.1016/j.ebiom.2018.10.004. Epub 2018 Oct 9.
• [252] Alterations of the Dutt1/Robo1 gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats.Mol Carcinog. 2004 Aug;40(4):241-6. doi: 10.1002/mc.20037.
• [253] Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer.Virchows Arch. 2017 May;470(5):553-560. doi: 10.1007/s00428-017-2102-6. Epub 2017 Mar 13.
• [254] The immune modulation of Clara cell-10 in human peripheral monocytes and dendritic cells.Int J Mol Med. 2010 Sep;26(3):415-23.
• [255] Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.BMC Cancer. 2018 Mar 6;18(1):259. doi: 10.1186/s12885-018-4104-4.
• [256] Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.Oncogene. 2017 Nov 16;36(46):6432-6445. doi: 10.1038/onc.2017.253. Epub 2017 Jul 24.
• [257] SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. Sci Rep. 2013 Oct 22;3:3012.
• [258] Immunohistochemistry and clinical value of sirtuin 2 in non-metastasized non-small cell lung cancer.J Thorac Dis. 2019 Sep;11(9):3973-3979. doi: 10.21037/jtd.2019.08.102.
• [259] Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.Mol Cancer Ther. 2018 Sep;17(9):2024-2033. doi: 10.1158/1535-7163.MCT-17-1178. Epub 2018 Jun 29.
• [260] Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.BMC Cancer. 2017 Dec 21;17(1):884. doi: 10.1186/s12885-017-3859-3.
• [261] Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors.Ann Thorac Surg. 2019 Jul;108(1):235-243. doi: 10.1016/j.athoracsur.2019.02.040. Epub 2019 Mar 22.
• [262] Effect of spleen tyrosine kinase on nonsmall cell lung cancer.J Cancer Res Ther. 2018;14(Supplement):S100-S104. doi: 10.4103/0973-1482.174170.
• [263] FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.Oncogene. 2018 Nov;37(46):6096-6104. doi: 10.1038/s41388-018-0399-5. Epub 2018 Jul 10.
• [264] PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy.Ann Surg Oncol. 2016 Nov;23(12):4093-4100. doi: 10.1245/s10434-016-5392-z. Epub 2016 Jul 5.
• [265] Analysis of the nuclear localization signal of TRF1 in non-small cell lung cancer.Biol Res. 2009;42(2):217-22. Epub 2009 Aug 20.
• [266] Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGF2-bioenergetics-mitochondrial priming.Oncotarget. 2016 Dec 13;7(50):82013-82027. doi: 10.18632/oncotarget.13307.
• [267] Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4(+) and CD8(+) T-cell Interplay.Cancer Res. 2018 Sep 1;78(17):4943-4956. doi: 10.1158/0008-5472.CAN-18-0729. Epub 2018 Jun 26.
• [268] The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.Technol Cancer Res Treat. 2017 Oct;16(5):645-653. doi: 10.1177/1533034616670443. Epub 2016 Sep 29.
• [269] Multicomponent analysis of the tumour microenvironment reveals low CD8 T cell number, low stromal caveolin-1 and high tenascin-C and their combination as significant prognostic markers in non-small cell lung cancer.Oncotarget. 2017 Jun 29;9(2):1760-1771. doi: 10.18632/oncotarget.18880. eCollection 2018 Jan 5.
• [270] AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.
• [271] CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation.Med Sci Monit. 2017 Jun 14;23:2906-2916. doi: 10.12659/msm.904177.
• [272] MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer.Cancer Res. 2019 Dec 15;79(24):6215-6226. doi: 10.1158/0008-5472.CAN-19-1982. Epub 2019 Oct 3.
• [273] Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival.Int J Cancer. 2019 Apr 15;144(8):1867-1876. doi: 10.1002/ijc.31896. Epub 2018 Dec 8.
• [274] Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC.J Immunother Cancer. 2019 Feb 11;7(1):42. doi: 10.1186/s40425-019-0511-6.
• [275] Mechanism of decorin protein inhibiting invasion and metastasis of non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1520-1527. doi: 10.26355/eurrev_201902_17110.
• [276] The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.Oncol Rep. 2005 Aug;14(2):421-4.
• [277] HOXA11 hypermethylation is associated with progression of non-small cell lung cancer.Oncotarget. 2013 Dec;4(12):2317-25. doi: 10.18632/oncotarget.1464.
• [278] Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer.J Clin Lab Anal. 2020 Jan;34(1):e22897. doi: 10.1002/jcla.22897. Epub 2019 Sep 28.
• [279] Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients.Exp Mol Pathol. 2013 Feb;94(1):301-8. doi: 10.1016/j.yexmp.2012.10.006. Epub 2012 Oct 9.
• [280] Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.Pharmacol Ther. 2020 Feb;206:107438. doi: 10.1016/j.pharmthera.2019.107438. Epub 2019 Nov 9.
• [281] Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study.Sci Rep. 2019 Feb 25;9(1):2652. doi: 10.1038/s41598-018-38153-7.
• [282] Variation of Trop2 on non-small-cell lung cancer and normal cell membranes revealed by super-resolution fluorescence imaging.Talanta. 2020 Jan 15;207:120312. doi: 10.1016/j.talanta.2019.120312. Epub 2019 Sep 3.
• [283] Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.Mol Carcinog. 2019 Jul;58(7):1094-1104. doi: 10.1002/mc.23017. Epub 2019 Apr 15.
• [284] Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.Lung Cancer. 2005 Jan;47(1):17-29. doi: 10.1016/j.lungcan.2004.05.016.
• [285] Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for nonsmall cell lung cancer.Oncol Rep. 2020 Jan;43(1):99-112. doi: 10.3892/or.2019.7407. Epub 2019 Nov 13.
• [286] CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor.Cancers (Basel). 2019 Mar 30;11(4):455. doi: 10.3390/cancers11040455.
• [287] Circular RNA circ_0020123 promotes non-small cell lung cancer progression by acting as a ceRNA for miR-488-3p to regulate ADAM9 expression.Biochem Biophys Res Commun. 2019 Jul 23;515(2):303-309. doi: 10.1016/j.bbrc.2019.05.158. Epub 2019 May 29.
• [288] Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.Br J Cancer. 2019 Apr;120(9):903-912. doi: 10.1038/s41416-019-0444-3. Epub 2019 Apr 8.
• [289] ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population.Anticancer Res. 2019 Jun;39(6):3269-3272. doi: 10.21873/anticanres.13469.
• [290] Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC.J Exp Clin Cancer Res. 2019 Feb 7;38(1):61. doi: 10.1186/s13046-019-1054-x.
• [291] Downregulation of DLL4 predicts poor survival in nonsmall cell lung cancer patients due to promotion of lymph node metastasis.Oncol Rep. 2018 Nov;40(5):2988-2996. doi: 10.3892/or.2018.6679. Epub 2018 Aug 31.
• [292] Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/-catenin Signaling.Clin Cancer Res. 2018 Apr 1;24(7):1748-1760. doi: 10.1158/1078-0432.CCR-17-1169. Epub 2017 Sep 28.
• [293] Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.Cancer Biol Ther. 2009 Sep;8(17):1671-9. doi: 10.4161/cbt.8.17.9322. Epub 2009 Sep 20.
• [294] Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.Oncologist. 2018 Jun;23(6):654-e58. doi: 10.1634/theoncologist.2017-0690. Epub 2018 Feb 7.
• [295] Regulation of ezrin tension by S-nitrosylation mediates non-small cell lung cancer invasion and metastasis.Theranostics. 2019 Apr 13;9(9):2555-2571. doi: 10.7150/thno.32479. eCollection 2019.
• [296] Inhibition of lung cancer growth and metastasis by DHA and its metabolite, RvD1, through miR-138-5p/FOXC1 pathway.J Exp Clin Cancer Res. 2019 Nov 29;38(1):479. doi: 10.1186/s13046-019-1478-3.
• [297] LncRNA FOXC2 antisense transcript accelerates non-small-cell lung cancer tumorigenesis via silencing p15.Am J Transl Res. 2019 Jul 15;11(7):4552-4560. eCollection 2019.
• [298] Potentiality of forkhead box Q1 as a biomarker for monitoring tumor features and predicting prognosis in non-small cell lung cancer.J Clin Lab Anal. 2020 Jan;34(1):e23031. doi: 10.1002/jcla.23031. Epub 2019 Nov 12.
• [299] Expression of bone morphogenetic proteins in human lung carcinomas.Ann Thorac Surg. 2005 Sep;80(3):1028-32. doi: 10.1016/j.athoracsur.2005.03.094.
• [300] Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p.Cell Death Dis. 2019 Dec 16;10(12):953. doi: 10.1038/s41419-019-2180-2.
• [301] Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.Mol Carcinog. 2020 Jan;59(1):104-115. doi: 10.1002/mc.23132. Epub 2019 Nov 12.
• [302] Low TIP30 Protein Expression is Associated with a High Risk of Metastasis and Poor Prognosis for Non-Small-Cell Lung Cancer.J Clin Med. 2019 Jan 12;8(1):83. doi: 10.3390/jcm8010083.
• [303] IL-27 inhibits non-small-cell lung cancer cell metastasis by miR-935 in vitro.Onco Targets Ther. 2019 Feb 21;12:1447-1454. doi: 10.2147/OTT.S173207. eCollection 2019.
• [304] IL-7-Mediated IL-7R-JAK3/STAT5 signalling pathway contributes to chemotherapeutic sensitivity in non-small-cell lung cancer.Cell Prolif. 2019 Nov;52(6):e12699. doi: 10.1111/cpr.12699. Epub 2019 Oct 10.
• [305] Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC).EBioMedicine. 2019 Jan;39:207-214. doi: 10.1016/j.ebiom.2018.11.036. Epub 2018 Nov 22.
• [306] Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer.Genet Mol Biol. 2019 Feb 25;42(1):15-25. doi: 10.1590/1678-4685-gmb-2017-0307. Print 2019 Jan-Mar.
• [307] Integrin 11 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence.Cancer Sci. 2020 Jan;111(1):200-208. doi: 10.1111/cas.14257. Epub 2019 Dec 18.
• [308] Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.Cancer Lett. 2019 Dec 1;466:23-34. doi: 10.1016/j.canlet.2019.09.005. Epub 2019 Sep 12.
• [309] miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway.Cancer Lett. 2019 Apr 10;447:56-65. doi: 10.1016/j.canlet.2019.01.027. Epub 2019 Jan 24.
• [310] Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.
• [311] MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.Clin Cancer Res. 2018 Dec 15;24(24):6523-6535. doi: 10.1158/1078-0432.CCR-18-0040. Epub 2018 Sep 7.
• [312] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.
• [313] Matrix metalloproteinase 12 promotes tumor propagation in the lung.J Thorac Cardiovasc Surg. 2018 May;155(5):2164-2175.e1. doi: 10.1016/j.jtcvs.2017.11.110. Epub 2018 Feb 21.
• [314] miR?84?p regulates migration and invasion in nonsmall cell lung cancer cell lines through regulation of MMP?4.Mol Med Rep. 2019 Mar;19(3):1747-1752. doi: 10.3892/mmr.2019.9813. Epub 2019 Jan 3.
• [315] 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment.Biomaterials. 2018 May;163:185-197. doi: 10.1016/j.biomaterials.2018.02.030. Epub 2018 Feb 13.
• [316] Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog.Cancer Med. 2019 Mar;8(3):1232-1245. doi: 10.1002/cam4.1992. Epub 2019 Feb 10.
• [317] Netrin? interference potentiates epithelialtomesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of nonsmall cell lung cancer.Int J Oncol. 2019 Apr;54(4):1457-1465. doi: 10.3892/ijo.2019.4716. Epub 2019 Feb 15.
• [318] Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.Mol Cell Biochem. 2018 Feb;439(1-2):163-169. doi: 10.1007/s11010-017-3145-3. Epub 2017 Aug 31.
• [319] Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer.Clin Chim Acta. 2020 Mar;502:55-65. doi: 10.1016/j.cca.2019.11.022. Epub 2019 Dec 9.
• [320] Flavonoid Composition and Antitumor Activity of Bee Bread Collected in Northeast Portugal.Molecules. 2017 Feb 7;22(2):248. doi: 10.3390/molecules22020248.
• [321] Serum and glucocorticoid-regulated kinase 1 (SGK1) is a predictor of poor prognosis in non-small cell lung cancer, and its dynamic pattern following treatment with SGK1 inhibitor and -ray irradiation was elucidated.Oncol Rep. 2018 Mar;39(3):1505-1515. doi: 10.3892/or.2018.6181. Epub 2018 Jan 3.
• [322] STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.Cancer Immunol Immunother. 2006 Dec;55(12):1515-23. doi: 10.1007/s00262-006-0165-3. Epub 2006 Apr 19.
• [323] STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.Biochem Biophys Res Commun. 2019 Nov 19;519(4):659-666. doi: 10.1016/j.bbrc.2019.09.032. Epub 2019 Sep 18.
• [324] MicroRNA-527 inhibits TGF-/SMAD induced epithelial-mesenchymal transition via downregulating SULF2 expression in non-small-cell lung cancer.Math Biosci Eng. 2019 May 23;16(5):4607-4621. doi: 10.3934/mbe.2019231.
• [325] Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients.Sci Rep. 2019 Oct 3;9(1):14288. doi: 10.1038/s41598-019-50756-2.
• [326] Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.Oncogene. 2019 Mar;38(11):1892-1904. doi: 10.1038/s41388-018-0534-3. Epub 2018 Nov 2.
• [327] Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14.Cancer Lett. 2018 Jul 28;427:74-84. doi: 10.1016/j.canlet.2018.04.022. Epub 2018 Apr 24.
• [328] miR-126/VCAM-1 regulation by naringin suppresses cell growth of human non-small cell lung cancer.Oncol Lett. 2018 Oct;16(4):4754-4760. doi: 10.3892/ol.2018.9204. Epub 2018 Jul 24.
• [329] Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer.Bioorg Med Chem. 2019 Feb 1;27(3):533-544. doi: 10.1016/j.bmc.2018.12.036. Epub 2018 Dec 28.
• [330] Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011 Feb;12(2):159-70.
• [331] Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.Med Sci Monit. 2017 Apr 26;23:1999-2006. doi: 10.12659/msm.904156.
• [332] Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance.Cancer Chemother Pharmacol. 2013 Feb;71(2):537-41. doi: 10.1007/s00280-012-2036-2. Epub 2012 Nov 24.
• [333] A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. Pharmacogenomics J. 2014 Feb;14(1):20-7.
• [334] Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma.Mol Cancer Ther. 2019 Nov;18(11):2085-2096. doi: 10.1158/1535-7163.MCT-18-1181. Epub 2019 Jul 24.
• [335] Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.EMBO Mol Med. 2016 Feb 1;8(2):105-16. doi: 10.15252/emmm.201505456.
• [336] ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.J Exp Clin Cancer Res. 2019 Apr 25;38(1):173. doi: 10.1186/s13046-019-1156-5.
• [337] Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase.J Mol Neurosci. 2014 Jul;53(3):335-44. doi: 10.1007/s12031-013-0136-z. Epub 2013 Oct 26.
• [338] Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer.Lung Cancer. 2015 Jun;88(3):310-8. doi: 10.1016/j.lungcan.2015.03.004. Epub 2015 Mar 23.
• [339] Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data.Tumour Biol. 2017 Mar;39(3):1010428317691683. doi: 10.1177/1010428317691683.
• [340] Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.Med Sci Monit. 2018 Dec 23;24:9364-9369. doi: 10.12659/MSM.911333.
• [341] Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo.Pharmacol Res. 2019 Oct;148:104406. doi: 10.1016/j.phrs.2019.104406. Epub 2019 Aug 20.
• [342] Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet. 2008 Dec;187(2):80-4. doi: 10.1016/j.cancergencyto.2008.08.001.
• [343] Overexpression of ADAMTS5 can regulate the migration and invasion of non-small cell lung cancer.Tumour Biol. 2016 Jul;37(7):8681-9. doi: 10.1007/s13277-015-4573-x. Epub 2016 Jan 6.
• [344] PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.Peptides. 2019 Oct;120:170017. doi: 10.1016/j.peptides.2018.09.005. Epub 2018 Sep 28.
• [345] MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6312-22. eCollection 2015.
• [346] Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.Lung Cancer. 2018 Nov;125:291-299. doi: 10.1016/j.lungcan.2018.10.010. Epub 2018 Oct 10.
• [347] Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of nonsmall cell lung cancer cells via the HMGB1/RAGE axis and the NFB/STAT3 pathway.Oncol Rep. 2019 Aug;42(2):817-825. doi: 10.3892/or.2019.7176. Epub 2019 May 30.
• [348] miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer.Cancer Lett. 2018 Jan 1;412:170-178. doi: 10.1016/j.canlet.2017.10.024. Epub 2017 Nov 5.
• [349] Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.Cancer Sci. 2019 Jan;110(1):433-442. doi: 10.1111/cas.13862. Epub 2018 Dec 6.
• [350] LukS-PV induces cell cycle arrest and apoptosis through p38/ERK MAPK signaling pathway in NSCLC cells.Biochem Biophys Res Commun. 2020 Jan 22;521(4):846-852. doi: 10.1016/j.bbrc.2019.10.181. Epub 2019 Nov 7.
• [351] Multi-subtype classification model for non-small cell lung cancer based on radiomics: SLS model.Med Phys. 2019 Jul;46(7):3091-3100. doi: 10.1002/mp.13551. Epub 2019 May 11.
• [352] Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression.Oncogenesis. 2018 Jun 13;7(6):49. doi: 10.1038/s41389-018-0054-6.
• [353] Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?.Oncotarget. 2017 Jun 13;8(24):39795-39804. doi: 10.18632/oncotarget.7794.
• [354] ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway.Lung. 2016 Aug;194(4):637-46. doi: 10.1007/s00408-016-9895-y. Epub 2016 May 11.
• [355] ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status.Cancer Lett. 2017 Dec 1;410:191-200. doi: 10.1016/j.canlet.2017.09.038. Epub 2017 Sep 29.
• [356] Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery.Clin Transl Oncol. 2017 Sep;19(9):1091-1098. doi: 10.1007/s12094-017-1643-0. Epub 2017 Mar 15.
• [357] Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.
• [358] Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.Cancers (Basel). 2019 May 2;11(5):618. doi: 10.3390/cancers11050618.
• [359] Annexin A2 Silencing Inhibits Proliferation and Epithelial-to-mesenchymal Transition through p53-Dependent Pathway in NSCLCs.J Cancer. 2019 Jan 29;10(5):1077-1085. doi: 10.7150/jca.29440. eCollection 2019.
• [360] Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.Autophagy. 2019 Mar;15(3):391-406. doi: 10.1080/15548627.2018.1511503. Epub 2018 Sep 6.
• [361] Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1 and APC2 gene expression in non-small cell lung cancer.Mol Cancer. 2018 Oct 22;17(1):153. doi: 10.1186/s12943-018-0896-8.
• [362] Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging.Exp Ther Med. 2019 Jan;17(1):244-250. doi: 10.3892/etm.2018.6936. Epub 2018 Nov 6.
• [363] Aquaporin-3 Inhibition Reduces the Growth of NSCLC Cells Induced by Hypoxia.Cell Physiol Biochem. 2016;38(1):129-40. doi: 10.1159/000438615. Epub 2016 Jan 15.
• [364] Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1.
• [365] TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.Cell Death Dis. 2019 Mar 25;10(4):283. doi: 10.1038/s41419-019-1519-z.
• [366] R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR.Life Sci. 2019 Oct 1;234:116742. doi: 10.1016/j.lfs.2019.116742. Epub 2019 Aug 8.
• [367] ASAP3 expression in non-small cell lung cancer: association with cancer development and patients' clinical outcome.Tumour Biol. 2014 Feb;35(2):1489-94. doi: 10.1007/s13277-013-1205-1.
• [368] Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.Clin Transl Oncol. 2016 Oct;18(10):1039-43. doi: 10.1007/s12094-016-1483-3. Epub 2016 Feb 9.
• [369] Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.Neoplasia. 2016 Sep;18(9):525-35. doi: 10.1016/j.neo.2016.07.004.
• [370] miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol Med Rep. 2015 Jan;11(1):571-6.
• [371] Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population.Lung Cancer. 2011 Jul;73(1):32-7. doi: 10.1016/j.lungcan.2010.11.001. Epub 2010 Dec 9.
• [372] AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.Nat Commun. 2019 Apr 18;10(1):1812. doi: 10.1038/s41467-019-09734-5.
• [373] The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer.J Thorac Dis. 2019 May;11(5):1772-1778. doi: 10.21037/jtd.2019.05.69.
• [374] Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.Mol Cancer Res. 2019 Feb;17(2):499-507. doi: 10.1158/1541-7786.MCR-18-0628. Epub 2018 Nov 21.
• [375] The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.Thorac Cancer. 2019 Sep;10(9):1770-1778. doi: 10.1111/1759-7714.13139. Epub 2019 Jul 18.
• [376] Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro.Tumour Biol. 2014 Jun;35(6):5287-93. doi: 10.1007/s13277-014-1688-4. Epub 2014 Feb 16.
• [377] Prognostic and Clinicopathological Significance of BAP1 Protein Expression in Different Types of Cancer-A Meta-Analysis.Genet Test Mol Biomarkers. 2018 Feb;22(2):115-126. doi: 10.1089/gtmb.2017.0176. Epub 2017 Dec 21.
• [378] Long intergenic noncoding RNA-p21 inhibits apoptosis by decreasing PUMA expression in non-small cell lung cancer. J Int Med Res. 2019 Jan;47(1):481-493.
• [379] Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.Science. 2016 Sep 9;353(6304):1161-5. doi: 10.1126/science.aaf5171.
• [380] The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-B activity and down-regulating Bfl-1.Mol Cancer. 2011 Aug 16;10:98. doi: 10.1186/1476-4598-10-98.
• [381] MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer.Tumour Biol. 2015 Jun;36(6):4357-65. doi: 10.1007/s13277-015-3075-1. Epub 2015 Jan 22.
• [382] Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPK signaling in STK11 mutant lung cancer.Autophagy. 2020 Apr;16(4):659-671. doi: 10.1080/15548627.2019.1634945. Epub 2019 Jun 28.
• [383] Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.J Pathol. 2018 Sep;246(1):67-76. doi: 10.1002/path.5110. Epub 2018 Jul 31.
• [384] Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.Cancers (Basel). 2019 Nov 21;11(12):1835. doi: 10.3390/cancers11121835.
• [385] miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1).Oncogene. 2014 Mar 20;33(12):1506-14. doi: 10.1038/onc.2013.108. Epub 2013 Apr 15.
• [386] Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer.Oncotarget. 2017 Jun 27;8(26):43080-43090. doi: 10.18632/oncotarget.17904.
• [387] Expression of bone morphogenetic protein 6 in non-small cell lung cancer and its significance.Oncol Lett. 2019 Feb;17(2):1946-1952. doi: 10.3892/ol.2018.9781. Epub 2018 Nov 30.
• [388] MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells.Int J Clin Exp Pathol. 2015 Sep 1;8(9):10847-53. eCollection 2015.
• [389] Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.Exp Mol Pathol. 2010 Jun;88(3):401-6. doi: 10.1016/j.yexmp.2010.02.003. Epub 2010 Mar 4.
• [390] Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.Biomed Res Int. 2013;2013:726375. doi: 10.1155/2013/726375. Epub 2013 Mar 19.
• [391] Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.Int J Cancer. 2020 Feb 15;146(4):1114-1124. doi: 10.1002/ijc.32515. Epub 2019 Jun 28.
• [392] MicroRNA-410 promotes cell proliferation by targeting BRD7 in non-small cell lung cancer.FEBS Lett. 2015 Aug 4;589(17):2218-23. doi: 10.1016/j.febslet.2015.06.031. Epub 2015 Jul 3.
• [393] miR?46a?p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression.Oncol Rep. 2019 Apr;41(4):2226-2240. doi: 10.3892/or.2019.7030. Epub 2019 Feb 25.
• [394] The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis.Tumour Biol. 2014 Apr;35(4):2949-57. doi: 10.1007/s13277-013-1379-6. Epub 2013 Nov 22.
• [395] C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.Oncogene. 2018 Aug;37(35):4821-4837. doi: 10.1038/s41388-018-0298-9. Epub 2018 May 18.
• [396] Differentially expressed and activated proteins associated with non small cell lung cancer tissues.Respir Res. 2015 Jun 24;16(1):74. doi: 10.1186/s12931-015-0234-2.
• [397] Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.Oncol Lett. 2017 Oct;14(4):5046-5050. doi: 10.3892/ol.2017.6740. Epub 2017 Aug 10.
• [398] PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.Lung Cancer. 2019 Mar;129:41-47. doi: 10.1016/j.lungcan.2019.01.004. Epub 2019 Jan 16.
• [399] CACNA1B (Ca(v)2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer.Dis Markers. 2017;2017:6136401. doi: 10.1155/2017/6136401. Epub 2017 Jan 3.
• [400] LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1.Onco Targets Ther. 2019 May 16;12:3779-3790. doi: 10.2147/OTT.S189468. eCollection 2019.
• [401] Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):733-742. doi: 10.1016/j.ijrobp.2019.11.397. Epub 2019 Dec 3.
• [402] Long Non-coding RNA PVT1 Competitively Binds MicroRNA-424-5p to Regulate CARM1 in Radiosensitivity of Non-Small-Cell Lung Cancer.Mol Ther Nucleic Acids. 2019 Jun 7;16:130-140. doi: 10.1016/j.omtn.2018.12.006. Epub 2018 Dec 15.
• [403] Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.Oncologist. 2012;17(12):1551-61. doi: 10.1634/theoncologist.2011-0419. Epub 2012 Jul 27.
• [404] MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer.Sci Rep. 2019 Feb 28;9(1):3008. doi: 10.1038/s41598-019-39453-2.
• [405] Correction: Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.Oncotarget. 2018 Jun 29;9(50):29537. doi: 10.18632/oncotarget.25751. eCollection 2018 Jun 29.
• [406] Transcriptomic analysis of human non-small lung cancer cells A549 treated by one synthetic curcumin derivative MHMD.Cell Mol Biol (Noisy-le-grand). 2017 Sep 30;63(9):35-39. doi: 10.14715/cmb/2017.63.9.7.
• [407] Glucocorticoid modulatory element-binding protein 1 (GMEB1) interacts with the de-ubiquitinase USP40 to stabilize CFLAR(L) and inhibit apoptosis in human non-small cell lung cancer cells.J Exp Clin Cancer Res. 2019 May 2;38(1):181. doi: 10.1186/s13046-019-1182-3.
• [408] A Novel Flavonoid Kushenol Z from Sophora flavescens Mediates mTOR Pathway by Inhibiting Phosphodiesterase and Akt Activity to Induce Apoptosis in Non-Small-Cell Lung Cancer Cells.Molecules. 2019 Dec 4;24(24):4425. doi: 10.3390/molecules24244425.
• [409] Activity of Antioxidant Enzymes in the Tumor and Adjacent Noncancerous Tissues of Non-Small-Cell Lung Cancer.Oxid Med Cell Longev. 2019 Oct 31;2019:2901840. doi: 10.1155/2019/2901840. eCollection 2019.
• [410] CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.PLoS One. 2010 Jan 29;5(1):e8972. doi: 10.1371/journal.pone.0008972.
• [411] Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.J Thorac Dis. 2018 Mar;10(3):1635-1647. doi: 10.21037/jtd.2018.02.31.
• [412] Association between CBR1 polymorphisms and NSCLC in the Chinese population.Oncol Lett. 2017 Nov;14(5):6291-6297. doi: 10.3892/ol.2017.6926. Epub 2017 Sep 14.
• [413] miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression.Onco Targets Ther. 2018 Dec 7;11:8865-8874. doi: 10.2147/OTT.S181433. eCollection 2018.
• [414] linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer.Life Sci. 2020 Jan 15;241:117134. doi: 10.1016/j.lfs.2019.117134. Epub 2019 Dec 4.
• [415] CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF- pathway in human non-small cell lung cancer.Biochem Biophys Res Commun. 2017 Jun 17;488(1):196-203. doi: 10.1016/j.bbrc.2017.05.034. Epub 2017 May 6.
• [416] The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients.Biomed Pharmacother. 2015 Feb;69:242-8. doi: 10.1016/j.biopha.2014.12.008. Epub 2014 Dec 12.
• [417] Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration.Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078-0432.CCR-16-2821. Epub 2017 May 3.
• [418] Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer.Exp Ther Med. 2018 Aug;16(2):730-738. doi: 10.3892/etm.2018.6274. Epub 2018 Jun 8.
• [419] MicroRNA?18 serves a tumorsuppressive role innonsmallcell lung cancer by directly targeting CCNB1.Int J Mol Med. 2020 Jan;45(1):33-44. doi: 10.3892/ijmm.2019.4396. Epub 2019 Nov 4.
• [420] miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer.Cell Death Dis. 2018 Feb 7;9(2):193. doi: 10.1038/s41419-017-0219-9.
• [421] miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.PLoS Genet. 2018 Dec 17;14(12):e1007790. doi: 10.1371/journal.pgen.1007790. eCollection 2018 Dec.
• [422] MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):679-689. doi: 10.26355/eurrev_201901_16881.
• [423] CCR4 Expression in Tumor-Infiltrating Regulatory T Cells in Patients with Squamous Cell Carcinoma of the Lung: A Prognostic Factor for Relapse and Survival.Cancer Invest. 2019;37(3):163-173. doi: 10.1080/07357907.2019.1582848. Epub 2019 Mar 25.
• [424] An assessment of the relationship between the expression of CCR7/CCL19 axis and selected regulatory miRNAs in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5389-5396. doi: 10.1007/s11033-019-04993-3. Epub 2019 Aug 28.
• [425] CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.Med Oncol. 2015 Mar;32(3):66. doi: 10.1007/s12032-015-0531-0. Epub 2015 Feb 18.
• [426] PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.Lung Cancer. 2019 Oct;136:136-144. doi: 10.1016/j.lungcan.2019.08.023. Epub 2019 Aug 31.
• [427] Single nucleotide polymorphism rs3746444 inmiR?99a affects susceptibility to nonsmall cell lung carcinoma by regulating the expression of CD200.Int J Mol Med. 2019 May;43(5):2221-2229. doi: 10.3892/ijmm.2019.4124. Epub 2019 Mar 5.
• [428] A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.EBioMedicine. 2018 Jun;32:102-110. doi: 10.1016/j.ebiom.2018.05.025. Epub 2018 Jun 1.
• [429] Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.J Transl Med. 2019 Apr 11;17(1):120. doi: 10.1186/s12967-019-1872-9.
• [430] Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/-catenin pathway.Onco Targets Ther. 2018 Dec 7;11:8875-8883. doi: 10.2147/OTT.S185521. eCollection 2018.
• [431] Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.Thorac Cancer. 2020 Jan;11(1):120-129. doi: 10.1111/1759-7714.13248. Epub 2019 Nov 24.
• [432] Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients.J Clin Med. 2019 May 24;8(5):741. doi: 10.3390/jcm8050741.
• [433] Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.Exp Mol Pathol. 2019 Aug;109:1-15. doi: 10.1016/j.yexmp.2019.04.004. Epub 2019 Apr 3.
• [434] Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.Sci Rep. 2018 Jun 12;8(1):8960. doi: 10.1038/s41598-018-27355-8.
• [435] Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.
• [436] CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.Lung Cancer. 2019 Apr;130:201-207. doi: 10.1016/j.lungcan.2019.02.025. Epub 2019 Feb 22.
• [437] Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens.Lung Cancer. 2001 Aug-Sep;33(2-3):181-94. doi: 10.1016/s0169-5002(01)00210-0.
• [438] Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer.Clin Cancer Res. 2015 Aug 1;21(15):3529-40. doi: 10.1158/1078-0432.CCR-14-2464. Epub 2015 Apr 21.
• [439] MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A.Biochem Biophys Res Commun. 2019 Apr 30;512(2):392-398. doi: 10.1016/j.bbrc.2019.03.082. Epub 2019 Mar 20.
• [440] MicroRNA-124 Functions as a Tumor Suppressor by Regulating CDH2 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.Cell Physiol Biochem. 2016;38(4):1563-74. doi: 10.1159/000443097. Epub 2016 Apr 14.
• [441] Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.PLoS One. 2016 Jun 30;11(6):e0158395. doi: 10.1371/journal.pone.0158395. eCollection 2016.
• [442] miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.Int J Clin Exp Pathol. 2014 Sep 15;7(10):7236-41. eCollection 2014.
• [443] Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.Eur J Med Chem. 2019 Nov 1;181:111535. doi: 10.1016/j.ejmech.2019.07.038. Epub 2019 Jul 25.
• [444] CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.Oncogene. 2019 Apr;38(14):2580-2594. doi: 10.1038/s41388-018-0603-7. Epub 2018 Dec 10.
• [445] Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.Oncotarget. 2016 Feb 16;7(7):8341-59. doi: 10.18632/oncotarget.7071.
• [446] Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.Oncotarget. 2016 Jul 12;7(28):43604-43615. doi: 10.18632/oncotarget.9871.
• [447] C/EBP Is a Transcriptional Regulator of Wee1 at the G?M Phase of the Cell Cycle.Cells. 2019 Feb 11;8(2):145. doi: 10.3390/cells8020145.
• [448] Identification and validation of key genes associated with non-small-cell lung cancer.J Cell Physiol. 2019 Dec;234(12):22742-22752. doi: 10.1002/jcp.28839. Epub 2019 May 24.
• [449] Human complement factor H is a novel diagnostic marker for lung adenocarcinoma.Int J Oncol. 2011 Jul;39(1):161-8. doi: 10.3892/ijo.2011.1010. Epub 2011 Apr 18.
• [450] Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population.Tumour Biol. 2015 Mar;36(3):1955-62. doi: 10.1007/s13277-014-2801-4. Epub 2014 Nov 15.
• [451] Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer.FEBS Lett. 2019 Jul;593(14):1827-1836. doi: 10.1002/1873-3468.13461. Epub 2019 Jun 7.
• [452] Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase inhibition.Curr Cancer Drug Targets. 2012 Jul;12(6):617-24. doi: 10.2174/156800912801784811.
• [453] Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer.Cancer Manag Res. 2019 Apr 24;11:3275-3283. doi: 10.2147/CMAR.S192036. eCollection 2019.
• [454] Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway.Tumour Biol. 2015 Jun;36(6):4091-100. doi: 10.1007/s13277-014-2911-z. Epub 2015 May 12.
• [455] 7-Nicotinic acetylcholine receptor antagonist QND7 suppresses non-small cell lung cancer cell proliferation and migration via inhibition of Akt/mTOR signaling.Biochem Biophys Res Commun. 2020 Jan 22;521(4):977-983. doi: 10.1016/j.bbrc.2019.11.018. Epub 2019 Nov 11.
• [456] Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations.Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17.
• [457] Neuronal acetylcholine receptor subunit alpha-9 (CHRNA9) polymorphisms are associated with NSCLC risk in a Chinese population.Med Oncol. 2014 May;31(5):932. doi: 10.1007/s12032-014-0932-5. Epub 2014 Mar 28.
• [458] Study on polymorphisms in CHRNA5/CHRNA3/CHRNB4 gene cluster and the associated with the risk of non-small cell lung cancer.Oncotarget. 2017 Dec 20;9(2):2435-2444. doi: 10.18632/oncotarget.23459. eCollection 2018 Jan 5.
• [459] IKK Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization.Comput Struct Biotechnol J. 2019 Feb 7;17:251-262. doi: 10.1016/j.csbj.2019.02.003. eCollection 2019.
• [460] Role of TGF--induced Claudin-4 expression through c-Jun signaling in non-small cell lung cancer.Cell Signal. 2016 Oct;28(10):1537-44. doi: 10.1016/j.cellsig.2016.07.006. Epub 2016 Jul 15.
• [461] Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.J Natl Cancer Inst. 2011 May 18;103(10):817-25. doi: 10.1093/jnci/djr075. Epub 2011 Apr 11.
• [462] Increased sensitivity of human lung adenocarcinoma cells to cisplatin associated with downregulated contactin-1.Biomed Pharmacother. 2015 Apr;71:172-84. doi: 10.1016/j.biopha.2014.11.004. Epub 2015 Mar 5.
• [463] Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.Clin Cancer Res. 2018 Jan 1;24(1):33-42. doi: 10.1158/1078-0432.CCR-17-1921. Epub 2017 Oct 24.
• [464] CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.Biochem Biophys Res Commun. 2018 Jun 2;500(2):132-138. doi: 10.1016/j.bbrc.2018.03.183. Epub 2018 Apr 19.
• [465] Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 2003 Nov 1;63(21):7038-41.
• [466] CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.Nature. 2017 Jun 1;546(7656):168-172. doi: 10.1038/nature22359. Epub 2017 May 24.
• [467] Enhanced glycometabolism as a mechanism of NQO1 potentiated growth of NSCLC revealed by metabolomic profiling.Biochem Biophys Res Commun. 2018 Jan 29;496(1):31-36. doi: 10.1016/j.bbrc.2017.12.160. Epub 2017 Dec 29.
• [468] Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer.Cancer Genet. 2017 Apr;212-213:8-12. doi: 10.1016/j.cancergen.2017.03.003. Epub 2017 Mar 20.
• [469] Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.Eur J Cancer Care (Engl). 2019 Jul;28(4):e13034. doi: 10.1111/ecc.13034. Epub 2019 Apr 10.
• [470] Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.Technol Cancer Res Treat. 2017 Feb;16(1):66-74. doi: 10.1177/1533034615627391. Epub 2016 Jul 8.
• [471] Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.
• [472] Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer.Neoplasia. 2017 Apr;19(4):271-278. doi: 10.1016/j.neo.2017.01.008. Epub 2017 Mar 7.
• [473] Cullin 3 overexpression inhibits lung cancer metastasis and is associated with survival of lung adenocarcinoma.Clin Exp Metastasis. 2020 Feb;37(1):115-124. doi: 10.1007/s10585-019-09988-9. Epub 2019 Aug 28.
• [474] Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.Cancer Sci. 2018 Jan;109(1):154-165. doi: 10.1111/cas.13422. Epub 2017 Nov 9.
• [475] B Cell-Attracting Chemokine-1 and Progranulin in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer: New Prognostic Factors.Adv Exp Med Biol. 2019;1150:11-16. doi: 10.1007/5584_2018_285.
• [476] Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese.Lung Cancer. 2011 Nov;74(2):164-9. doi: 10.1016/j.lungcan.2011.03.005. Epub 2011 Apr 22.
• [477] Correlation analysis of mRNA expression and prognosis of hOGG1 gene polymorphism in patients with non-small cell lung cancer.Oncol Lett. 2019 Sep;18(3):2310-2315. doi: 10.3892/ol.2019.10586. Epub 2019 Jul 5.
• [478] Prognostic relevance of estrogen receptor , and aromatase expression in non-small cell lung cancer.Steroids. 2016 Sep;113:5-13. doi: 10.1016/j.steroids.2016.05.008. Epub 2016 May 24.
• [479] Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19.
• [480] CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention.Biomed Res Int. 2017;2017:1529564. doi: 10.1155/2017/1529564. Epub 2017 Mar 9.
• [481] Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk.Int J Mol Sci. 2016 Sep 22;17(10):1597. doi: 10.3390/ijms17101597.
• [482] The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.Cancer Res. 2018 Sep 1;78(17):4865-4877. doi: 10.1158/0008-5472.CAN-17-3977. Epub 2018 Jul 16.
• [483] Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.Clin Lung Cancer. 2013 Sep;14(5):502-7. doi: 10.1016/j.cllc.2013.03.003. Epub 2013 May 9.
• [484] A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma.Tumour Biol. 2014 Jan;35(1):455-62. doi: 10.1007/s13277-013-1063-x. Epub 2013 Aug 11.
• [485] Death-associated protein kinase 3 controls the tumor progression of A549 cells through ERK MAPK/c-Myc signaling.Oncol Rep. 2017 Feb;37(2):1100-1106. doi: 10.3892/or.2017.5359. Epub 2017 Jan 9.
• [486] Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.Molecules. 2019 May 25;24(10):2011. doi: 10.3390/molecules24102011.
• [487] Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.J Cancer Res Clin Oncol. 2017 Aug;143(8):1449-1459. doi: 10.1007/s00432-017-2405-7. Epub 2017 Apr 5.
• [488] Elevated RTP801 promotes cell proliferation in non-small cell lung cancer.IUBMB Life. 2018 Apr;70(4):310-319. doi: 10.1002/iub.1727. Epub 2018 Feb 27.
• [489] Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1.Sci Rep. 2019 Oct 28;9(1):15400. doi: 10.1038/s41598-019-51066-3.
• [490] Ligand-based pharmacophore mapping and virtual screening for identification of potential discoidin domain receptor 1 inhibitors.J Biomol Struct Dyn. 2020 Jun;38(9):2800-2808. doi: 10.1080/07391102.2019.1640132. Epub 2019 Aug 8.
• [491] DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating -catenin signaling pathway.Cancer Sci. 2015 Oct;106(10):1303-12. doi: 10.1111/cas.12755. Epub 2015 Sep 3.
• [492] lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway.Cell Physiol Biochem. 2018;50(1):179-195. doi: 10.1159/000493967. Epub 2018 Oct 2.
• [493] Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.Clin Cancer Res. 2011 Mar 1;17(5):1190-9. doi: 10.1158/1078-0432.CCR-10-2331. Epub 2011 Jan 11.
• [494] Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.Lung Cancer. 2019 Sep;135:104-109. doi: 10.1016/j.lungcan.2019.05.022. Epub 2019 May 21.
• [495] A NIK-SIX signalling axis controls inflammation by targeted silencing of non-canonical NF-B.Nature. 2019 Apr;568(7751):249-253. doi: 10.1038/s41586-019-1041-6. Epub 2019 Mar 20.
• [496] Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.Neoplasma. 2017;64(2):182-191. doi: 10.4149/neo_2017_203.
• [497] DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell.Cancer Biother Radiopharm. 2015 Mar;30(2):100-6. doi: 10.1089/cbr.2014.1797.
• [498] Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis.Sci Rep. 2015 May 21;5:10338. doi: 10.1038/srep10338.
• [499] Tumor suppressor HLJ1 binds and functionally alters nucleophosmin via activating enhancer binding protein 2alpha complex formation.Cancer Res. 2010 Feb 15;70(4):1656-67. doi: 10.1158/0008-5472.CAN-09-2453. Epub 2010 Feb 9.
• [500] Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer.Oncogene. 2015 Jan 29;34(5):621-30. doi: 10.1038/onc.2013.580. Epub 2014 Jan 27.
• [501] Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.Chem Biol Drug Des. 2018 Dec;92(6):1988-1997. doi: 10.1111/cbdd.13370. Epub 2018 Aug 26.
• [502] Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).Int J Cancer. 2017 Apr 1;140(7):1620-1632. doi: 10.1002/ijc.30571. Epub 2017 Feb 2.
• [503] Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.BMC Cancer. 2016 Jun 6;16:354. doi: 10.1186/s12885-016-2392-0.
• [504] Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.Int J Cancer. 2013 May 1;132(9):1986-95. doi: 10.1002/ijc.27881. Epub 2012 Oct 20.
• [505] DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.Clin Cancer Res. 2015 Jan 15;21(2):428-38. doi: 10.1158/1078-0432.CCR-14-1150.
• [506] Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer.J Biol Chem. 2011 Mar 25;286(12):10177-84. doi: 10.1074/jbc.M110.163295. Epub 2011 Jan 24.
• [507] Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.Cancer Res. 2014 Nov 1;74(21):5948-54. doi: 10.1158/0008-5472.CAN-14-0809. Epub 2014 Aug 21.
• [508] DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.J Cell Mol Med. 2019 Nov;23(11):7427-7437. doi: 10.1111/jcmm.14609. Epub 2019 Aug 27.
• [509] Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.PLoS One. 2016 Aug 17;11(8):e0159954. doi: 10.1371/journal.pone.0159954. eCollection 2016.
• [510] Overexpression of microRNA-936 suppresses non-small cell lung cancer cell proliferation and invasion via targeting E2F2.Exp Ther Med. 2018 Sep;16(3):2696-2702. doi: 10.3892/etm.2018.6490. Epub 2018 Jul 20.
• [511] Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis.Eur Rev Med Pharmacol Sci. 2015 Sep;19(18):3375-84.
• [512] Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway.Cell Physiol Biochem. 2018;51(5):2136-2147. doi: 10.1159/000495831. Epub 2018 Dec 6.
• [513] Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.Cell Death Dis. 2018 Jan 26;9(2):129. doi: 10.1038/s41419-017-0120-6.
• [514] The role of PKR/eIF2 signaling pathway in prognosis of non-small cell lung cancer.PLoS One. 2011;6(11):e24855. doi: 10.1371/journal.pone.0024855. Epub 2011 Nov 10.
• [515] -elemene regulates endoplasmic reticulum stress to induce the apoptosis of NSCLC cells through PERK/IRE1/ATF6 pathway.Biomed Pharmacother. 2017 Sep;93:490-497. doi: 10.1016/j.biopha.2017.06.073. Epub 2017 Jun 30.
• [516] Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.J Thorac Oncol. 2011 Jan;6(1):132-8. doi: 10.1097/JTO.0b013e318200f415.
• [517] Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer.Oncotarget. 2015 Oct 20;6(32):33006-18. doi: 10.18632/oncotarget.5026.
• [518] Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.BMC Pulm Med. 2014 Nov 7;14:174. doi: 10.1186/1471-2466-14-174.
• [519] Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells.Oncol Lett. 2018 Apr;15(4):4541-4549. doi: 10.3892/ol.2018.7832. Epub 2018 Jan 22.
• [520] Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.Gene. 2018 Aug 15;667:62-69. doi: 10.1016/j.gene.2018.04.077. Epub 2018 May 11.
• [521] Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer.Transl Oncol. 2020 Jan;13(1):17-24. doi: 10.1016/j.tranon.2019.09.003. Epub 2019 Nov 13.
• [522] EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma.Oncogenesis. 2019 Sep 4;8(9):49. doi: 10.1038/s41389-019-0159-6.
• [523] Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells.Mol Med Rep. 2016 Apr;13(4):3190-6. doi: 10.3892/mmr.2016.4904. Epub 2016 Feb 18.
• [524] EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration.Cancer Res. 2011 Feb 1;71(3):1156-66. doi: 10.1158/0008-5472.CAN-10-0717. Epub 2011 Jan 25.
• [525] EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.Mol Med Rep. 2012 Aug;6(2):405-8. doi: 10.3892/mmr.2012.936. Epub 2012 Jun 6.
• [526] LncRNA DGCR5 regulates the non-small cell lung cancer cell growth, migration, and invasion through regulating miR-211-5p/EPHB6 axis.Biofactors. 2019 Sep;45(5):788-794. doi: 10.1002/biof.1539. Epub 2019 Jun 26.
• [527] Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.PLoS One. 2013 Oct 14;8(10):e77459. doi: 10.1371/journal.pone.0077459. eCollection 2013.
• [528] Single Nucleotide Polymorphisms of the ERAP1 Gene and Risk of NSCLC: A Comparison of Genetically Distant Populations, Chinese and Caucasian.Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):117-122. doi: 10.1007/s00005-016-0436-4. Epub 2017 Jan 12.
• [529] Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling.J Drug Target. 2020 Mar;28(3):300-306. doi: 10.1080/1061186X.2019.1650368. Epub 2019 Aug 5.
• [530] Increased Expression of IRE1 Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells.Anticancer Agents Med Chem. 2018;18(4):550-555. doi: 10.2174/1871520617666170719155517.
• [531] G-Protein-Coupled Estrogen Receptor Antagonist G15 Decreases Estrogen-Induced Development of Non-Small Cell Lung Cancer.Oncol Res. 2019 Feb 21;27(3):283-292. doi: 10.3727/096504017X15035795904677. Epub 2017 Aug 25.
• [532] Estrogen-related receptor alpha triggers the proliferation and migration of human non-small cell lung cancer via interleukin-6.Cell Biochem Funct. 2018 Jul;36(5):255-262. doi: 10.1002/cbf.3337. Epub 2018 Jun 3.
• [533] Testicular orphan nuclear receptor 4-associated protein 16 promotes non-small cell lung carcinoma by activating estrogen receptor and blocking testicular orphan nuclear receptor2.Oncol Rep. 2013 Jan;29(1):297-305. doi: 10.3892/or.2012.2107. Epub 2012 Oct 26.
• [534] Aberrant hypomethylation and overexpression of the eyes absent homologue 2 suppresses tumor cell growth of human lung adenocarcinoma cells.Oncol Rep. 2015 Nov;34(5):2333-42. doi: 10.3892/or.2015.4245. Epub 2015 Sep 2.
• [535] miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells.J Drug Target. 2017 Feb;25(2):125-131. doi: 10.1080/1061186X.2016.1207647. Epub 2016 Sep 16.
• [536] Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression.PLoS One. 2013 Nov 12;8(11):e79173. doi: 10.1371/journal.pone.0079173. eCollection 2013.
• [537] Expression of flTF and asTF splice variants in various cell strains and tissues.Mol Med Rep. 2019 Mar;19(3):2077-2086. doi: 10.3892/mmr.2019.9843. Epub 2019 Jan 10.
• [538] Sanguinarine exhibits antitumor activity via up-regulation of Fas-associated factor 1 in non-small cell lung cancer.J Biochem Mol Toxicol. 2017 Aug;31(8). doi: 10.1002/jbt.21914. Epub 2017 Mar 14.
• [539] FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC. Cancers (Basel). 2019 May 11;11(5). pii: E652.
• [540] Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLC-MS and UHPLC-TOF-MS/MS and its anti-non-small cell lung tumors effects in vitro and in vivo.J Sep Sci. 2019 Aug;42(15):2471-2481. doi: 10.1002/jssc.201801165. Epub 2019 Jul 4.
• [541] Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.Bosn J Basic Med Sci. 2019 Nov 8;19(4):355-367. doi: 10.17305/bjbms.2019.4227.
• [542] Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.Oncotarget. 2016 Aug 23;7(34):54415-54429. doi: 10.18632/oncotarget.10074.
• [543] Fibroblast growth factor 18 promotes proliferation and migration of H460 cells via the ERK and p38 signaling pathways.Oncol Rep. 2017 Feb;37(2):1235-1242. doi: 10.3892/or.2016.5301. Epub 2016 Dec 7.
• [544] Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.Eur J Med Chem. 2020 Feb 1;187:111943. doi: 10.1016/j.ejmech.2019.111943. Epub 2019 Dec 5.
• [545] Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.J Thorac Oncol. 2019 Jan;14(1):54-62. doi: 10.1016/j.jtho.2018.09.014. Epub 2018 Sep 26.
• [546] Fhit, a tumor suppressor protein, induces autophagy via 14-3-3 in non-small cell lung cancer cells.Oncotarget. 2017 May 9;8(19):31923-31937. doi: 10.18632/oncotarget.16652.
• [547] Long Intergenic Noncoding RNA 00261 Acts as a Tumor Suppressor in Non-Small Cell Lung Cancer via Regulating miR-105/FHL1 Axis.J Cancer. 2019 Oct 19;10(25):6414-6421. doi: 10.7150/jca.32251. eCollection 2019.
• [548] Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.J Immunother Cancer. 2019 Dec 11;7(1):346. doi: 10.1186/s40425-019-0812-9.
• [549] FMNL1 down-regulation suppresses bone metastasis through reducing TGF-1 expression in non-small cell lung cancer (NSCLC).Biomed Pharmacother. 2019 Sep;117:109126. doi: 10.1016/j.biopha.2019.109126. Epub 2019 Jul 12.
• [550] Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.
• [551] Combined use of EpCAM and FR enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer.Sci Rep. 2018 Jan 19;8(1):1188. doi: 10.1038/s41598-018-19391-1.
• [552] HGF/MET Regulated Epithelial-Mesenchymal Transitions And Metastasis By FOSL2 In Non-Small Cell Lung Cancer.Onco Targets Ther. 2019 Nov 5;12:9227-9237. doi: 10.2147/OTT.S217595. eCollection 2019.
• [553] Effects of FOXJ2 on TGF-1-induced epithelial-mesenchymal transition through Notch signaling pathway in non-small lung cancer.Cell Biol Int. 2017 Jan;41(1):79-83. doi: 10.1002/cbin.10680. Epub 2016 Nov 18.
• [554] Circular RNA HIPK3 induces cell proliferation and inhibits apoptosis in non-small cell lung cancer through sponging miR-149.Cancer Biol Ther. 2020;21(2):113-121. doi: 10.1080/15384047.2019.1669995. Epub 2019 Oct 10.
• [555] Knockdown of fascin-1 expression suppresses cell migration and invasion of non-small cell lung cancer by regulating the MAPK pathway.Biochem Biophys Res Commun. 2018 Mar 4;497(2):694-699. doi: 10.1016/j.bbrc.2018.02.134. Epub 2018 Feb 16.
• [556] Dysregulation of FURIN by prostaglandin-endoperoxide synthase 2 in lung epithelial NCI-H292 cells.Mol Carcinog. 2014 Mar;53(3):192-200. doi: 10.1002/mc.21963. Epub 2012 Oct 12.
• [557] Elevated FUS/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer.Oncol Lett. 2018 Aug;16(2):1791-1800. doi: 10.3892/ol.2018.8816. Epub 2018 May 25.
• [558] Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14?CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0.
• [559] Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection.Cancer Med. 2019 Nov;8(16):6894-6903. doi: 10.1002/cam4.2579. Epub 2019 Sep 27.
• [560] TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells.Biol Res. 2019 Jul 11;52(1):35. doi: 10.1186/s40659-019-0244-5.
• [561] Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.Cancer Biomark. 2018;22(3):417-426. doi: 10.3233/CBM-170995.
• [562] GAP43, a novel metastasis promoter in non-small cell lung cancer.J Transl Med. 2018 Nov 12;16(1):310. doi: 10.1186/s12967-018-1682-5.
• [563] Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.Thorac Cancer. 2020 Jan;11(1):156-165. doi: 10.1111/1759-7714.13258. Epub 2019 Nov 27.
• [564] Identification of a long non-coding RNA gene, growth hormone secretagogue receptor opposite strand, which stimulates cell migration in non-small cell lung cancer cell lines.Int J Oncol. 2013 Aug;43(2):566-74. doi: 10.3892/ijo.2013.1969. Epub 2013 May 30.
• [565] The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model.BMC Cancer. 2017 Sep 19;17(1):655. doi: 10.1186/s12885-017-3646-1.
• [566] Cx32 mediates norepinephrine-promoted EGFR-TKI resistance in a gap junction-independent manner in non-small-cell lung cancer.J Cell Physiol. 2019 Dec;234(12):23146-23159. doi: 10.1002/jcp.28881. Epub 2019 May 31.
• [567] IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage.Cancers (Basel). 2019 Nov 27;11(12):1879. doi: 10.3390/cancers11121879.
• [568] GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.PLoS One. 2017 Aug 3;12(8):e0182410. doi: 10.1371/journal.pone.0182410. eCollection 2017.
• [569] GLUL Ablation Can Confer Drug Resistance to Cancer Cells via a Malate-Aspartate Shuttle-Mediated Mechanism.Cancers (Basel). 2019 Dec 5;11(12):1945. doi: 10.3390/cancers11121945.
• [570] Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.Radiat Oncol. 2015 Jul 16;10:145. doi: 10.1186/s13014-015-0457-x.
• [571] The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway innon-small cell lung cancer.Cancer Lett. 2018 Jan 1;412:194-207. doi: 10.1016/j.canlet.2017.10.017. Epub 2017 Oct 23.
• [572] Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.Oncotarget. 2014 Nov 15;5(21):10434-45. doi: 10.18632/oncotarget.2142.
• [573] Overexpression of GPR35 confers drug resistance in NSCLC cells by -arrestin/Akt signaling.Onco Targets Ther. 2018 Sep 26;11:6249-6257. doi: 10.2147/OTT.S175606. eCollection 2018.
• [574] Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer.Mol Cancer. 2015 Apr 1;14:73. doi: 10.1186/s12943-015-0342-0.
• [575] Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.PLoS One. 2012;7(10):e44368. doi: 10.1371/journal.pone.0044368. Epub 2012 Oct 29.
• [576] GRHL2 suppresses tumor metastasis via regulation of transcriptional activity of RhoG in non-small cell lung cancer.Am J Transl Res. 2017 Sep 15;9(9):4217-4226. eCollection 2017.
• [577] Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway.Oncol Lett. 2017 Jul;14(1):1005-1010. doi: 10.3892/ol.2017.6234. Epub 2017 May 24.
• [578] MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer.Aging (Albany NY). 2019 Sep 8;11(17):6734-6761. doi: 10.18632/aging.102201. Epub 2019 Sep 8.
• [579] Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.BMC Cancer. 2011 Jun 5;11:220. doi: 10.1186/1471-2407-11-220.
• [580] GRK5 functions as an oncogenic factor in non-small-cell lung cancer.Cell Death Dis. 2018 Feb 20;9(3):295. doi: 10.1038/s41419-018-0299-1.
• [581] Inhibition of metabotropic glutamate receptor 1 suppresses tumor growth and angiogenesis in experimental non-small cell lung cancer.Eur J Pharmacol. 2016 Jul 15;783:103-11. doi: 10.1016/j.ejphar.2016.04.053. Epub 2016 Apr 29.
• [582] GSK-3 regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models.J Exp Clin Cancer Res. 2019 Feb 1;38(1):46. doi: 10.1186/s13046-019-1050-1.
• [583] Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer.Pathol Res Pract. 2018 Jan;214(1):44-52. doi: 10.1016/j.prp.2017.11.015. Epub 2017 Nov 21.
• [584] High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.J Immunother Cancer. 2019 Dec 16;7(1):351. doi: 10.1186/s40425-019-0827-2.
• [585] Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor.Neoplasia. 2017 Feb;19(2):55-64. doi: 10.1016/j.neo.2016.11.005. Epub 2016 Dec 23.
• [586] Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis.J Exp Clin Cancer Res. 2019 Jan 6;38(1):5. doi: 10.1186/s13046-018-0996-8.
• [587] Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.J Med Chem. 2019 Jan 24;62(2):857-874. doi: 10.1021/acs.jmedchem.8b01590. Epub 2018 Dec 20.
• [588] Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.Int J Cancer. 2018 Aug 1;143(3):657-667. doi: 10.1002/ijc.31349. Epub 2018 Mar 25.
• [589] Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC.Bioorg Chem. 2019 May;86:696-704. doi: 10.1016/j.bioorg.2019.02.047. Epub 2019 Feb 22.
• [590] High Serum HDGF Levels Are Predictive of Bone Metastasis and Unfavorable Prognosis in Non-Small Cell Lung Cancer.Tohoku J Exp Med. 2017 Jun;242(2):101-108. doi: 10.1620/tjem.242.101.
• [591] Significance of miR-15a-5p and CNKSR3 as Novel Prognostic Biomarkers in Non-Small Cell Lung Cancer.Anticancer Agents Med Chem. 2018;18(12):1695-1701. doi: 10.2174/1871520618666180718100656.
• [592] Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.J Exp Clin Cancer Res. 2019 Nov 12;38(1):462. doi: 10.1186/s13046-019-1407-5.
• [593] Human Leukocyte Antigen G Polymorphism and Expression Are Associated with an Increased Risk of Non-Small-Cell Lung Cancer and Advanced Disease Stage.PLoS One. 2016 Aug 12;11(8):e0161210. doi: 10.1371/journal.pone.0161210. eCollection 2016.
• [594] MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells.Cancer Manag Res. 2019 Jan 10;11:637-649. doi: 10.2147/CMAR.S185117. eCollection 2019.
• [595] Knockdown of lncRNA ZFAS1-suppressed non-small cell lung cancer progression via targeting the miR-150-5p/HMGA2 signaling.J Cell Biochem. 2020 Aug;121(8-9):3814-3824. doi: 10.1002/jcb.29542. Epub 2019 Nov 6.
• [596] Long non-coding RNA CACNA1G-AS1 promotes cell migration, invasion and epithelial-mesenchymal transition by HNRNPA2B1 in non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):993-1002. doi: 10.26355/eurrev_201802_14381.
• [597] The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction.Oncol Lett. 2018 Jun;15(6):8556-8572. doi: 10.3892/ol.2018.8381. Epub 2018 Mar 29.
• [598] Knockdown of MPP8 suppresses cell proliferation via regulation of HOXA5 in non-small cell lung cancer cells.Cell Mol Biol (Noisy-le-grand). 2018 Jan 31;64(1):27-31. doi: 10.14715/cmb/2018.64.1.6.
• [599] The effects and mechanisms of a biosynthetic ginsenoside 3,12-Di-O-Glc-PPD on non-small cell lung cancer.Onco Targets Ther. 2019 Sep 9;12:7375-7385. doi: 10.2147/OTT.S217039. eCollection 2019.
• [600] A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.J Inorg Biochem. 2019 Apr;193:133-142. doi: 10.1016/j.jinorgbio.2019.01.014. Epub 2019 Jan 29.
• [601] The HRH4 rs11662595 mutation is associated with histamine H(4) receptor dysfunction and with increased epithelial-to-mesenchymal transition progress in non-small cell lung cancer.Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2954-2963. doi: 10.1016/j.bbadis.2017.08.018. Epub 2017 Aug 25.
• [602] A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.
• [603] Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.Lung Cancer. 2015 Feb;87(2):107-16. doi: 10.1016/j.lungcan.2014.12.012. Epub 2014 Dec 25.
• [604] Prognostic value of the mRNA expression of members of the HSP90 family in non-small cell lung cancer.Exp Ther Med. 2019 Apr;17(4):2657-2665. doi: 10.3892/etm.2019.7228. Epub 2019 Jan 31.
• [605] HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-B signaling pathway.Oncol Lett. 2018 Mar;15(3):3883-3889. doi: 10.3892/ol.2018.7800. Epub 2018 Jan 16.
• [606] Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.Korean J Intern Med. 2019 Mar;34(2):401-408. doi: 10.3904/kjim.2017.015. Epub 2018 Sep 6.
• [607] Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer.Tumour Biol. 2017 Mar;39(3):1010428317695918. doi: 10.1177/1010428317695918.
• [608] Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner.Int J Biol Sci. 2019 Jun 2;15(7):1500-1513. doi: 10.7150/ijbs.33146. eCollection 2019.
• [609] Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.
• [610] Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer.Cancer Sci. 2011 Nov;102(11):1977-90. doi: 10.1111/j.1349-7006.2011.02079.x. Epub 2011 Oct 10.
• [611] MicroRNA 615-3p Inhibits the Tumor Growth and Metastasis of NSCLC via Inhibiting IGF2.Oncol Res. 2019 Feb 5;27(2):269-279. doi: 10.3727/096504018X15215019227688. Epub 2018 Mar 21.
• [612] IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.Cell Physiol Biochem. 2014;34(5):1578-88. doi: 10.1159/000366361. Epub 2014 Oct 31.
• [613] Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?.Clin Exp Metastasis. 2014 Jun;31(5):535-41. doi: 10.1007/s10585-014-9647-4. Epub 2014 Mar 29.
• [614] Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.Anticancer Res. 2019 Aug;39(8):4185-4190. doi: 10.21873/anticanres.13578.
• [615] Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene. 2000 Sep 7;19(38):4432-6.
• [616] IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.Oncol Rep. 2016 Mar;35(3):1483-92. doi: 10.3892/or.2015.4516. Epub 2015 Dec 24.
• [617] IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-B/Notch1 pathway in non-small cell lung cancer.Int J Cancer. 2019 Aug 15;145(4):1099-1110. doi: 10.1002/ijc.32151. Epub 2019 Feb 7.
• [618] Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study.Mol Biol Rep. 2020 Jan;47(1):583-592. doi: 10.1007/s11033-019-05164-0. Epub 2019 Nov 9.
• [619] Expression of IL-17A, E, and F and their receptors in non-small-cell lung cancer.J Biol Regul Homeost Agents. 2018 Sep-Oct;32(5):1105-1116.
• [620] IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF.Eur J Cancer. 2011 Aug;47(12):1908-18. doi: 10.1016/j.ejca.2011.04.012. Epub 2011 May 10.
• [621] IL?1/IL?1R inhibit tumor growth and invasion in nonsmall cell lung cancer cells via suppressing Wnt/catenin signaling and PDL1 expression.Int J Mol Med. 2019 Nov;44(5):1697-1706. doi: 10.3892/ijmm.2019.4354. Epub 2019 Sep 26.
• [622] Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.Int Immunopharmacol. 2019 May;70:125-134. doi: 10.1016/j.intimp.2019.02.027. Epub 2019 Feb 22.
• [623] Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients.Pathol Oncol Res. 2020 Jan;26(1):499-505. doi: 10.1007/s12253-018-0545-y. Epub 2018 Nov 20.
• [624] The Role of Interleukin-31 Polymorphisms in Non-Small Cell Lung Cancer Genetic Susceptibility and Clinical Outcome.Genet Test Mol Biomarkers. 2018 May;22(5):314-319. doi: 10.1089/gtmb.2017.0256.
• [625] IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway.Thorac Cancer. 2018 May;9(5):621-629. doi: 10.1111/1759-7714.12628. Epub 2018 Mar 25.
• [626] Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.Chin Med J (Engl). 2012 Jun;125(11):2004-11.
• [627] IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.Med Oncol. 2017 Dec 1;35(1):2. doi: 10.1007/s12032-017-1062-7.
• [628] Activin upregulation by NF-B is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.Cancer Res. 2015 Jan 15;75(2):426-35. doi: 10.1158/0008-5472.CAN-13-2702. Epub 2014 Nov 28.
• [629] SHIP1 inhibits cell growth, migration, and invasion in nonsmall cell lung cancer through the PI3K/AKT pathway.Oncol Rep. 2019 Apr;41(4):2337-2350. doi: 10.3892/or.2019.6990. Epub 2019 Jan 30.
• [630] A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers.J Biol Chem. 2019 May 24;294(21):8664-8673. doi: 10.1074/jbc.RA118.006805. Epub 2019 Mar 11.
• [631] The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.EBioMedicine. 2018 Nov;37:188-204. doi: 10.1016/j.ebiom.2018.10.044. Epub 2018 Oct 30.
• [632] Interferon regulatory factor3 mediates Poly(I:C)-induced innate immune response and apoptosis in nonsmall cell lung cancer.Int J Oncol. 2018 May;52(5):1623-1632. doi: 10.3892/ijo.2018.4300. Epub 2018 Mar 5.
• [633] IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function.Cell Cycle. 2019 Dec;18(23):3300-3312. doi: 10.1080/15384101.2019.1674053. Epub 2019 Oct 9.
• [634] microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2.J Cell Biochem. 2019 Aug;120(8):13453-13463. doi: 10.1002/jcb.28619. Epub 2019 Mar 25.
• [635] SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.
• [636] Cinnamaldehyde induces cell apoptosis mediated by a novel circular RNA hsa_circ_0043256 in non-small cell lung cancer.Biochem Biophys Res Commun. 2017 Nov 25;493(3):1260-1266. doi: 10.1016/j.bbrc.2017.09.136. Epub 2017 Sep 27.
• [637] Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.Gene. 2018 Feb 15;643:74-82. doi: 10.1016/j.gene.2017.12.003. Epub 2017 Dec 5.
• [638] Glucose Transporter 1 Promotes the Malignant Phenotype of Non-Small Cell Lung Cancer through Integrin 1/Src/FAK Signaling.J Cancer. 2019 Aug 27;10(20):4989-4997. doi: 10.7150/jca.30772. eCollection 2019.
• [639] Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by (18)F-fluorothymidine.Clin Cancer Res. 2018 Jul 1;24(13):3126-3136. doi: 10.1158/1078-0432.CCR-17-3657. Epub 2018 Apr 4.
• [640] Low-Dose IFN Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer.Cancer Res. 2019 Jul 15;79(14):3737-3748. doi: 10.1158/0008-5472.CAN-19-0596. Epub 2019 May 13.
• [641] TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.Exp Ther Med. 2018 Jan;15(1):365-370. doi: 10.3892/etm.2017.5426. Epub 2017 Nov 1.
• [642] Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer.Int J Cancer. 2015 Sep 15;137(6):1306-17. doi: 10.1002/ijc.29490. Epub 2015 May 29.
• [643] Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.Mol Cancer Res. 2018 Oct;16(10):1458-1469. doi: 10.1158/1541-7786.MCR-17-0637. Epub 2018 Jun 22.
• [644] Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells.J Biol Chem. 2014 Mar 14;289(11):7483-96. doi: 10.1074/jbc.M113.521625. Epub 2014 Jan 30.
• [645] JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.Oncogene. 2019 Jul;38(28):5643-5657. doi: 10.1038/s41388-019-0814-6. Epub 2019 Apr 9.
• [646] Retinoblastoma binding protein 2 (RBP2) promotes HIF-1-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway.PLoS One. 2014 Aug 27;9(8):e106032. doi: 10.1371/journal.pone.0106032. eCollection 2014.
• [647] Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.Clin Cancer Res. 2020 Jan 1;26(1):274-281. doi: 10.1158/1078-0432.CCR-19-1237. Epub 2019 Sep 23.
• [648] AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. J Cell Biochem. 2019 Jan;120(1):756-767. doi: 10.1002/jcb.27434. Epub 2018 Aug 26.
• [649] Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma.Front Oncol. 2019 Nov 5;9:1123. doi: 10.3389/fonc.2019.01123. eCollection 2019.
• [650] Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.Med Sci Monit. 2019 Dec 5;25:9280-9289. doi: 10.12659/MSM.918620.
• [651] KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population.Hum Immunol. 2012 Sep;73(9):927-31. doi: 10.1016/j.humimm.2012.07.323. Epub 2012 Jul 23.
• [652] A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.
• [653] Expression of KISS1 and KISS1R (GPR54) may be used as favorable prognostic markers for patients with non-small cell lung cancer.Int J Oncol. 2013 Aug;43(2):521-30. doi: 10.3892/ijo.2013.1967. Epub 2013 May 27.
• [654] Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.Clin Cancer Res. 2018 Sep 1;24(17):4297-4308. doi: 10.1158/1078-0432.CCR-17-3795. Epub 2018 May 15.
• [655] Klotho is identified as a target for theranostics in non-small cell lung cancer.Theranostics. 2019 Oct 12;9(25):7474-7489. doi: 10.7150/thno.35582. eCollection 2019.
• [656] Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.Front Oncol. 2019 Sep 11;9:886. doi: 10.3389/fonc.2019.00886. eCollection 2019.
• [657] Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer.Clin Chem. 2010 Jun;56(6):987-97. doi: 10.1373/clinchem.2009.138917. Epub 2010 Apr 1.
• [658] Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer.Oncotarget. 2019 Nov 26;10(63):6805-6815. doi: 10.18632/oncotarget.27308. eCollection 2019 Nov 26.
• [659] Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis.Cancer Manag Res. 2019 Aug 7;11:7485-7497. doi: 10.2147/CMAR.S218926. eCollection 2019.
• [660] Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and Np63/p40.Hum Pathol. 2018 Aug;78:177-181. doi: 10.1016/j.humpath.2018.01.023. Epub 2018 Feb 2.
• [661] LARP1 is regulated by the XIST/miR-374a axis and functions as an oncogene in non-small cell lung carcinoma.Oncol Rep. 2017 Dec;38(6):3659-3667. doi: 10.3892/or.2017.6040. Epub 2017 Oct 17.
• [662] Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway.Oncotarget. 2017 Aug 24;8(43):75102-75113. doi: 10.18632/oncotarget.20527. eCollection 2017 Sep 26.
• [663] Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.Oncotarget. 2018 Jun 8;9(44):27346-27362. doi: 10.18632/oncotarget.25213. eCollection 2018 Jun 8.
• [664] Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs.Int J Mol Sci. 2019 Mar 31;20(7):1607. doi: 10.3390/ijms20071607.
• [665] Inhibitory Effect of MiR-449b on Cancer Cell Growth and Invasion through LGR4 in Non-Small-Cell Lung Carcinoma.Curr Med Sci. 2018 Aug;38(4):582-589. doi: 10.1007/s11596-018-1917-y. Epub 2018 Aug 20.
• [666] The role of LGR5 and ALDH1A1 in non-small cell lung cancer: Cancer progression and prognosis.Biochem Biophys Res Commun. 2015 Jun 26;462(2):91-8. doi: 10.1016/j.bbrc.2015.04.029. Epub 2015 Apr 13.
• [667] miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients.Cell Biosci. 2019 Aug 7;9:63. doi: 10.1186/s13578-019-0326-7. eCollection 2019.
• [668] MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1.Mol Med Rep. 2016 Nov;14(5):4422-4428. doi: 10.3892/mmr.2016.5769. Epub 2016 Sep 23.
• [669] MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC.Mol Cancer. 2019 May 9;18(1):93. doi: 10.1186/s12943-019-1020-4.
• [670] Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer.PLoS One. 2017 Feb 24;12(2):e0172787. doi: 10.1371/journal.pone.0172787. eCollection 2017.
• [671] Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.
• [672] Forkhead box C1 promotes metastasis and invasion of non-small cell lung cancer by binding directly to the lysyl oxidase promoter.Cancer Sci. 2019 Dec;110(12):3663-3676. doi: 10.1111/cas.14213. Epub 2019 Nov 12.
• [673] Lipoprotein lipase in non-small cell lung cancer tissue is highly expressed in a subpopulation of tumor-associated macrophages.Pathol Res Pract. 2013 Aug;209(8):516-20. doi: 10.1016/j.prp.2013.06.004. Epub 2013 Jun 28.
• [674] APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.Cancer Lett. 2016 Jun 1;375(2):313-322. doi: 10.1016/j.canlet.2016.03.017. Epub 2016 Mar 11.
• [675] The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.J Oncol. 2019 Mar 26;2019:4536302. doi: 10.1155/2019/4536302. eCollection 2019.
• [676] MiRNA-500a-3p inhibits cell proliferation and invasion by targeting lymphocyte antigen 6 complex locus K (LY6K) in human non-small cell lung cancer.Neoplasma. 2018 Sep 19;65(5):673-682. doi: 10.4149/neo_2018_170516N355. Epub 2018 Sep 4.
• [677] The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome.World J Surg Oncol. 2014 Aug 21;12:268. doi: 10.1186/1477-7819-12-268.
• [678] Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.Clin Respir J. 2018 Jun;12(6):2020-2028. doi: 10.1111/crj.12769. Epub 2018 Feb 15.
• [679] MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(?0201 alleles.Cell Immunol. 2015 Sep;297(1):10-8. doi: 10.1016/j.cellimm.2015.05.004. Epub 2015 Jun 6.
• [680] MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer.Oncol Lett. 2018 Jun;15(6):8777-8783. doi: 10.3892/ol.2018.8362. Epub 2018 Mar 28.
• [681] Study on Attenuating Angiogenesis and Epithelial-Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818797587. doi: 10.1177/1533033818797587.
• [682] Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.J Neural Transm (Vienna). 2018 Nov;125(11):1553-1566. doi: 10.1007/s00702-018-1927-8. Epub 2018 Sep 27.
• [683] Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.Clin Lung Cancer. 2018 Nov;19(6):e853-e859. doi: 10.1016/j.cllc.2018.07.004. Epub 2018 Aug 4.
• [684] MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.J Cancer. 2019 Jun 2;10(11):2472-2479. doi: 10.7150/jca.29426. eCollection 2019.
• [685] miR-582-5p is a potential prognostic marker in human non-small cell lung cancer and functions as a tumor suppressor by targeting MAP3K2.Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7760-7767. doi: 10.26355/eurrev_201811_16397.
• [686] MiroRNA-188 Acts as Tumor Suppressor in Non-Small-Cell Lung Cancer by Targeting MAP3K3.Mol Pharm. 2018 Apr 2;15(4):1682-1689. doi: 10.1021/acs.molpharmaceut.8b00071. Epub 2018 Mar 16.
• [687] PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.EBioMedicine. 2019 Apr;42:311-325. doi: 10.1016/j.ebiom.2019.03.045. Epub 2019 Mar 25.
• [688] Expression Of Intracellular Components of the NF-B Alternative Pathway (NF-B2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients.Sci Rep. 2019 Oct 4;9(1):14299. doi: 10.1038/s41598-019-50528-y.
• [689] Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response.Exp Mol Med. 2019 Feb 21;51(2):1-20. doi: 10.1038/s12276-019-0209-3.
• [690] KIF20A silence inhibits the migration, invasion and proliferation of non-small cell lung cancer and regulates the JNK pathway.Clin Exp Pharmacol Physiol. 2020 Jan;47(1):135-142. doi: 10.1111/1440-1681.13183. Epub 2019 Oct 22.
• [691] Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.Front Pharmacol. 2018 Feb 8;9:21. doi: 10.3389/fphar.2018.00021. eCollection 2018.
• [692] Epigenetic activation of SIN1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.Biochem Biophys Res Commun. 2017 Jan 29;483(1):645-651. doi: 10.1016/j.bbrc.2016.12.089. Epub 2016 Dec 18.
• [693] A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.Cell Rep. 2013 Nov 27;5(4):868-77. doi: 10.1016/j.celrep.2013.10.025. Epub 2013 Nov 14.
• [694] ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.Mol Pharm. 2017 Oct 2;14(10):3239-3247. doi: 10.1021/acs.molpharmaceut.7b00216. Epub 2017 Sep 6.
• [695] Downregulated MCOLN1 Attenuates The Progression Of Non-Small-Cell Lung Cancer By Inhibiting Lysosome-Autophagy.Cancer Manag Res. 2019 Sep 23;11:8607-8617. doi: 10.2147/CMAR.S216538. eCollection 2019.
• [696] Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.J Clin Lab Anal. 2018 Oct;32(8):e22576. doi: 10.1002/jcla.22576. Epub 2018 May 23.
• [697] Association of MDM2 gene SNP 309 polymorphism and human non-small cell lung cancer susceptibility: A meta-analysis.Pathol Res Pract. 2019 Sep;215(9):152538. doi: 10.1016/j.prp.2019.152538. Epub 2019 Jul 13.
• [698] Methionine Aminopeptidase 2 as a Potential Therapeutic Target for Human Non-Small-Cell Lung Cancers.Adv Clin Exp Med. 2016 Jan-Feb;25(1):117-28. doi: 10.17219/acem/60715.
• [699] RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis.Exp Mol Med. 2018 Jan 26;50(1):e434. doi: 10.1038/emm.2017.247.
• [700] MAP kinase-interacting serine/threonine kinase 2 promotes proliferation, metastasis, and predicts poor prognosis in non-small cell lung cancer.Sci Rep. 2017 Sep 6;7(1):10612. doi: 10.1038/s41598-017-10397-9.
• [701] Aberrant methylation of mutL homolog 1 is associated with increased risk of non-small cell lung cancer.J Clin Lab Anal. 2018 Jun;32(5):e22370. doi: 10.1002/jcla.22370. Epub 2017 Dec 5.
• [702] IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line.Anticancer Res. 2009 Nov;29(11):4497-501.
• [703] SPOCK1 contributes to the third-generation EGFR tyrosine kinase inhibitors resistance in lung cancer.J Cell Biochem. 2019 Aug;120(8):12566-12573. doi: 10.1002/jcb.28523. Epub 2019 Mar 1.
• [704] LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15.Cell Biol Int. 2019 Apr;43(4):384-393. doi: 10.1002/cbin.11092. Epub 2019 Feb 6.
• [705] MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer.J Cancer. 2017 Jun 30;8(9):1704-1716. doi: 10.7150/jca.16961. eCollection 2017.
• [706] MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2.Life Sci. 2017 Nov 1;188:87-95. doi: 10.1016/j.lfs.2017.08.018. Epub 2017 Sep 1.
• [707] Association and clinical implication of the USP10 and MSH2 proteins in non-small cell lung cancer.Oncol Lett. 2019 Jan;17(1):1128-1138. doi: 10.3892/ol.2018.9702. Epub 2018 Nov 15.
• [708] Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway.Cell Physiol Biochem. 2017;44(2):455-466. doi: 10.1159/000485012. Epub 2017 Nov 15.
• [709] Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo.Exp Ther Med. 2019 Jan;17(1):739-747. doi: 10.3892/etm.2018.7015. Epub 2018 Nov 27.
• [710] The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.Lung Cancer. 2018 Sep;123:127-135. doi: 10.1016/j.lungcan.2018.07.015. Epub 2018 Jul 19.
• [711] OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.Sci Rep. 2019 Dec 2;9(1):18101. doi: 10.1038/s41598-019-54843-2.
• [712] Metastasis-Associated 1 (MTA1) Gene Expression Promotes Angiogenesis in Mouse Xenografts from Human Non-Small Cell Lung Cancer (NSCLC) Cells.Med Sci Monit. 2019 Jan 17;25:484-491. doi: 10.12659/MSM.912321.
• [713] Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma.Lung Cancer. 2009 Jan;63(1):39-44. doi: 10.1016/j.lungcan.2008.04.019. Epub 2008 Jun 13.
• [714] circMTDH.4/miR-630/AEG-1 axis participates in the regulation of proliferation, migration, invasion, chemoresistance, and radioresistance of NSCLC.Mol Carcinog. 2020 Feb;59(2):141-153. doi: 10.1002/mc.23135. Epub 2019 Nov 20.
• [715] mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition.Acta Pharmacol Sin. 2019 Aug;40(8):1085-1094. doi: 10.1038/s41401-019-0215-y. Epub 2019 Feb 22.
• [716] Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.Clin Chim Acta. 2018 Feb;477:160-165. doi: 10.1016/j.cca.2017.11.003. Epub 2017 Nov 4.
• [717] Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer.Int J Biol Macromol. 2019 Jan;121:270-278. doi: 10.1016/j.ijbiomac.2018.10.004. Epub 2018 Oct 2.
• [718] DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival.Cell Physiol Biochem. 2015;36(4):1419-29. doi: 10.1159/000430307.
• [719] MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB.Cancer Lett. 2014 May 28;347(1):65-74. doi: 10.1016/j.canlet.2014.01.019. Epub 2014 Jan 29.
• [720] ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6.
• [721] MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.Tumour Biol. 2014 Dec;35(12):12189-200. doi: 10.1007/s13277-014-2527-3. Epub 2014 Sep 2.
• [722] DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.
• [723] Phosphorylation of nucleolin is indispensable to its involvement in the proliferation and migration of non-small cell lung cancer cells.Oncol Rep. 2019 Jan;41(1):590-598. doi: 10.3892/or.2018.6787. Epub 2018 Oct 12.
• [724] miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3.Oncol Lett. 2017 May;13(5):3905-3911. doi: 10.3892/ol.2017.5904. Epub 2017 Mar 24.
• [725] RET fusions in solid tumors.Cancer Treat Rev. 2019 Dec;81:101911. doi: 10.1016/j.ctrv.2019.101911. Epub 2019 Oct 30.
• [726] Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.
• [727] Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.Tumour Biol. 2017 Jul;39(7):1010428317709639. doi: 10.1177/1010428317709639.
• [728] miR-363-3p inhibits migration, invasion, and epithelial-mesenchymal transition by targeting NEDD9 and SOX4 in non-small-cell lung cancer.J Cell Physiol. 2020 Feb;235(2):1808-1820. doi: 10.1002/jcp.29099. Epub 2019 Jul 22.
• [729] Deguelin inhibits epithelial-to-mesenchymal transition and metastasis of human non-small cell lung cancer cells by regulating NIMA-related kinase 2. Thorac Cancer. 2017 Jul;8(4):320-327. doi: 10.1111/1759-7714.12444. Epub 2017 May 16.
• [730] Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.Nat Commun. 2019 Nov 6;10(1):5043. doi: 10.1038/s41467-019-12925-9.
• [731] Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism. Toxicol Lett. 2018 Oct 1;295:88-98.
• [732] Nm23-H1 inhibits hypoxia induced epithelial-mesenchymal transition and stemness in non-small cell lung cancer cells.Biol Chem. 2019 May 27;400(6):765-776. doi: 10.1515/hsz-2018-0351.
• [733] LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4879-4887. doi: 10.26355/eurrev_201808_15624.
• [734] Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer.Medicine (Baltimore). 2018 Dec;97(52):e13817. doi: 10.1097/MD.0000000000013817.
• [735] Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth.Redox Biol. 2019 Apr;22:101116. doi: 10.1016/j.redox.2019.101116. Epub 2019 Feb 6.
• [736] Association between 18F-FDG uptake in PET/CT, Nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.Neoplasma. 2019 Jul 23;66(4):619-626. doi: 10.4149/neo_2018_181007N742.
• [737] Prognostic role of liver X receptor-alpha in resected stage II and III non-small-cell lung cancer.Clin Respir J. 2018 Jan;12(1):241-246. doi: 10.1111/crj.12522. Epub 2016 Jul 25.
• [738] Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients.Thorac Cancer. 2019 Apr;10(4):715-727. doi: 10.1111/1759-7714.12989. Epub 2019 Feb 25.
• [739] Long non-coding RNA BRE-AS1 represses non-small cell lung cancer cell growth and survival via up-regulating NR4A3.Arch Biochem Biophys. 2018 Dec 15;660:53-63. doi: 10.1016/j.abb.2018.09.013. Epub 2018 Sep 15.
• [740] MCLA-128 Fights NRG1 Fusion-Positive Cancers.Cancer Discov. 2019 Dec;9(12):1636. doi: 10.1158/2159-8290.CD-NB2019-128. Epub 2019 Nov 4.
• [741] The Biological-Behavioral Effect Of Neuritin On Non-Small Cell Lung Cancer Vascular Endothelial Cells Via VEGFR And Notch1.Onco Targets Ther. 2019 Nov 20;12:9747-9755. doi: 10.2147/OTT.S212771. eCollection 2019.
• [742] The regulation of Neuropilin 1 expression by miR-338-3p promotes non-small cell lung cancer via changes in EGFR signaling.Mol Carcinog. 2019 Jun;58(6):1019-1032. doi: 10.1002/mc.22990. Epub 2019 Feb 27.
• [743] CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Mol Cancer. 2017 Feb 3;16(1):34.
• [744] Neurotrophin system activation in pleural effusions.Growth Factors. 2010 Aug;28(4):221-31. doi: 10.3109/08977191003677402.
• [745] Isolation and structural characterization of degradation products of afatinib dimaleate by LC-Q-TOF/MS/MS and NMR: cytotoxicity evaluation of afatinib and isolated degradation products.J Pharm Biomed Anal. 2019 Mar 20;166:139-146. doi: 10.1016/j.jpba.2019.01.004. Epub 2019 Jan 7.
• [746] Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.Eur J Pharmacol. 2019 Dec 15;865:172735. doi: 10.1016/j.ejphar.2019.172735. Epub 2019 Oct 12.
• [747] Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.Am J Transl Res. 2017 Apr 15;9(4):1708-1719. eCollection 2017.
• [748] HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.Int J Cancer. 2008 Dec 1;123(11):2616-25. doi: 10.1002/ijc.23823.
• [749] Ornithine aminotransferase promoted the proliferation and metastasis of non-small cell lung cancer via upregulation of miR-21.J Cell Physiol. 2019 Aug;234(8):12828-12838. doi: 10.1002/jcp.27939. Epub 2018 Dec 13.
• [750] Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.Clin Lung Cancer. 2010 Mar 1;11(2):114-9. doi: 10.3816/CLC.2010.n.015.
• [751] Blocking OLFM4/HIF-1 axis alleviates hypoxia-induced invasion, epithelial-mesenchymal transition, and chemotherapy resistance in non-small-cell lung cancer.J Cell Physiol. 2019 Sep;234(9):15035-15043. doi: 10.1002/jcp.28144. Epub 2019 Jan 24.
• [752] Effect of -opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.Br J Cancer. 2012 Mar 13;106(6):1148-52. doi: 10.1038/bjc.2011.574. Epub 2012 Feb 16.
• [753] Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis.Front Oncol. 2019 Apr 5;9:235. doi: 10.3389/fonc.2019.00235. eCollection 2019.
• [754] Synthesis and evaluation of a ligand targeting the and opioid receptors for drug delivery to lung cancer.Bioorg Med Chem Lett. 2017 May 1;27(9):2074-2078. doi: 10.1016/j.bmcl.2016.06.067. Epub 2016 Jun 28.
• [755] Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma.Int J Clin Exp Pathol. 2015 May 1;8(5):5080-8. eCollection 2015.
• [756] Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
• [757] Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.Oncol Rep. 2016 Jul;36(1):551-8. doi: 10.3892/or.2016.4780. Epub 2016 Apr 28.
• [758] Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.Sci Transl Med. 2017 Mar 8;9(380):eaag0339. doi: 10.1126/scitranslmed.aag0339. Epub 2017 Mar 8.
• [759] MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/-catenin axis in non-small-cell lung cancer.Cancer Sci. 2019 Jun;110(6):1883-1896. doi: 10.1111/cas.14014. Epub 2019 Apr 29.
• [760] MicroRNA-7-5p induces cell growth inhibition, cell cycle arrest and apoptosis by targeting PAK2 in non-small cell lung cancer.FEBS Open Bio. 2019 Nov;9(11):1983-1993. doi: 10.1002/2211-5463.12738. Epub 2019 Oct 24.
• [761] Gene polymorphisms of SFTPB rs7316, rs9752 and PAOX rs1046175 affect the diagnostic value of plasma Pro-SFTPB and DAS in Chinese Han non-small-cell lung cancer patients.J Cell Biochem. 2019 Sep;120(9):14804-14812. doi: 10.1002/jcb.28741. Epub 2019 Apr 23.
• [762] Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Biochem Biophys Res Commun. 2020 Jan 29;522(1):121-126. doi: 10.1016/j.bbrc.2019.11.050. Epub 2019 Nov 18.
• [763] WT1-interacting protein inhibits cell proliferation and tumorigenicity in non-small-cell lung cancer via the AKT/FOXO1 axis.Mol Oncol. 2019 May;13(5):1059-1074. doi: 10.1002/1878-0261.12462. Epub 2019 Feb 22.
• [764] Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.Curr Cancer Drug Targets. 2017;17(2):169-176. doi: 10.2174/1568009616666160331124759.
• [765] lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients.Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581.
• [766] Human positive coactivator 4 is a potential novel therapeutic target in non-small cell lung cancer.Cancer Gene Ther. 2012 Oct;19(10):690-6. doi: 10.1038/cgt.2012.52. Epub 2012 Aug 24.
• [767] Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358. doi: 10.1007/s00262-019-02367-z. Epub 2019 Jul 20.
• [768] Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.
• [769] Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.Cancer Med. 2018 Jul;7(7):3474-3483. doi: 10.1002/cam4.1500. Epub 2018 May 15.
• [770] A comprehensive analysis of the predicted targets of miR-642b-3p associated with the long non-coding RNA HOXA11-AS in NSCLC cells.Oncol Lett. 2018 May;15(5):6147-6160. doi: 10.3892/ol.2018.8105. Epub 2018 Feb 22.
• [771] PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.Oncotarget. 2017 Jan 3;8(1):1449-1468. doi: 10.18632/oncotarget.13640.
• [772] PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the apoptosis of non-small cell lung cancer cells.Biosci Rep. 2019 May 14;39(5):BSR20182099. doi: 10.1042/BSR20182099. Print 2019 May 31.
• [773] Elevated proportion of collapsed microvessels indicate poor survival outcome in patients with non-small cell lung cancer.Tumori. 2019 Dec;105(6):494-500. doi: 10.1177/0300891619871103. Epub 2019 Sep 3.
• [774] Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.J Biol Chem. 2019 Jul 5;294(27):10530-10543. doi: 10.1074/jbc.RA119.007784. Epub 2019 May 24.
• [775] Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells.Cancer Lett. 2016 May 1;374(2):279-91. doi: 10.1016/j.canlet.2016.02.014. Epub 2016 Feb 15.
• [776] The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.Biochem Biophys Res Commun. 2014 Aug 15;451(1):119-25. doi: 10.1016/j.bbrc.2014.07.076. Epub 2014 Jul 24.
• [777] miR-126-5p targets Malate Dehydrogenase 1 in non-small cell lung carcinomas.Biochem Biophys Res Commun. 2018 May 5;499(2):314-320. doi: 10.1016/j.bbrc.2018.03.154. Epub 2018 Mar 26.
• [778] PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.Cancer Lett. 2019 Mar 1;444:116-126. doi: 10.1016/j.canlet.2018.12.015. Epub 2018 Dec 21.
• [779] Pin1 expression contributes to lung cancer: Prognosis and carcinogenesis.Cancer Biol Ther. 2010 Jan;9(2):111-9. doi: 10.4161/cbt.9.2.10341. Epub 2010 Jan 17.
• [780] The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway.Mol Cancer. 2017 Apr 4;16(1):74. doi: 10.1186/s12943-017-0637-4.
• [781] Antitumor activity of SR splicing-factor 5 knockdown by downregulating pyruvate kinase M2 in non-small cell lung cancer cells.J Cell Biochem. 2019 Oct;120(10):17303-17311. doi: 10.1002/jcb.28992. Epub 2019 May 20.
• [782] Immunohistochemical expression of cytosolic phospholipase A2 in non-small cell lung carcinoma.Asian Pac J Cancer Prev. 2010;11(5):1367-72.
• [783] Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.Oncol Rep. 2018 Jan;39(1):53-60. doi: 10.3892/or.2017.6086. Epub 2017 Nov 9.
• [784] PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.Cell Death Dis. 2017 Oct 26;8(10):e3143. doi: 10.1038/cddis.2017.553.
• [785] The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.Cancer Res. 2012 May 1;72(9):2275-84. doi: 10.1158/0008-5472.CAN-11-3159. Epub 2012 Mar 9.
• [786] Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.J Clin Lab Anal. 2019 Sep;33(7):e22943. doi: 10.1002/jcla.22943. Epub 2019 Jul 3.
• [787] Cyclophilin A promotes non-small cell lung cancer metastasis via p38 MAPK.Thorac Cancer. 2018 Jan;9(1):120-128. doi: 10.1111/1759-7714.12548. Epub 2017 Nov 7.
• [788] Cyclophilin B promotes cell proliferation, migration, invasion and angiogenesis via regulating the STAT3 pathway in non-small cell lung cancer.Pathol Res Pract. 2019 Jun;215(6):152417. doi: 10.1016/j.prp.2019.04.009. Epub 2019 Apr 17.
• [789] APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP.EBioMedicine. 2019 Jun;44:138-149. doi: 10.1016/j.ebiom.2019.05.028. Epub 2019 May 16.
• [790] Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. doi: 10.1186/s13046-019-1120-4.
• [791] Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.Asia Pac J Clin Oncol. 2017 Oct;13(5):e212-e223. doi: 10.1111/ajco.12586. Epub 2016 Aug 12.
• [792] Distinctive requirement of PKC in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells.Oncogene. 2019 Jul;38(27):5396-5412. doi: 10.1038/s41388-019-0796-4. Epub 2019 Mar 28.
• [793] Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression.Onco Targets Ther. 2019 Jul 18;12:5835-5848. doi: 10.2147/OTT.S207211. eCollection 2019.
• [794] Co-dependency of PKC and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.Oncogene. 2017 Jul 27;36(30):4370-4378. doi: 10.1038/onc.2017.27. Epub 2017 Apr 3.
• [795] PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.Int J Biochem Cell Biol. 2015 Mar;60:34-42. doi: 10.1016/j.biocel.2014.12.018. Epub 2015 Jan 9.
• [796] Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro.Cancer Manag Res. 2018 Sep 13;10:3551-3560. doi: 10.2147/CMAR.S165831. eCollection 2018.
• [797] PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.Onco Targets Ther. 2018 Aug 14;11:4869-4876. doi: 10.2147/OTT.S166412. eCollection 2018.
• [798] Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition. Chem Biol Interact. 2019 Apr 25;303:14-21. doi: 10.1016/j.cbi.2019.02.020. Epub 2019 Feb 22.
• [799] Protease Serine S1 Family Member 8 (PRSS8) Inhibits Tumor Growth In Vitro and In Vivo in Human Non-Small Cell Lung Cancer.Oncol Res. 2017 May 24;25(5):781-787. doi: 10.3727/096504016X14772417575982. Epub 2016 Oct 27.
• [800] Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.J Cancer Res Clin Oncol. 2019 Feb;145(2):383-392. doi: 10.1007/s00432-018-2799-x. Epub 2018 Nov 22.
• [801] PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Oncoimmunology. 2017 Feb 6;6(3):e1284722. doi: 10.1080/2162402X.2017.1284722. eCollection 2017.
• [802] Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-/SMAD3 signaling pathway.Oncotarget. 2017 Jan 24;8(4):5909-5923. doi: 10.18632/oncotarget.13947.
• [803] Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.Cancer Res. 2015 Oct 1;75(19):4198-210. doi: 10.1158/0008-5472.CAN-15-1062. Epub 2015 Sep 10.
• [804] The RNA-binding protein HuR stabilizes cytosolic phospholipase A2 mRNA under interleukin-1 treatment in non-small cell lung cancer A549 Cells.J Biol Chem. 2011 Oct 14;286(41):35499-35508. doi: 10.1074/jbc.M111.263582. Epub 2011 Aug 23.
• [805] MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.Oncol Res. 2020 Mar 27;28(2):147-159. doi: 10.3727/096504019X15732109856009. Epub 2019 Nov 11.
• [806] A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.
• [807] Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression.J Ethnopharmacol. 2019 Jun 12;237:128-140. doi: 10.1016/j.jep.2019.03.027. Epub 2019 Mar 22.
• [808] miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.FASEB J. 2019 Jun;33(6):6933-6947. doi: 10.1096/fj.201802547R. Epub 2019 Mar 28.
• [809] Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer.Cancer. 2011 Nov 15;117(22):5121-32. doi: 10.1002/cncr.26168. Epub 2011 Apr 26.
• [810] Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.
• [811] A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.Cancer Res. 2014 May 15;74(10):2892-902. doi: 10.1158/0008-5472.CAN-13-2775. Epub 2014 Mar 20.
• [812] Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.Asian Pac J Cancer Prev. 2015;16(4):1421-5. doi: 10.7314/apjcp.2015.16.4.1421.
• [813] hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment.Int J Biol Markers. 2013 Jan 27;27(4):e400-4. doi: 10.5301/JBM.2012.9420.
• [814] Role of miR-520b in non-small cell lung cancer.Exp Ther Med. 2018 Nov;16(5):3987-3995. doi: 10.3892/etm.2018.6732. Epub 2018 Sep 12.
• [815] MiR-296-3p may affect the proliferation and migration of non-small cell lung cancer cells via regulating RABL3.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5823-5830. doi: 10.26355/eurrev_201907_18321.
• [816] Non-canonical Raf-1/p70S6K signalling in non-small-cell lung cancer.J Cell Mol Med. 2019 Nov;23(11):7632-7640. doi: 10.1111/jcmm.14636. Epub 2019 Sep 21.
• [817] Anticancer activity of 2'-hydroxyflavanone towards lung cancer.Oncotarget. 2018 Nov 16;9(90):36202-36219. doi: 10.18632/oncotarget.26329. eCollection 2018 Nov 16.
• [818] Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer.Int J Clin Oncol. 2016 Dec;21(6):1051-1061. doi: 10.1007/s10147-016-1002-0. Epub 2016 Jun 15.
• [819] Gene promoter methylation and cancer: An umbrella review.Gene. 2019 Aug 20;710:333-340. doi: 10.1016/j.gene.2019.06.023. Epub 2019 Jun 13.
• [820] Therapeutic effect of -secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.Cancer Cell. 2012 Aug 14;22(2):222-34. doi: 10.1016/j.ccr.2012.06.014.
• [821] MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China.PLoS One. 2014 Aug 1;9(8):e103698. doi: 10.1371/journal.pone.0103698. eCollection 2014.
• [822] Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.Cancer Med. 2020 Jan;9(2):487-495. doi: 10.1002/cam4.2706. Epub 2019 Nov 25.
• [823] RGS4 Regulates Proliferation And Apoptosis Of NSCLC Cells Via microRNA-16 And Brain-Derived Neurotrophic Factor.Onco Targets Ther. 2019 Oct 25;12:8701-8714. doi: 10.2147/OTT.S221657. eCollection 2019.
• [824] Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer.Respirology. 2017 Oct;22(7):1379-1385. doi: 10.1111/resp.13075. Epub 2017 May 23.
• [825] The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.Mol Ther. 2017 Mar 1;25(3):739-751. doi: 10.1016/j.ymthe.2016.12.018. Epub 2017 Jan 25.
• [826] Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer.Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21.
• [827] Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).Lung Cancer. 2013 Aug;81(2):252-8. doi: 10.1016/j.lungcan.2013.04.014. Epub 2013 May 10.
• [828] ROCK1 promotes migration and invasion of nonsmallcell lung cancer cells through the PTEN/PI3K/FAK pathway.Int J Oncol. 2019 Oct;55(4):833-844. doi: 10.3892/ijo.2019.4864. Epub 2019 Aug 30.
• [829] Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.Oncotarget. 2016 Jun 21;7(25):37524-37535. doi: 10.18632/oncotarget.6852.
• [830] Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.Cancer Res. 2011 Apr 15;71(8):3132-41. doi: 10.1158/0008-5472.CAN-10-2662. Epub 2011 Apr 12.
• [831] Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer.Oncotarget. 2015 Sep 22;6(28):24912-21. doi: 10.18632/oncotarget.4701.
• [832] Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis.Oncotarget. 2017 Apr 4;8(14):23978-23995. doi: 10.18632/oncotarget.15074.
• [833] Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.Br J Cancer. 2016 Aug 23;115(5):549-52. doi: 10.1038/bjc.2016.220. Epub 2016 Jul 21.
• [834] Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.Pathology. 2019 Apr;51(3):240-245. doi: 10.1016/j.pathol.2018.11.009. Epub 2019 Feb 21.
• [835] Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3 and osteopontin.Mol Cell Biochem. 2016 Jul;418(1-2):21-9. doi: 10.1007/s11010-016-2727-9. Epub 2016 May 28.
• [836] MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.Oncogene. 2015 Jan 22;34(4):413-23. doi: 10.1038/onc.2013.574. Epub 2014 Jan 27.
• [837] RRM2 Regulated By LINC00667/miR-143-3p Signal Is Responsible For Non-Small Cell Lung Cancer Cell Progression.Onco Targets Ther. 2019 Nov 20;12:9927-9939. doi: 10.2147/OTT.S221339. eCollection 2019.
• [838] Association of CAA and TATC Insertion/Deletion Genetic Polymorphisms in RTN4 3'-UTR with Hepatocellular Carcinoma Risk.Pathol Oncol Res. 2018 Jan;24(1):31-34. doi: 10.1007/s12253-017-0204-8. Epub 2017 Jan 31.
• [839] Potential therapeutic impact of CD13 expression in non-small cell lung cancer.PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017.
• [840] SNHG20 knockdown suppresses proliferation, migration and invasion, and promotes apoptosis in non-small cell lung cancer through acting as a miR-154 sponge.Biomed Pharmacother. 2019 Apr;112:108648. doi: 10.1016/j.biopha.2019.108648. Epub 2019 Feb 16.
• [841] MicroRNA?29 inhibition suppresses the viability and invasion of nonsmall cell lung cancer cells by directly targeting RUNX3.Mol Med Rep. 2019 May;19(5):3933-3940. doi: 10.3892/mmr.2019.9990. Epub 2019 Feb 27.
• [842] Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features.Cancer Genet Cytogenet. 2010 Feb;197(1):39-45. doi: 10.1016/j.cancergencyto.2009.10.008.
• [843] Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.Med Oncol. 2017 Mar;34(3):45. doi: 10.1007/s12032-017-0900-y. Epub 2017 Feb 14.
• [844] Clinical significance of calcium-binding protein S100A8 and S100A9 expression in non-small cell lung cancer.Thorac Cancer. 2018 Jul;9(7):800-804. doi: 10.1111/1759-7714.12649. Epub 2018 May 7.
• [845] Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value.Pathol Res Pract. 2019 Mar;215(3):427-432. doi: 10.1016/j.prp.2018.11.011. Epub 2018 Nov 12.
• [846] Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.Oncotarget. 2017 Mar 21;8(12):18901-18913. doi: 10.18632/oncotarget.14782.
• [847] SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.Anticancer Res. 2018 Feb;38(2):723-736. doi: 10.21873/anticanres.12278.
• [848] SCUBE2 inhibits the proliferation, migration and invasion of human non-small cell lung cancer cells through regulation of the sonic hedgehog signaling pathway.Gene. 2018 Sep 25;672:143-149. doi: 10.1016/j.gene.2018.06.012. Epub 2018 Jun 5.
• [849] Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an Eselectin ligand in nonsmall cell lung cancer.Int J Oncol. 2019 Nov;55(5):1033-1048. doi: 10.3892/ijo.2019.4886. Epub 2019 Sep 26.
• [850] Aberrant Expression of miR-362 Promotes Lung Cancer Metastasis through Downregulation of Sema3A.J Immunol Res. 2018 Aug 1;2018:1687097. doi: 10.1155/2018/1687097. eCollection 2018.
• [851] The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.Int J Cancer. 2019 May 1;144(9):2227-2238. doi: 10.1002/ijc.31958. Epub 2018 Dec 6.
• [852] Small ubiquitin-like modifier/sentrin-specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non-small cell lung cancer.J Clin Lab Anal. 2018 Nov;32(9):e22611. doi: 10.1002/jcla.22611. Epub 2018 Jul 24.
• [853] Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs).Epigenetics. 2011 Feb;6(2):224-35. doi: 10.4161/epi.6.2.13700. Epub 2011 Feb 1.
• [854] Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells.J Cancer. 2017 Jul 5;8(11):2069-2078. doi: 10.7150/jca.19143. eCollection 2017.
• [855] EGF-induced nuclear localization of SHCBP1 activates -catenin signaling and promotes cancer progression.Oncogene. 2019 Jan;38(5):747-764. doi: 10.1038/s41388-018-0473-z. Epub 2018 Sep 3.
• [856] The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.Cancer Discov. 2019 Nov;9(11):1606-1627. doi: 10.1158/2159-8290.CD-18-1261. Epub 2019 Jul 26.
• [857] Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.J Cell Mol Med. 2019 Apr;23(4):2872-2889. doi: 10.1111/jcmm.14194. Epub 2019 Feb 1.
• [858] Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis.Onco Targets Ther. 2018 Apr 13;11:2157-2167. doi: 10.2147/OTT.S157836. eCollection 2018.
• [859] SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.Tumour Biol. 2014 Nov;35(11):10699-705. doi: 10.1007/s13277-014-2372-4. Epub 2014 Jul 29.
• [860] Downregulation of SIRT6 is associated with poor prognosis in patients with non-small cell lung cancer.J Int Med Res. 2018 Apr;46(4):1517-1527. doi: 10.1177/0300060517750298. Epub 2018 Jan 24.
• [861] Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.Oncol Lett. 2018 Sep;16(3):2873-2880. doi: 10.3892/ol.2018.9000. Epub 2018 Jun 20.
• [862] Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.Am J Clin Oncol. 2018 May;41(5):513-518. doi: 10.1097/COC.0000000000000316.
• [863] Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPAR/PTEN/mTOR signaling pathway.BMC Cancer. 2018 Apr 11;18(1):407. doi: 10.1186/s12885-018-4224-x.
• [864] CRISP-R/Cas9 Mediated Deletion of Copper Transport Genes CTR1 and DMT1 in NSCLC Cell Line H1299. Biological and Pharmacological Consequences.Cells. 2019 Apr 6;8(4):322. doi: 10.3390/cells8040322.
• [865] Expression of peptide transporter 1has a positive correlation in protoporphyrin IX accumulation induced by 5-aminolevulinic acid with photodynamic detection of non-small cell lung cancer and metastatic brain tumor specimens originating from non-small cell lung cancer.Photodiagnosis Photodyn Ther. 2019 Mar;25:309-316. doi: 10.1016/j.pdpdt.2019.01.009. Epub 2019 Jan 11.
• [866] High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncol Lett. 2017 Nov;14(5):5727-5734.
• [867] Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution.Ann Transl Med. 2019 Jun;7(12):253. doi: 10.21037/atm.2019.04.65.
• [868] Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019 Apr;19(2):164-177.
• [869] CD44-SLC1A2 fusion transcripts in primary colorectal cancer.Pathol Oncol Res. 2015 Jul;21(3):759-64. doi: 10.1007/s12253-014-9887-2. Epub 2015 Jan 10.
• [870] Delta-Tocotrienol Modulates Glutamine Dependence by Inhibiting ASCT2 and LAT1 Transporters in Non-Small Cell Lung Cancer (NSCLC) Cells: A Metabolomic Approach.Metabolites. 2019 Mar 13;9(3):50. doi: 10.3390/metabo9030050.
• [871] The POU-Domain Transcription Factor Oct-6/POU3F1 as a Regulator of Cellular Response to Genotoxic Stress.Cancers (Basel). 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810.
• [872] The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.
• [873] Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.Cancer Epidemiol. 2014 Dec;38(6):728-32. doi: 10.1016/j.canep.2014.08.008. Epub 2014 Sep 20.
• [874] Correction to: The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer.J Biomed Sci. 2019 Feb 13;26(1):18. doi: 10.1186/s12929-019-0508-y.
• [875] Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1.Cancer Lett. 2017 May 1;393:8-15. doi: 10.1016/j.canlet.2017.01.036. Epub 2017 Feb 13.
• [876] Co-expression analysis revealed PTCH1-3'UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: implicating the novel function of PTCH1.Oncotarget. 2017 Dec 13;9(4):4798-4813. doi: 10.18632/oncotarget.23219. eCollection 2018 Jan 12.
• [877] Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer.Expert Opin Biol Ther. 2019 Jun;19(6):509-515. doi: 10.1080/14712598.2019.1610380. Epub 2019 Apr 29.
• [878] The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.Cancer Chemother Pharmacol. 2018 Jan;81(1):1-15. doi: 10.1007/s00280-017-3473-8. Epub 2017 Nov 10.
• [879] Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.Lung Cancer. 2018 Sep;123:30-35. doi: 10.1016/j.lungcan.2018.06.004. Epub 2018 Jun 9.
• [880] Iodide sensitizes genetically modified non-small cell lung cancer cells to ionizing radiation.Cancer Gene Ther. 2006 Jan 1;13(1):74-81. doi: 10.1038/sj.cgt.7700875.
• [881] Neuroepithelial transforming gene 1 functions as a potential prognostic marker for patients with non-small cell lung cancer.Mol Med Rep. 2015 Nov;12(5):7439-46. doi: 10.3892/mmr.2015.4385. Epub 2015 Sep 29.
• [882] xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.Oncogene. 2018 Sep;37(36):5007-5019. doi: 10.1038/s41388-018-0307-z. Epub 2018 May 23.
• [883] Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.BMC Cancer. 2019 Mar 19;19(1):246. doi: 10.1186/s12885-019-5438-2.
• [884] Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer.Oncol Rep. 2013 Apr;29(4):1308-14. doi: 10.3892/or.2013.2266. Epub 2013 Jan 31.
• [885] SNPs in the TGF- signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer.PLoS One. 2012;7(12):e51713. doi: 10.1371/journal.pone.0051713. Epub 2012 Dec 17.
• [886] MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7.Onco Targets Ther. 2018 Nov 28;11:8445-8454. doi: 10.2147/OTT.S172393. eCollection 2018.
• [887] SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.Nat Commun. 2019 Feb 4;10(1):557. doi: 10.1038/s41467-019-08380-1.
• [888] Enhanced Acid Sphingomyelinase Activity Drives Immune Evasion and Tumor Growth in Non-Small Cell Lung Carcinoma.Cancer Res. 2017 Nov 1;77(21):5963-5976. doi: 10.1158/0008-5472.CAN-16-3313. Epub 2017 Sep 7.
• [889] Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.Front Oncol. 2019 Apr 26;9:306. doi: 10.3389/fonc.2019.00306. eCollection 2019.
• [890] Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.JCI Insight. 2019 Oct 17;4(20):e131340. doi: 10.1172/jci.insight.131340.
• [891] Downregulation of SOX2 may be targeted by miR-590-5p and inhibits epithelial-to-mesenchymal transition in non-small-cell lung cancer.Exp Ther Med. 2019 Aug;18(2):1189-1195. doi: 10.3892/etm.2019.7642. Epub 2019 Jun 4.
• [892] miR-497-5p inhibits tumor cell growth and invasion by targeting SOX5 in non-small-cell lung cancer.J Cell Biochem. 2019 Jun;120(6):10587-10595. doi: 10.1002/jcb.28345. Epub 2019 Feb 28.
• [893] Sp1 transcriptionally regulates BRK1 expression in non-small cell lung cancer cells.Gene. 2014 Jun 1;542(2):134-40. doi: 10.1016/j.gene.2014.03.043. Epub 2014 Mar 25.
• [894] SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.
• [895] Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.Thorac Cancer. 2017 May;8(3):138-146. doi: 10.1111/1759-7714.12413. Epub 2017 Mar 17.
• [896] Increased SPK1 expression promotes cell growth by activating the ERK1/2 signaling in non-small-cell lung cancer.Anticancer Drugs. 2019 Jun;30(5):458-465. doi: 10.1097/CAD.0000000000000733.
• [897] The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.Int J Cancer. 2018 May 15;142(10):2153-2162. doi: 10.1002/ijc.31234. Epub 2018 Jan 4.
• [898] CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target.Int J Cancer. 2013 Apr 15;132(8):1761-70. doi: 10.1002/ijc.27873. Epub 2012 Oct 29.
• [899] SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC.Front Oncol. 2019 Jul 30;9:586. doi: 10.3389/fonc.2019.00586. eCollection 2019.
• [900] MircoRNA-33a inhibits epithelial-to-mesenchymal transition and metastasis and could be a prognostic marker in non-small cell lung cancer.Sci Rep. 2015 Sep 2;5:13677. doi: 10.1038/srep13677.
• [901] Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner.Oncogene. 2017 Apr 27;36(17):2457-2471. doi: 10.1038/onc.2016.404. Epub 2016 Nov 7.
• [902] The many faces of SRPK1.J Pathol. 2017 Mar;241(4):437-440. doi: 10.1002/path.4846. Epub 2017 Feb 1.
• [903] Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer.Eur J Histochem. 2019 Dec 11;63(4):3067. doi: 10.4081/ejh.2019.3067.
• [904] Tumor-associated macrophages promote tumor metastasis via the TGF-/SOX9 axis in non-small cell lung cancer.Oncotarget. 2017 Sep 16;8(59):99801-99815. doi: 10.18632/oncotarget.21068. eCollection 2017 Nov 21.
• [905] Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer.Mol Imaging. 2013 Oct;12(7):1-10.
• [906] Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.Cancer Sci. 2020 Mar;111(3):826-839. doi: 10.1111/cas.14199. Epub 2020 Jan 31.
• [907] Expression profile and prognostic values of STAT family members in non-small cell lung cancer.Am J Transl Res. 2019 Aug 15;11(8):4866-4880. eCollection 2019.
• [908] The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.J Surg Oncol. 2011 Dec;104(7):836-40. doi: 10.1002/jso.21948. Epub 2011 Jun 7.
• [909] Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction.Neoplasma. 2017;64(6):869-879. doi: 10.4149/neo_2017_608.
• [910] Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells.Oncotarget. 2016 Sep 20;7(38):61366-61377. doi: 10.18632/oncotarget.11351.
• [911] Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through -catenin signaling pathway.Cell Death Dis. 2018 Apr 1;9(4):425. doi: 10.1038/s41419-018-0461-9.
• [912] miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.Nat Commun. 2018 Nov 30;9(1):5110. doi: 10.1038/s41467-018-07561-8.
• [913] Long noncoding RNA MIAT promotes the growth and metastasis of non-small cell lung cancer by upregulating TDP43.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3383-3389. doi: 10.26355/eurrev_201904_17702.
• [914] TBL1XR1 is involved in c-Met-mediated tumorigenesis of human nonsmall cell lung cancer.Cancer Gene Ther. 2020 Apr;27(3-4):136-146. doi: 10.1038/s41417-019-0111-0. Epub 2019 Jun 27.
• [915] Impaired T-bet-pSTAT1 and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma.Br J Cancer. 2015 Sep 15;113(6):902-13. doi: 10.1038/bjc.2015.255. Epub 2015 Sep 8.
• [916] Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.Oncogene. 2011 Sep 1;30(35):3802-12. doi: 10.1038/onc.2011.94. Epub 2011 Apr 11.
• [917] Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model.Oncotarget. 2016 Feb 2;7(5):5258-72. doi: 10.18632/oncotarget.6676.
• [918] Modulation of telomere shelterin by TRF1 [corrected] and TRF2 interacts with telomerase to maintain the telomere length in non-small cell lung cancer.Lung Cancer. 2007 Dec;58(3):310-6. doi: 10.1016/j.lungcan.2007.06.019. Epub 2007 Aug 2.
• [919] Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.Biomed Res Int. 2017;2017:8983763. doi: 10.1155/2017/8983763. Epub 2017 Jan 26.
• [920] Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells.Cancer Lett. 2012 Dec 28;325(2):220-6. doi: 10.1016/j.canlet.2012.07.009. Epub 2012 Jul 13.
• [921] MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.Int J Oncol. 2019 Jan;54(1):128-138. doi: 10.3892/ijo.2018.4610. Epub 2018 Oct 29.
• [922] Thrombomodulin regulates doxorubicin sensitivity through epithelial-mesenchymal transition in non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):95-101.
• [923] Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases.PLoS One. 2016 Aug 11;11(8):e0161007. doi: 10.1371/journal.pone.0161007. eCollection 2016.
• [924] Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer.Biochem Biophys Res Commun. 2019 Mar 12;510(3):462-466. doi: 10.1016/j.bbrc.2019.01.131. Epub 2019 Feb 2.
• [925] Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.J Histochem Cytochem. 2009 Nov;57(11):1087-97. doi: 10.1369/jhc.2009.952804. Epub 2009 Aug 3.
• [926] MHC class II expression in lung cancer.Lung Cancer. 2017 Oct;112:75-80. doi: 10.1016/j.lungcan.2017.07.030. Epub 2017 Jul 29.
• [927] High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer.J Cancer Res Clin Oncol. 2014 Apr;140(4):633-43. doi: 10.1007/s00432-014-1616-4. Epub 2014 Feb 19.
• [928] High TMPRSS11D protein expression predicts poor overall survival in non-small cell lung cancer.Oncotarget. 2017 Feb 21;8(8):12812-12819. doi: 10.18632/oncotarget.14559.
• [929] Thymosin beta 4 silencing suppresses proliferation and invasion of non-small cell lung cancer cells by repressing Notch1 activation.Acta Biochim Biophys Sin (Shanghai). 2016 Sep;48(9):788-94. doi: 10.1093/abbs/gmw070. Epub 2016 Aug 12.
• [930] Src Promotes Metastasis of Human Non-Small Cell Lung Cancer Cells through Fn14-Mediated NF-B Signaling.Med Sci Monit. 2018 Mar 3;24:1282-1294. doi: 10.12659/msm.906266.
• [931] APRIL promotes non-small cell lung cancer growth and metastasis by targeting ERK1/2 signaling.Oncotarget. 2017 Nov 27;8(65):109289-109300. doi: 10.18632/oncotarget.22672. eCollection 2017 Dec 12.
• [932] OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.Transl Lung Cancer Res. 2019 Aug;8(4):352-366. doi: 10.21037/tlcr.2019.08.15.
• [933] Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.Eur J Pharmacol. 2019 Mar 15;847:91-96. doi: 10.1016/j.ejphar.2019.01.028. Epub 2019 Jan 25.
• [934] Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer.Adv Exp Med Biol. 2018;1047:1-6. doi: 10.1007/5584_2017_111.
• [935] The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.Cell Cycle. 2018;17(14):1772-1783. doi: 10.1080/15384101.2018.1496745. Epub 2018 Aug 2.
• [936] LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non-small Cell Lung Cancer Patients.J Bone Miner Res. 2020 Apr;35(4):671-680. doi: 10.1002/jbmr.3942. Epub 2020 Jan 7.
• [937] Activated cdc42-associated kinase is up-regulated in non-small-cell lung cancer and necessary for FGFR-mediated AKT activation.Mol Carcinog. 2016 May;55(5):853-63. doi: 10.1002/mc.22327. Epub 2015 May 6.
• [938] Tankyrase 2 (TNKS2) polymorphism associated with risk in developing non-small cell lung cancer in a Chinese population.Pathol Res Pract. 2015 Oct;211(10):766-71. doi: 10.1016/j.prp.2015.07.003. Epub 2015 Jul 8.
• [939] An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.Ann Thorac Surg. 2018 Jun;105(6):1664-1670. doi: 10.1016/j.athoracsur.2018.01.036. Epub 2018 Feb 14.
• [940] Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.Cancer Med. 2020 Jan;9(2):605-614. doi: 10.1002/cam4.2743. Epub 2019 Dec 3.
• [941] Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.PLoS One. 2017 Mar 29;12(3):e0174515. doi: 10.1371/journal.pone.0174515. eCollection 2017.
• [942] Prognostic significance of TOP2A in non-small cell lung cancer revealed by bioinformatic analysis.Cancer Cell Int. 2019 Sep 11;19:239. doi: 10.1186/s12935-019-0956-1. eCollection 2019.
• [943] Sodium butyrate-activated TRAF6-TXNIP pathway affects A549 cells proliferation and migration.Cancer Med. 2020 May;9(10):3477-3488. doi: 10.1002/cam4.2564. Epub 2019 Oct 2.
• [944] Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer.Mol Pharm. 2017 Dec 4;14(12):4572-4582. doi: 10.1021/acs.molpharmaceut.7b00711. Epub 2017 Nov 13.
• [945] Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer.PLoS One. 2012;7(5):e37657. doi: 10.1371/journal.pone.0037657. Epub 2012 May 30.
• [946] Downregulation of TRIM28 inhibits growth and increases apoptosis of nude mice with nonsmall cell lung cancer xenografts.Mol Med Rep. 2018 Jan;17(1):835-842. doi: 10.3892/mmr.2017.7955. Epub 2017 Nov 3.
• [947] Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-B pathway.J Pathol. 2018 Nov;246(3):366-378. doi: 10.1002/path.5144. Epub 2018 Oct 4.
• [948] CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.Oncogene. 2015 Jul;34(27):3527-35. doi: 10.1038/onc.2014.280. Epub 2014 Sep 1.
• [949] Overexpression of TRPV3 Correlates with Tumor Progression in Non-Small Cell Lung Cancer.Int J Mol Sci. 2016 Mar 24;17(4):437. doi: 10.3390/ijms17040437.
• [950] Expression and prognostic roles of TRPV5 and TRPV6 in non-small cell lung cancer after curative resection.Asian Pac J Cancer Prev. 2014;15(6):2559-63. doi: 10.7314/apjcp.2014.15.6.2559.
• [951] TSPAN7 promotes the migration and proliferation of lung cancer cells via epithelial-to-mesenchymal transition.Onco Targets Ther. 2018 Dec 13;11:8815-8822. doi: 10.2147/OTT.S167902. eCollection 2018.
• [952] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).Oncotarget. 2017 Nov 21;8(64):107621-107629. doi: 10.18632/oncotarget.22581. eCollection 2017 Dec 8.
• [953] Correlations of Twist Expression with Pathological and Computed Tomography (CT) Characteristics and Prognosis of Non-Small Cell Lung Cancer (NSCLC).Med Sci Monit. 2019 Feb 4;25:977-983. doi: 10.12659/MSM.912674.
• [954] The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.Oncotarget. 2017 Dec 14;8(70):115270-115279. doi: 10.18632/oncotarget.23252. eCollection 2017 Dec 29.
• [955] Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells. Toxicology. 2019 Apr 1;417:54-63.
• [956] Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo.Sci Rep. 2015 Mar 30;5:9476. doi: 10.1038/srep09476.
• [957] Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.Sci Signal. 2017 Jan 10;10(461):eaaf8223. doi: 10.1126/scisignal.aaf8223.
• [958] Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.Cancer Sci. 2020 Feb;111(2):610-620. doi: 10.1111/cas.14284. Epub 2020 Jan 19.
• [959] Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.Cell Physiol Biochem. 2018;49(2):780-797. doi: 10.1159/000493041. Epub 2018 Aug 30.
• [960] Thermogenic protein UCP1 and UCP3 expression in non-small cell lung cancer: relation with glycolysis and anaerobic metabolism.Cancer Biol Med. 2017 Nov;14(4):396-404. doi: 10.20892/j.issn.2095-3941.2017.0089.
• [961] Overexpression of glucosylceramide synthase and its significance in the clinical outcome of non-small cell lung cancer.Chin Med J (Engl). 2014;127(17):3071-6.
• [962] Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.J Thorac Oncol. 2011 Jan;6(1):121-7. doi: 10.1097/JTO.0b013e318200e4e8.
• [963] Thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, orotate phosphoribosyltransferase mRNA expression in lung cancer metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration: a pilot study.Clin Lung Cancer. 2011 Sep;12(5):293-7. doi: 10.1016/j.cllc.2011.06.001. Epub 2011 Jul 24.
• [964] USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy.Mol Cancer. 2013 Aug 10;12:91. doi: 10.1186/1476-4598-12-91.
• [965] Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT/MAPK signaling.Biomed Pharmacother. 2019 Jun;114:108831. doi: 10.1016/j.biopha.2019.108831. Epub 2019 Apr 12.
• [966] Ubiquitin-specific protease 44 inhibits cell growth by suppressing AKT signaling in non-small cell lung cancer.Kaohsiung J Med Sci. 2019 Sep;35(9):535-541. doi: 10.1002/kjm2.12096. Epub 2019 Jun 14.
• [967] Overexpression of USP5 contributes to tumorigenesis in non-small cell lung cancer via the stabilization of -catenin protein.Am J Cancer Res. 2018 Nov 1;8(11):2284-2295. eCollection 2018.
• [968] The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA.Biochem Biophys Res Commun. 2019 May 7;512(3):479-485. doi: 10.1016/j.bbrc.2019.03.093. Epub 2019 Mar 21.
• [969] Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.Oncogene. 2018 Oct;37(40):5387-5402. doi: 10.1038/s41388-018-0342-9. Epub 2018 Jun 7.
• [970] Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.Clin Cancer Res. 2018 Sep 1;24(17):4089-4097. doi: 10.1158/1078-0432.CCR-18-0483. Epub 2018 Jul 17.
• [971] Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer.Tumour Biol. 2015 Mar;36(3):2185-91. doi: 10.1007/s13277-014-2829-5. Epub 2014 Nov 26.
• [972] CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.Int J Clin Exp Pathol. 2015 Dec 1;8(12):15729-38. eCollection 2015.
• [973] Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.Evid Based Complement Alternat Med. 2019 Nov 6;2019:7241927. doi: 10.1155/2019/7241927. eCollection 2019.
• [974] Expression of V-set immunoregulatory receptor in malignant mesothelioma.Mod Pathol. 2020 Feb;33(2):263-270. doi: 10.1038/s41379-019-0328-3. Epub 2019 Jul 30.
• [975] Eugenol inhibits non-small cell lung cancer by repressing expression of NF-B-regulated TRIM59.Phytother Res. 2019 May;33(5):1562-1569. doi: 10.1002/ptr.6352. Epub 2019 Apr 1.
• [976] MicroRNA-1253 suppresses cell proliferation and invasion of non-small-cell lung carcinoma by targeting WNT5A.Cell Death Dis. 2018 Feb 7;9(2):189. doi: 10.1038/s41419-017-0218-x.
• [977] Clinical significance of aberrant Wnt7a promoter methylation in human non-small cell lung cancer in Koreans.J Korean Med Sci. 2015 Feb;30(2):155-61. doi: 10.3346/jkms.2015.30.2.155. Epub 2015 Jan 21.
• [978] The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.Cell Oncol (Dordr). 2016 Dec;39(6):511-522. doi: 10.1007/s13402-016-0291-7. Epub 2016 Jul 29.
• [979] MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.
• [980] MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2436-2443. doi: 10.26355/eurrev_201903_17390.
• [981] MicroRNA-133a inhibits the proliferation of non-small cell lung cancer by targeting YES1.Oncol Lett. 2019 Dec;18(6):6759-6765. doi: 10.3892/ol.2019.11030. Epub 2019 Nov 1.
• [982] Distinct expression and prognostic value of OTU domain-containing proteins in non-small-cell lung cancer.Oncol Lett. 2019 Nov;18(5):5417-5427. doi: 10.3892/ol.2019.10883. Epub 2019 Sep 19.
• [983] Clinical significance of epithelial-mesenchymal transition-related markers expression in the micrometastatic sentinel lymph node of NSCLC.Clin Transl Oncol. 2020 Mar;22(3):381-391. doi: 10.1007/s12094-019-02138-3. Epub 2019 May 28.
• [984] Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer. 2010 Jul 13;9:188. doi: 10.1186/1476-4598-9-188.
• [985] Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.
• [986] Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tumor tissues as prognostic factors in NSCLC patients.Med Sci Monit. 2010 Aug;16(8):CR357-64.
• [987] CUL7 is a novel antiapoptotic oncogene.Cancer Res. 2007 Oct 15;67(20):9616-22. doi: 10.1158/0008-5472.CAN-07-0644.
• [988] Expression and clinical significance of CXCR5/CXCL13 in human nonsmall cell lung carcinoma.Int J Oncol. 2014 Dec;45(6):2232-40. doi: 10.3892/ijo.2014.2688. Epub 2014 Sep 30.
• [989] CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.Acta Oncol. 2007;46(3):361-6. doi: 10.1080/02841860600902197.
• [990] Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer.Lung Cancer. 2007 Apr;56(1):17-23. doi: 10.1016/j.lungcan.2006.11.007. Epub 2006 Dec 18.
• [991] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [992] Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402. Epub 2012 Sep 10.
• [993] TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.Anticancer Res. 2010 Oct;30(10):4309-15.
• [994] Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2.Mol Cancer Ther. 2010 Jun;9(6):1697-708. doi: 10.1158/1535-7163.MCT-09-1077. Epub 2010 Jun 8.
• [995] Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors.Hum Immunol. 2010 Oct;71(10):976-81. doi: 10.1016/j.humimm.2010.06.019. Epub 2010 Jun 30.
• [996] Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.BMC Cell Biol. 2009 Nov 30;10:84. doi: 10.1186/1471-2121-10-84.
• [997] Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers.Int J Cancer. 2006 Feb 15;118(4):797-801. doi: 10.1002/ijc.21462.
• [998] The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.BMC Cancer. 2016 Feb 8;16:71. doi: 10.1186/s12885-016-2104-9.
• [999] Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung.Hum Mutat. 2008 May;29(5):609-16. doi: 10.1002/humu.20707.
• [1000] Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.Eur Rev Med Pharmacol Sci. 2019 May;23(10):4210-4219. doi: 10.26355/eurrev_201905_17925.
• [1001] Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003. Epub 2008 Jul 11.
• [1002] Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line.Mol Immunol. 2006 Feb;43(6):710-6. doi: 10.1016/j.molimm.2005.03.013. Epub 2005 Apr 14.
• [1003] LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases).Lung Cancer. 2010 Apr;68(1):58-65. doi: 10.1016/j.lungcan.2009.05.020. Epub 2009 Jun 25.
• [1004] Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.Lung Cancer. 2008 Jan;59(1):69-75. doi: 10.1016/j.lungcan.2007.07.019. Epub 2007 Sep 4.
• [1005] ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.Br J Cancer. 2014 Apr 15;110(8):2030-9. doi: 10.1038/bjc.2014.88. Epub 2014 Mar 6.
• [1006] Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.Lung Cancer. 2007 Mar;55(3):303-11. doi: 10.1016/j.lungcan.2006.10.019. Epub 2006 Nov 21.
• [1007] Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer.Med Oncol. 2010 Jun;27(2):268-77. doi: 10.1007/s12032-009-9203-2. Epub 2009 Mar 24.
• [1008] The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.Cancer Biother Radiopharm. 2009 Jun;24(3):357-67. doi: 10.1089/cbr.2008.0612.
• [1009] Cardiac troponin I is abnormally expressed in non-small cell lung cancer tissues and human cancer cells.Int J Clin Exp Pathol. 2014 Mar 15;7(4):1314-24. eCollection 2014.
• [1010] ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.Front Pharmacol. 2018 Nov 20;9:1312. doi: 10.3389/fphar.2018.01312. eCollection 2018.
• [1011] ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients.J Cancer Res Ther. 2018;14(4):881-886. doi: 10.4103/jcrt.JCRT_890_17.
• [1012] Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C.Cancer Res. 1992 Sep 1;52(17):4752-7.
• [1013] Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer. 2009 Jan;63(1):121-7.
• [1014] Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA.Cancer. 2003 May 15;97(10):2504-11. doi: 10.1002/cncr.11378.
• [1015] ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome.Oncology. 2017;93(4):270-278. doi: 10.1159/000477619. Epub 2017 Jul 6.
• [1016] MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014 Feb 28;343(2):249-57.
• [1017] ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer.Cancer Chemother Pharmacol. 2019 Dec;84(6):1229-1239. doi: 10.1007/s00280-019-03959-3. Epub 2019 Sep 17.
• [1018] Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.Br J Cancer. 2006 Jun 19;94(12):1927-35. doi: 10.1038/sj.bjc.6603167. Epub 2006 May 16.
• [1019] LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Jun 28;38(1):280. doi: 10.1186/s13046-019-1276-y.
• [1020] Expression of Na+-K+-2Cl- cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and EGFR-mutated adenocarcinoma patients.QJM. 2016 Apr;109(4):237-44. doi: 10.1093/qjmed/hcv207. Epub 2015 Nov 11.
• [1021] Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer.Tumour Biol. 2015 May;36(5):3931-9. doi: 10.1007/s13277-014-3036-0. Epub 2015 Jan 13.
• [1022] Loss of SLC25A11 causes suppression of NSCLC and melanoma tumor formation.EBioMedicine. 2019 Feb;40:184-197. doi: 10.1016/j.ebiom.2019.01.036. Epub 2019 Jan 25.
• [1023] In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.Oncotarget. 2016 Nov 29;7(48):79526-79543. doi: 10.18632/oncotarget.12755.
• [1024] Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.Mol Cancer Ther. 2016 Jun;15(6):1387-96. doi: 10.1158/1535-7163.MCT-15-0089. Epub 2016 Feb 16.
• [1025] Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.Med Oncol. 2014 Apr;31(4):865. doi: 10.1007/s12032-014-0865-z. Epub 2014 Feb 18.
• [1026] Glucose transporter 3 gene variant is associated with survival outcome of patients with non-small cell lung cancer after surgical resection.Gene. 2019 Jun 30;703:58-64. doi: 10.1016/j.gene.2019.04.013. Epub 2019 Apr 4.
• [1027] The Constituents of the Stems of Cissus assamica and Their Bioactivities.Molecules. 2018 Oct 28;23(11):2799. doi: 10.3390/molecules23112799.
• [1028] SLC39A4 expression is associated with enhanced cell migration, cisplatin resistance, and poor survival in non-small cell lung cancer.Sci Rep. 2017 Aug 3;7(1):7211. doi: 10.1038/s41598-017-07830-4.
• [1029] ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.J Cancer Res Clin Oncol. 2019 Jun;145(6):1427-1436. doi: 10.1007/s00432-019-02906-2. Epub 2019 Mar 28.
• [1030] Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation.Anticancer Res. 2000 May-Jun;20(3A):1499-502.
• [1031] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. doi: 10.1073/pnas.0504952102. Epub 2005 Jul 26.
• [1032] Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma.Cancer Epidemiol. 2013 Oct;37(5):653-9. doi: 10.1016/j.canep.2013.04.010. Epub 2013 Jun 7.
• [1033] Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.
• [1034] The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.
• [1035] Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.Onco Targets Ther. 2017 Mar 30;10:1921-1932. doi: 10.2147/OTT.S128416. eCollection 2017.
• [1036] NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan.Lung Cancer. 2009 Apr;64(1):9-12. doi: 10.1016/j.lungcan.2008.07.001. Epub 2008 Aug 15.
• [1037] Differential transcription of the human spermidine/spermine N1-acetyltransferase (SSAT) gene in human lung carcinoma cells.Biochem J. 1996 Jan 15;313 ( Pt 2)(Pt 2):691-6. doi: 10.1042/bj3130691.
• [1038] Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer.Int J Cancer. 2006 May 15;118(10):2522-8. doi: 10.1002/ijc.21669.
• [1039] AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.Acta Biomater. 2019 Jun;91:195-208. doi: 10.1016/j.actbio.2019.04.053. Epub 2019 Apr 26.
• [1040] AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.Theranostics. 2018 Jan 1;8(3):676-692. doi: 10.7150/thno.21463. eCollection 2018.
• [1041] Diagnostic value of serum dihydrodiol dehydrogenase 2 levels in patients with non-small-cell lung cancer.Int J Biol Markers. 2018 Jun 1:1724600818776832. doi: 10.1177/1724600818776832. Online ahead of print.
• [1042] Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.Drug Des Devel Ther. 2015 Sep 3;9:5087-97. doi: 10.2147/DDDT.S87197. eCollection 2015.
• [1043] Decoction of Chinese Herbal Medicine Fuzheng Kang-Ai Induces Lung Cancer Cell Apoptosis via STAT3/Bcl-2/Caspase-3 Pathway.Evid Based Complement Alternat Med. 2018 Jun 25;2018:8567905. doi: 10.1155/2018/8567905. eCollection 2018.
• [1044] Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.Cancer Cell. 2018 Jan 8;33(1):91-107.e6. doi: 10.1016/j.ccell.2017.12.003.
• [1045] Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.J Thorac Oncol. 2011 Aug;6(8):1320-9. doi: 10.1097/JTO.0b013e3182208e26.
• [1046] Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway.Mol Carcinog. 2019 Nov;58(11):2026-2039. doi: 10.1002/mc.23095. Epub 2019 Aug 9.
• [1047] Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.Cancer Sci. 2013 Dec;104(12):1586-92. doi: 10.1111/cas.12278. Epub 2013 Oct 21.
• [1048] Interaction of the CYP1A1 gene polymorphism and smoking in non-small cell lung cancer susceptibility.Genet Mol Res. 2016 Jan 4;14(4):19411-7. doi: 10.4238/2015.December.30.2.
• [1049] Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer.Oncol Lett. 2017 Dec;14(6):7538-7544. doi: 10.3892/ol.2017.7162. Epub 2017 Oct 10.
• [1050] Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.
• [1051] Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.Cancer Med. 2016 Dec;5(12):3564-3571. doi: 10.1002/cam4.960. Epub 2016 Nov 22.
• [1052] Genetic Polymorphisms in the Vitamin D Pathway and Non-small Cell Lung Cancer Survival.Pathol Oncol Res. 2020 Jul;26(3):1709-1715. doi: 10.1007/s12253-019-00702-4. Epub 2019 Oct 17.
• [1053] Expression of hypoxia-inducible factor prolyl hydroxylase 3 HIFPH3 in human non-small cell lung cancer (NSCLC) and its correlation with prognosis.Asian Pac J Cancer Prev. 2014;15(14):5819-23. doi: 10.7314/apjcp.2014.15.14.5819.
• [1054] Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer.Oncol Rep. 2007 Mar;17(3):565-72.
• [1055] FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.Oncotarget. 2014 May 15;5(9):2475-86. doi: 10.18632/oncotarget.1723.
• [1056] Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.Cancer Res. 2019 Jan 1;79(1):125-132. doi: 10.1158/0008-5472.CAN-18-1938. Epub 2018 Nov 6.
• [1057] NF-B upregulates glutamine-fructose-6-phosphate transaminase 2 to promote migration in non-small cell lung cancer.Cell Commun Signal. 2019 Mar 18;17(1):24. doi: 10.1186/s12964-019-0335-5.
• [1058] Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma.Mol Ther Nucleic Acids. 2017 Dec 15;9:263-273. doi: 10.1016/j.omtn.2017.10.001. Epub 2017 Oct 7.
• [1059] THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.Acta Pharmacol Sin. 2019 Jun;40(6):814-822. doi: 10.1038/s41401-018-0187-3. Epub 2018 Nov 16.
• [1060] Oleuropein-Induced Apoptosis Is Mediated by Mitochondrial Glyoxalase 2 in NSCLC A549 Cells: A Mechanistic Inside and a Possible Novel Nonenzymatic Role for an Ancient Enzyme.Oxid Med Cell Longev. 2019 Jul 22;2019:8576961. doi: 10.1155/2019/8576961. eCollection 2019.
• [1061] Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.BMC Cancer. 2017 Aug 2;17(1):513. doi: 10.1186/s12885-017-3500-5.
• [1062] Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway.Pharmazie. 2018 Jul 1;73(7):386-392. doi: 10.1691/ph.2018.8313.
• [1063] Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer.Ther Adv Med Oncol. 2019 May 19;11:1758835919846798. doi: 10.1177/1758835919846798. eCollection 2019.
• [1064] Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer.Yonsei Med J. 2019 Nov;60(11):1005-1012. doi: 10.3349/ymj.2019.60.11.1005.
• [1065] Antitumor effects of hsamiR661?p on nonsmall cell lung cancer in vivo and in vitro.Oncol Rep. 2019 May;41(5):2987-2996. doi: 10.3892/or.2019.7084. Epub 2019 Mar 21.
• [1066] Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients.Int J Cancer. 2019 Aug 1;145(3):621-631. doi: 10.1002/ijc.32128. Epub 2019 Feb 1.
• [1067] Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population.Cancer. 2010 Dec 15;116(24):5700-9. doi: 10.1002/cncr.25301. Epub 2010 Aug 24.
• [1068] Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.Pharmacogenetics. 2001 Mar;11(2):157-68. doi: 10.1097/00008571-200103000-00006.
• [1069] 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.
• [1070] Integration of Metabolomics and Transcriptomics To Reveal Metabolic Characteristics and Key Targets Associated with Cisplatin Resistance in Nonsmall Cell Lung Cancer.J Proteome Res. 2019 Sep 6;18(9):3259-3267. doi: 10.1021/acs.jproteome.9b00209. Epub 2019 Aug 16.
• [1071] In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.
• [1072] Status of the Parkinson's disease gene family expression in non-small-cell lung cancer.World J Surg Oncol. 2015 Aug 7;13:238. doi: 10.1186/s12957-015-0646-y.
• [1073] Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions.Anticancer Res. 2019 Dec;39(12):6723-6730. doi: 10.21873/anticanres.13887.
• [1074] Role of leukotriene B4 12-hydroxydehydrogenase in -galactosylceramide-pulsed dendritic cell therapy for non-small cell lung cancer.Biochem Biophys Res Commun. 2018 Nov 17;506(1):27-32. doi: 10.1016/j.bbrc.2018.10.048. Epub 2018 Oct 15.
• [1075] Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.J Cancer Res Ther. 2013 Oct-Dec;9(4):660-3. doi: 10.4103/0973-1482.126473.
• [1076] Expression of THOP1 and its relationship to prognosis in non-small cell lung cancer.PLoS One. 2014 Sep 2;9(9):e106665. doi: 10.1371/journal.pone.0106665. eCollection 2014.
• [1077] Repression of lncRNA-SVUGP2 mediated by EZH2 contributes to the development of non-small cell lung cancer via brisking Wnt/-catenin signal.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3400-3409. doi: 10.1080/21691401.2019.1648279.
• [1078] CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients.Neoplasma. 2010;57(6):512-21. doi: 10.4149/neo_2010_06_512.
• [1079] NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer.Cancer Prev Res (Phila). 2008 Sep;1(4):241-9. doi: 10.1158/1940-6207.CAPR-08-0055.
• [1080] Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.Clin Cancer Res. 2007 Mar 1;13(5):1399-404. doi: 10.1158/1078-0432.CCR-06-1730.
• [1081] Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.J Clin Oncol. 2006 May 20;24(15):2237-44. doi: 10.1200/JCO.2005.03.0239. Epub 2006 Apr 24.
• [1082] Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors.Eur J Pharm Sci. 2019 Sep 1;137:105010. doi: 10.1016/j.ejps.2019.105010. Epub 2019 Jul 17.
• [1083] Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.Oncotarget. 2016 May 31;7(22):33165-78. doi: 10.18632/oncotarget.8890.
• [1084] Lack of expression of aminoacylase-1 in small cell lung cancer. Evidence for inactivation of genes encoded by chromosome 3p.J Clin Invest. 1989 Jun;83(6):2120-4. doi: 10.1172/JCI114125.
• [1085] Clinical verification of plasma messenger RNA as novel noninvasive biomarker identified through bioinformatics analysis for lung cancer.Oncotarget. 2017 Jul 4;8(27):43978-43989. doi: 10.18632/oncotarget.16701.
• [1086] ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.Cancers (Basel). 2019 Dec 6;11(12):1963. doi: 10.3390/cancers11121963.
• [1087] ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer.Br J Cancer. 2011 Feb 15;104(4):700-6. doi: 10.1038/sj.bjc.6606012. Epub 2011 Feb 1.
• [1088] Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer.Int J Cancer. 2001 Nov 20;95(6):384-7. doi: 10.1002/1097-0215(20011120)95:6<384::aid-ijc1068>3.0.co;2-d.
• [1089] Cullin-4B E3 ubiquitin ligase mediates Apaf-1 ubiquitination to regulate caspase-9 activity.PLoS One. 2019 Jul 22;14(7):e0219782. doi: 10.1371/journal.pone.0219782. eCollection 2019.
• [1090] Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma.Oncogene. 1995 Sep 7;11(5):999-1003.
• [1091] ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.
• [1092] Long Noncoding RNA KCNQ1OT1 Promotes the Progression of Non-Small Cell Lung Cancer via Regulating miR-204-5p/ATG3 Axis.Onco Targets Ther. 2019 Dec 10;12:10787-10797. doi: 10.2147/OTT.S226044. eCollection 2019.
• [1093] Multi-Gene Expression in Anthracosis of the Lungs as One of the Risk Factors for Non-Small Cell Lung Cancer.Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3129-3133. doi: 10.22034/APJCP.2017.18.11.3129.
• [1094] A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.Mol Oncol. 2018 Jun;12(6):913-924. doi: 10.1002/1878-0261.12204. Epub 2018 May 4.
• [1095] Regulation of BTG3 by microRNA-20b-5p in non-small cell lung cancer.Oncol Lett. 2019 Jul;18(1):137-144. doi: 10.3892/ol.2019.10333. Epub 2019 May 7.
• [1096] Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.Virchows Arch. 2006 Jun;448(6):830-7. doi: 10.1007/s00428-006-0199-0. Epub 2006 Apr 12.
• [1097] Loss of cables protein expression in human non-small cell lung cancer: a tissue microarray study.Hum Pathol. 2003 Feb;34(2):143-9. doi: 10.1053/hupa.2003.26.
• [1098] Cloning, expression and chromosomal localization of human Ca2+/calmodulin-dependent protein kinase kinase.J Biomed Sci. 1998;5(2):141-9. doi: 10.1007/BF02258368.
• [1099] Adenylyl cyclaseassociated protein1targeted nanoparticles as a novel strategy for the treatment of metastatic nonsmall cell lung cancer.Int J Oncol. 2019 Aug;55(2):462-472. doi: 10.3892/ijo.2019.4822. Epub 2019 Jun 6.
• [1100] MS4A1 dysregulation in asbestos-related lung squamous cell carcinoma is due to CD20 stromal lymphocyte expression.PLoS One. 2012;7(4):e34943. doi: 10.1371/journal.pone.0034943. Epub 2012 Apr 13.
• [1101] Clinical significance of CD151 gene expression in non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):4109-14.
• [1102] Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis.J Cell Physiol. 2018 Sep;233(9):7164-7172. doi: 10.1002/jcp.26543. Epub 2018 Apr 6.
• [1103] CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-B axis in human non-small-cell lung cancer.Cell Death Dis. 2019 Feb 4;10(2):99. doi: 10.1038/s41419-019-1371-1.
• [1104] High expression of Cks1 in human non-small cell lung carcinomas.Biochem Biophys Res Commun. 2003 Apr 11;303(3):978-84. doi: 10.1016/s0006-291x(03)00469-8.
• [1105] A TERT-CLPTM1 locus polymorphism (rs401681) is associated with EGFR mutation in non-small cell lung cancer.Pathol Res Pract. 2017 Nov;213(11):1340-1343. doi: 10.1016/j.prp.2017.09.028. Epub 2017 Oct 7.
• [1106] Genetic and epigenetic silencing of mircoRNA-506-3p enhances COTL1 oncogene expression to foster non-small lung cancer progression.Oncotarget. 2017 Jan 3;8(1):644-657. doi: 10.18632/oncotarget.13501.
• [1107] Krppel-Like Factor 8 Overexpression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer.Pathol Oncol Res. 2019 Jan;25(1):115-121. doi: 10.1007/s12253-017-0321-4. Epub 2017 Oct 6.
• [1108] Knockdown of CPEB4 expression suppresses cell migration and invasion via Akt pathway in non-small cell lung cancer.Cell Biol Int. 2018 Nov;42(11):1484-1491. doi: 10.1002/cbin.10930. Epub 2018 Feb 1.
• [1109] Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer.Br J Cancer. 2011 Jan 18;104(2):316-23. doi: 10.1038/sj.bjc.6606027. Epub 2010 Dec 14.
• [1110] CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.J Thorac Oncol. 2018 Nov;13(11):1792-1797. doi: 10.1016/j.jtho.2018.07.008. Epub 2018 Aug 7.
• [1111] Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer.Oncol Lett. 2017 Jun;13(6):4661-4668. doi: 10.3892/ol.2017.6088. Epub 2017 Apr 24.
• [1112] DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells.Oncogene. 2018 Mar;37(9):1251-1262. doi: 10.1038/s41388-017-0025-y. Epub 2017 Dec 15.
• [1113] NOX4 supports glycolysis and promotes glutamine metabolism in non-small cell lung cancer cells.Free Radic Biol Med. 2016 Dec;101:236-248. doi: 10.1016/j.freeradbiomed.2016.10.500. Epub 2016 Oct 27.
• [1114] Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.Cancer Res. 2001 Mar 15;61(6):2727-31.
• [1115] Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer.Cancer Res. 1999 Apr 15;59(8):1846-51.
• [1116] The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer.Carcinogenesis. 2013 May;34(5):1069-80. doi: 10.1093/carcin/bgt005. Epub 2013 Jan 9.
• [1117] Dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer.Mol Carcinog. 2010 Aug;49(8):760-70. doi: 10.1002/mc.20651.
• [1118] Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.Aging (Albany NY). 2018 May 11;10(5):973-987. doi: 10.18632/aging.101441.
• [1119] Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA.Cancer Manag Res. 2018 Sep 28;10:4039-4050. doi: 10.2147/CMAR.S170033. eCollection 2018.
• [1120] Expression analysis of angiogenesis-related genes in Bulgarian patients with early-stage non-small cell lung cancer.Tumori. 2011 Jan-Feb;97(1):86-94. doi: 10.1177/030089161109700116.
• [1121] MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.Sci Rep. 2017 Jan 11;7:40384. doi: 10.1038/srep40384.
• [1122] Decreased eIF3e Expression Can Mediate Epithelial-to-Mesenchymal Transition through Activation of the TGF Signaling Pathway.Mol Cancer Res. 2015 Oct;13(10):1421-30. doi: 10.1158/1541-7786.MCR-14-0645. Epub 2015 Jun 8.
• [1123] MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.Oncogene. 2003 Sep 11;22(39):8031-41. doi: 10.1038/sj.onc.1206928.
• [1124] Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancer.Cancer Gene Ther. 2019 May;26(5-6):157-165. doi: 10.1038/s41417-018-0058-6. Epub 2018 Nov 12.
• [1125] Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer.Int J Biochem Cell Biol. 2018 Jan;94:98-106. doi: 10.1016/j.biocel.2017.12.002. Epub 2017 Dec 5.
• [1126] EPB41L3 is a potential tumor suppressor gene and prognostic indicator in esophageal squamous cell carcinoma.Int J Oncol. 2018 May;52(5):1443-1454. doi: 10.3892/ijo.2018.4316. Epub 2018 Mar 14.
• [1127] Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts.Int J Radiat Biol. 2001 Feb;77(2):185-94. doi: 10.1080/09553000010008540.
• [1128] Long noncoding antisense RNA FAM83A-AS1 promotes lung cancer cell progression by increasing FAM83A.J Cell Biochem. 2019 Jun;120(6):10505-10512. doi: 10.1002/jcb.28336. Epub 2019 Jan 18.
• [1129] Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.J Thorac Oncol. 2018 Dec;13(12):1873-1883. doi: 10.1016/j.jtho.2018.08.2023. Epub 2018 Sep 7.
• [1130] Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.Lung Cancer. 2004 Dec;46(3):313-23. doi: 10.1016/j.lungcan.2004.05.013.
• [1131] MiR-760 enhances TRAIL sensitivity in non-small cell lung cancer via targeting the protein FOXA1.Biomed Pharmacother. 2018 Mar;99:523-529. doi: 10.1016/j.biopha.2018.01.076. Epub 2018 Feb 20.
• [1132] Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/-catenin signaling in non-small-cell lung cancer.Mol Carcinog. 2018 Jul;57(7):842-853. doi: 10.1002/mc.22805. Epub 2018 Apr 14.
• [1133] Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer.Oncotarget. 2016 May 3;7(18):25291-303. doi: 10.18632/oncotarget.8052.
• [1134] GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer.Cancer Biol Ther. 2019;20(9):1206-1212. doi: 10.1080/15384047.2019.1599665. Epub 2019 May 16.
• [1135] Overexpression of golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating the matrix metallopeptidase 13.Am J Cancer Res. 2018 Mar 1;8(3):551-565. eCollection 2018.
• [1136] Clinical significance of reduced GPRC5A expression in surgically resected non-small cell lung cancer.Oncol Lett. 2019 Jan;17(1):502-507. doi: 10.3892/ol.2018.9537. Epub 2018 Oct 2.
• [1137] Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo.Mol Cancer Res. 2011 Dec;9(12):1746-54. doi: 10.1158/1541-7786.MCR-11-0286. Epub 2011 Oct 12.
• [1138] Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26.
• [1139] Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial-Mesenchymal Transition.Am J Respir Crit Care Med. 2016 Apr 15;193(8):869-80. doi: 10.1164/rccm.201412-2226OC.
• [1140] Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.Mol Carcinog. 2019 Mar;58(3):321-333. doi: 10.1002/mc.22930. Epub 2018 Nov 12.
• [1141] icroRNA?21 promotes the progression of nonsmall cell lung cancer by targeting HOPX and regulating the Wnt/catenin signaling pathway.Mol Med Rep. 2019 Jul;20(1):151-161. doi: 10.3892/mmr.2019.10226. Epub 2019 May 9.
• [1142] microRNA?77 inhibits cell proliferation and invasion in nonsmall cell lung cancer by directly targeting homeobox A1.Mol Med Rep. 2019 Mar;19(3):1875-1882. doi: 10.3892/mmr.2019.9804. Epub 2019 Jan 2.
• [1143] MicroRNA-625 inhibits the progression of nonsmall cell lung cancer by directly targeting HOXB5 and deactivating the Wnt/-catenin pathway.Int J Mol Med. 2019 Jul;44(1):346-356. doi: 10.3892/ijmm.2019.4203. Epub 2019 May 20.
• [1144] Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.Anticancer Res. 2018 Jan;38(1):179-186. doi: 10.21873/anticanres.12206.
• [1145] The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.Cancer Res. 2000 Nov 1;60(21):6116-33.
• [1146] Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma.Genes Chromosomes Cancer. 1993 May;7(1):47-53. doi: 10.1002/gcc.2870070108.
• [1147] Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines.J Clin Endocrinol Metab. 1996 Jul;81(7):2653-62. doi: 10.1210/jcem.81.7.8675593.
• [1148] Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer.Cancer Manag Res. 2019 Jul 15;11:6593-6602. doi: 10.2147/CMAR.S204924. eCollection 2019.
• [1149] Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.J Cell Biochem. 2019 Jan;120(1):872-881. doi: 10.1002/jcb.27448. Epub 2018 Aug 21.
• [1150] Down-regulation of miR-500 and miR-628 suppress non-small cell lung cancer proliferation, migration and invasion by targeting ING1.Biomed Pharmacother. 2018 Dec;108:1628-1639. doi: 10.1016/j.biopha.2018.09.145. Epub 2018 Oct 10.
• [1151] Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer.Cancers (Basel). 2019 Oct 21;11(10):1601. doi: 10.3390/cancers11101601.
• [1152] miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/-catenin pathway.Oncol Lett. 2019 Nov;18(5):4621-4628. doi: 10.3892/ol.2019.10805. Epub 2019 Sep 4.
• [1153] Int6 expression can predict survival in early-stage non-small cell lung cancer patients.Clin Cancer Res. 2005 May 1;11(9):3198-204. doi: 10.1158/1078-0432.CCR-04-2308.
• [1154] Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.Cancer Lett. 2011 Apr 1;303(1):21-8. doi: 10.1016/j.canlet.2010.12.011. Epub 2011 Jan 20.
• [1155] Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?.Cancer Res Treat. 2016 Jan;48(1):98-105. doi: 10.4143/crt.2014.364. Epub 2015 Mar 13.
• [1156] The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.Oncology. 2011;80(5-6):333-40. doi: 10.1159/000329098. Epub 2011 Jul 26.
• [1157] Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer.J Cancer Res Clin Oncol. 2016 Dec;142(12):2479-2487. doi: 10.1007/s00432-016-2253-x. Epub 2016 Sep 6.
• [1158] Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.Clin Cancer Res. 2012 Apr 15;18(8):2173-83. doi: 10.1158/1078-0432.CCR-11-2557. Epub 2012 Mar 7.
• [1159] Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.Pathol Oncol Res. 2018 Apr;24(2):207-214. doi: 10.1007/s12253-017-0225-3. Epub 2017 Apr 22.
• [1160] High developmental pluripotencyassociated 4 expression promotes cell proliferation and glycolysis, and predicts poor prognosis in nonsmallcell lung cancer.Mol Med Rep. 2019 Jul;20(1):445-454. doi: 10.3892/mmr.2019.10272. Epub 2019 May 22.
• [1161] Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer.Lung Cancer. 2006 Jan;51(1):79-88. doi: 10.1016/j.lungcan.2005.08.012. Epub 2005 Oct 12.
• [1162] Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.J Biol Chem. 2007 Feb 9;282(6):3507-19. doi: 10.1074/jbc.M610141200. Epub 2006 Dec 11.
• [1163] Neuroglobin and myoglobin in non-small cell lung cancer: expression, regulation and prognosis.Lung Cancer. 2011 Dec;74(3):411-8. doi: 10.1016/j.lungcan.2011.05.001. Epub 2011 Jun 2.
• [1164] The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.Oncogene. 2002 Jul 18;21(31):4822-9. doi: 10.1038/sj.onc.1205581.
• [1165] LOH at the APC/MCC gene (5Q21) is frequent in early stages of non-small cell lung cancer.Pathol Res Pract. 1999;195(10):677-80. doi: 10.1016/S0344-0338(99)80058-2.
• [1166] The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.J Exp Clin Cancer Res. 2015 Oct 14;34:121. doi: 10.1186/s13046-015-0235-5.
• [1167] Loss of imprinting of PEG1/MEST in lung cancer cell lines.Oncol Rep. 2004 Dec;12(6):1273-8.
• [1168] A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.Sci Transl Med. 2018 Mar 7;10(431):eaan8840. doi: 10.1126/scitranslmed.aan8840.
• [1169] MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC).Med Sci Monit. 2018 Oct 22;24:7541-7547. doi: 10.12659/MSM.909772.
• [1170] DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.Oncol Rep. 2004 Jul;12(1):177-80.
• [1171] NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy.Onco Targets Ther. 2017 Sep 19;10:4625-4633. doi: 10.2147/OTT.S144895. eCollection 2017.
• [1172] The prognostic significance of N-myc downregulated gene 1 in lung adenocarcinoma.Pathol Int. 2018 Apr;68(4):224-231. doi: 10.1111/pin.12644. Epub 2018 Feb 12.
• [1173] Knockdown of Nemolike kinase promotes metastasis in nonsmallcell lung cancer.Oncol Rep. 2019 Sep;42(3):1090-1100. doi: 10.3892/or.2019.7226. Epub 2019 Jul 9.
• [1174] Tobacco smoking, NBS1 polymorphisms, and survival in lung and upper aerodigestive tract cancers with semi-Bayes adjustment for hazard ratio variation.Cancer Causes Control. 2014 Jan;25(1):11-23. doi: 10.1007/s10552-013-0303-0. Epub 2013 Oct 29.
• [1175] Detection of tumor specific gene expression in bone marrow and peripheral blood from patients with small cell lung carcinoma.Cancer. 2003 Feb 15;97(4):1057-62. doi: 10.1002/cncr.11108.
• [1176] High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages.Int J Cancer. 1993 Sep 30;55(3):375-9. doi: 10.1002/ijc.2910550306.
• [1177] miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED.Cancer Res. 2010 May 1;70(9):3638-46. doi: 10.1158/0008-5472.CAN-09-3341. Epub 2010 Apr 13.
• [1178] Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.J Pathol. 2002 Oct;198(2):142-56. doi: 10.1002/path.1121.
• [1179] Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients.Lung Cancer. 2012 Jan;75(1):110-8. doi: 10.1016/j.lungcan.2011.05.024.
• [1180] PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients.Thorac Cancer. 2019 Nov;10(11):2124-2132. doi: 10.1111/1759-7714.13196. Epub 2019 Sep 30.
• [1181] Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.PLoS One. 2014 Aug 19;9(8):e104265. doi: 10.1371/journal.pone.0104265. eCollection 2014.
• [1182] MiR-486-5p Serves as a Good Biomarker in Nonsmall Cell Lung Cancer and Suppresses Cell Growth With the Involvement of a Target PIK3R1.Front Genet. 2019 Jul 26;10:688. doi: 10.3389/fgene.2019.00688. eCollection 2019.
• [1183] PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagy.Pharmacol Rep. 2019 Dec;71(6):1184-1189. doi: 10.1016/j.pharep.2019.08.002. Epub 2019 Aug 14.
• [1184] (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.Life Sci. 1997;61(17):1657-66. doi: 10.1016/s0024-3205(97)00771-6.
• [1185] Differential Expression And Effects Of Peroxiredoxin-6 On Drug Resistance And Cancer Stem Cell-Like Properties In Non-Small Cell Lung Cancer.Onco Targets Ther. 2019 Dec 2;12:10477-10486. doi: 10.2147/OTT.S211125. eCollection 2019.
• [1186] Exosome-mediated transfer of lncRNA RP11?38N2.4 promotes erlotinib resistance in non-small cell lung cancer.Int J Oncol. 2018 Aug;53(2):527-538. doi: 10.3892/ijo.2018.4412. Epub 2018 May 17.
• [1187] Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer.Oncol Lett. 2018 Jun;15(6):8796-8804. doi: 10.3892/ol.2018.8387. Epub 2018 Mar 29.
• [1188] Prognostic significance of miR-23b in combination with P-gp, MRP and LRP/MVP expression in non-small cell lung cancer.Neoplasma. 2016;63(4):576-87. doi: 10.4149/neo_2016_411.
• [1189] Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential.Clin Exp Metastasis. 1999 May;17(3):213-9. doi: 10.1023/a:1006617016451.
• [1190] Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach.Pharmacol Res. 2020 May;155:104415. doi: 10.1016/j.phrs.2019.104415. Epub 2019 Aug 26.
• [1191] Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis.Lung Cancer. 2001 Oct;34(1):47-52. doi: 10.1016/s0169-5002(01)00223-9.
• [1192] RalGPS2 Is Essential for Survival and Cell Cycle Progression of Lung Cancer Cells Independently of Its Established Substrates Ral GTPases.PLoS One. 2016 May 5;11(5):e0154840. doi: 10.1371/journal.pone.0154840. eCollection 2016.
• [1193] Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients.Future Oncol. 2014 May;10(7):1175-85. doi: 10.2217/fon.14.25.
• [1194] Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers.Mutat Res. 1998 Nov;406(1):9-23. doi: 10.1016/s1383-5726(98)00006-5.
• [1195] Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity.Clin Chim Acta. 2017 Jan;464:118-122. doi: 10.1016/j.cca.2016.11.027. Epub 2016 Nov 19.
• [1196] TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.Clin Cancer Res. 2003 Oct 15;9(13):4705-13.
• [1197] AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer.Tumour Biol. 2012 Apr;33(2):307-14. doi: 10.1007/s13277-011-0266-2. Epub 2011 Nov 19.
• [1198] The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).Anticancer Res. 2002 Jul-Aug;22(4):2073-6.
• [1199] Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.Br J Cancer. 1996 Jan;73(2):148-53. doi: 10.1038/bjc.1996.28.
• [1200] SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo.Cell Signal. 2015 Jun;27(6):1208-13. doi: 10.1016/j.cellsig.2015.02.027. Epub 2015 Mar 4.
• [1201] Identification of TDE2 gene and its expression in non-small cell lung cancer.Int J Cancer. 2003 Nov 1;107(2):238-43. doi: 10.1002/ijc.11391.
• [1202] miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-I.Life Sci. 2019 Aug 15;231:116539. doi: 10.1016/j.lfs.2019.06.014. Epub 2019 Jun 6.
• [1203] Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.Respir Med. 2005 Sep;99(9):1164-74. doi: 10.1016/j.rmed.2005.02.009.
• [1204] NRF2 regulates serine biosynthesis in non-small cell lung cancer.Nat Genet. 2015 Dec;47(12):1475-81. doi: 10.1038/ng.3421. Epub 2015 Oct 19.
• [1205] Siva-1 emerges as a tissue-specific oncogene beyond its classic role of a proapoptotic gene.Onco Targets Ther. 2018 Oct 1;11:6361-6367. doi: 10.2147/OTT.S173001. eCollection 2018.
• [1206] Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases.J Neurosurg. 2019 Jun 21;133(2):313-320. doi: 10.3171/2019.4.JNS19446.
• [1207] Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines.Exp Ther Med. 2019 Jan;17(1):953-959. doi: 10.3892/etm.2018.7001. Epub 2018 Nov 21.
• [1208] A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.Mol Oncol. 2017 May;11(5):534-551. doi: 10.1002/1878-0261.12052. Epub 2017 Apr 11.
• [1209] Knockdown of miR?35 increases paclitaxel sensitivity via regulation of SOX7 in nonsmallcell lung cancer.Mol Med Rep. 2018 Sep;18(3):3397-3402. doi: 10.3892/mmr.2018.9330. Epub 2018 Jul 27.
• [1210] Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer.Cancer Res. 2009 Mar 15;69(6):2234-43. doi: 10.1158/0008-5472.CAN-08-3338. Epub 2009 Mar 3.
• [1211] Inhibition of PC4 radiosensitizes non-small cell lung cancer by transcriptionally suppressing XLF.Cancer Med. 2018 Apr;7(4):1326-1337. doi: 10.1002/cam4.1332. Epub 2018 Mar 9.
• [1212] T-boxtranscription factor brachyury promotes tumor cell invasion and metastasis in non-small cell lung cancer via upregulation of matrix metalloproteinase 12.Oncol Rep. 2016 Jul;36(1):306-14. doi: 10.3892/or.2016.4792. Epub 2016 May 9.
• [1213] TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark.Biochemistry. 2020 Feb 4;59(4):389-399. doi: 10.1021/acs.biochem.9b00771. Epub 2019 Dec 2.
• [1214] Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression.J Lab Clin Med. 2002 Nov;140(5):320-8. doi: 10.1067/mlc.2002.128317.
• [1215] TMEM100 expression suppresses metastasis and enhances sensitivity to chemotherapy in gastric cancer.Biol Chem. 2020 Feb 25;401(2):285-296. doi: 10.1515/hsz-2019-0161.
• [1216] Hypomethylation of the thymosin (10) gene is not associated with its overexpression in non-small cell lung cancer.Mol Cells. 2011 Oct;32(4):343-8. doi: 10.1007/s10059-011-0073-z. Epub 2011 Oct 17.
• [1217] Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.Mol Cancer Res. 2019 May;17(5):1207-1219. doi: 10.1158/1541-7786.MCR-18-0731. Epub 2019 Jan 15.
• [1218] Expression of LUN gene that encodes a novel RING finger protein is correlated with development and progression of non-small cell lung cancer.Lung Cancer. 2004 Oct;46(1):21-8. doi: 10.1016/j.lungcan.2004.03.009.
• [1219] Significance of TRIM29 and -catenin expression in non-small-cell lung cancer.J Chin Med Assoc. 2012 Jun;75(6):269-74. doi: 10.1016/j.jcma.2012.04.015. Epub 2012 May 31.
• [1220] LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.Cancer Biol Ther. 2019;20(3):261-271. doi: 10.1080/15384047.2018.1529091. Epub 2018 Nov 27.
• [1221] A-kinase-interacting protein 1 overexpression correlates with deteriorative tumor features and worse survival profiles, and promotes cell proliferation but represses apoptosis in non-small-cell lung cancer.J Clin Lab Anal. 2020 Feb;34(2):e23061. doi: 10.1002/jcla.23061. Epub 2019 Dec 11.
• [1222] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.Cancer Res. 2005 Dec 15;65(24):11314-25. doi: 10.1158/0008-5472.CAN-05-1507.
• [1223] SRSF1-dependent alternative splicing attenuates BIN1 expression in non-small cell lung cancer.J Cell Biochem. 2020 Feb;121(2):946-953. doi: 10.1002/jcb.29366. Epub 2019 Sep 3.
• [1224] Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.Hum Mol Genet. 2005 Apr 15;14(8):997-1007. doi: 10.1093/hmg/ddi092. Epub 2005 Mar 3.
• [1225] Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients.Onco Targets Ther. 2019 Jan 29;12:921-932. doi: 10.2147/OTT.S180507. eCollection 2019.
• [1226] Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors.Cancer Res. 2006 Nov 1;66(21):10621-9. doi: 10.1158/0008-5472.CAN-06-1687.
• [1227] A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis.Cancer Res. 2005 Jul 1;65(13):5638-46. doi: 10.1158/0008-5472.CAN-05-0600.
• [1228] Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells.Cancer Res. 2006 Dec 15;66(24):11907-12. doi: 10.1158/0008-5472.CAN-06-2754.
• [1229] PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer.Int J Cancer. 2020 May 1;146(9):2563-2575. doi: 10.1002/ijc.32675. Epub 2019 Nov 6.
• [1230] A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).Ann Oncol. 2006 Jun;17(6):1007-13. doi: 10.1093/annonc/mdl042. Epub 2006 Mar 13.
• [1231] Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.Carcinogenesis. 2006 Mar;27(3):560-7. doi: 10.1093/carcin/bgi232. Epub 2005 Sep 29.
• [1232] Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.Semin Oncol. 2019 Aug-Oct;46(4-5):380-384. doi: 10.1053/j.seminoncol.2019.10.002. Epub 2019 Nov 6.
• [1233] Aberrant methylation of FBN2 in human non-small cell lung cancer.Lung Cancer. 2005 Oct;50(1):43-9. doi: 10.1016/j.lungcan.2005.04.013.
• [1234] LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.Thorac Cancer. 2020 Feb;11(2):295-304. doi: 10.1111/1759-7714.13256. Epub 2019 Dec 2.
• [1235] Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation.J Biol Chem. 2005 May 20;280(20):19625-34. doi: 10.1074/jbc.M409392200. Epub 2005 Feb 10.
• [1236] Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).Lung Cancer. 2019 Mar;129:63-71. doi: 10.1016/j.lungcan.2018.12.009. Epub 2018 Dec 10.
• [1237] Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer.Oncol Rep. 2006 Nov;16(5):981-8.
• [1238] Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.
• [1239] Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.Exp Cell Res. 2006 Feb 1;312(3):256-65. doi: 10.1016/j.yexcr.2005.10.026. Epub 2005 Dec 13.
• [1240] Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer.J Exp Clin Cancer Res. 2019 Mar 11;38(1):122. doi: 10.1186/s13046-019-1124-0.
• [1241] Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis.Cancer Res. 2006 Nov 1;66(21):10339-48. doi: 10.1158/0008-5472.CAN-06-2137.
• [1242] Decreased expression of NEDD4L contributes to NSCLC progression and metastasis.Biochem Biophys Res Commun. 2019 May 28;513(2):398-404. doi: 10.1016/j.bbrc.2019.04.001. Epub 2019 Apr 6.
• [1243] Trial watch: Peptide-based vaccines in anticancer therapy.Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018.
• [1244] Phosphatidylethanolamine-binding protein 4 promotes the epithelial-to-mesenchymal transition in non-small cell lung cancer cells by activating the sonic hedgehog signaling pathway.J Cell Biochem. 2019 Apr;120(4):5386-5395. doi: 10.1002/jcb.27817. Epub 2018 Oct 26.
• [1245] Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer.Cancer Res. 2005 Aug 15;65(16):7102-10. doi: 10.1158/0008-5472.CAN-04-1877.
• [1246] Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer.BMC Cancer. 2006 Jul 26;6:200. doi: 10.1186/1471-2407-6-200.
• [1247] Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.Cancer Res. 2005 Jul 1;65(13):5561-70. doi: 10.1158/0008-5472.CAN-04-4603.
• [1248] miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).Neoplasma. 2020 Jan;67(1):147-157. doi: 10.4149/neo_2019_190511N420. Epub 2019 Nov 4.
• [1249] Six2 promotes non-small cell lung cancer cell stemness via transcriptionally and epigenetically regulating E-cadherin.Cell Prolif. 2019 Jul;52(4):e12617. doi: 10.1111/cpr.12617. Epub 2019 Apr 22.
• [1250] MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.Oncol Res. 2019 Aug 8;27(8):879-887. doi: 10.3727/096504018X15451308507747. Epub 2019 Apr 14.
• [1251] Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis.Mol Cancer Ther. 2018 Nov;17(11):2427-2438. doi: 10.1158/1535-7163.MCT-17-1198. Epub 2018 Sep 6.
• [1252] Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment.Cell Death Dis. 2019 Mar 4;10(3):218. doi: 10.1038/s41419-019-1447-y.
• [1253] ARMc8 indicates aggressive colon cancers and promotes invasiveness and migration of colon cancer cells.Tumour Biol. 2015 Nov;36(11):9005-13. doi: 10.1007/s13277-015-3664-z. Epub 2015 Jun 18.
• [1254] MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line.Cancer Res Treat. 2018 Jul;50(3):936-949. doi: 10.4143/crt.2017.302. Epub 2017 Oct 12.
• [1255] Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridiumperfringens enterotoxin.Mol Oncol. 2020 Feb;14(2):261-276. doi: 10.1002/1878-0261.12615. Epub 2020 Jan 8.
• [1256] TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells.Exp Cell Res. 2018 Dec 15;373(1-2):44-56. doi: 10.1016/j.yexcr.2018.08.012. Epub 2018 Aug 9.
• [1257] Development of novel real-time RT-qPCR methodologies for quantification of the COL11A1 mRNA general and C transcripts and evaluation in non-small cell lung cancer specimens.J BUON. 2018 Nov-Dec;23(6):1699-1710.
• [1258] Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. doi: 10.26355/eurrev_201901_16879.
• [1259] Circular RNA ZFR accelerates non-small cell lung cancer progression by acting as a miR-101-3p sponge to enhance CUL4B expression.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3410-3416. doi: 10.1080/21691401.2019.1652623.
• [1260] CXCL5 regulation of proliferation and migration in human non-small cell lung cancer cells.J Physiol Biochem. 2018 May;74(2):313-324. doi: 10.1007/s13105-018-0619-z. Epub 2018 Mar 10.
• [1261] DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.J Hematol Oncol. 2018 Apr 10;11(1):53. doi: 10.1186/s13045-018-0597-1.
• [1262] Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating 2AR signaling.J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. doi: 10.1186/s13046-019-1162-7.
• [1263] Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach.Oncotarget. 2019 Apr 2;10(26):2546-2560. doi: 10.18632/oncotarget.26817. eCollection 2019 Apr 2.
• [1264] Overexpression of Flap Endonuclease 1 Correlates with Enhanced Proliferation and Poor Prognosis of Non-Small-Cell Lung Cancer.Am J Pathol. 2018 Jan;188(1):242-251. doi: 10.1016/j.ajpath.2017.09.011. Epub 2017 Oct 14.
• [1265] MicroRNA-198-5p inhibits the migration and invasion of non-small lung cancer cells by targeting fucosyltransferase 8.Clin Exp Pharmacol Physiol. 2019 Oct;46(10):955-967. doi: 10.1111/1440-1681.13154. Epub 2019 Aug 30.
• [1266] Knockdown of high mobility group box 3 impairs cell viability and colony formation but increases apoptosis in A549 human non-small cell lung cancer cells.Oncol Lett. 2019 Mar;17(3):2937-2945. doi: 10.3892/ol.2019.9927. Epub 2019 Jan 14.
• [1267] Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer.Thorac Cancer. 2019 May;10(5):1069-1077. doi: 10.1111/1759-7714.13046. Epub 2019 Mar 21.
• [1268] Galectin-9 in non-small cell lung cancer.Lung Cancer. 2019 Oct;136:80-85. doi: 10.1016/j.lungcan.2019.08.014. Epub 2019 Aug 16.
• [1269] Role of transcription factor FOXA1 in nonsmall cell lung cancer.Mol Med Rep. 2018 Jan;17(1):509-521. doi: 10.3892/mmr.2017.7885. Epub 2017 Oct 26.
• [1270] Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.Carcinogenesis. 2018 May 3;39(5):719-727. doi: 10.1093/carcin/bgy044.
• [1271] Circular RNA circ-FOXM1 facilitates cell progression as ceRNA to target PPDPF and MACC1 by sponging miR-1304-5p in non-small cell lung cancer.Biochem Biophys Res Commun. 2019 May 21;513(1):207-212. doi: 10.1016/j.bbrc.2019.03.213. Epub 2019 Apr 4.
• [1272] MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.Int J Med Sci. 2019 Jan 1;16(1):68-74. doi: 10.7150/ijms.27595. eCollection 2019.
• [1273] miR-600 inhibits lung cancer via downregulating the expression of METTL3.Cancer Manag Res. 2019 Feb 1;11:1177-1187. doi: 10.2147/CMAR.S181058. eCollection 2019.
• [1274] NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/-catenin signaling.Am J Cancer Res. 2017 Mar 1;7(3):565-573. eCollection 2017.
• [1275] OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair.Cancer Cell Int. 2019 Apr 15;19:99. doi: 10.1186/s12935-019-0816-z. eCollection 2019.
• [1276] Rab11-FIP2 suppressed tumor growth via regulation of PGK1 ubiquitination in non-small cell lung cancer.Biochem Biophys Res Commun. 2019 Jan 1;508(1):60-65. doi: 10.1016/j.bbrc.2018.11.108. Epub 2018 Nov 22.
• [1277] Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2.J Biomed Sci. 2005;12(1):65-77. doi: 10.1007/s11373-004-8185-5.
• [1278] Effects of retinoic acid-inducible gene-I-like receptors activations and ionizing radiation cotreatment on cytotoxicity against human non-small cell lung cancer in vitro.Oncol Lett. 2018 Apr;15(4):4697-4705. doi: 10.3892/ol.2018.7867. Epub 2018 Jan 26.
• [1279] Clinicopathological significance of BGP expression in non-small-cell lung carcinoma: relationship with histological type, microvessel density and patients' survival.Pathology. 2006 Dec;38(6):555-60. doi: 10.1080/00313020601024029.
• [1280] SEL1L expression in non-small cell lung cancer.Hum Pathol. 2006 May;37(5):505-12. doi: 10.1016/j.humpath.2005.12.012. Epub 2006 Mar 20.
• [1281] Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer.J Cell Biochem. 2019 Nov;120(11):18724-18735. doi: 10.1002/jcb.29182. Epub 2019 Jun 20.
• [1282] SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis.Nat Cell Biol. 2019 Feb;21(2):214-225. doi: 10.1038/s41556-018-0266-1. Epub 2019 Jan 28.
• [1283] SFRP2 modulates nonsmall cell lung cancer A549cell apoptosis and metastasis by regulating mitochondrial fission via Wnt pathways.Mol Med Rep. 2019 Aug;20(2):1925-1932. doi: 10.3892/mmr.2019.10393. Epub 2019 Jun 18.
• [1284] A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer.Front Oncol. 2019 Jul 31;9:693. doi: 10.3389/fonc.2019.00693. eCollection 2019.
• [1285] miR-802 inhibits the proliferation, invasion, and epithelial-mesenchymal transition of glioblastoma multiforme cells by directly targeting SIX4.Cell Biochem Funct. 2020 Jan;38(1):66-76. doi: 10.1002/cbf.3451. Epub 2019 Nov 8.
• [1286] Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy.Mol Cancer Ther. 2019 Mar;18(3):656-666. doi: 10.1158/1535-7163.MCT-18-0067. Epub 2018 Nov 26.
• [1287] No erythropoietin-induced growth is observed in non-small cell lung cancer cells.Int J Oncol. 2018 Feb;52(2):518-526. doi: 10.3892/ijo.2017.4225. Epub 2017 Dec 12.
• [1288] SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-B.Thorac Cancer. 2019 Jan;10(1):33-40. doi: 10.1111/1759-7714.12895. Epub 2018 Nov 4.
• [1289] Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-1 and miRNA21 cooperation.PLoS One. 2019 Jul 25;14(7):e0219597. doi: 10.1371/journal.pone.0219597. eCollection 2019.
• [1290] TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients.Mol Carcinog. 2019 May;58(5):767-776. doi: 10.1002/mc.22969. Epub 2019 Jan 22.
• [1291] Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses.J Cancer. 2019 Jan 29;10(4):843-852. doi: 10.7150/jca.27856. eCollection 2019.
• [1292] Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells.Cell Signal. 2019 Sep;61:10-19. doi: 10.1016/j.cellsig.2019.05.004. Epub 2019 May 7.
• [1293] The expression and correlation between chemokine CCL7 and ABCE1 in non-small cell lung cancer.Exp Ther Med. 2018 Oct;16(4):3004-3010. doi: 10.3892/etm.2018.6568. Epub 2018 Aug 2.
• [1294] High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.PLoS One. 2015 Aug 13;10(8):e0135576. doi: 10.1371/journal.pone.0135576. eCollection 2015.
• [1295] Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders.Transl Oncol. 2019 Feb;12(2):368-374. doi: 10.1016/j.tranon.2018.11.004. Epub 2018 Nov 30.
• [1296] The Proto-oncogene PKC regulates the alternative splicing of Bcl-x pre-mRNA.Mol Cancer Res. 2012 May;10(5):660-9. doi: 10.1158/1541-7786.MCR-11-0363. Epub 2012 Apr 20.
• [1297] Long non-coding RNA 1308 promotes cell invasion by regulating the miR-124/ADAM 15 axis in non-small-cell lung cancer cells.Cancer Manag Res. 2018 Dec 3;10:6599-6609. doi: 10.2147/CMAR.S187973. eCollection 2018.
• [1298] MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5831-5839. doi: 10.26355/eurrev_201907_18323.
• [1299] Leucine rich repeat LGI family member 3: Integrative analyses reveal its prognostic association with non-small cell lung cancer.Oncol Lett. 2019 Sep;18(3):3388-3398. doi: 10.3892/ol.2019.10648. Epub 2019 Jul 22.
• [1300] The expression of ADAM23 and its correlation with promoter methylation in non-small-cell lung carcinoma.Int J Exp Pathol. 2011 Oct;92(5):333-9. doi: 10.1111/j.1365-2613.2011.00766.x. Epub 2011 Mar 23.
• [1301] Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.PLoS One. 2012;7(8):e42086. doi: 10.1371/journal.pone.0042086. Epub 2012 Aug 2.
• [1302] Adducins inhibit lung cancer cell migration through mechanisms involving regulation of cell-matrix adhesion and cadherin-11 expression.Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):395-408. doi: 10.1016/j.bbamcr.2018.10.001. Epub 2018 Oct 2.
• [1303] miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.Biochem Biophys Res Commun. 2014 Mar 28;446(1):179-86. doi: 10.1016/j.bbrc.2014.02.073. Epub 2014 Feb 28.
• [1304] Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer.Carcinogenesis. 2017 Oct 1;38(10):1029-1035. doi: 10.1093/carcin/bgx079.
• [1305] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.BMC Cancer. 2019 Aug 5;19(1):769. doi: 10.1186/s12885-019-5948-y.
• [1306] Adiponectin inhibits migration and invasion by reversing epithelialmesenchymal transition in nonsmall cell lung carcinoma.Oncol Rep. 2018 Sep;40(3):1330-1338. doi: 10.3892/or.2018.6523. Epub 2018 Jun 25.
• [1307] LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.Front Oncol. 2019 Oct 22;9:1103. doi: 10.3389/fonc.2019.01103. eCollection 2019.
• [1308] Actin Filament-Associated Protein 1-Like 1 Mediates Proliferation and Survival in Non-Small Cell Lung Cancer Cells.Med Sci Monit. 2018 Jan 11;24:215-224. doi: 10.12659/msm.905900.
• [1309] Prognostic and diagnostic significance of long non-coding RNA AGAP2-AS1 levels in patients with non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2017 May;21(10):2392-2396.
• [1310] Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth.Oncotarget. 2018 Mar 30;9(24):16718-16730. doi: 10.18632/oncotarget.24676. eCollection 2018 Mar 30.
• [1311] Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.Oncotarget. 2015 Feb 20;6(5):2812-26. doi: 10.18632/oncotarget.2802.
• [1312] miR-1908 Overexpression Inhibits Proliferation, Changing Akt Activity and p53 Expression in Hypoxic NSCLC Cells.Oncol Res. 2016;24(1):9-15. doi: 10.3727/096504016X14570992647168.
• [1313] Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival.PLoS One. 2017 Jul 13;12(7):e0180471. doi: 10.1371/journal.pone.0180471. eCollection 2017.
• [1314] miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.Genes Chromosomes Cancer. 2013 Oct;52(10):895-911. doi: 10.1002/gcc.22085. Epub 2013 Aug 9.
• [1315] Dueling KRAS(G12C) Inhibitors Achieve Responses.Cancer Discov. 2020 Jan;10(1):10. doi: 10.1158/2159-8290.CD-ND2019-012. Epub 2019 Dec 10.
• [1316] AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line.Anticancer Res. 2019 Sep;39(9):4637-4642. doi: 10.21873/anticanres.13644.
• [1317] miR-425 regulates cell proliferation, migration and apoptosis by targeting AMPH-1 in non-small-cell lung cancer.Pathol Res Pract. 2019 Dec;215(12):152705. doi: 10.1016/j.prp.2019.152705. Epub 2019 Oct 23.
• [1318] A novel function of anaphase promoting complex subunit 10 in tumor progression in non-small cell lung cancer.Cell Cycle. 2019 May;18(9):1019-1032. doi: 10.1080/15384101.2019.1609830. Epub 2019 Apr 25.
• [1319] Angiopoietin-like protein 2 facilitates non-small cell lung cancer progression by promoting the polarization of M2 tumor-associated macrophages.Am J Cancer Res. 2017 Nov 1;7(11):2220-2233. eCollection 2017.
• [1320] ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.Sci Rep. 2017 Jun 30;7(1):4430. doi: 10.1038/s41598-017-04818-y.
• [1321] Diversin increases the proliferation and invasion ability of non-small-cell lung cancer cells via JNK pathway.Cancer Lett. 2014 Mar 28;344(2):232-8. doi: 10.1016/j.canlet.2013.10.033. Epub 2013 Nov 15.
• [1322] Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy.Clin Cancer Res. 2012 Oct 1;18(19):5507-14. doi: 10.1158/1078-0432.CCR-12-1202. Epub 2012 Aug 7.
• [1323] Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells.J Nat Med. 2018 Jun;72(3):724-733. doi: 10.1007/s11418-018-1211-0. Epub 2018 Apr 7.
• [1324] RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/-catenin signaling.Cell Death Dis. 2018 Sep 20;9(10):942. doi: 10.1038/s41419-018-0972-4.
• [1325] APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.Oncogene. 2018 Jul;37(29):3924-3936. doi: 10.1038/s41388-018-0245-9. Epub 2018 Apr 26.
• [1326] Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways.Biochem Biophys Res Commun. 2018 Jun 22;501(2):520-526. doi: 10.1016/j.bbrc.2018.05.029.
• [1327] Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain metastases.Oncotarget. 2019 Oct 29;10(59):6334-6348. doi: 10.18632/oncotarget.27274. eCollection 2019 Oct 29.
• [1328] Cinnamtannin D1 from Rhododendron formosanum Induces Autophagy via the Inhibition of Akt/mTOR and Activation of ERK1/2 in Non-Small-Cell Lung Carcinoma Cells.J Agric Food Chem. 2015 Dec 9;63(48):10407-17. doi: 10.1021/acs.jafc.5b04375. Epub 2015 Nov 23.
• [1329] Upregulated circRNA ARHGAP10 Predicts an Unfavorable Prognosis in NSCLC through Regulation of the miR-150-5p/GLUT-1 Axis.Mol Ther Nucleic Acids. 2019 Dec 6;18:219-231. doi: 10.1016/j.omtn.2019.08.016. Epub 2019 Aug 21.
• [1330] Differential expressions of MDM2 and TAP73 in cancer and cancer-adjacent tissues in patients with non-small-cell lung carcinoma.Pulmonology. 2018 Feb 13:S2173-5115(17)30153-7. doi: 10.1016/j.rppnen.2017.08.008. Online ahead of print.
• [1331] Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer.Oncogene. 2014 Feb 27;33(9):1181-9. doi: 10.1038/onc.2013.42. Epub 2013 Mar 11.
• [1332] ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.Int J Cancer. 2018 Apr 1;142(7):1379-1391. doi: 10.1002/ijc.31169. Epub 2017 Dec 4.
• [1333] ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients.Lab Invest. 2018 May;98(5):670-681. doi: 10.1038/s41374-018-0022-y. Epub 2018 Jan 30.
• [1334] Prognostic value of TIM-1 expression in human non-small-cell lung cancer.J Transl Med. 2019 May 28;17(1):178. doi: 10.1186/s12967-019-1931-2.
• [1335] MiR-503 targets PI3K p85 and IKK- and suppresses progression of non-small cell lung cancer.Int J Cancer. 2014 Oct 1;135(7):1531-42. doi: 10.1002/ijc.28799. Epub 2014 Mar 27.
• [1336] Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.Int J Cancer. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.
• [1337] Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.Cancer Lett. 2019 Aug 28;458:76-85. doi: 10.1016/j.canlet.2019.05.016. Epub 2019 May 21.
• [1338] Alex3 suppresses non-small cell lung cancer invasion via AKT/Slug/E-cadherin pathway.Tumour Biol. 2017 Jul;39(7):1010428317701441. doi: 10.1177/1010428317701441.
• [1339] ARNT2 is downregulated and serves as a potential tumor suppressor gene in non-small cell lung cancer.Tumour Biol. 2015 Mar;36(3):2111-9. doi: 10.1007/s13277-014-2820-1. Epub 2015 Jan 23.
• [1340] Role of artemin in non-small cell lung cancer.Thorac Cancer. 2018 May;9(5):555-562. doi: 10.1111/1759-7714.12615. Epub 2018 Mar 25.
• [1341] Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7.
• [1342] miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM.Oncol Rep. 2017 Apr;37(4):1980-1988. doi: 10.3892/or.2017.5448. Epub 2017 Feb 14.
• [1343] Role of ATG10 expression quantitative trait loci in non-small cell lung cancer survival.Int J Cancer. 2016 Oct 1;139(7):1564-73. doi: 10.1002/ijc.30205. Epub 2016 Jun 15.
• [1344] MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2650-2658.
• [1345] The Thr300Ala variant of ATG16L1 is associated with decreased risk of brain metastasis in patients with non-small cell lung cancer.Autophagy. 2017 Jun 3;13(6):1053-1063. doi: 10.1080/15548627.2017.1308997. Epub 2017 Apr 25.
• [1346] Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.J Thorac Oncol. 2018 May;13(5):660-675. doi: 10.1016/j.jtho.2018.01.028. Epub 2018 Feb 15.
• [1347] MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2444-2452. doi: 10.26355/eurrev_201903_17391.
• [1348] Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy.Biosci Rep. 2019 Jul 5;39(7):BSR20182082. doi: 10.1042/BSR20182082. Print 2019 Jul 31.
• [1349] Knockdown of copper chaperone antioxidant-1 by RNA interference inhibits copper-stimulated proliferation of non-small cell lung carcinoma cells.Oncol Rep. 2013 Jul;30(1):269-75. doi: 10.3892/or.2013.2436. Epub 2013 Apr 29.
• [1350] LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):660-669. doi: 10.26355/eurrev_201901_16880.
• [1351] Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer.FEBS J. 2020 Feb;287(4):783-799. doi: 10.1111/febs.15051. Epub 2019 Sep 20.
• [1352] Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cells.Oncotarget. 2017 Oct 16;8(55):94711-94725. doi: 10.18632/oncotarget.21885. eCollection 2017 Nov 7.
• [1353] MiR-140-3p suppressed cell growth and invasion by downregulating the expression of ATP8A1 in non-small cell lung cancer.Tumour Biol. 2016 Mar;37(3):2973-85. doi: 10.1007/s13277-015-3452-9. Epub 2015 Sep 28.
• [1354] Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.Lung Cancer. 2015 Mar;87(3):318-20. doi: 10.1016/j.lungcan.2015.01.002. Epub 2015 Jan 10.
• [1355] Circular RNA ATXN7 is upregulated in non-small cell lung cancer and promotes disease progression.Oncol Lett. 2019 Jun;17(6):4803-4810. doi: 10.3892/ol.2019.10168. Epub 2019 Mar 19.
• [1356] Association between AXIN1 Gene Polymorphisms and Bladder Cancer in Chinese Han Population.Dis Markers. 2019 Apr 15;2019:3949343. doi: 10.1155/2019/3949343. eCollection 2019.
• [1357] RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers.Tumour Biol. 2017 Aug;39(8):1010428317700001. doi: 10.1177/1010428317700001.
• [1358] TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer.BMC Genomics. 2014;15 Suppl 9(Suppl 9):S2. doi: 10.1186/1471-2164-15-S9-S2. Epub 2014 Dec 8.
• [1359] B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer.J Clin Pathol. 2018 Jul;71(7):642-647. doi: 10.1136/jclinpath-2017-204860. Epub 2018 Feb 26.
• [1360] Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.J Clin Invest. 2014 May;124(5):2037-49. doi: 10.1172/JCI72522. Epub 2014 Apr 8.
• [1361] Bag-1 Silence Sensitizes Non-Small Cell Lung Cancer Cells To Cisplatin Through Multiple Gene Pathways.Onco Targets Ther. 2019 Oct 31;12:8977-8989. doi: 10.2147/OTT.S218182. eCollection 2019.
• [1362] Association of the FAM46A gene VNTRs and BAG6 rs3117582 SNP with non small cell lung cancer (NSCLC) in Croatian and Norwegian populations.PLoS One. 2015 Apr 17;10(4):e0122651. doi: 10.1371/journal.pone.0122651. eCollection 2015.
• [1363] Downregulation of the TGF Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGF Signaling and Invasion.Cancer Res. 2016 Jul 1;76(13):3785-801. doi: 10.1158/0008-5472.CAN-15-1326. Epub 2016 May 17.
• [1364] BARD1: an independent predictor of survival in non-small cell lung cancer.Int J Cancer. 2012 Jul 1;131(1):83-94. doi: 10.1002/ijc.26346. Epub 2011 Dec 21.
• [1365] Downregulation of BarH-like homeobox 2 promotes cell proliferation, migration and aerobic glycolysis through Wnt/-catenin signaling, and predicts a poor prognosis in non-small cell lung carcinoma.Thorac Cancer. 2018 Mar;9(3):390-399. doi: 10.1111/1759-7714.12593. Epub 2018 Jan 17.
• [1366] miR-942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non-small-cell lung cancer.J Cell Physiol. 2019 Dec;234(12):23596-23607. doi: 10.1002/jcp.28928. Epub 2019 Jun 24.
• [1367] KIAA1211 plays an oncogenic role in human non-small cell lung cancer.J Cancer. 2019 Oct 22;10(26):6747-6753. doi: 10.7150/jca.35951. eCollection 2019.
• [1368] Decreased SARI expression predicts poor prognosis of Chinese patients with non-small cell lung cancer.Int J Clin Exp Pathol. 2013 Sep 15;6(10):2056-63. eCollection 2013.
• [1369] Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.Ann Surg Oncol. 2013 Dec;20 Suppl 3(0 3):S701-8. doi: 10.1245/s10434-013-3184-2. Epub 2013 Aug 1.
• [1370] Mitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-X(L)/p53-mediated amplification mechanisms.Cell Death Dis. 2014 Dec 18;5(12):e1579. doi: 10.1038/cddis.2014.547.
• [1371] PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.J Liposome Res. 2018 Sep;28(3):236-248. doi: 10.1080/08982104.2017.1327542. Epub 2017 May 24.
• [1372] Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.Cell Death Dis. 2018 Nov 14;9(11):1134. doi: 10.1038/s41419-018-1174-9.
• [1373] The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.Tumour Biol. 2013 Jun;34(3):1641-50. doi: 10.1007/s13277-013-0697-z. Epub 2013 Feb 20.
• [1374] DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells.Cell Death Dis. 2017 May 25;8(5):e2810. doi: 10.1038/cddis.2017.218.
• [1375] Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.Lung Cancer. 2020 Jan;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. Epub 2019 Nov 4.
• [1376] Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.Clin Respir J. 2018 Feb;12(2):633-638. doi: 10.1111/crj.12572. Epub 2016 Nov 20.
• [1377] MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells.FEBS Lett. 2015 Mar 24;589(7):805-11. doi: 10.1016/j.febslet.2015.02.013. Epub 2015 Feb 26.
• [1378] Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.Cell Death Differ. 2014 May;21(5):774-82. doi: 10.1038/cdd.2014.6. Epub 2014 Jan 31.
• [1379] The role of lncRNA MALAT1 in bone metastasis in patients with non-small cell lung cancer.Oncol Rep. 2016 Sep;36(3):1679-85. doi: 10.3892/or.2016.4909. Epub 2016 Jun 29.
• [1380] Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas.APMIS. 2013 Jul;121(7):592-604. doi: 10.1111/apm.12026. Epub 2012 Dec 8.
• [1381] BOK displays cell death-independent tumor suppressor activity in non-small-cell lung carcinoma.Int J Cancer. 2017 Nov 15;141(10):2050-2061. doi: 10.1002/ijc.30906. Epub 2017 Aug 7.
• [1382] Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer.Front Med. 2020 Feb;14(1):60-67. doi: 10.1007/s11684-019-0694-8. Epub 2019 May 18.
• [1383] Loss of BRMS1 promotes a mesenchymal phenotype through NF-B-dependent regulation of Twist1.Mol Cell Biol. 2015 Jan;35(1):303-17. doi: 10.1128/MCB.00869-14. Epub 2014 Nov 3.
• [1384] Silencing of Btbd7 Inhibited Epithelial-Mesenchymal Transition and Chemoresistance in CD133(+) Lung Carcinoma A549 Cells.Oncol Res. 2017 May 24;25(5):819-829. doi: 10.3727/096504016X14772349843854. Epub 2016 Oct 26.
• [1385] Overexpression of BZW1 is an independent poor prognosis marker and its down-regulation suppresses lung adenocarcinoma metastasis.Sci Rep. 2019 Oct 10;9(1):14624. doi: 10.1038/s41598-019-50874-x.
• [1386] FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.Lung Cancer. 2012 Jun;76(3):416-22. doi: 10.1016/j.lungcan.2011.11.009. Epub 2011 Dec 2.
• [1387] Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.Lung Cancer. 2018 Nov;125:157-163. doi: 10.1016/j.lungcan.2018.09.012. Epub 2018 Sep 17.
• [1388] Hypermethylation of normal mucosa of esophagus-specific 1 is associated with an unfavorable prognosis in patients with non-small cell lung cancer.Oncol Lett. 2018 Aug;16(2):2409-2415. doi: 10.3892/ol.2018.8915. Epub 2018 Jun 6.
• [1389] DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.Exp Cell Res. 2019 Jan 15;374(2):304-314. doi: 10.1016/j.yexcr.2018.12.001. Epub 2018 Dec 4.
• [1390] CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases.J Am Acad Dermatol. 2018 Dec;79(6):1039-1046. doi: 10.1016/j.jaad.2018.06.025. Epub 2018 Jun 19.
• [1391] Downregulation of Calbindin 1 by miR-454-3p Suppresses Cell Proliferation in Nonsmall Cell Lung Cancer In Vitro.Cancer Biother Radiopharm. 2019 Mar;34(2):119-127. doi: 10.1089/cbr.2018.2598. Epub 2019 Jan 14.
• [1392] Genome-wide association study of survival in early-stage non-small cell lung cancer.Ann Surg Oncol. 2015 Feb;22(2):630-5. doi: 10.1245/s10434-014-3983-0. Epub 2014 Aug 22.
• [1393] miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer.Clin Transl Oncol. 2018 Apr;20(4):457-466. doi: 10.1007/s12094-017-1730-2. Epub 2017 Sep 4.
• [1394] Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2.Med Oncol. 2015 Mar;32(3):51. doi: 10.1007/s12032-015-0500-7. Epub 2015 Jan 31.
• [1395] Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.PLoS One. 2012;7(5):e36903. doi: 10.1371/journal.pone.0036903. Epub 2012 May 15.
• [1396] Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer.Oncotarget. 2017 Jun 1;8(42):73198-73207. doi: 10.18632/oncotarget.18336. eCollection 2017 Sep 22.
• [1397] Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression.Tumour Biol. 2016 Nov;37(11):15157-15164. doi: 10.1007/s13277-016-5411-5. Epub 2016 Sep 27.
• [1398] A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer.Sci Rep. 2018 Jun 4;8(1):8549. doi: 10.1038/s41598-018-26864-w.
• [1399] PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.PLoS One. 2012;7(3):e33752. doi: 10.1371/journal.pone.0033752. Epub 2012 Mar 26.
• [1400] Long non-coding RNA SDPR-AS affects the development of non-small cell lung cancer by regulating SDPR through p38 MAPK/ERK signals.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3172-3179. doi: 10.1080/21691401.2019.1642904.
• [1401] Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.Cancer Res. 2018 Sep 1;78(17):4984-4996. doi: 10.1158/0008-5472.CAN-17-3858. Epub 2018 Jun 26.
• [1402] Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8391-8402. doi: 10.26355/eurrev_201910_19150.
• [1403] LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.J Cell Mol Med. 2019 Mar;23(3):1852-1864. doi: 10.1111/jcmm.14085. Epub 2018 Dec 4.
• [1404] CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer.Asia Pac J Clin Oncol. 2018 Oct;14(5):e283-e288. doi: 10.1111/ajco.12820. Epub 2017 Nov 10.
• [1405] Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.Theranostics. 2017 Apr 10;7(6):1612-1632. doi: 10.7150/thno.17573. eCollection 2017.
• [1406] CCDC106 promotes non-small cell lung cancer cell proliferation.Oncotarget. 2017 Apr 18;8(16):26662-26670. doi: 10.18632/oncotarget.15792.
• [1407] The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.
• [1408] Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed.Onco Targets Ther. 2019 Jul 8;12:5355-5358. doi: 10.2147/OTT.S211582. eCollection 2019.
• [1409] Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells.Hum Pathol. 2016 Oct;56:64-73. doi: 10.1016/j.humpath.2016.06.001. Epub 2016 Jun 21.
• [1410] CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.Mol Carcinog. 2019 Jan;58(1):126-134. doi: 10.1002/mc.22914. Epub 2018 Oct 9.
• [1411] Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.Sci Rep. 2015 Nov 3;5:16053. doi: 10.1038/srep16053.
• [1412] The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer.Int J Biol Markers. 2019 Jun;34(2):156-162. doi: 10.1177/1724600819829758. Epub 2019 May 3.
• [1413] Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response.Clin Lung Cancer. 2015 Jul;16(4):298-304.e1-2. doi: 10.1016/j.cllc.2014.12.008. Epub 2014 Dec 30.
• [1414] CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients.Biomed Pharmacother. 2015 Aug;74:222-7. doi: 10.1016/j.biopha.2015.08.004. Epub 2015 Aug 28.
• [1415] Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.BMC Cancer. 2017 Feb 15;17(1):138. doi: 10.1186/s12885-017-3132-9.
• [1416] Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity.Eur J Med Chem. 2017 Aug 18;136:212-222. doi: 10.1016/j.ejmech.2017.05.017. Epub 2017 May 5.
• [1417] Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer.Oncotarget. 2017 Jul 18;8(38):64170-64179. doi: 10.18632/oncotarget.19369. eCollection 2017 Sep 8.
• [1418] CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer.Oncol Lett. 2017 May;13(5):3703-3708. doi: 10.3892/ol.2017.5925. Epub 2017 Mar 27.
• [1419] Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells.Oncoimmunology. 2018 Feb 12;7(6):e1428156. doi: 10.1080/2162402X.2018.1428156. eCollection 2018.
• [1420] Label-Free Surface Protein Profiling of Extracellular Vesicles by an Electrokinetic Sensor.ACS Sens. 2019 May 24;4(5):1399-1408. doi: 10.1021/acssensors.9b00418. Epub 2019 May 7.
• [1421] Expressions of KAI1 and E-cadherin in nonsmall cell lung cancer and their correlation with vasculogenic mimicry.Medicine (Baltimore). 2018 Oct;97(40):e12293. doi: 10.1097/MD.0000000000012293.
• [1422] Radioimmunoimaging of (125)I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer.Oncol Lett. 2019 Dec;18(6):6413-6422. doi: 10.3892/ol.2019.11036. Epub 2019 Nov 1.
• [1423] CD99 is a novel prognostic stromal marker in non-small cell lung cancer.Int J Cancer. 2012 Nov 15;131(10):2264-73. doi: 10.1002/ijc.27518. Epub 2012 Apr 24.
• [1424] MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer.Oncol Lett. 2017 May;13(5):3896-3904. doi: 10.3892/ol.2017.5888. Epub 2017 Mar 22.
• [1425] Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report.Cell Oncol (Dordr). 2019 Aug;42(4):571-578. doi: 10.1007/s13402-019-00438-y. Epub 2019 Mar 18.
• [1426] Expression of CDCA3 Is a Prognostic Biomarker andPotential Therapeutic Target in Non-Small CellLungCancer.J Thorac Oncol. 2017 Jul;12(7):1071-1084. doi: 10.1016/j.jtho.2017.04.018. Epub 2017 May 6.
• [1427] Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.Onco Targets Ther. 2019 May 13;12:3545-3563. doi: 10.2147/OTT.S198621. eCollection 2019.
• [1428] Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer.Asian Pac J Cancer Prev. 2014;15(12):4925-8. doi: 10.7314/apjcp.2014.15.12.4925.
• [1429] Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.Int J Oncol. 2001 Aug;19(2):277-81.
• [1430] Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.Am J Physiol Lung Cell Mol Physiol. 2019 May 1;316(5):L918-L933. doi: 10.1152/ajplung.00334.2018. Epub 2019 Jan 10.
• [1431] Long noncoding RNA TUG1 is downregulated in non-small cell lung cancer and can regulate CELF1 on binding to PRC2.BMC Cancer. 2016 Aug 2;16:583. doi: 10.1186/s12885-016-2569-6.
• [1432] CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.Carcinogenesis. 2020 May 14;41(3):377-389. doi: 10.1093/carcin/bgz113.
• [1433] KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT.J Mol Med (Berl). 2019 Jan;97(1):127-140. doi: 10.1007/s00109-018-1721-y. Epub 2018 Nov 26.
• [1434] Centromere protein U promotes cell proliferation, migration and invasion involving Wnt/-catenin signaling pathway in non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7768-7777. doi: 10.26355/eurrev_201811_16400.
• [1435] High CEP55 expression is associated with poor prognosis in non-small-cell lung cancer.Onco Targets Ther. 2018 Aug 17;11:4979-4990. doi: 10.2147/OTT.S165750. eCollection 2018.
• [1436] CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.Thorac Cancer. 2018 May;9(5):652-655. doi: 10.1111/1759-7714.12617. Epub 2018 Mar 8.
• [1437] Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.J Clin Invest. 2016 Jan;126(1):254-65. doi: 10.1172/JCI79775. Epub 2015 Dec 7.
• [1438] Involvement of caspase? in apoptosis enhancement by cotreatment with retinoic acidinducible geneIlike receptor agonist and ionizing radiation in human nonsmall cell lung cancer.Mol Med Rep. 2018 Dec;18(6):5286-5294. doi: 10.3892/mmr.2018.9536. Epub 2018 Oct 8.
• [1439] Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.Respir Res. 2017 Jun 15;18(1):118. doi: 10.1186/s12931-017-0604-z.
• [1440] Comparison of cofilin? and Twist? protein expression in human nonsmall cell lung cancer tissues.Oncol Rep. 2019 Aug;42(2):805-816. doi: 10.3892/or.2019.7193. Epub 2019 Jun 10.
• [1441] MiR-520b inhibited metastasis and proliferation of non-small cell lung cancer by targeting CHAF1A.Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7742-7749. doi: 10.26355/eurrev_201811_16396.
• [1442] CHAF1B promotes proliferation and reduces apoptosis in 95D lung cancer cells and predicts a poor prognosis in nonsmall cell lung cancer.Oncol Rep. 2019 Apr;41(4):2518-2528. doi: 10.3892/or.2019.6994. Epub 2019 Feb 1.
• [1443] CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.Clin Lung Cancer. 2015 Nov;16(6):447-56. doi: 10.1016/j.cllc.2015.05.009. Epub 2015 Jun 2.
• [1444] CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration.Mol Cancer Res. 2015 Jul;13(7):1119-29. doi: 10.1158/1541-7786.MCR-14-0165-T. Epub 2015 Mar 17.
• [1445] CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC).Gene. 2017 Jun 30;618:65-68. doi: 10.1016/j.gene.2017.04.010. Epub 2017 Apr 8.
• [1446] Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.Neuroendocrinology. 2020;110(3-4):185-197. doi: 10.1159/000500202. Epub 2019 Apr 16.
• [1447] Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).J Cancer Res Clin Oncol. 2019 Sep;145(9):2285-2292. doi: 10.1007/s00432-019-02989-x. Epub 2019 Aug 1.
• [1448] CHMP4C Disruption Sensitizes the Human Lung Cancer Cells to Irradiation.Int J Mol Sci. 2015 Dec 24;17(1):18. doi: 10.3390/ijms17010018.
• [1449] Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.Clin Cancer Res. 2011 Dec 15;17(24):7712-22. doi: 10.1158/1078-0432.CCR-11-0619. Epub 2011 Oct 20.
• [1450] Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.Int J Cancer. 2010 Dec 1;127(11):2699-706. doi: 10.1002/ijc.25282.
• [1451] Genetic variants of CHRNA5-A3 and CHRNB3-A6 predict survival of patients with advanced non-small cell lung cancer.Oncotarget. 2016 May 3;7(18):26436-43. doi: 10.18632/oncotarget.8510.
• [1452] MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1.Pathol Oncol Res. 2019 Jul;25(3):1181-1190. doi: 10.1007/s12253-018-0552-z. Epub 2019 Jan 12.
• [1453] SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.Mol Cancer Res. 2015 Jan;13(1):41-9. doi: 10.1158/1541-7786.MCR-14-0239. Epub 2014 Aug 20.
• [1454] Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.Chin J Nat Med. 2019 Oct;17(10):768-777. doi: 10.1016/S1875-5364(19)30093-7.
• [1455] AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients.Int J Oncol. 2017 Feb;50(2):365-372. doi: 10.3892/ijo.2017.3834. Epub 2017 Jan 2.
• [1456] Research Advances in CKLF-like MARVEL Transmembrane Domain-containing Family in Non-small Cell Lung Cancer.Int J Biol Sci. 2019 Sep 7;15(12):2576-2583. doi: 10.7150/ijbs.33733. eCollection 2019.
• [1457] Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.BMC Cancer. 2012 Jul 23;12:309. doi: 10.1186/1471-2407-12-309.
• [1458] Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.Oncoimmunology. 2018 Jan 29;7(5):e1423184. doi: 10.1080/2162402X.2017.1423184. eCollection 2018.
• [1459] CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients.J Cancer. 2019 Oct 19;10(25):6374-6383. doi: 10.7150/jca.30139. eCollection 2019.
• [1460] Research on circadian clock genes in non-small-cell lung carcinoma.Chronobiol Int. 2019 Jun;36(6):739-750. doi: 10.1080/07420528.2018.1509080. Epub 2019 Apr 24.
• [1461] CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.World J Surg Oncol. 2017 Jan 28;15(1):34. doi: 10.1186/s12957-016-1094-z.
• [1462] Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.Oncoimmunology. 2019 Jun 14;8(10):e1629261. doi: 10.1080/2162402X.2019.1629261. eCollection 2019.
• [1463] CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation.Oncotarget. 2015 Dec 1;6(38):41092-107. doi: 10.18632/oncotarget.5732.
• [1464] TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.PLoS One. 2015 Nov 24;10(11):e0142596. doi: 10.1371/journal.pone.0142596. eCollection 2015.
• [1465] The CNPY2 enhances epithelial-mesenchymal transition via activating the AKT/GSK3 pathway in non-small cell lung cancer.Cell Biol Int. 2018 Aug;42(8):959-964. doi: 10.1002/cbin.10961. Epub 2018 Apr 17.
• [1466] The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer.Oncol Rep. 2016 Jan;35(1):436-46. doi: 10.3892/or.2015.4373. Epub 2015 Nov 2.
• [1467] MiR-384 induces apoptosis and autophagy of non-small cell lung cancer cells through the negative regulation of Collagen -1(X) chain gene.Biosci Rep. 2019 Feb 1;39(2):BSR20181523. doi: 10.1042/BSR20181523. Print 2019 Feb 28.
• [1468] BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.J Am Acad Dermatol. 2020 Apr;82(4):854-861. doi: 10.1016/j.jaad.2019.08.045. Epub 2019 Aug 23.
• [1469] High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.Tumour Biol. 2013 Feb;34(1):415-20. doi: 10.1007/s13277-012-0565-2. Epub 2012 Oct 30.
• [1470] COMMD9 promotes TFDP1/E2F1 transcriptional activity via interaction with TFDP1 in non-small cell lung cancer.Cell Signal. 2017 Jan;30:59-66. doi: 10.1016/j.cellsig.2016.11.016. Epub 2016 Nov 19.
• [1471] Long noncoding RNA LINC00657 induced by SP1 contributes to the non-small cell lung cancer progression through targeting miR-26b-5p/COMMD8 axis.J Cell Physiol. 2020 Apr;235(4):3340-3349. doi: 10.1002/jcp.29222. Epub 2019 Sep 30.
• [1472] Meloxicam inhibits the growth of non-small cell lung cancer.Anticancer Res. 2000 Sep-Oct;20(5A):2867-72.
• [1473] COX7A1 suppresses the viability of human non-small cell lung cancer cells via regulating autophagy.Cancer Med. 2019 Dec;8(18):7762-7773. doi: 10.1002/cam4.2659. Epub 2019 Oct 30.
• [1474] Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer.Cancer Sci. 2014 Sep;105(9):1135-41. doi: 10.1111/cas.12472. Epub 2014 Sep 3.
• [1475] High expression of Copine1 promotes cell growth and metastasis in human lung adenocarcinoma.Int J Oncol. 2018 Dec;53(6):2369-2378. doi: 10.3892/ijo.2018.4558. Epub 2018 Sep 12.
• [1476] CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer.Oncol Lett. 2019 Sep;18(3):2835-2844. doi: 10.3892/ol.2019.10659. Epub 2019 Jul 24.
• [1477] Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer.J Korean Med Sci. 2018 May 16;33(26):e178. doi: 10.3346/jkms.2018.33.e178. eCollection 2018 Jun 25.
• [1478] Overexpression of HN1L promotes cell malignant proliferation in non-small cell lung cancer.Cancer Biol Ther. 2017 Nov 2;18(11):904-915. doi: 10.1080/15384047.2017.1385678. Epub 2017 Oct 20.
• [1479] Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.J Cancer. 2019 Jul 10;10(17):4151-4158. doi: 10.7150/jca.30507. eCollection 2019.
• [1480] MiR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1.Oncotarget. 2016 Mar 29;7(13):16703-15. doi: 10.18632/oncotarget.7697.
• [1481] Expression and potential mechanism of metabolism-related genes and CRLS1 in non-small cell lung cancer.Oncol Lett. 2018 Feb;15(2):2661-2668. doi: 10.3892/ol.2017.7591. Epub 2017 Dec 12.
• [1482] LNC CRYBG3 inhibits tumor growth by inducing M phase arrest.J Cancer. 2019 Jun 2;10(12):2764-2770. doi: 10.7150/jca.31703. eCollection 2019.
• [1483] Expression of Cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients.Sci Rep. 2015 Feb 4;5:8230. doi: 10.1038/srep08230.
• [1484] Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer.Cancer Res. 2011 Apr 1;71(7):2572-81. doi: 10.1158/0008-5472.CAN-10-2046. Epub 2011 Feb 16.
• [1485] Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer.J Transl Med. 2019 Aug 7;17(1):257. doi: 10.1186/s12967-019-1986-0.
• [1486] Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.Br J Pharmacol. 2019 Dec;176(24):4609-4624. doi: 10.1111/bph.14793. Epub 2019 Dec 26.
• [1487] Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer.Anticancer Res. 2015 Jun;35(6):3575-9.
• [1488] CtBP2 promotes proliferation and reduces drug sensitivity in non-small cell lung cancer via the Wnt/-catenin pathway.Neoplasma. 2018 Nov 15;65(6):888-897. doi: 10.4149/neo_2018_171220N828. Epub 2018 Sep 4.
• [1489] Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.Eur J Cardiothorac Surg. 2017 Jul 1;52(1):55-62. doi: 10.1093/ejcts/ezx049.
• [1490] Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer.Biosci Rep. 2019 Dec 20;39(12):BSR20193094. doi: 10.1042/BSR20193094.
• [1491] CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.BMC Cancer. 2018 Apr 10;18(1):400. doi: 10.1186/s12885-018-4317-6.
• [1492] LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.Mol Cells. 2019 Mar 31;42(3):270-283. doi: 10.14348/molcells.2019.2364. Epub 2019 Feb 19.
• [1493] Overexpression of small GTPases directly correlates with expression of -catenin and their coexpression predicts a poor clinical outcome in nonsmall cell lung cancer.Mol Carcinog. 2013 May;52(5):338-47. doi: 10.1002/mc.21854. Epub 2011 Dec 27.
• [1494] miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene.J Exp Clin Cancer Res. 2018 Jul 9;37(1):141. doi: 10.1186/s13046-018-0824-1.
• [1495] CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection.Medicine (Baltimore). 2018 Mar;97(10):e0101. doi: 10.1097/MD.0000000000010101.
• [1496] miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6.Onco Targets Ther. 2019 Jan 25;12:835-848. doi: 10.2147/OTT.S184235. eCollection 2019.
• [1497] Cytoglobin has bimodal: tumour suppressor and oncogene functions in lung cancer cell lines.Hum Mol Genet. 2013 Aug 15;22(16):3207-17. doi: 10.1093/hmg/ddt174. Epub 2013 Apr 15.
• [1498] The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations.Hum Genet. 2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25.
• [1499] Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer.Am J Med Sci. 2015 May;349(5):425-31. doi: 10.1097/MAJ.0000000000000436.
• [1500] Low Expression of ASK1-Interacting Protein-1 Is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early Stage Non-Small Cell Lung Cancer.Onco Targets Ther. 2019 Dec 10;12:10739-10747. doi: 10.2147/OTT.S222332. eCollection 2019.
• [1501] Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer.J Biol Chem. 2012 Nov 16;287(47):39967-81. doi: 10.1074/jbc.M112.397042. Epub 2012 Sep 18.
• [1502] Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).Folia Histochem Cytobiol. 2009;47(2):275-80. doi: 10.2478/v10042-009-0091-2.
• [1503] Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.Clin Cancer Res. 2011 May 1;17(9):2934-46. doi: 10.1158/1078-0432.CCR-10-1803. Epub 2011 Jan 17.
• [1504] Mutation and expression of the DCC gene in human lung cancer.Neoplasia. 2000 Jul-Aug;2(4):300-5. doi: 10.1038/sj.neo.7900094.
• [1505] Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)((6)-p-cymene) complex in human non-small cell lung cancer via p53-dependent pathway.J Inorg Biochem. 2019 May;194:52-64. doi: 10.1016/j.jinorgbio.2019.01.019. Epub 2019 Feb 23.
• [1506] Cytoplasmic p27(Kip1) promotes tumorigenesis via suppression of RhoB activity.J Pathol. 2019 Jan;247(1):60-71. doi: 10.1002/path.5167. Epub 2018 Dec 11.
• [1507] CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16868-73. doi: 10.1073/pnas.1306358110. Epub 2013 Sep 30.
• [1508] DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses.Tumour Biol. 2016 Oct;37(10):14183-14191. doi: 10.1007/s13277-016-5203-y. Epub 2016 Aug 23.
• [1509] Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas.J Biol Chem. 2012 Nov 2;287(45):37917-25. doi: 10.1074/jbc.M112.378299. Epub 2012 Sep 17.
• [1510] DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of -catenin.Cancer Lett. 2017 Aug 1;400:194-202. doi: 10.1016/j.canlet.2017.02.029. Epub 2017 Mar 1.
• [1511] DDX23-Linc00630-HDAC1 axis activates the Notch pathway to promote metastasis.Oncotarget. 2017 Jun 13;8(24):38937-38949. doi: 10.18632/oncotarget.17156.
• [1512] DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.Oncogene. 2014 Mar 20;33(12):1515-26. doi: 10.1038/onc.2013.107. Epub 2013 Apr 15.
• [1513] Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool.J Vis Exp. 2016 May 27;(111):53900. doi: 10.3791/53900.
• [1514] The DEAD-box RNA helicase 51 controls non-small cell lung cancer proliferation by regulating cell cycle progression via multiple pathways.Sci Rep. 2016 May 20;6:26108. doi: 10.1038/srep26108.
• [1515] Enediyne-activated, EGFR-targeted human -defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.Lab Invest. 2018 Dec;98(12):1538-1548. doi: 10.1038/s41374-018-0109-5. Epub 2018 Sep 11.
• [1516] Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D.Sci Rep. 2016 Jan 19;6:19346. doi: 10.1038/srep19346.
• [1517] Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.Cancer Biol Ther. 2018;19(11):1023-1032. doi: 10.1080/15384047.2018.1472193. Epub 2018 Oct 12.
• [1518] High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.Oncol Lett. 2017 Dec;14(6):6801-6808. doi: 10.3892/ol.2017.7027. Epub 2017 Sep 22.
• [1519] MiR-598 Suppresses Invasion and Migration by Negative Regulation of Derlin-1 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer.Cell Physiol Biochem. 2018;47(1):245-256. doi: 10.1159/000489803. Epub 2018 May 11.
• [1520] Long Non-coding RNA JHDM1D-AS1 Interacts with DHX15 Protein to Enhance Non-Small-Cell Lung Cancer Growth and Metastasis.Mol Ther Nucleic Acids. 2019 Dec 6;18:831-840. doi: 10.1016/j.omtn.2019.09.028. Epub 2019 Oct 10.
• [1521] Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI.Lab Invest. 2016 Sep;96(9):1004-15. doi: 10.1038/labinvest.2016.77. Epub 2016 Aug 8.
• [1522] RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.Am J Transl Res. 2017 Feb 15;9(2):674-682. eCollection 2017.
• [1523] Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.Cell Rep. 2018 Aug 14;24(7):1790-1801. doi: 10.1016/j.celrep.2018.07.043.
• [1524] DISC1 overexpression promotes non-small cell lung cancer cell proliferation.Oncotarget. 2017 May 22;8(39):65199-65210. doi: 10.18632/oncotarget.18055. eCollection 2017 Sep 12.
• [1525] The hedgehog processing pathway is required for NSCLC growth and survival.Oncogene. 2013 May 2;32(18):2335-45. doi: 10.1038/onc.2012.243. Epub 2012 Jun 25.
• [1526] DKK4-knockdown enhances chemosensitivity of A549/DTX cells to docetaxel.Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):899-906. doi: 10.1093/abbs/gmx086.
• [1527] DLC-1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGF-1 signaling.Exp Cell Res. 2020 Jan 15;386(2):111732. doi: 10.1016/j.yexcr.2019.111732. Epub 2019 Nov 23.
• [1528] Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.Med Oncol. 2016 Jul;33(7):75. doi: 10.1007/s12032-016-0791-3. Epub 2016 Jun 10.
• [1529] Prognostic and predictive value of HURP in nonsmall cell lung cancer.Oncol Rep. 2018 Apr;39(4):1682-1692. doi: 10.3892/or.2018.6280. Epub 2018 Feb 26.
• [1530] LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis.Onco Targets Ther. 2019 May 22;12:3945-3954. doi: 10.2147/OTT.S196865. eCollection 2019.
• [1531] Selective ATP hydrolysis inhibition in F1Fo ATP synthase enhances radiosensitivity in non-small-cell lung cancer cells (A549).Oncotarget. 2017 Jun 27;8(32):53602-53612. doi: 10.18632/oncotarget.18657. eCollection 2017 Aug 8.
• [1532] Tid1-S regulates the mitochondrial localization of EGFR in non-small cell lung carcinoma.Oncogenesis. 2017 Jul 17;6(7):e361. doi: 10.1038/oncsis.2017.62.
• [1533] Fatty acid synthesis pathway genetic variants and clinical outcome of non-small cell lung cancer patients after surgery.Asian Pac J Cancer Prev. 2014;15(17):7097-103. doi: 10.7314/apjcp.2014.15.17.7097.
• [1534] Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells.Int J Nanomedicine. 2017 Mar 31;12:2531-2551. doi: 10.2147/IJN.S129274. eCollection 2017.
• [1535] TdIF1: a putative oncogene in NSCLC tumor progression.Signal Transduct Target Ther. 2018 Oct 19;3:28. doi: 10.1038/s41392-018-0030-9. eCollection 2018.
• [1536] Inhibition of RAC1-GEF DOCK3 by miR-512-3p contributes to suppression of metastasis in non-small cell lung cancer.Int J Biochem Cell Biol. 2015 Apr;61:103-14. doi: 10.1016/j.biocel.2015.02.005. Epub 2015 Feb 14.
• [1537] DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53.J Exp Clin Cancer Res. 2019 Feb 12;38(1):72. doi: 10.1186/s13046-019-1068-4.
• [1538] High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer.Oncotarget. 2015 Sep 15;6(27):23399-416. doi: 10.18632/oncotarget.4351.
• [1539] A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.Ann Oncol. 2017 Feb 1;28(2):298-304. doi: 10.1093/annonc/mdw608.
• [1540] Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2.J Cancer Res Clin Oncol. 2017 Jan;143(1):59-69. doi: 10.1007/s00432-016-2250-0. Epub 2016 Sep 14.
• [1541] Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/-catenin signaling pathway in human lung cancer.Carcinogenesis. 2012 Oct;33(10):1863-70. doi: 10.1093/carcin/bgs226. Epub 2012 Jul 12.
• [1542] Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human nonsmall lung cancer cells by regulating the YAP pathway.Oncol Rep. 2018 Aug;40(2):609-620. doi: 10.3892/or.2018.6486. Epub 2018 Jun 12.
• [1543] Genetic Variant of Notch Regulator DTX1 Predicts Survival After Lung Cancer Surgery.Ann Surg Oncol. 2019 Oct;26(11):3756-3764. doi: 10.1245/s10434-019-07614-2. Epub 2019 Jul 16.
• [1544] TOB1-AS1 suppresses non-small cell lung cancer cell migration and invasion through a ceRNA network.Exp Ther Med. 2019 Dec;18(6):4249-4258. doi: 10.3892/etm.2019.8103. Epub 2019 Oct 15.
• [1545] Nimbolide suppresses non-small cell lung cancer cell invasion and migration via manipulation of DUSP4 expression and ERK1/2 signaling.Biomed Pharmacother. 2017 Aug;92:340-346. doi: 10.1016/j.biopha.2017.05.072. Epub 2017 May 26.
• [1546] Dishevelled-3 activates p65 to upregulate p120-catenin transcription via a p38-dependent pathway in non-small cell lung cancer.Mol Carcinog. 2015 Jun;54 Suppl 1:E112-21. doi: 10.1002/mc.22196. Epub 2014 Aug 22.
• [1547] DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.Mol Carcinog. 2008 May;47(5):326-37. doi: 10.1002/mc.20389.
• [1548] High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC.Mol Med Rep. 2019 Jun;19(6):4881-4889. doi: 10.3892/mmr.2019.10146. Epub 2019 Apr 10.
• [1549] Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer.Pulm Pharmacol Ther. 1999;12(5):291-302. doi: 10.1006/pupt.1999.0210.
• [1550] Hypoxia-sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR-30a-3p in non-small cell lung cancer.Mol Oncol. 2019 Apr;13(4):840-856. doi: 10.1002/1878-0261.12437. Epub 2019 Jan 30.
• [1551] microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.Br J Biomed Sci. 2019 Jan;76(1):17-23. doi: 10.1080/09674845.2018.1520066. Epub 2018 Oct 30.
• [1552] miR-223-5p Suppresses Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by Targeting E2F8.Oncol Res. 2019 Feb 5;27(2):261-268. doi: 10.3727/096504018X15219188894056. Epub 2018 Apr 3.
• [1553] The clinical and pathological significance of RCAS1 expression as a prognostic biomarker in non-small cell lung cancer.In Vivo. 2014 May-Jun;28(3):375-81.
• [1554] Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.Carcinogenesis. 2015 Dec;36(12):1453-63. doi: 10.1093/carcin/bgv146. Epub 2015 Oct 7.
• [1555] Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma.Sci Rep. 2017 Aug 17;7(1):8649. doi: 10.1038/s41598-017-08851-9.
• [1556] A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin.J Proteomics. 2019 Mar 20;195:114-124. doi: 10.1016/j.jprot.2019.01.009. Epub 2019 Jan 17.
• [1557] Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation.Int J Oncol. 2012 Feb;40(2):402-8. doi: 10.3892/ijo.2011.1191. Epub 2011 Sep 7.
• [1558] Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.Oncotarget. 2016 Sep 13;7(37):60332-60347. doi: 10.18632/oncotarget.11219.
• [1559] MicroRNA-20a promotes proliferation and invasion by directly targeting early growth response 2 in non-small cell lung carcinoma.Oncol Lett. 2018 Jan;15(1):271-277. doi: 10.3892/ol.2017.7299. Epub 2017 Oct 31.
• [1560] KSRP suppresses cell invasion and metastasis through miR-23a-mediated EGR3 mRNA degradation in non-small cell lung cancer.Biochim Biophys Acta Gene Regul Mech. 2017 Oct;1860(10):1013-1024. doi: 10.1016/j.bbagrm.2017.08.005. Epub 2017 Aug 25.
• [1561] A positive feedback loop between ZNF205-AS1 and EGR4 promotes non-small cell lung cancer growth.J Cell Mol Med. 2019 Feb;23(2):1495-1508. doi: 10.1111/jcmm.14056. Epub 2018 Dec 16.
• [1562] Targeting the IL-1/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.Oncogene. 2020 Feb;39(8):1739-1755. doi: 10.1038/s41388-019-1099-5. Epub 2019 Nov 18.
• [1563] Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.Biomed Pharmacother. 2019 Apr;112:108590. doi: 10.1016/j.biopha.2019.01.051. Epub 2019 Feb 19.
• [1564] eIF2, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.Cancer Sci. 2018 Jun;109(6):1843-1852. doi: 10.1111/cas.13602. Epub 2018 May 25.
• [1565] EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer.Cancer Biomark. 2018;23(2):291-300. doi: 10.3233/CBM-181628.
• [1566] Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.Oncotarget. 2018 Dec 25;9(101):37520-37533. doi: 10.18632/oncotarget.26494. eCollection 2018 Dec 25.
• [1567] Correction to: Expression of Concern: Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer.Med Oncol. 2019 May 3;36(6):53. doi: 10.1007/s12032-019-1276-y.
• [1568] Association between eIF3 polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients.Br J Clin Pharmacol. 2013 Feb;75(2):516-23. doi: 10.1111/j.1365-2125.2012.04379.x.
• [1569] Long Noncoding RNA FAL1 Promotes Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through the PTEN/AKT Signaling Axis in Non-Small Cell Lung Cancer.Cell Physiol Biochem. 2017;43(1):339-352. doi: 10.1159/000480414. Epub 2017 Aug 31.
• [1570] Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.Eur J Cancer. 2018 Sep;101:165-180. doi: 10.1016/j.ejca.2018.07.001. Epub 2018 Aug 1.
• [1571] Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.J Cell Biochem. 2020 Mar;121(3):2690-2703. doi: 10.1002/jcb.29489. Epub 2019 Nov 6.
• [1572] Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.Front Oncol. 2019 May 7;9:363. doi: 10.3389/fonc.2019.00363. eCollection 2019.
• [1573] Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.Exp Mol Pathol. 2013 Dec;95(3):313-8. doi: 10.1016/j.yexmp.2013.07.001. Epub 2013 Aug 3.
• [1574] Expression of engrailed homeobox 2 regulates the proliferation, migration and invasion of non-small cell lung cancer cells.Oncol Lett. 2018 Jul;16(1):536-542. doi: 10.3892/ol.2018.8693. Epub 2018 May 10.
• [1575] Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.Oncotarget. 2017 May 30;8(22):36664-36673. doi: 10.18632/oncotarget.17067.
• [1576] Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province, Central China.J Clin Lab Anal. 2020 Jan;34(1):e23027. doi: 10.1002/jcla.23027. Epub 2019 Sep 6.
• [1577] Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.Cancer Immunol Res. 2019 Jun;7(6):896-909. doi: 10.1158/2326-6066.CIR-18-0713. Epub 2019 May 3.
• [1578] C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer.Theranostics. 2019 Jul 9;9(18):5134-5148. doi: 10.7150/thno.34887. eCollection 2019.
• [1579] Overexpression of Epsin3 enhances migration and invasion of glioma cells by inducing epithelialmesenchymal transition.Oncol Rep. 2018 Nov;40(5):3049-3059. doi: 10.3892/or.2018.6691. Epub 2018 Sep 10.
• [1580] FoxO3a inhibiting expression of EPS8 to prevent progression of NSCLC: A new negative loop of EGFR signaling.EBioMedicine. 2019 Feb;40:198-209. doi: 10.1016/j.ebiom.2019.01.053. Epub 2019 Feb 7.
• [1581] An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.Int J Cancer. 2018 Mar 15;142(6):1218-1229. doi: 10.1002/ijc.31153. Epub 2017 Nov 24.
• [1582] XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.Cancer Chemother Pharmacol. 2017 Apr;79(4):791-800. doi: 10.1007/s00280-017-3280-2. Epub 2017 Mar 17.
• [1583] Endoplasmic reticulum-Golgi intermediate compartment protein 3 knockdown suppresses lung cancer through endoplasmic reticulum stress-induced autophagy.Oncotarget. 2016 Oct 4;7(40):65335-65347. doi: 10.18632/oncotarget.11678.
• [1584] Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1- is a poor prognostic marker for non-small cell lung cancer.Oncol Lett. 2018 Nov;16(5):5753-5760. doi: 10.3892/ol.2018.9339. Epub 2018 Aug 21.
• [1585] Reference genes for gene expression studies on non-small cell lung cancer.Acta Biochim Pol. 2009;56(2):307-16. Epub 2009 Jun 18.
• [1586] Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.Oncotarget. 2017 Jul 25;8(30):49217-49223. doi: 10.18632/oncotarget.17455.
• [1587] Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.Cancer Res. 2018 Apr 15;78(8):1986-1999. doi: 10.1158/0008-5472.CAN-17-0315. Epub 2018 Feb 5.
• [1588] The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.Cancer Res. 2012 Aug 1;72(15):3764-74. doi: 10.1158/0008-5472.CAN-11-3990. Epub 2012 Jun 1.
• [1589] Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103.
• [1590] ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptionally.Mol Carcinog. 2020 Jan;59(1):73-86. doi: 10.1002/mc.23130. Epub 2019 Oct 31.
• [1591] Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.Carcinogenesis. 2017 Apr 1;38(4):419-424. doi: 10.1093/carcin/bgx014.
• [1592] EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.Oncogene. 2014 Sep 4;33(36):4464-73. doi: 10.1038/onc.2013.396. Epub 2013 Oct 7.
• [1593] SPOP promotes FADD degradation and inhibits NF-B activity in non-small cell lung cancer.Biochem Biophys Res Commun. 2018 Sep 26;504(1):289-294. doi: 10.1016/j.bbrc.2018.08.176. Epub 2018 Sep 4.
• [1594] miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer.Cell Prolif. 2018 Feb;51(1):e12406. doi: 10.1111/cpr.12406. Epub 2017 Nov 12.
• [1595] Decreased FAM107A Expression in Patients with Non-small Cell Lung Cancer.Adv Exp Med Biol. 2015;852:39-48. doi: 10.1007/5584_2014_109.
• [1596] FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival.Oncoimmunology. 2016 Dec 14;6(1):e1256526. doi: 10.1080/2162402X.2016.1256526. eCollection 2017.
• [1597] MiR-940 inhibits the progression of NSCLC by targeting FAM83F.Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5964-5971. doi: 10.26355/eurrev_201809_15927.
• [1598] FAM98A promotes proliferation of non-small cell lung cancer cells via the P38-ATF2 signaling pathway.Cancer Manag Res. 2018 Jul 27;10:2269-2278. doi: 10.2147/CMAR.S163323. eCollection 2018.
• [1599] ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2.
• [1600] TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.Exp Lung Res. 2012 Nov;38(9-10):463-74. doi: 10.3109/01902148.2012.731625.
• [1601] IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5.Open Biol. 2018 Oct 10;8(10):180086. doi: 10.1098/rsob.180086.
• [1602] Establishment and characterization of primary lung cancer cell lines from Chinese population.Acta Pharmacol Sin. 2011 Mar;32(3):385-92. doi: 10.1038/aps.2010.214.
• [1603] LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4800-4806. doi: 10.26355/eurrev_201906_18065.
• [1604] FBXL3 is regulated by miRNA-4735-3p and suppresses cell proliferation and migration in non-small cell lung cancer.Pathol Res Pract. 2019 Feb;215(2):358-365. doi: 10.1016/j.prp.2018.12.008. Epub 2018 Dec 11.
• [1605] FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells.Respir Res. 2018 Oct 25;19(1):206. doi: 10.1186/s12931-018-0910-0.
• [1606] The novel ubiquitin ligase complex, SCF(Fbxw4), interacts with the COP9 signalosome in an F-box dependent manner, is mutated, lost and under-expressed in human cancers.PLoS One. 2013 May 2;8(5):e63610. doi: 10.1371/journal.pone.0063610. Print 2013.
• [1607] Role for ERK1/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis.Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9570-E9579. doi: 10.1073/pnas.1810209115. Epub 2018 Sep 24.
• [1608] Snapback primer mediated clamping PCR for detection of EGFR and KRAS mutations in NSCLC patients by high resolution melting analysis.Biomed Res Int. 2014;2014:407537. doi: 10.1155/2014/407537. Epub 2014 May 4.
• [1609] Upregulation of LncRNA FEZF-AS1 is associated with advanced clinical stages and family history of cancer in patients with NSCLC.Pathol Res Pract. 2018 Jun;214(6):857-861. doi: 10.1016/j.prp.2018.04.014. Epub 2018 Apr 24.
• [1610] S6K2 promises an important therapeutic potential for cancer.Future Oncol. 2019 Jan;15(1):95-102. doi: 10.2217/fon-2018-0332. Epub 2018 Nov 1.
• [1611] Downregulation of fibroblast growth factor 5 inhibits cell growth and invasion of human nonsmall-cell lung cancer cells.J Cell Biochem. 2019 May;120(5):8238-8246. doi: 10.1002/jcb.28107. Epub 2018 Dec 5.
• [1612] miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2).J Exp Clin Cancer Res. 2018 Sep 18;37(1):230. doi: 10.1186/s13046-018-0882-4.
• [1613] FKBP3 Promotes Proliferation of Non-Small Cell Lung Cancer Cells through Regulating Sp1/HDAC2/p27.Theranostics. 2017 Jul 22;7(12):3078-3089. doi: 10.7150/thno.18067. eCollection 2017.
• [1614] 4.1N is involved in a flotillin-1/-catenin/Wnt pathway and suppresses cell proliferation and migration in non-small cell lung cancer cell lines.Tumour Biol. 2016 Sep;37(9):12713-12723. doi: 10.1007/s13277-016-5146-3. Epub 2016 Jul 22.
• [1615] Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.Int J Clin Exp Pathol. 2015 Jan 1;8(1):601-7. eCollection 2015.
• [1616] Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605.
• [1617] Expression of Irisin/FNDC5 in Cancer Cells and Stromal Fibroblasts of Non-small Cell Lung Cancer.Cancers (Basel). 2019 Oct 11;11(10):1538. doi: 10.3390/cancers11101538.
• [1618] FOSBPCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer.Cancers (Basel). 2019 Jan 17;11(1):107. doi: 10.3390/cancers11010107.
• [1619] Transcription factor FOXA2-centered transcriptional regulation network in non-small cell lung cancer.Biochem Biophys Res Commun. 2015 Aug 7;463(4):961-7. doi: 10.1016/j.bbrc.2015.06.042. Epub 2015 Jun 18.
• [1620] FOXD1 Promotes Cell Growth and Metastasis by Activation of Vimentin in NSCLC.Cell Physiol Biochem. 2018;51(6):2716-2731. doi: 10.1159/000495962. Epub 2018 Dec 12.
• [1621] lncRNA FOXD2-AS1 confers cisplatin resistance of non-small-cell lung cancer via regulation of miR185-5p-SIX1 axis.Onco Targets Ther. 2019 Jul 30;12:6105-6117. doi: 10.2147/OTT.S197454. eCollection 2019.
• [1622] Serum Fork-Head Box D3 (FOXD3) Expression Is Down-Regulated in and Associated with Diagnosis of Patients with Non-Small Cell Lung Cancer.Med Sci Monit. 2018 Dec 31;24:9504-9508. doi: 10.12659/MSM.896748.
• [1623] Profiling analysis of FOX gene family members identified FOXE1 as potential regulator of NSCLC development.Cell Mol Biol (Noisy-le-grand). 2016 Sep 30;62(11):57-62.
• [1624] Polymorphisms in Epithelial-Mesenchymal Transition-Related Genes and the Prognosis of Surgically Treated Non-small Cell Lung Cancer.Ann Surg Oncol. 2017 Oct;24(11):3386-3395. doi: 10.1245/s10434-017-6002-4. Epub 2017 Aug 1.
• [1625] MiR-378 promotes the cell proliferation of non-small cell lung cancer by inhibiting FOXG1.Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):1011-1019. doi: 10.26355/eurrev_201802_14383.
• [1626] Overexpression of miR-425-5p is associated with poor prognosis and tumor progression in non-small cell lung cancer.Cancer Biomark. 2020;27(2):147-156. doi: 10.3233/CBM-190782.
• [1627] Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes.Oncol Rep. 2017 Apr;37(4):2335-2347. doi: 10.3892/or.2017.5461. Epub 2017 Feb 16.
• [1628] Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor.Oncol Lett. 2018 May;15(5):7221-7230. doi: 10.3892/ol.2018.8210. Epub 2018 Mar 8.
• [1629] MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4.Sci Rep. 2016 Dec 15;6:39001. doi: 10.1038/srep39001.
• [1630] Upregulated microRNA?71?p promotes tumor progression by suppressing forkhead box P2 expression in nonsmallcell lung cancer.Mol Med Rep. 2019 Oct;20(4):3149-3159. doi: 10.3892/mmr.2019.10563. Epub 2019 Aug 6.
• [1631] FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.Tumour Biol. 2015 Sep;36(10):8185-91. doi: 10.1007/s13277-015-3498-8. Epub 2015 May 21.
• [1632] FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.Int J Cancer. 2020 Jan 1;146(1):208-222. doi: 10.1002/ijc.32530. Epub 2019 Jul 26.
• [1633] Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population.Medicine (Baltimore). 2019 Aug;98(31):e16511. doi: 10.1097/MD.0000000000016511.
• [1634] FRS2beta, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding.Oncogene. 2010 May 27;29(21):3087-99. doi: 10.1038/onc.2010.69. Epub 2010 Mar 15.
• [1635] Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.Epigenetics. 2018;13(3):214-227. doi: 10.1080/15592294.2016.1229730. Epub 2018 Apr 18.
• [1636] Long noncoding RNA RMRP promotes proliferation and invasion via targeting miR-1-3p in non-small-cell lung cancer.J Cell Biochem. 2019 Sep;120(9):15170-15181. doi: 10.1002/jcb.28779. Epub 2019 May 3.
• [1637] Elevated fibrous sheath interacting protein 1 levels are associated with poor prognosis in non-small cell lung cancer patients.Oncotarget. 2017 Feb 14;8(7):12186-12193. doi: 10.18632/oncotarget.14575.
• [1638] In vitro study of FUZ as a novel potential therapeutic target in non-small-cell lung cancer.Life Sci. 2018 Mar 15;197:91-100. doi: 10.1016/j.lfs.2018.02.007. Epub 2018 Feb 6.
• [1639] miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.Biomed Pharmacother. 2016 Dec;84:123-129. doi: 10.1016/j.biopha.2016.09.027. Epub 2016 Sep 16.
• [1640] miRNA-99b-5p targets FZD8 to inhibit non-small cell lung cancer proliferation, migration and invasion.Onco Targets Ther. 2019 Apr 8;12:2615-2621. doi: 10.2147/OTT.S199196. eCollection 2019.
• [1641] Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells.Oncotarget. 2015 Sep 29;6(29):28282-95. doi: 10.18632/oncotarget.5061.
• [1642] MicroRNA-590-5p suppresses the proliferation and invasion of non-small cell lung cancer by regulating GAB1.Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5954-5963. doi: 10.26355/eurrev_201809_15926.
• [1643] miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer.Oncol Lett. 2018 Sep;16(3):3525-3530. doi: 10.3892/ol.2018.9053. Epub 2018 Jun 29.
• [1644] Genetic variants of JNK and p38 pathways and risk of non-small cell lung cancer in an Eastern Chinese population.Int J Cancer. 2017 Feb 15;140(4):807-817. doi: 10.1002/ijc.30508. Epub 2016 Nov 16.
• [1645] Upregulated circular RNA circ_0016760 indicates unfavorable prognosis in NSCLC and promotes cell progression through miR-1287/GAGE1 axis.Biochem Biophys Res Commun. 2018 Sep 10;503(3):2089-2094. doi: 10.1016/j.bbrc.2018.07.164. Epub 2018 Aug 6.
• [1646] GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.Oncotarget. 2015 Dec 8;6(39):41916-28. doi: 10.18632/oncotarget.6019.
• [1647] PIASy antagonizes Ras-driven NSCLC survival by promoting GATA2 SUMOylation.J Cancer. 2018 Apr 18;9(9):1689-1697. doi: 10.7150/jca.24137. eCollection 2018.
• [1648] Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.
• [1649] Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.Cell Physiol Biochem. 2018;50(3):987-1004. doi: 10.1159/000494482. Epub 2018 Oct 24.
• [1650] The TGF-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling.Cancer Lett. 2018 Sep 28;432:156-168. doi: 10.1016/j.canlet.2018.06.013. Epub 2018 Jun 15.
• [1651] Transferrin-decorated thymoquinone-loaded PEG-PLGA nanoparticles exhibit anticarcinogenic effect in non-small cell lung carcinoma via the modulation of miR-34a and miR-16.Biomater Sci. 2019 Oct 1;7(10):4325-4344. doi: 10.1039/c9bm00912d. Epub 2019 Aug 14.
• [1652] Interaction between the bone morphogenetic proteins and Ras/MAP-kinase signalling pathways in lung cancer.Br J Cancer. 2005 Oct 17;93(8):949-52. doi: 10.1038/sj.bjc.6602790.
• [1653] Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer.Diagn Pathol. 2014 Nov 4;9:201. doi: 10.1186/s13000-014-0201-0.
• [1654] Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.Cancer Lett. 2010 Oct 28;296(2):216-24. doi: 10.1016/j.canlet.2010.04.008. Epub 2010 May 7.
• [1655] GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.Peptides. 2012 Sep;37(1):63-8. doi: 10.1016/j.peptides.2012.07.010. Epub 2012 Jul 20.
• [1656] GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.J Cell Physiol. 2020 Nov;235(11):7747-7756. doi: 10.1002/jcp.29381. Epub 2019 Nov 4.
• [1657] Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.J Exp Clin Cancer Res. 2019 Feb 21;38(1):96. doi: 10.1186/s13046-019-1057-7.
• [1658] p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity.Eur J Cancer. 2000 Mar;36(4):489-95. doi: 10.1016/s0959-8049(99)00261-0.
• [1659] Prediction of NSCLC recurrence from microarray data with GEP.IET Syst Biol. 2017 Jun;11(3):77-85. doi: 10.1049/iet-syb.2016.0033.
• [1660] Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer.Cancer Lett. 2013 Dec 1;341(2):265-73. doi: 10.1016/j.canlet.2013.08.020. Epub 2013 Aug 17.
• [1661] Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25.
• [1662] Downregulation of microRNA-196a inhibits stem cell self-renewal ability and stemness in non-small-cell lung cancer through upregulating GPX3 expression.Int J Biochem Cell Biol. 2019 Oct;115:105571. doi: 10.1016/j.biocel.2019.105571. Epub 2019 Jul 25.
• [1663] Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis.Oncol Lett. 2019 Mar;17(3):3001-3008. doi: 10.3892/ol.2019.9888. Epub 2019 Jan 4.
• [1664] Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report.Oncol Lett. 2018 Oct;16(4):4219-4222. doi: 10.3892/ol.2018.9158. Epub 2018 Jul 17.
• [1665] Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in nonsmall cell lung cancer.Oncol Rep. 2018 Oct;40(4):1971-1984. doi: 10.3892/or.2018.6634. Epub 2018 Aug 7.
• [1666] Genetic polymorphisms of glutathione S-transferase M1 and T1, and evaluation of oxidative stress in patients with non-small cell lung cancer.Eur J Med Res. 2014 Dec 4;19(1):67. doi: 10.1186/s40001-014-0067-3.
• [1667] Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.J Immunol. 2013 Aug 15;191(4):2009-17. doi: 10.4049/jimmunol.1301317. Epub 2013 Jul 12.
• [1668] Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010 Nov;24(5):1297-305. doi: 10.3892/or_00000986.
• [1669] Recognition of histone acetylation by the GAS41 YEATS domain promotes H2A.Z deposition in non-small cell lung cancer.Genes Dev. 2018 Jan 1;32(1):58-69. doi: 10.1101/gad.303784.117. Epub 2018 Feb 1.
• [1670] G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells.Cell Death Dis. 2017 Apr 6;8(4):e2726. doi: 10.1038/cddis.2017.65.
• [1671] Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.Oncotarget. 2017 Apr 18;8(16):26927-26940. doi: 10.18632/oncotarget.15879.
• [1672] TIM-3 expression and its association with overall survival in primary osteosarcoma.Oncol Lett. 2019 Nov;18(5):5294-5300. doi: 10.3892/ol.2019.10855. Epub 2019 Sep 12.
• [1673] A novel pathway in NSCLC cells: miR?91, targeting NFIA, is induced by chronic hypoxia, and promotes cell proliferation and migration.Mol Med Rep. 2017 Mar;15(3):1319-1325. doi: 10.3892/mmr.2017.6100. Epub 2017 Jan 4.
• [1674] Long noncoding RNA actin filament-associated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer.Cancer Sci. 2019 Jul;110(7):2211-2225. doi: 10.1111/cas.14039. Epub 2019 May 29.
• [1675] HEATR1 modulates cell survival in non-small cell lung cancer via activation of the p53/PUMA signaling pathway.Onco Targets Ther. 2019 May 21;12:4001-4011. doi: 10.2147/OTT.S195826. eCollection 2019.
• [1676] Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients.Ann Oncol. 2010 Aug;21(8):1675-1681. doi: 10.1093/annonc/mdp592. Epub 2010 Jan 11.
• [1677] HEPACAM inhibited the growth and migration of cancer cells in the progression of non-small cell lung cancer.Tumour Biol. 2016 Feb;37(2):2621-7. doi: 10.1007/s13277-015-4084-9. Epub 2015 Sep 22.
• [1678] Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.BMC Cancer. 2016 May 14;16:312. doi: 10.1186/s12885-016-2339-5.
• [1679] HERC4 exerts an anti-tumor role through destabilizing the oncoprotein Smo.Biochem Biophys Res Commun. 2019 Jun 11;513(4):1013-1018. doi: 10.1016/j.bbrc.2019.04.113. Epub 2019 Apr 19.
• [1680] Identification of HERC5 and its potential role in NSCLC progression.Int J Cancer. 2015 May 15;136(10):2264-72. doi: 10.1002/ijc.29298. Epub 2014 Nov 9.
• [1681] Hes3 Enhances the Malignant Phenotype of Lung Cancer through Upregulating Cyclin D1, Cyclin D3 and MMP7 Expression.Int J Med Sci. 2019 Mar 9;16(3):470-476. doi: 10.7150/ijms.28139. eCollection 2019.
• [1682] HES5 promotes cellular proliferation of non-small cell lung cancer through STAT3 signaling.Oncol Rep. 2017 Jan;37(1):474-482. doi: 10.3892/or.2016.5268. Epub 2016 Nov 22.
• [1683] LncRNA PRNCR1 interacts with HEY2 to abolish miR-448-mediated growth inhibition in non-small cell lung cancer.Biomed Pharmacother. 2018 Nov;107:1540-1547. doi: 10.1016/j.biopha.2018.08.105. Epub 2018 Sep 5.
• [1684] HHIP overexpression inhibits the proliferation, migration and invasion of non-small cell lung cancer.PLoS One. 2019 Nov 25;14(11):e0225755. doi: 10.1371/journal.pone.0225755. eCollection 2019.
• [1685] Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.Oncotarget. 2016 May 24;7(21):30350-64. doi: 10.18632/oncotarget.8734.
• [1686] MicroRNA-300 targets hypoxia inducible factor-3 alpha to inhibit tumorigenesis of human non-small cell lung cancer.Neoplasma. 2017;64(4):554-562. doi: 10.4149/neo_2017_409.
• [1687] WITHDRAWN: Upregulation of HINT2 Inhibits Non-Small Cell Lung Cancer Cell Invasion Via COX-2/PGE?Mediated Activation of -catenin Signaling.Oncol Res. 2017 Aug 11. doi: 10.3727/096504017X15021536183508. Online ahead of print.
• [1688] Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions.Hum Immunol. 2018 Jul;79(7):558-563. doi: 10.1016/j.humimm.2018.04.003. Epub 2018 Apr 12.
• [1689] Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.Korean J Intern Med. 2019 Jan;34(1):50-59. doi: 10.3904/kjim.2018.179. Epub 2018 Sep 3.
• [1690] Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.
• [1691] Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.Mol Cell Biochem. 2015 Apr;402(1-2):75-82. doi: 10.1007/s11010-014-2315-9. Epub 2015 Jan 8.
• [1692] Suppression of nucleosome-binding protein 1 by miR-326 impedes cell proliferation and invasion in non-small cell lung cancer cells.Oncol Rep. 2016 Feb;35(2):1117-24. doi: 10.3892/or.2015.4403. Epub 2015 Nov 6.
• [1693] Living or dying by RNA processing: caspase expression in NSCLC.J Clin Invest. 2010 Nov;120(11):3798-801. doi: 10.1172/JCI45037. Epub 2010 Oct 25.
• [1694] A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.BMC Genomics. 2013;14 Suppl 6(Suppl 6):S5. doi: 10.1186/1471-2164-14-S6-S5. Epub 2013 Oct 25.
• [1695] Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-1-mediated epithelial to mesenchymal transition in lung cancer cells.BMC Cancer. 2019 Sep 6;19(1):894. doi: 10.1186/s12885-019-6119-x.
• [1696] The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.Onco Targets Ther. 2019 Jul 22;12:5897-5906. doi: 10.2147/OTT.S210223. eCollection 2019.
• [1697] HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress.Cancer Res. 2018 Nov 1;78(21):6196-6208. doi: 10.1158/0008-5472.CAN-18-1377. Epub 2018 Sep 5.
• [1698] Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients.Cancer Epidemiol. 2014 Aug;38(4):414-8. doi: 10.1016/j.canep.2014.03.013. Epub 2014 May 3.
• [1699] Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data.Am J Transl Res. 2019 Jan 15;11(1):45-66. eCollection 2019.
• [1700] Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.Int J Oncol. 2018 Oct;53(4):1557-1579. doi: 10.3892/ijo.2018.4508. Epub 2018 Jul 30.
• [1701] HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.Mol Genet Genomics. 2019 Feb;294(1):85-93. doi: 10.1007/s00438-018-1489-3. Epub 2018 Sep 8.
• [1702] Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion.Cell Oncol (Dordr). 2019 Jun;42(3):275-285. doi: 10.1007/s13402-019-00424-4. Epub 2019 Jan 29.
• [1703] MicroRNA-1197 downregulation inhibits proliferation and migration in human non- small cell lung cancer cells by upregulating HOXC11.Biomed Pharmacother. 2019 Sep;117:109041. doi: 10.1016/j.biopha.2019.109041. Epub 2019 Jun 7.
• [1704] Evidence for an oncogenic role of HOXC6 in human non-small cell lung cancer.PeerJ. 2019 Apr 9;7:e6629. doi: 10.7717/peerj.6629. eCollection 2019.
• [1705] Homeobox C8 is a transcriptional repressor of E-cadherin gene expression in non-small cell lung cancer.Int J Biochem Cell Biol. 2019 Sep;114:105557. doi: 10.1016/j.biocel.2019.06.005. Epub 2019 Jun 13.
• [1706] miR-224 enhances invasion and metastasis by targeting HOXD10 in non-small cell lung cancer cells.Oncol Lett. 2018 May;15(5):7069-7075. doi: 10.3892/ol.2018.8245. Epub 2018 Mar 12.
• [1707] Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.Lung Cancer. 2016 Oct;100:77-84. doi: 10.1016/j.lungcan.2016.08.001. Epub 2016 Aug 6.
• [1708] microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.Oncol Rep. 2016 Dec;36(6):3529-3535. doi: 10.3892/or.2016.5149. Epub 2016 Oct 5.
• [1709] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.
• [1710] Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.PLoS One. 2013 Nov 12;8(11):e79634. doi: 10.1371/journal.pone.0079634. eCollection 2013.
• [1711] Heparan sulfate D-glucosamine 3-O-sulfotransferase 3B1 is a novel regulator of transforming growth factor-beta-mediated epithelial-to-mesenchymal transition and regulated by miR-218 in nonsmall cell lung cancer.J Cancer Res Ther. 2018 Jan;14(1):24-29. doi: 10.4103/jcrt.JCRT_659_17.
• [1712] Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma.Medicine (Baltimore). 2017 Feb;96(6):e5903. doi: 10.1097/MD.0000000000005903.
• [1713] Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment.Sci Rep. 2019 Oct 7;9(1):14394. doi: 10.1038/s41598-019-50840-7.
• [1714] Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer.Front Immunol. 2019 Mar 22;10:454. doi: 10.3389/fimmu.2019.00454. eCollection 2019.
• [1715] The expression levels and prognostic value of high temperature required A2 (HtrA2) in NSCLC.Pathol Res Pract. 2014 Dec;210(12):939-43. doi: 10.1016/j.prp.2014.06.030. Epub 2014 Jul 9.
• [1716] Antagonism between HTRA3 and TGF1 Contributes to Metastasis in Non-Small Cell Lung Cancer.Cancer Res. 2019 Jun 1;79(11):2853-2864. doi: 10.1158/0008-5472.CAN-18-2507. Epub 2019 Apr 2.
• [1717] HUWE1 controls the development of non-small cell lung cancer through down-regulation of p53.Theranostics. 2018 Jun 6;8(13):3517-3529. doi: 10.7150/thno.24401. eCollection 2018.
• [1718] Development and Evaluation of (18)F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC.Sci Rep. 2017 Jun 9;7(1):3121. doi: 10.1038/s41598-017-01443-7.
• [1719] IARS2 silencing induces non-small cell lung cancer cells proliferation inhibition, cell cycle arrest and promotes cell apoptosis.Neoplasma. 2016;63(1):64-71. doi: 10.4149/neo_2016_008.
• [1720] Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44.Mol Ther Nucleic Acids. 2020 Mar 6;19:218-227. doi: 10.1016/j.omtn.2019.10.039. Epub 2019 Nov 14.
• [1721] Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients.Onco Targets Ther. 2019 Oct 3;12:8139-8149. doi: 10.2147/OTT.S220698. eCollection 2019.
• [1722] Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer.Int J Cancer. 2019 Apr 15;144(8):2020-2032. doi: 10.1002/ijc.31926. Epub 2018 Dec 8.
• [1723] Interferon- and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNF-independent manner.Cancer Cell Int. 2018 Jun 14;18:84. doi: 10.1186/s12935-018-0579-y. eCollection 2018.
• [1724] Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer.Tumour Biol. 2017 Apr;39(4):1010428317695928. doi: 10.1177/1010428317695928.
• [1725] MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2.Life Sci. 2018 Apr 15;199:104-111. doi: 10.1016/j.lfs.2018.03.005. Epub 2018 Mar 3.
• [1726] Prognostic value of insulin-like growth factor 2 mRNA-binding protein 3 and vascular endothelial growth factor-A in patients with primary non-small-cell lung cancer.Oncol Lett. 2019 Nov;18(5):4744-4752. doi: 10.3892/ol.2019.10835. Epub 2019 Sep 10.
• [1727] Reduced interleukin-38 in non-small cell lung cancer is associated with tumour progression.Open Biol. 2018 Oct 31;8(10):180132. doi: 10.1098/rsob.180132.
• [1728] ILF2 promotes anchorage independence through direct regulation of PTEN.Oncol Lett. 2019 Aug;18(2):1689-1696. doi: 10.3892/ol.2019.10510. Epub 2019 Jun 21.
• [1729] C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn.Tumour Biol. 2015 Aug;36(8):5979-85. doi: 10.1007/s13277-015-3274-9. Epub 2015 Mar 4.
• [1730] INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer.Oncogene. 2017 Mar;36(10):1430-1439. doi: 10.1038/onc.2016.311. Epub 2016 Sep 19.
• [1731] Genome-wide analysis of lncRNAs in 3'-untranslated regions: CR933609 acts as a decoy to protect the INO80D gene.Int J Oncol. 2018 Jul;53(1):417-433. doi: 10.3892/ijo.2018.4398. Epub 2018 May 8.
• [1732] lncINS-IGF2 Promotes Cell Proliferation and Migration by Promoting G1/S Transition in Lung Cancer.Technol Cancer Res Treat. 2019 Jan 1;18:1533033818823029. doi: 10.1177/1533033818823029.
• [1733] Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.J Natl Cancer Inst. 2019 Jul 1;111(7):664-674. doi: 10.1093/jnci/djy166.
• [1734] Identification of stable housekeeping genes in response to ionizing radiation in cancer research.Sci Rep. 2017 Mar 6;7:43763. doi: 10.1038/srep43763.
• [1735] MAP4K3/GLK Promotes Lung Cancer Metastasis by Phosphorylating and Activating IQGAP1.Cancer Res. 2019 Oct 1;79(19):4978-4993. doi: 10.1158/0008-5472.CAN-19-1402. Epub 2019 Aug 20.
• [1736] Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer.Int J Cancer. 2018 Nov 15;143(10):2400-2408. doi: 10.1002/ijc.31660. Epub 2018 Sep 21.
• [1737] IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.Eur Respir J. 2017 Apr 12;49(4):1600711. doi: 10.1183/13993003.00711-2016. Print 2017 Apr.
• [1738] CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer.J Formos Med Assoc. 2017 Feb;116(2):114-122. doi: 10.1016/j.jfma.2016.01.009. Epub 2016 Apr 22.
• [1739] A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.Lung Cancer. 2019 Sep;135:47-55. doi: 10.1016/j.lungcan.2019.07.008. Epub 2019 Jul 9.
• [1740] Genome-wide identification of transcription factors that are critical to non-small cell lung cancer.Cancer Lett. 2018 Oct 10;434:132-143. doi: 10.1016/j.canlet.2018.07.020. Epub 2018 Jul 18.
• [1741] Development and Validation of Tumor-educated Blood Platelets Integrin Alpha 2b (ITGA2B) RNA for Diagnosis and Prognosis of Non-small-cell Lung Cancer through RNA-seq.Int J Biol Sci. 2019 Jul 24;15(9):1977-1992. doi: 10.7150/ijbs.36284. eCollection 2019.
• [1742] Correlation of integrin alpha 7 with clinicopathological characteristics and survival profiles, as well as its regulatory role in cell proliferation, apoptosis, and stemness in non-small-cell lung cancer.J Clin Lab Anal. 2019 Oct;33(8):e22973. doi: 10.1002/jcla.22973. Epub 2019 Aug 16.
• [1743] Epigenetic downregulated ITGBL1 promotes non-small cell lung cancer cell invasion through Wnt/PCP signaling.Tumour Biol. 2016 Feb;37(2):1663-9. doi: 10.1007/s13277-015-3919-8. Epub 2015 Aug 26.
• [1744] Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.Epigenetics. 2015;10(10):903-12. doi: 10.1080/15592294.2015.1078049. Epub 2015 Aug 7.
• [1745] MicroRNA-374b inhibits the tumor growth and promotes apoptosis in non-small cell lung cancer tissue through the p38/ERK signaling pathway by targeting JAM-2.J Thorac Dis. 2018 Sep;10(9):5489-5498. doi: 10.21037/jtd.2018.09.93.
• [1746] MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/-catenin pathway in non-small cell lung cancer.Life Sci. 2017 Nov 1;188:163-171. doi: 10.1016/j.lfs.2017.09.002. Epub 2017 Sep 4.
• [1747] Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma.Oncotarget. 2017 May 22;8(39):65186-65198. doi: 10.18632/oncotarget.18053. eCollection 2017 Sep 12.
• [1748] Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer.Am J Cancer Res. 2019 Aug 1;9(8):1830-1845. eCollection 2019.
• [1749] Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA2alpha in phorbol ester-treated non-small cell lung cancer A549 cells.Nucleic Acids Res. 2008 Jan;36(1):217-27. doi: 10.1093/nar/gkm1027. Epub 2007 Nov 19.
• [1750] The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer.Br J Pharmacol. 2014 Jul;171(13):3196-211. doi: 10.1111/bph.12661.
• [1751] Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.Oncotarget. 2015 Feb 10;6(4):2164-79. doi: 10.18632/oncotarget.2941.
• [1752] Kctd20 promotes the development of non-small cell lung cancer through activating Fak/AKT pathway and predicts poor overall survival of patients.Mol Carcinog. 2017 Sep;56(9):2058-2065. doi: 10.1002/mc.22660. Epub 2017 May 2.
• [1753] RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer.J Exp Clin Cancer Res. 2019 Nov 27;38(1):478. doi: 10.1186/s13046-019-1479-2.
• [1754] Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget. 2016 Jun 14;7(24):36101-36114. doi: 10.18632/oncotarget.9137.
• [1755] Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.Yonsei Med J. 2018 Jan;59(1):13-19. doi: 10.3349/ymj.2018.59.1.13.
• [1756] KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer.Clin Cancer Res. 2007 Jun 1;13(11):3229-34. doi: 10.1158/1078-0432.CCR-07-0393.
• [1757] Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival.Int J Cancer. 2020 Jul 15;147(2):392-403. doi: 10.1002/ijc.32739. Epub 2019 Dec 19.
• [1758] KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p.Cell Biochem Funct. 2019 Aug;37(6):424-431. doi: 10.1002/cbf.3420. Epub 2019 Jul 22.
• [1759] KIF3A binds to -arrestin for suppressing Wnt/-catenin signalling independently of primary cilia in lung cancer.Sci Rep. 2016 Sep 6;6:32770. doi: 10.1038/srep32770.
• [1760] KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.Oncogene. 2019 Jan;38(3):406-420. doi: 10.1038/s41388-018-0440-8. Epub 2018 Aug 16.
• [1761] Upregulation of KIN17 is associated with non-small cell lung cancer invasiveness.Oncol Lett. 2017 Apr;13(4):2274-2280. doi: 10.3892/ol.2017.5707. Epub 2017 Feb 9.
• [1762] Genetic polymorphisms and expression of HLA-G and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer.Tissue Antigens. 2015 Jun;85(6):466-75. doi: 10.1111/tan.12561. Epub 2015 Apr 9.
• [1763] High expression of kinesin light chain-2, a novel target of miR-125b, is associated with poor clinical outcome of elderly non-small-cell lung cancer patients.Br J Cancer. 2015 Mar 3;112(5):874-82. doi: 10.1038/bjc.2015.3. Epub 2015 Feb 10.
• [1764] Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.J Biol Chem. 2015 Aug 28;290(35):21336-51. doi: 10.1074/jbc.M114.635730. Epub 2015 Apr 24.
• [1765] The KLF6 splice variant KLF6-SV1 promotes proliferation and invasion of non-small cell lung cancer by up-regultating PI3K-AKT signaling pathway.J Cancer. 2019 Aug 29;10(22):5324-5331. doi: 10.7150/jca.34212. eCollection 2019.
• [1766] miR-185 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer by Targeting KLF7.Oncol Res. 2019 Sep 23;27(9):1015-1023. doi: 10.3727/096504018X15247341491655. Epub 2018 May 1.
• [1767] Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.Tumour Biol. 2015 Jul;36(7):4979-86. doi: 10.1007/s13277-015-3148-1. Epub 2015 Feb 13.
• [1768] LINC00472 Acts as a Tumor Suppressor in NSCLC through KLLN-Mediated p53-Signaling Pathway via MicroRNA-149-3p and MicroRNA-4270.Mol Ther Nucleic Acids. 2019 Sep 6;17:563-577. doi: 10.1016/j.omtn.2019.06.003. Epub 2019 Jun 15.
• [1769] Exome sequencing identifies frequent mutation of MLL2 in non-small cell lung carcinoma from Chinese patients.Sci Rep. 2014 Aug 12;4:6036. doi: 10.1038/srep06036.
• [1770] KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2018 Jul;19(4):e489-e501. doi: 10.1016/j.cllc.2018.03.005. Epub 2018 Mar 16.
• [1771] Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.J Transl Med. 2013 Sep 26;11:232. doi: 10.1186/1479-5876-11-232.
• [1772] A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.Sci Rep. 2019 Mar 26;9(1):5207. doi: 10.1038/s41598-019-41585-4.
• [1773] Aberrant messenger RNA splicing of the cytokeratin 8 in lung cancer.Lung Cancer. 2003 Nov;42(2):153-61. doi: 10.1016/s0169-5002(03)00288-5.
• [1774] A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer.Ann Oncol. 2015 Jun;26(6):1142-1148. doi: 10.1093/annonc/mdv100. Epub 2015 Feb 24.
• [1775] HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.Tumour Biol. 2017 Jul;39(7):1010428317709675. doi: 10.1177/1010428317709675.
• [1776] Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer.Cancers (Basel). 2019 Jan 9;11(1):63. doi: 10.3390/cancers11010063.
• [1777] Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.Cell Physiol Biochem. 2018;51(1):337-355. doi: 10.1159/000495233. Epub 2018 Nov 19.
• [1778] Wnt signaling pathway pharmacogenetics in non-small cell lung cancer.Pharmacogenomics J. 2014 Dec;14(6):509-22. doi: 10.1038/tpj.2014.21. Epub 2014 Jul 1.
• [1779] LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.BMC Cancer. 2019 Sep 9;19(1):898. doi: 10.1186/s12885-019-6128-9.
• [1780] miR-17-92/p38 Dysregulation Enhances Wnt Signaling and Selects Lgr6+ Cancer Stem-like Cells during Lung Adenocarcinoma Progression.Cancer Res. 2016 Jul 1;76(13):4012-22. doi: 10.1158/0008-5472.CAN-15-3302. Epub 2016 May 4.
• [1781] Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer.Oncol Lett. 2017 Sep;14(3):3429-3436. doi: 10.3892/ol.2017.6607. Epub 2017 Jul 18.
• [1782] LHX3 is an early stage and radiosensitivity prognostic biomarker in lung adenocarcinoma.Oncol Rep. 2017 Sep;38(3):1482-1490. doi: 10.3892/or.2017.5833. Epub 2017 Jul 18.
• [1783] Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.Sci Rep. 2017 Apr 10;7(1):781. doi: 10.1038/s41598-017-00901-6.
• [1784] Relationship between genetic polymorphisms of DNA ligase 1 and non-small cell lung cancer susceptibility and radiosensitivity.Genet Mol Res. 2015 Jun 26;14(2):7047-52. doi: 10.4238/2015.June.26.14.
• [1785] The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.Med Oncol. 2014 May;31(5):959. doi: 10.1007/s12032-014-0959-7. Epub 2014 Apr 11.
• [1786] LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.Lung Cancer. 2018 Nov;125:174-184. doi: 10.1016/j.lungcan.2018.09.017. Epub 2018 Sep 24.
• [1787] Overexpression of LIMD2 promotes the progression of non-small cell lung cancer.Oncol Lett. 2019 Aug;18(2):2073-2081. doi: 10.3892/ol.2019.10473. Epub 2019 Jun 12.
• [1788] RNA-Seq analysis of non-small cell lung cancer in female never-smokers reveals candidate cancer-associated long non-coding RNAs.Pathol Res Pract. 2016 Jun;212(6):549-54. doi: 10.1016/j.prp.2016.03.006. Epub 2016 Mar 19.
• [1789] Metabolic enzymes expressed by cancer cells impact the immune infiltrate.Oncoimmunology. 2019 Mar 30;8(6):e1571389. doi: 10.1080/2162402X.2019.1571389. eCollection 2019.
• [1790] Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis.Oncotarget. 2017 Aug 18;8(62):104813-104830. doi: 10.18632/oncotarget.20338. eCollection 2017 Dec 1.
• [1791] LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.Oncotarget. 2018 Jul 3;9(51):29601-29618. doi: 10.18632/oncotarget.25642. eCollection 2018 Jul 3.
• [1792] LOXL1 Is Regulated by Integrin 11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity.Cancers (Basel). 2019 May 22;11(5):705. doi: 10.3390/cancers11050705.
• [1793] LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.J Exp Clin Cancer Res. 2019 Feb 21;38(1):95. doi: 10.1186/s13046-019-1092-4.
• [1794] The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.
• [1795] Exosomal Leucine-Rich-Alpha2-Glycoprotein 1 Derived from Non-Small-Cell Lung Cancer Cells Promotes Angiogenesis via TGF- Signal Pathway.Mol Ther Oncolytics. 2019 Aug 7;14:313-322. doi: 10.1016/j.omto.2019.08.001. eCollection 2019 Sep 27.
• [1796] LncRNA-PCAT-1 promotes non-small cell lung cancer progression by regulating miR-149-5p/LRIG2 axis.J Cell Biochem. 2019 May;120(5):7725-7733. doi: 10.1002/jcb.28046. Epub 2018 Dec 19.
• [1797] Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.Genome Med. 2018 Jul 20;10(1):55. doi: 10.1186/s13073-018-0562-1.
• [1798] Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.Front Immunol. 2019 May 21;10:1113. doi: 10.3389/fimmu.2019.01113. eCollection 2019.
• [1799] Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.Bioinformatics. 2016 May 1;32(9):1373-9. doi: 10.1093/bioinformatics/btw010. Epub 2016 Jan 10.
• [1800] Long non-coding RNA OGFRP1 regulates LYPD3 expression by sponging miR-124-3p and promotes non-small cell lung cancer progression.Biochem Biophys Res Commun. 2018 Oct 28;505(2):578-585. doi: 10.1016/j.bbrc.2018.09.146. Epub 2018 Sep 28.
• [1801] MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.Oncotarget. 2017 Jun 13;8(24):38825-38840. doi: 10.18632/oncotarget.16404.
• [1802] Inhibition of cell proliferation and migration in nonsmall cell lung cancer cells through the suppression of LYPLA1.Oncol Rep. 2019 Feb;41(2):973-980. doi: 10.3892/or.2018.6857. Epub 2018 Nov 9.
• [1803] Leucine zipper tumor suppressor 2 inhibits cell proliferation and regulates Lef/Tcf-dependent transcription through Akt/GSK3 signaling pathway in lung cancer.J Histochem Cytochem. 2013 Sep;61(9):659-70. doi: 10.1369/0022155413495875. Epub 2013 Jun 12.
• [1804] MiR-1275 promotes non-small cell lung cancer cell proliferation and metastasis by regulating LZTS3 expression.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2680-2687. doi: 10.26355/eurrev_201805_14964.
• [1805] Silencing of NRAGE induces autophagy via AMPK/Ulk1/Atg13 signaling pathway in NSCLC cells.Tumour Biol. 2017 Jun;39(6):1010428317709676. doi: 10.1177/1010428317709676.
• [1806] LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis.Cancer Manag Res. 2018 Jun 8;10:1449-1459. doi: 10.2147/CMAR.S164227. eCollection 2018.
• [1807] Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.Lung Cancer. 2019 Mar;129:85-91. doi: 10.1016/j.lungcan.2019.01.001. Epub 2019 Jan 8.
• [1808] Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.Exp Cell Res. 2014 Apr 1;322(2):345-54. doi: 10.1016/j.yexcr.2014.02.002. Epub 2014 Feb 12.
• [1809] Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.Clin Cancer Res. 2018 Aug 15;24(16):3857-3866. doi: 10.1158/1078-0432.CCR-17-3451. Epub 2018 May 1.
• [1810] Depletion of end-binding protein 1 (EB1) promotes apoptosis of human non-small-cell lung cancer cells via reactive oxygen species and Bax-mediated mitochondrial dysfunction.Cancer Lett. 2013 Oct 1;339(1):15-24. doi: 10.1016/j.canlet.2013.07.027. Epub 2013 Jul 27.
• [1811] The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.Lung Cancer. 2016 Dec;102:96-100. doi: 10.1016/j.lungcan.2016.11.003. Epub 2016 Nov 6.
• [1812] Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.Int J Mol Sci. 2019 May 2;20(9):2173. doi: 10.3390/ijms20092173.
• [1813] Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer.Mol Ther Nucleic Acids. 2019 Sep 6;17:256-263. doi: 10.1016/j.omtn.2019.06.002. Epub 2019 Jun 13.
• [1814] Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.Int J Cancer. 2018 Oct 1;143(7):1741-1752. doi: 10.1002/ijc.31545. Epub 2018 May 13.
• [1815] Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics.Sci Rep. 2017 Jan 3;7:39498. doi: 10.1038/srep39498.
• [1816] MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in non-small cell lung cancer.Mol Carcinog. 2016 Nov;55(11):1714-1727. doi: 10.1002/mc.22421. Epub 2015 Oct 28.
• [1817] Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC.Mol Cancer Ther. 2015 Jun;14(6):1434-44. doi: 10.1158/1535-7163.MCT-14-0846. Epub 2015 Mar 25.
• [1818] SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):6935-6943. doi: 10.26355/eurrev_201908_18733.
• [1819] MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas.Oncol Rep. 2015 May;33(5):2599-605. doi: 10.3892/or.2015.3822. Epub 2015 Feb 27.
• [1820] Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer.Lung Cancer. 2011 May;72(2):229-37. doi: 10.1016/j.lungcan.2010.08.020. Epub 2010 Sep 29.
• [1821] Hypermethylation of MDFI promoter with NSCLC is specific for females, non-smokers and people younger than 65.Oncol Lett. 2018 Jun;15(6):9017-9024. doi: 10.3892/ol.2018.8535. Epub 2018 Apr 18.
• [1822] Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival.J Cancer. 2017 Jul 5;8(11):2088-2096. doi: 10.7150/jca.19373. eCollection 2017.
• [1823] Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling.Sci Rep. 2014 Jun 24;4:5414. doi: 10.1038/srep05414.
• [1824] Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes.Cancer Lett. 2012 Aug 28;321(2):195-202. doi: 10.1016/j.canlet.2012.02.009. Epub 2012 Feb 14.
• [1825] Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.Asian Pac J Cancer Prev. 2015;16(3):875-80. doi: 10.7314/apjcp.2015.16.3.875.
• [1826] Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.Tumour Biol. 2014 Dec;35(12):12005-13. doi: 10.1007/s13277-014-2499-3. Epub 2014 Oct 2.
• [1827] MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells.J Cell Physiol. 2019 Jul;234(7):11265-11275. doi: 10.1002/jcp.27784. Epub 2018 Nov 29.
• [1828] Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.J Transl Med. 2017 Mar 24;15(1):65. doi: 10.1186/s12967-017-1168-x.
• [1829] Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis.PLoS One. 2014 Dec 2;9(12):e114104. doi: 10.1371/journal.pone.0114104. eCollection 2014.
• [1830] Aberrant expression of embryonic mesendoderm factor MESP1 promotes tumorigenesis.EBioMedicine. 2019 Dec;50:55-66. doi: 10.1016/j.ebiom.2019.11.012. Epub 2019 Nov 21.
• [1831] MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.
• [1832] Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.Cell Mol Immunol. 2015 Nov;12(6):768-76. doi: 10.1038/cmi.2014.101. Epub 2014 Nov 3.
• [1833] MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer.Oncotarget. 2016 Feb 23;7(8):9118-34. doi: 10.18632/oncotarget.7001.
• [1834] C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.Oncogene. 2011 Sep 29;30(39):4107-17. doi: 10.1038/onc.2011.116. Epub 2011 Apr 18.
• [1835] DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.J Histochem Cytochem. 2013 Jul;61(7):510-21. doi: 10.1369/0022155413488120. Epub 2013 Apr 9.
• [1836] Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis InVitro and InVivo.Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):49-62. doi: 10.1016/j.ijrobp.2018.01.036. Epub 2018 Jan 31.
• [1837] Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140-5p regulates tumor growth in non-small cell lung cancer.Biochem Biophys Res Commun. 2014 Jul 18;450(1):844-50. doi: 10.1016/j.bbrc.2014.06.075. Epub 2014 Jun 24.
• [1838] Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.Am J Respir Crit Care Med. 2014 Oct 1;190(7):780-90. doi: 10.1164/rccm.201310-1903OC.
• [1839] MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.Cancer Biomark. 2016 Sep 26;17(3):323-333. doi: 10.3233/CBM-160644.
• [1840] Aberrant high expression level of MORC2 is a common character in multiple cancers.Hum Pathol. 2018 Jun;76:58-67. doi: 10.1016/j.humpath.2018.03.011. Epub 2018 Mar 16.
• [1841] Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.Cancer Res. 2001 Jan 15;61(2):538-49.
• [1842] Expression and clinical contribution of MRGD mRNA in non-small cell lung cancers.J BUON. 2015 Jul-Aug;20(4):1101-6.
• [1843] Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma.Cancer Res. 1995 Jul 15;55(14):2968-71.
• [1844] p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.Cancer Sci. 2018 Dec;109(12):3783-3793. doi: 10.1111/cas.13818. Epub 2018 Oct 26.
• [1845] Knockdown of Immature Colon Carcinoma Transcript 1 Inhibits Proliferation and Promotes Apoptosis of Non-Small Cell Lung Cancer Cells.Technol Cancer Res Treat. 2017 Oct;16(5):559-569. doi: 10.1177/1533034616657977. Epub 2016 Jul 13.
• [1846] Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer.Oncogene. 2020 Jan;39(5):1152-1164. doi: 10.1038/s41388-019-1031-z. Epub 2019 Sep 30.
• [1847] Systematic analysis of mRNA expression profiles in NSCLC cell lines to screen metastasis-related genes.Mol Med Rep. 2016 Dec;14(6):5093-5103. doi: 10.3892/mmr.2016.5911. Epub 2016 Nov 1.
• [1848] Expression of metallothionein-III in patients with non-small cell lung cancer.Anticancer Res. 2013 Mar;33(3):965-74.
• [1849] Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.Mol Med Rep. 2018 Apr;17(4):4899-4908. doi: 10.3892/mmr.2018.8535. Epub 2018 Feb 1.
• [1850] MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3.Tumour Biol. 2014 Apr;35(4):3487-94. doi: 10.1007/s13277-013-1460-1. Epub 2013 Nov 29.
• [1851] MTBP promotes migration and invasion by regulation of ZEB2-mediated epithelial-mesenchymal transition in lung cancer cells.Onco Targets Ther. 2018 Oct 10;11:6741-6756. doi: 10.2147/OTT.S167963. eCollection 2018.
• [1852] Prognostic roles of mitochondrial transcription termination factors in non-small cell lung cancer.Oncol Lett. 2019 Oct;18(4):3453-3462. doi: 10.3892/ol.2019.10680. Epub 2019 Jul 29.
• [1853] Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer.Neoplasia. 2017 Jan;19(1):8-16. doi: 10.1016/j.neo.2016.11.009. Epub 2016 Dec 7.
• [1854] Methylenetetrahydrofolate Dehydrogenase 1 Silencing Expedites the Apoptosis of Non-Small Cell Lung Cancer Cells via Modulating DNA Methylation.Med Sci Monit. 2018 Oct 21;24:7499-7507. doi: 10.12659/MSM.910265.
• [1855] Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.J Cell Mol Med. 2020 Jan;24(2):1568-1577. doi: 10.1111/jcmm.14844. Epub 2019 Nov 28.
• [1856] Study on molecular mechanism of MiRNA-29a in promoting proliferation and invasion of non-small-cell lung cancer by inhibiting MTSS1.Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5531-5538. doi: 10.26355/eurrev_201809_15814.
• [1857] DNA methylation regulates Microtubule-associated tumor suppressor 1 in human non-small cell lung carcinoma.Exp Cell Res. 2019 Jan 15;374(2):323-332. doi: 10.1016/j.yexcr.2018.12.004. Epub 2018 Dec 7.
• [1858] Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers.Cancer Biomark. 2015;15(5):645-51. doi: 10.3233/CBM-150504.
• [1859] Cytotoxic Effects of 24-Methylenecyloartanyl Ferulate on A549 Nonsmall Cell Lung Cancer Cells through MYBBP1A Up-Regulation and AKT and Aurora B Kinase Inhibition.J Agric Food Chem. 2018 Apr 11;66(14):3726-3733. doi: 10.1021/acs.jafc.8b00491. Epub 2018 Mar 29.
• [1860] MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF- pathway in NSCLC.Oncogene. 2019 Feb;38(6):896-912. doi: 10.1038/s41388-018-0484-9. Epub 2018 Sep 4.
• [1861] Prognostic significance of MYH9 expression in resected non-small cell lung cancer.PLoS One. 2015 Mar 31;10(3):e0121460. doi: 10.1371/journal.pone.0121460. eCollection 2015.
• [1862] NF-B-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10.Oncotarget. 2015 Apr 10;6(10):8244-54. doi: 10.18632/oncotarget.3135.
• [1863] MicroRNA-5195-3p plays a suppressive role in cell proliferation, migration and invasion by targeting MYO6 in human non-small cell lung cancer.Biosci Biotechnol Biochem. 2019 Feb;83(2):212-220. doi: 10.1080/09168451.2018.1540288. Epub 2018 Nov 2.
• [1864] Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer.Tumour Biol. 2015 May;36(5):3693-701. doi: 10.1007/s13277-014-3008-4. Epub 2015 Mar 1.
• [1865] A new mouse model to study the role of ectopic Nanos3 expression in cancer.BMC Cancer. 2019 Jun 17;19(1):598. doi: 10.1186/s12885-019-5807-x.
• [1866] k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer.J Cancer Res Ther. 2017;13(4):699-701. doi: 10.4103/jcrt.JCRT_468_17.
• [1867] High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
• [1868] NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B.J Cell Mol Med. 2019 Oct;23(10):6965-6977. doi: 10.1111/jcmm.14581. Epub 2019 Aug 26.
• [1869] Circulating innate immune markers and outcomes in treatment-nave advanced non-small cell lung cancer patients.Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14.
• [1870] Overexpression and biological function of TMEM48 in non-small cell lung carcinoma.Tumour Biol. 2016 Feb;37(2):2575-86. doi: 10.1007/s13277-015-4014-x. Epub 2015 Sep 21.
• [1871] High expression of NDRG3 associates with unfavorable overall survival in non-small cell lung cancer.Cancer Biomark. 2018 Feb 6;21(2):461-469. doi: 10.3233/CBM-170711.
• [1872] Mitochondrial NDUFA4L2 protein promotes the vitality of lung cancer cells by repressing oxidative stress.Thorac Cancer. 2019 Apr;10(4):676-685. doi: 10.1111/1759-7714.12984. Epub 2019 Feb 2.
• [1873] The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I.Sci Rep. 2016 Aug 12;6:31357. doi: 10.1038/srep31357.
• [1874] Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non-small cell lung cancer patients.Mol Carcinog. 2017 Dec;56(12):2558-2565. doi: 10.1002/mc.22700. Epub 2017 Aug 3.
• [1875] GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization.Funct Integr Genomics. 2020 Jan;20(1):17-28. doi: 10.1007/s10142-019-00696-x. Epub 2019 Jul 3.
• [1876] A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.Sci Rep. 2014 Feb 26;4:4186. doi: 10.1038/srep04186.
• [1877] The tumor suppressor Caliban regulates DNA damage-induced apoptosis through p53-dependent and -independent activity.Oncogene. 2013 Aug 15;32(33):3857-66. doi: 10.1038/onc.2012.395. Epub 2012 Sep 10.
• [1878] ERBB2-induced inflammation in lung carcinogenesis.Mol Biol Rep. 2012 Aug;39(8):7911-7. doi: 10.1007/s11033-012-1635-7. Epub 2012 May 1.
• [1879] Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.PLoS One. 2017 Oct 31;12(10):e0187289. doi: 10.1371/journal.pone.0187289. eCollection 2017.
• [1880] Specific -tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells.PLoS One. 2011;6(6):e21717. doi: 10.1371/journal.pone.0021717. Epub 2011 Jun 29.
• [1881] Copy number variation, increased gene expression, and molecular mechanisms of neurofascin in lung cancer.Mol Carcinog. 2017 Sep;56(9):2076-2085. doi: 10.1002/mc.22664. Epub 2017 May 2.
• [1882] miR-194 suppresses high glucose-induced non-small cell lung cancer cell progression by targeting NFAT5.Thorac Cancer. 2019 May;10(5):1051-1059. doi: 10.1111/1759-7714.13038. Epub 2019 Mar 21.
• [1883] MiR-338 regulates NFATc1 expression and inhibits the proliferation and epithelial-mesenchymal transition of human non-small-cell lung cancer cells.Mol Genet Genomic Med. 2020 Feb;8(2):e1091. doi: 10.1002/mgg3.1091. Epub 2019 Dec 11.
• [1884] Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16.
• [1885] Micronodules Detected on Computed Tomography During the National Lung Screening Trial: Prevalence and Relation to Positive Studies and Lung Cancer.J Thorac Oncol. 2019 Sep;14(9):1538-1546. doi: 10.1016/j.jtho.2019.05.045. Epub 2019 Jul 8.
• [1886] The more potential performance of nidogen 2 methylation by tissue or plasma DNA over brichoalveolar lavage DNA in diagnosis of nonsmall cell lung cancer.J Cancer Res Ther. 2018 Jun;14(Supplement):S341-S346. doi: 10.4103/0973-1482.235352.
• [1887] Inhibition of NIPBL enhances the chemosensitivity of non-small-cell lung cancer cells via the DNA damage response and autophagy pathway.Onco Targets Ther. 2018 Apr 5;11:1941-1948. doi: 10.2147/OTT.S158655. eCollection 2018.
• [1888] Intronic variant of EGFR is associated with GBAS expression and survival outcome of early-stage non-small cell lung cancer.Thorac Cancer. 2018 Aug;9(8):916-923. doi: 10.1111/1759-7714.12757. Epub 2018 May 28.
• [1889] Nitrilase 1 modulates lung tumor progression in vitro and in vivo.Oncotarget. 2016 Apr 19;7(16):21381-92. doi: 10.18632/oncotarget.7820.
• [1890] Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis.BMC Cancer. 2011 May 20;11:186. doi: 10.1186/1471-2407-11-186.
• [1891] Analysis of gene expression profiles of non-small cell lung cancer at different stages reveals significantly altered biological functions and candidate genes.Oncol Rep. 2017 Mar;37(3):1736-1746. doi: 10.3892/or.2017.5380. Epub 2017 Jan 17.
• [1892] Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.Mol Oncol. 2020 Feb;14(2):277-293. doi: 10.1002/1878-0261.12608. Epub 2019 Dec 15.
• [1893] One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.Clin Cancer Res. 2011 Feb 15;17(4):638-9. doi: 10.1158/1078-0432.CCR-10-3081. Epub 2010 Dec 16.
• [1894] Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.Eur J Pharmacol. 2010 Jul 10;637(1-3):38-45. doi: 10.1016/j.ejphar.2010.03.057. Epub 2010 Apr 11.
• [1895] NME4 may enhance nonsmall cell lung cancer progression by overcoming cell cycle arrest and promoting cellular proliferation.Mol Med Rep. 2019 Aug;20(2):1629-1636. doi: 10.3892/mmr.2019.10413. Epub 2019 Jun 24.
• [1896] Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses.Gene. 2018 Dec 15;678:137-142. doi: 10.1016/j.gene.2018.08.032. Epub 2018 Aug 7.
• [1897] miR?45 inhibits human nonsmall-cell lung cancer growth by dual-targeting RIOK2 and NOB1.Int J Oncol. 2018 Jul;53(1):257-265. doi: 10.3892/ijo.2018.4393. Epub 2018 May 3.
• [1898] Association between CLOCK, PER3 and CCRN4L with nonsmall cell lung cancer in Brazilian patients.Mol Med Rep. 2014 Jul;10(1):435-40. doi: 10.3892/mmr.2014.2224. Epub 2014 May 8.
• [1899] Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.Cell Mol Biol Lett. 2018 Nov 27;23:54. doi: 10.1186/s11658-018-0119-8. eCollection 2018.
• [1900] NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer.Nat Commun. 2018 Aug 6;9(1):3112. doi: 10.1038/s41467-018-05582-x.
• [1901] NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.PLoS One. 2010 Aug 5;5(8):e11994. doi: 10.1371/journal.pone.0011994.
• [1902] Preliminary mechanisms of regulating PDL1 expression in nonsmall cell lung cancer during the EMT process.Oncol Rep. 2018 Aug;40(2):775-782. doi: 10.3892/or.2018.6474. Epub 2018 Jun 5.
• [1903] Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.
• [1904] Notch-regulated ankyrin-repeat protein is a novel tissue biomarker that predicts poor prognosis in non-small cell lung cancer.Oncol Lett. 2018 Aug;16(2):1885-1891. doi: 10.3892/ol.2018.8826. Epub 2018 May 30.
• [1905] High-resolution genomic profiles of human lung cancer.Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30. doi: 10.1073/pnas.0504126102. Epub 2005 Jun 27.
• [1906] Numb Gene Enhances Radiation Sensitivity of Nonsmall Cell Lung Cancer Stem Cells.Cancer Biother Radiopharm. 2016 Jun;31(5):180-8. doi: 10.1089/cbr.2016.2053.
• [1907] Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.Anat Rec (Hoboken). 2012 Dec;295(12):2114-21. doi: 10.1002/ar.22571. Epub 2012 Sep 7.
• [1908] Nogo-B receptor promotes epithelial-mesenchymal transition in non-small cell lung cancer cells through the Ras/ERK/Snail1 pathway.Cancer Lett. 2018 Apr 1;418:135-146. doi: 10.1016/j.canlet.2018.01.030. Epub 2018 Jan 11.
• [1909] NUSAP1 knockdown inhibits cell growth and metastasis of non-small-cell lung cancer through regulating BTG2/PI3K/Akt signaling.J Cell Physiol. 2020 Apr;235(4):3886-3893. doi: 10.1002/jcp.29282. Epub 2019 Oct 11.
• [1910] Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.Cell Death Dis. 2019 May 24;10(6):400. doi: 10.1038/s41419-019-1597-y.
• [1911] THUMPD3-AS1 Is Correlated With Non-Small Cell Lung Cancer And Regulates Self-Renewal Through miR-543 And ONECUT2.Onco Targets Ther. 2019 Nov 19;12:9849-9860. doi: 10.2147/OTT.S227995. eCollection 2019.
• [1912] Helional-induced activation of human olfactory receptor 2J3 promotes apoptosis and inhibits proliferation in a non-small-cell lung cancer cell line.Eur J Cell Biol. 2017 Jan;96(1):34-46. doi: 10.1016/j.ejcb.2016.11.004. Epub 2016 Dec 5.
• [1913] Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation.PLoS One. 2013 Sep 13;8(9):e72889. doi: 10.1371/journal.pone.0072889. eCollection 2013.
• [1914] OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.Theranostics. 2019 Jan 1;9(1):179-195. doi: 10.7150/thno.29545. eCollection 2019.
• [1915] Deubiquitinase OTUD6B Isoforms Are Important Regulators of Growth and Proliferation.Mol Cancer Res. 2017 Feb;15(2):117-127. doi: 10.1158/1541-7786.MCR-16-0281-T. Epub 2016 Nov 18.
• [1916] Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma.Front Oncol. 2019 Sep 11;9:862. doi: 10.3389/fonc.2019.00862. eCollection 2019.
• [1917] MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1.Oncol Rep. 2017 Nov;38(5):3071-3077. doi: 10.3892/or.2017.5956. Epub 2017 Sep 14.
• [1918] Pathways regulating the expression of the immunomodulatory protein glycodelin in nonsmall cell lung cancer.Int J Oncol. 2019 Feb;54(2):515-526. doi: 10.3892/ijo.2018.4654. Epub 2018 Dec 5.
• [1919] Overexpression of PAFAH1B1 is associated with tumor metastasis and poor survival in non-small cell lung cancer.Lung Cancer. 2012 Sep;77(3):585-92. doi: 10.1016/j.lungcan.2012.05.105. Epub 2012 Jun 29.
• [1920] Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.
• [1921] PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.Autophagy. 2020 Jul;16(7):1236-1247. doi: 10.1080/15548627.2019.1659654. Epub 2019 Aug 30.
• [1922] PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer.Onco Targets Ther. 2019 May 13;12:3625-3633. doi: 10.2147/OTT.S181432. eCollection 2019.
• [1923] Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation.J Biol Chem. 2011 Mar 11;286(10):8149-8157. doi: 10.1074/jbc.M110.196113. Epub 2010 Dec 28.
• [1924] The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling.Cell Death Dis. 2019 Apr 25;10(5):349. doi: 10.1038/s41419-019-1591-4.
• [1925] Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.BMC Cancer. 2014 Mar 14;14:185. doi: 10.1186/1471-2407-14-185.
• [1926] Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer.J Exp Clin Cancer Res. 2013 May 20;32(1):29. doi: 10.1186/1756-9966-32-29.
• [1927] Roles of pyruvate carboxylase in human diseases: from diabetes to cancers and infection.J Mol Med (Berl). 2018 Apr;96(3-4):237-247. doi: 10.1007/s00109-018-1622-0. Epub 2018 Jan 23.
• [1928] Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.Cancer Res. 2004 Jun 15;64(12):4171-9. doi: 10.1158/0008-5472.CAN-03-2982.
• [1929] Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.Cancer Biomark. 2012-2013;12(1):11-9. doi: 10.3233/CBM-2012-00280.
• [1930] PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.Cancer Res. 2017 Jan 1;77(1):187-197. doi: 10.1158/0008-5472.CAN-16-1267-T. Epub 2016 Nov 7.
• [1931] Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth.Mol Cell. 2015 Oct 15;60(2):195-207. doi: 10.1016/j.molcel.2015.08.013.
• [1932] Pecanex functions as a competitive endogenous RNA of S-phase kinase associated protein 2 in lung cancer.Cancer Lett. 2017 Oct 10;406:36-46. doi: 10.1016/j.canlet.2017.07.030. Epub 2017 Aug 5.
• [1933] The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer.Mol Cell Biochem. 2011 Dec;358(1-2):257-63. doi: 10.1007/s11010-011-0976-1. Epub 2011 Jul 12.
• [1934] miR-103 Functions as a Tumor Suppressor by Directly Targeting Programmed Cell Death 10 in NSCLC.Oncol Res. 2018 May 7;26(4):519-528. doi: 10.3727/096504017X15000757094686. Epub 2017 Jul 21.
• [1935] MicroRNA-421 promotes proliferation and invasion of non-small cell lung cancer cells through targeting PDCD4.Pathol Res Pract. 2019 Oct;215(10):152555. doi: 10.1016/j.prp.2019.152555. Epub 2019 Jul 23.
• [1936] Genetic variation in PDCD6 and susceptibility to lung cancer.Asian Pac J Cancer Prev. 2012;13(9):4689-93. doi: 10.7314/apjcp.2012.13.9.4689.
• [1937] The programmed cell death 6 interacting protein insertion/deletion polymorphism is associated with non-small cell lung cancer risk in a Chinese Han population.Tumour Biol. 2014 Sep;35(9):8679-83. doi: 10.1007/s13277-014-2081-z. Epub 2014 May 29.
• [1938] Combination of CALR and PDIA3 is a potential prognostic biomarker for non-small cell lung cancer.Oncotarget. 2017 Jun 16;8(57):96945-96957. doi: 10.18632/oncotarget.18547. eCollection 2017 Nov 14.
• [1939] Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.Cancer Res. 2015 Nov 15;75(22):4937-48. doi: 10.1158/0008-5472.CAN-15-1113. Epub 2015 Oct 21.
• [1940] Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.Lung Cancer. 2018 Dec;126:64-71. doi: 10.1016/j.lungcan.2018.10.021. Epub 2018 Oct 28.
• [1941] SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.Ann Diagn Pathol. 2017 Feb;26:47-51. doi: 10.1016/j.anndiagpath.2016.10.006. Epub 2016 Oct 20.
• [1942] PELI3 mediates pro-tumor actions of down-regulated miR-365a-5p in non-small cell lung cancer.Biol Res. 2019 Apr 17;52(1):24. doi: 10.1186/s40659-019-0230-y.
• [1943] PELP1 is a novel oncogene in gastric tumorigenesis and negatively regulated by miR-15 family microRNAs.Cancer Biomark. 2019;26(1):1-9. doi: 10.3233/CBM-182279.
• [1944] Circadian clock gene Per2 downregulation in nonsmall cell lung cancer is associated with tumour progression and metastasis.Oncol Rep. 2018 Nov;40(5):3040-3048. doi: 10.3892/or.2018.6704. Epub 2018 Sep 13.
• [1945] Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.Mol Cancer Ther. 2013 Apr;12(4):481-90. doi: 10.1158/1535-7163.MCT-12-0654. Epub 2013 Jan 31.
• [1946] MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines.Oncol Rep. 2017 May;37(5):3146-3154. doi: 10.3892/or.2017.5566. Epub 2017 Apr 11.
• [1947] A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer.Cell Metab. 2019 Dec 3;30(6):1107-1119.e8. doi: 10.1016/j.cmet.2019.09.014. Epub 2019 Oct 10.
• [1948] PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).BMC Cancer. 2018 Dec 10;18(1):1238. doi: 10.1186/s12885-018-5140-9.
• [1949] Association between polymorphisms in CHRNA3 and PHACTR2 gene and environment and NSCLC risk in Chinese population.Acta Biochim Pol. 2014;61(4):765-8. Epub 2014 Nov 14.
• [1950] Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12198-206. eCollection 2015.
• [1951] PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing.Cancer Med. 2019 May;8(5):2429-2441. doi: 10.1002/cam4.2115. Epub 2019 Apr 1.
• [1952] MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2.FEBS Lett. 2014 Aug 25;588(17):3055-61. doi: 10.1016/j.febslet.2014.06.020. Epub 2014 Jun 16.
• [1953] Overexpression of PHRF1 attenuates the proliferation and tumorigenicity of non-small cell lung cancer cells.Oncotarget. 2016 Sep 27;7(39):64360-64370. doi: 10.18632/oncotarget.11842.
• [1954] PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.Sci Rep. 2019 Aug 27;9(1):12437. doi: 10.1038/s41598-019-48763-4.
• [1955] Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.PLoS One. 2017 Oct 31;12(10):e0187308. doi: 10.1371/journal.pone.0187308. eCollection 2017.
• [1956] TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.Autophagy. 2018;14(12):2035-2048. doi: 10.1080/15548627.2018.1491493. Epub 2018 Sep 20.
• [1957] MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.Clin Lung Cancer. 2016 Sep;17(5):e65-e75. doi: 10.1016/j.cllc.2016.03.012. Epub 2016 Apr 6.
• [1958] MicroRNA-1204 promotes cell proliferation by regulating PITX1 in non-small-cell lung cancer.Cell Biol Int. 2019 Mar;43(3):253-264. doi: 10.1002/cbin.11083. Epub 2019 Jan 28.
• [1959] The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer.Oncotarget. 2015 Oct 13;6(31):31544-56. doi: 10.18632/oncotarget.3003.
• [1960] Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.Cancer Sci. 2013 Nov;104(11):1447-54. doi: 10.1111/cas.12250. Epub 2013 Sep 5.
• [1961] Transcription factor PREP1 induces EMT and metastasis by controlling the TGF--SMAD3 pathway in non-small cell lung adenocarcinoma.Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3775-84. doi: 10.1073/pnas.1407074111. Epub 2014 Aug 25.
• [1962] Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.Pathol Res Pract. 2019 Jul;215(7):152438. doi: 10.1016/j.prp.2019.152438. Epub 2019 May 13.
• [1963] p0071 interacts with E-cadherin in the cytoplasm so as to promote the invasion and metastasis of non-small cell lung cancer.Mol Carcinog. 2018 Jan;57(1):89-96. doi: 10.1002/mc.22734. Epub 2017 Sep 25.
• [1964] Placenta-specific 8 is a potential novel target for osimertinib resistance in non-small cell lung cancer.Oncol Lett. 2019 Jul;18(1):955-961. doi: 10.3892/ol.2019.10344. Epub 2019 May 13.
• [1965] Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non-Small Cell Lung Cancer Patients.J Thorac Oncol. 2017 Apr;12(4):644-656. doi: 10.1016/j.jtho.2016.12.025. Epub 2017 Jan 16.
• [1966] Distinct Prognostic Values of Phospholipase C Beta Family Members for Non-Small Cell Lung Carcinoma.Biomed Res Int. 2019 Apr 7;2019:4256524. doi: 10.1155/2019/4256524. eCollection 2019.
• [1967] Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4.Cancer Biomark. 2019;26(1):79-91. doi: 10.3233/CBM-190142.
• [1968] Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.
• [1969] RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.J Cell Physiol. 2018 Dec;233(12):9548-9562. doi: 10.1002/jcp.26858. Epub 2018 Jun 28.
• [1970] Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.BMC Genomics. 2016 Dec 22;17(Suppl 13):1029. doi: 10.1186/s12864-016-3322-x.
• [1971] Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.Cell Biochem Biophys. 2014 Nov;70(2):1227-37. doi: 10.1007/s12013-014-0046-x.
• [1972] Identification of suitable reference genes for gene expression studies using quantitative polymerase chain reaction in lung cancer in vitro.Mol Med Rep. 2015 May;11(5):3767-73. doi: 10.3892/mmr.2015.3159. Epub 2015 Jan 8.
• [1973] Downregulation of basic fibroblast growth factor increases cisplatin sensitivity in A549 non-small cell lung cancer cells.J Cancer Res Ther. 2018;14(7):1519-1524. doi: 10.4103/jcrt.JCRT_481_18.
• [1974] PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner.Oncogenesis. 2019 Sep 24;8(10):53. doi: 10.1038/s41389-019-0162-y.
• [1975] CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.Cancer Med. 2018 Feb;7(2):325-335. doi: 10.1002/cam4.1292. Epub 2018 Jan 22.
• [1976] Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers.Biochimie. 2010 Mar;92(3):292-306. doi: 10.1016/j.biochi.2009.12.007. Epub 2009 Dec 23.
• [1977] Different splicing isoforms of ERCC1 affect the expression of its overlapping genes CD3EAP and PPP1R13L, and indicate a potential application in non-small cell lung cancer treatment.Int J Oncol. 2018 Jun;52(6):2155-2165. doi: 10.3892/ijo.2018.4347. Epub 2018 Mar 29.
• [1978] Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A.Tumour Biol. 2014 Jan;35(1):631-40. doi: 10.1007/s13277-013-1087-2.
• [1979] Characterization of spontaneous and TGF--induced cell motility of primary human normal and neoplastic mammary cells in vitro using novel real-time technology.PLoS One. 2013;8(2):e56591. doi: 10.1371/journal.pone.0056591. Epub 2013 Feb 14.
• [1980] Fluorescence imaging of biochemical relationship between ubiquitinated histone 2A and Polycomb complex protein BMI1.Biophys Chem. 2019 Oct;253:106225. doi: 10.1016/j.bpc.2019.106225. Epub 2019 Jul 11.
• [1981] Potential Oncogenic Role of the Papillary Renal Cell Carcinoma Gene in Non-Small Cell Lung Cancers.Yonsei Med J. 2019 Apr;60(4):326-335. doi: 10.3349/ymj.2019.60.4.326.
• [1982] PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro.Chin Med J (Engl). 2015 Feb 5;128(3):373-7. doi: 10.4103/0366-6999.150109.
• [1983] Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.Clin Cancer Res. 2008 Apr 15;14(8):2326-33. doi: 10.1158/1078-0432.CCR-07-4457.
• [1984] MicroRNA-122 negatively associates with peroxiredoxin-II expression in human gefitinib-resistant lung cancer stem cells.Cancer Gene Ther. 2019 Sep;26(9-10):292-304. doi: 10.1038/s41417-018-0050-1. Epub 2018 Oct 19.
• [1985] MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity via Direct Binding to the STAT3 DNA-Binding Domain.Theranostics. 2017 Oct 16;7(18):4632-4642. doi: 10.7150/thno.18630. eCollection 2017.
• [1986] COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer.J Cancer Res Clin Oncol. 2017 Jul;143(7):1133-1141. doi: 10.1007/s00432-017-2381-y. Epub 2017 Mar 3.
• [1987] Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.Biomed Pharmacother. 2019 Jan;109:1851-1859. doi: 10.1016/j.biopha.2018.09.151. Epub 2018 Nov 26.
• [1988] PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer.Br J Cancer. 2014 Jan 21;110(2):353-62. doi: 10.1038/bjc.2013.728. Epub 2013 Nov 26.
• [1989] Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non-small cell lung cancer patients.Thorac Cancer. 2019 May;10(5):1203-1212. doi: 10.1111/1759-7714.13064. Epub 2019 Apr 11.
• [1990] Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer.Genes Chromosomes Cancer. 2013 Mar;52(3):305-15. doi: 10.1002/gcc.22030. Epub 2012 Dec 8.
• [1991] Notch3 is important for TGF--induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1.Cancer Gene Ther. 2014 Sep;21(9):364-72. doi: 10.1038/cgt.2014.39. Epub 2014 Aug 1.
• [1992] Expression of prothymosin in lung cancer is associated with squamous cell carcinoma and smoking.Oncol Lett. 2019 Jun;17(6):5740-5746. doi: 10.3892/ol.2019.10248. Epub 2019 Apr 12.
• [1993] Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.J Exp Clin Cancer Res. 2019 Aug 6;38(1):341. doi: 10.1186/s13046-019-1349-y.
• [1994] Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.Oncogene. 2015 Jul;34(29):3791-803. doi: 10.1038/onc.2014.312. Epub 2014 Sep 29.
• [1995] MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.Tumour Biol. 2016 Aug;37(8):11289-97. doi: 10.1007/s13277-016-4955-8. Epub 2016 Mar 7.
• [1996] PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.J Thorac Oncol. 2015 Sep;10(9):1364-1369. doi: 10.1097/JTO.0000000000000624.
• [1997] Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.Oncol Rep. 2015 Sep;34(3):1137-45. doi: 10.3892/or.2015.4082. Epub 2015 Jun 25.
• [1998] MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.Pathol Res Pract. 2018 May;214(5):776-783. doi: 10.1016/j.prp.2018.02.002. Epub 2018 Feb 14.
• [1999] PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.Epigenetics. 2020 Jun-Jul;15(6-7):604-617. doi: 10.1080/15592294.2019.1676597. Epub 2019 Oct 13.
• [2000] Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin.Biochem Biophys Res Commun. 2018 Jan 1;495(1):1240-1248. doi: 10.1016/j.bbrc.2017.11.126. Epub 2017 Nov 21.
• [2001] Distinct expression pattern and prognostic values of pituitary tumor transforming gene family genes in non-small cell lung cancer.Oncol Lett. 2019 Nov;18(5):4481-4494. doi: 10.3892/ol.2019.10844. Epub 2019 Sep 10.
• [2002] A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.Neoplasia. 2017 Jul;19(7):530-536. doi: 10.1016/j.neo.2017.02.004. Epub 2017 Jun 3.
• [2003] PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells.Cell Death Dis. 2019 Aug 8;10(8):595. doi: 10.1038/s41419-019-1839-z.
• [2004] PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488.Biomed Pharmacother. 2019 Mar;111:588-595. doi: 10.1016/j.biopha.2018.12.089. Epub 2018 Dec 31.
• [2005] Rab11a promotes proliferation and invasion through regulation of YAP in non-small cell lung cancer.Oncotarget. 2017 Apr 25;8(17):27800-27811. doi: 10.18632/oncotarget.15359.
• [2006] microRNA-338-3p functions as a tumor suppressor in human nonsmallcell lung carcinoma and targets Ras-related protein 14.Mol Med Rep. 2015 Feb;11(2):1400-6. doi: 10.3892/mmr.2014.2880. Epub 2014 Nov 6.
• [2007] Downregulation of Rab17 promotes cell proliferation and invasion in non-small cell lung cancer through STAT3/HIF-1/VEGF signaling.Thorac Cancer. 2020 Feb;11(2):379-388. doi: 10.1111/1759-7714.13278. Epub 2019 Dec 16.
• [2008] MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18.BMC Cancer. 2014 Sep 24;14:703. doi: 10.1186/1471-2407-14-703.
• [2009] Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer.Genet Mol Res. 2015 Oct 30;14(4):13998-4008. doi: 10.4238/2015.October.29.19.
• [2010] Targeted Delivery of Rab26 siRNA with Precisely Tailored DNA Prism for Lung Cancer Therapy.Chembiochem. 2019 May 2;20(9):1139-1144. doi: 10.1002/cbic.201800761. Epub 2019 Feb 27.
• [2011] Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma.Thorac Cancer. 2019 Feb;10(2):143-149. doi: 10.1111/1759-7714.12919. Epub 2018 Nov 27.
• [2012] RAB38 is a potential prognostic factor for tumor recurrence in non-small cell lung cancer.Oncol Lett. 2019 Sep;18(3):2598-2604. doi: 10.3892/ol.2019.10547. Epub 2019 Jun 28.
• [2013] Rab8 GTPase regulates Klotho-mediated inhibition of cell growth and progression by directly modulating its surface expression in human non-small cell lung cancer.EBioMedicine. 2019 Nov;49:118-132. doi: 10.1016/j.ebiom.2019.10.040. Epub 2019 Nov 6.
• [2014] RAC2 promotes abnormal proliferation of quiescent cells by enhanced JUNB expression via the MAL-SRF pathway.Cell Cycle. 2018;17(9):1115-1123. doi: 10.1080/15384101.2018.1480217. Epub 2018 Jul 9.
• [2015] RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.Clin Cancer Res. 2018 Jan 15;24(2):341-350. doi: 10.1158/1078-0432.CCR-17-1455. Epub 2017 Oct 13.
• [2016] Silencing of RAD51AP1 suppresses epithelial-mesenchymal transition and metastasis in non-small cell lung cancer.Thorac Cancer. 2019 Sep;10(9):1748-1763. doi: 10.1111/1759-7714.13124. Epub 2019 Jul 17.
• [2017] Overexpression of RAD51B predicts a preferable prognosis for non-small cell lung cancer patients.Oncotarget. 2017 Sep 6;8(53):91471-91480. doi: 10.18632/oncotarget.20676. eCollection 2017 Oct 31.
• [2018] RAD52 motifcontaining protein1 promotes nonsmall cell lung cancer cell proliferation and survival via cell cycle regulation.Oncol Rep. 2018 Aug;40(2):833-840. doi: 10.3892/or.2018.6459. Epub 2018 May 23.
• [2019] DNA damage sensor protein hRad9, a novel molecular target for lung cancer treatment.Oncol Rep. 2008 Nov;20(5):1047-52.
• [2020] Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.J Biol Chem. 2011 Feb 11;286(6):4902-11. doi: 10.1074/jbc.M110.198374. Epub 2010 Dec 6.
• [2021] RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.Oncogene. 2018 Dec;37(50):6463-6476. doi: 10.1038/s41388-018-0424-8. Epub 2018 Aug 3.
• [2022] MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A.Exp Cell Res. 2020 Feb 1;387(1):111752. doi: 10.1016/j.yexcr.2019.111752. Epub 2019 Dec 2.
• [2023] SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.Cell Cycle. 2014;13(6):941-52. doi: 10.4161/cc.27804. Epub 2014 Jan 16.
• [2024] miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells.Tumour Biol. 2015 Jul;36(7):5031-8. doi: 10.1007/s13277-015-3154-3. Epub 2015 Feb 9.
• [2025] Rasip1 is a RUNX1 target gene and promotes migration of NSCLC cells.Cancer Manag Res. 2018 Oct 12;10:4537-4552. doi: 10.2147/CMAR.S168438. eCollection 2018.
• [2026] Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.Oncogene. 2008 Mar 13;27(12):1805-11. doi: 10.1038/sj.onc.1210805. Epub 2007 Sep 24.
• [2027] RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer.Lung Cancer. 2014 Jan;83(1):23-9. doi: 10.1016/j.lungcan.2013.10.014. Epub 2013 Oct 31.
• [2028] RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion.Tumour Biol. 2016 Apr;37(4):4865-71. doi: 10.1007/s13277-015-4343-9. Epub 2015 Nov 2.
• [2029] The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer.Oncotarget. 2017 Aug 12;8(45):78734-78748. doi: 10.18632/oncotarget.20223. eCollection 2017 Oct 3.
• [2030] The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p.EBioMedicine. 2019 Jun;44:182-193. doi: 10.1016/j.ebiom.2019.05.032. Epub 2019 May 31.
• [2031] Nicotine upregulates FGFR3 and RB1 expression and promotes non-small cell lung cancer cell proliferation and epithelial-to-mesenchymal transition via downregulation of miR-99b and miR-192.Biomed Pharmacother. 2018 May;101:656-662. doi: 10.1016/j.biopha.2018.02.113. Epub 2018 Mar 22.
• [2032] RBAK is upregulated in non-small cell lung cancer and promotes cell migration and invasion.Exp Ther Med. 2019 Oct;18(4):2942-2948. doi: 10.3892/etm.2019.7900. Epub 2019 Aug 16.
• [2033] Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.J Cancer Res Clin Oncol. 2019 Apr;145(4):873-879. doi: 10.1007/s00432-019-02850-1. Epub 2019 Feb 13.
• [2034] RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis.Biotechnol Lett. 2018 Mar;40(3):543-550. doi: 10.1007/s10529-017-2504-1. Epub 2017 Dec 29.
• [2035] Overexpression of HCC1/CAPER may play a role in lung cancer carcinogenesis.Tumour Biol. 2014 Jul;35(7):6311-7. doi: 10.1007/s13277-014-1819-y. Epub 2014 Mar 19.
• [2036] Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells.World J Surg Oncol. 2014 Dec 2;12:367. doi: 10.1186/1477-7819-12-367.
• [2037] shRNAmediated silencing of TARBP2 inhibits NCIH1299 nonsmall cell lung cancer cell invasion and migration via the JNK/STAT3/AKT pathway.Mol Med Rep. 2016 Oct;14(4):3725-30. doi: 10.3892/mmr.2016.5723. Epub 2016 Sep 6.
• [2038] RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer.PLoS One. 2013 Dec 20;8(12):e84735. doi: 10.1371/journal.pone.0084735. eCollection 2013.
• [2039] RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.Surg Oncol. 2016 Sep;25(3):147-51. doi: 10.1016/j.suronc.2016.05.006. Epub 2016 May 10.
• [2040] RCCD1 depletion attenuates TGF--induced EMT and cell migration bystabilizing cytoskeletal microtubules in NSCLC cells.Cancer Lett. 2017 Aug 1;400:18-29. doi: 10.1016/j.canlet.2017.04.021. Epub 2017 Apr 26.
• [2041] Overexpression of RCN1 correlates with poor prognosis and progression in non-small cell lung cancer.Hum Pathol. 2019 Jan;83:140-148. doi: 10.1016/j.humpath.2018.08.014. Epub 2018 Aug 30.
• [2042] Effects of RECQ1 helicase silencing on non-small cell lung cancer cells.Biomed Pharmacother. 2016 Oct;83:1227-1232. doi: 10.1016/j.biopha.2016.07.053. Epub 2016 Aug 23.
• [2043] EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in nonsmall cell lung cancer cells.Oncol Rep. 2018 Jul;40(1):29-38. doi: 10.3892/or.2018.6417. Epub 2018 May 8.
• [2044] Identification of an E3 ligase-encoding gene RFWD3 in non-small cell lung cancer.Front Med. 2020 Jun;14(3):318-326. doi: 10.1007/s11684-019-0708-6. Epub 2019 Sep 28.
• [2045] MiR-4319 hinders YAP expression to restrain non-small cell lung cancer growth through regulation of LIN28-mediated RFX5 stability.Biomed Pharmacother. 2019 Jul;115:108956. doi: 10.1016/j.biopha.2019.108956. Epub 2019 May 14.
• [2046] Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.Clin Cancer Res. 2018 Mar 15;24(6):1402-1414. doi: 10.1158/1078-0432.CCR-17-2074. Epub 2018 Jan 8.
• [2047] Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: AMulticenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).Clin Lung Cancer. 2018 Nov;19(6):e865-e869. doi: 10.1016/j.cllc.2018.07.009. Epub 2018 Aug 7.
• [2048] Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.Clin Epigenetics. 2019 Nov 12;11(1):157. doi: 10.1186/s13148-019-0770-6.
• [2049] miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17.Cancer Sci. 2017 Dec;108(12):2366-2372. doi: 10.1111/cas.13401. Epub 2017 Oct 12.
• [2050] MiR-92a Family: A Novel Diagnostic Biomarker and Potential Therapeutic Target in Human Cancers.Front Mol Biosci. 2019 Oct 1;6:98. doi: 10.3389/fmolb.2019.00098. eCollection 2019.
• [2051] Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett. 2010 Nov 1;297(1):117-25. doi: 10.1016/j.canlet.2010.05.004.
• [2052] A Protective Role for RHOJ in NonSmall Cell Lung Cancer Based on Integrated Bioinformatics Analysis.J Comput Biol. 2020 Jul;27(7):1092-1103. doi: 10.1089/cmb.2019.0209. Epub 2019 Oct 23.
• [2053] The RHOV gene is overexpressed in human non-small cell lung cancer.Cancer Genet. 2013 Nov;206(11):393-7. doi: 10.1016/j.cancergen.2013.10.006. Epub 2013 Nov 5.
• [2054] Prognostic significance of RIN1 gene expression in human non-small cell lung cancer.Acta Histochem. 2012 Sep;114(5):463-8. doi: 10.1016/j.acthis.2011.08.008. Epub 2011 Sep 16.
• [2055] Down-regulation of lncRNA XIST inhibits cell proliferation via regulating miR-744/RING1 axis in non-small cell lung cancer.Clin Sci (Lond). 2019 Jul 18;133(14):1567-1579. doi: 10.1042/CS20190519. Print 2019 Jul 31.
• [2056] Integrated High Throughput Analysis Identifies GSK3 as a Crucial Determinant of p53-Mediated Apoptosis in Lung Cancer Cells.Cell Physiol Biochem. 2017;42(3):1177-1191. doi: 10.1159/000478873. Epub 2017 Jun 30.
• [2057] Rnd3 regulates lung cancer cell proliferation through notch signaling.PLoS One. 2014 Nov 5;9(11):e111897. doi: 10.1371/journal.pone.0111897. eCollection 2014.
• [2058] RNF111/Arkadia is regulated by DNA methylation and affects TGF-/Smad signaling associated invasion in NSCLC cells.Lung Cancer. 2015 Oct;90(1):32-40. doi: 10.1016/j.lungcan.2015.07.010. Epub 2015 Jul 26.
• [2059] Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/-catenin signaling pathway.PLoS One. 2014 Jan 14;9(1):e85377. doi: 10.1371/journal.pone.0085377. eCollection 2014.
• [2060] Overexpression of RNF187 induces cell EMT and apoptosis resistance in NSCLC.J Cell Physiol. 2019 Aug;234(8):14161-14169. doi: 10.1002/jcp.28111. Epub 2019 Jan 9.
• [2061] RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-B-mediated ERK reactivation.Cell Death Dis. 2018 May 22;9(6):587. doi: 10.1038/s41419-018-0651-5.
• [2062] Ring finger protein 38 promote non-small cell lung cancer progression by endowing cell EMT phenotype.J Cancer. 2018 Feb 12;9(5):841-850. doi: 10.7150/jca.23138. eCollection 2018.
• [2063] RNAi silencing targeting RNF8 enhances radiosensitivity of a non-small cell lung cancer cell line A549.Int J Radiat Biol. 2013 Sep;89(9):708-15. doi: 10.3109/09553002.2013.792964. Epub 2013 May 15.
• [2064] A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors.Cell Cycle. 2013 Apr 15;12(8):1267-78. doi: 10.4161/cc.24363. Epub 2013 Mar 21.
• [2065] Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.J Clin Lab Anal. 2020 Mar;34(3):e23091. doi: 10.1002/jcla.23091. Epub 2019 Nov 10.
• [2066] Over-expressed RPL34 promotes malignant proliferation of non-small cell lung cancer cells.Gene. 2016 Jan 15;576(1 Pt 3):421-8. doi: 10.1016/j.gene.2015.10.053. Epub 2015 Oct 23.
• [2067] MicroRNA-147b suppresses the proliferation and invasion of non-small-cell lung cancer cells through downregulation of Wnt/-catenin signalling via targeting of RPS15A.Clin Exp Pharmacol Physiol. 2020 Mar;47(3):449-458. doi: 10.1111/1440-1681.13203. Epub 2019 Nov 24.
• [2068] Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.J Exp Clin Cancer Res. 2015 Oct 21;34:126. doi: 10.1186/s13046-015-0239-1.
• [2069] The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.Oncotarget. 2017 Jan 17;8(3):5233-5246. doi: 10.18632/oncotarget.14125.
• [2070] Alternative splicing of S6K1 promotes non-small cell lung cancer survival.Tumour Biol. 2016 Oct;37(10):13369-13376. doi: 10.1007/s13277-016-5253-1. Epub 2016 Jul 27.
• [2071] Overexpressed C14orf166 associates with disease progression and poor prognosis in non-small-cell lung cancer.Biosci Rep. 2018 Sep 13;38(5):BSR20180479. doi: 10.1042/BSR20180479. Print 2018 Oct 31.
• [2072] RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy.Cancer Lett. 2015 Dec 28;369(2):386-95. doi: 10.1016/j.canlet.2015.09.003. Epub 2015 Sep 21.
• [2073] Prognostic Roles of mRNA Expression of S100 in Non-Small-Cell Lung Cancer.Biomed Res Int. 2018 Jan 21;2018:9815806. doi: 10.1155/2018/9815806. eCollection 2018.
• [2074] Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11. Oncotarget. 2015 May 20;6(14):12156-73. doi: 10.18632/oncotarget.3495.
• [2075] Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.Thorac Cancer. 2018 Sep;9(9):1136-1144. doi: 10.1111/1759-7714.12797. Epub 2018 Jul 26.
• [2076] Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.PLoS One. 2013;8(2):e57053. doi: 10.1371/journal.pone.0057053. Epub 2013 Feb 25.
• [2077] Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE.PLoS One. 2010 Feb 11;5(2):e9162. doi: 10.1371/journal.pone.0009162.
• [2078] Overexpression of SAMD9 suppresses tumorigenesis and progression during non small cell lung cancer.Biochem Biophys Res Commun. 2014 Nov 7;454(1):157-61. doi: 10.1016/j.bbrc.2014.10.054. Epub 2014 Oct 17.
• [2079] Synthesis, anti-proliferative activity, SAR study, and preliminary in vivo toxicity study of substituted N,N'-bis(arylmethyl)benzimidazolium salts against a panel of non-small cell lung cancer cell lines.Bioorg Med Chem. 2017 Jan 1;25(1):421-439. doi: 10.1016/j.bmc.2016.11.009. Epub 2016 Nov 5.
• [2080] The RNA-binding protein SART3 promotes miR-34a biogenesis and G(1) cell cycle arrest in lung cancer cells.J Biol Chem. 2019 Nov 15;294(46):17188-17196. doi: 10.1074/jbc.AC119.010419. Epub 2019 Oct 16.
• [2081] Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.Carcinogenesis. 2013 Feb;34(2):307-13. doi: 10.1093/carcin/bgs356. Epub 2012 Nov 8.
• [2082] Scavenger Receptor A1 Prevents Metastasis of Non-Small Cell Lung Cancer via Suppression of Macrophage Serum Amyloid A1.Cancer Res. 2017 Apr 1;77(7):1586-1598. doi: 10.1158/0008-5472.CAN-16-1569. Epub 2017 Feb 15.
• [2083] Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Thorac Cancer. 2018 Jan;9(1):159-163. doi: 10.1111/1759-7714.12518. Epub 2017 Oct 3.
• [2084] Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.Lung Cancer. 2015 Feb;87(2):162-8. doi: 10.1016/j.lungcan.2014.12.005. Epub 2014 Dec 18.
• [2085] SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response.Theranostics. 2019 Aug 14;9(22):6380-6395. doi: 10.7150/thno.34443. eCollection 2019.
• [2086] miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis.Oncol Rep. 2013 Jul;30(1):492-8. doi: 10.3892/or.2013.2453. Epub 2013 May 13.
• [2087] SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.Cancer Res Treat. 2016 Jan;48(1):398-402. doi: 10.4143/crt.2014.254. Epub 2015 Feb 17.
• [2088] LncRNA LINC02418 regulates proliferation and apoptosis of non-small cell lung cancer cells by regulating miR-4677-3p/SEC61G.Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10354-10362. doi: 10.26355/eurrev_201912_19673.
• [2089] Expression of 3q oncogene SEC62 in atypical fibroxanthoma-immunohistochemical analysis of 41 cases and correlation with clinical, viral and histopathologic features.Oncol Lett. 2019 Feb;17(2):1768-1776. doi: 10.3892/ol.2018.9767. Epub 2018 Nov 27.
• [2090] A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer.Lung Cancer. 2011 Feb;71(2):123-9. doi: 10.1016/j.lungcan.2010.04.016. Epub 2010 May 14.
• [2091] Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.Cancer Lett. 2005 Jul 8;225(1):131-9. doi: 10.1016/j.canlet.2004.10.041. Epub 2004 Dec 22.
• [2092] MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C.J Cell Mol Med. 2015 Dec;19(12):2793-805. doi: 10.1111/jcmm.12666. Epub 2015 Aug 18.
• [2093] Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.Lancet Respir Med. 2017 Nov;5(11):891-902. doi: 10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19.
• [2094] Differential expression of PAI-RBP1, C1orf142, and COTL1 in non-small cell lung cancer cell lines with different tumor metastatic potential.J Investig Med. 2012 Apr;60(4):689-94. doi: 10.2310/JIM.0b013e31824963b6.
• [2095] Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer.Glycoconj J. 2019 Feb;36(1):57-68. doi: 10.1007/s10719-018-09853-z. Epub 2019 Jan 3.
• [2096] Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.Sci Rep. 2016 Aug 25;6:32258. doi: 10.1038/srep32258.
• [2097] Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions.Oncogene. 2003 Nov 27;22(54):8677-87. doi: 10.1038/sj.onc.1207127.
• [2098] Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.Carcinogenesis. 2017 Feb 1;38(2):184-195. doi: 10.1093/carcin/bgw124.
• [2099] SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.BMC Cancer. 2019 Jul 25;19(1):736. doi: 10.1186/s12885-019-5944-2.
• [2100] Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer.Mol Cancer. 2019 Jan 21;18(1):13. doi: 10.1186/s12943-019-0943-0.
• [2101] Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.Oncotarget. 2017 May 30;8(22):36354-36367. doi: 10.18632/oncotarget.16754.
• [2102] DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.J Exp Clin Cancer Res. 2012 Sep 25;31(1):80. doi: 10.1186/1756-9966-31-80.
• [2103] Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer.Clin Cancer Res. 2005 Aug 1;11(15):5417-24. doi: 10.1158/1078-0432.CCR-04-2087.
• [2104] Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer.Oncotarget. 2018 Aug 3;9(60):31572-31589. doi: 10.18632/oncotarget.25803. eCollection 2018 Aug 3.
• [2105] SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.J Mol Med (Berl). 2013 Mar;91(3):381-93. doi: 10.1007/s00109-012-0955-3. Epub 2012 Sep 12.
• [2106] Shisa3 is associated with prolonged survival through promoting -catenin degradation in lung cancer.Am J Respir Crit Care Med. 2014 Aug 15;190(4):433-44. doi: 10.1164/rccm.201312-2256OC.
• [2107] SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.Nat Commun. 2019 Jun 10;10(1):2532. doi: 10.1038/s41467-019-10367-x.
• [2108] DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.Diagn Mol Pathol. 2012 Jun;21(2):93-104. doi: 10.1097/PDM.0b013e318240503b.
• [2109] Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer.Hum Pathol. 2014 Sep;45(9):1936-43. doi: 10.1016/j.humpath.2014.04.023. Epub 2014 Jun 18.
• [2110] MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer.Front Genet. 2017 Feb 2;8:8. doi: 10.3389/fgene.2017.00008. eCollection 2017.
• [2111] Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.
• [2112] Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.Yonsei Med J. 2017 May;58(3):581-591. doi: 10.3349/ymj.2017.58.3.581.
• [2113] miR-210-3p regulates the proliferation and apoptosis of non-small cell lung cancer cells by targeting SIN3A.Exp Ther Med. 2019 Oct;18(4):2565-2573. doi: 10.3892/etm.2019.7867. Epub 2019 Aug 8.
• [2114] The SIPA1 -313A>G polymorphism is associated with prognosis in inoperable non-small cell lung cancer.Tumour Biol. 2015 Feb;36(2):1273-8. doi: 10.1007/s13277-014-2753-8. Epub 2014 Oct 29.
• [2115] SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.Oncogene. 2017 May 11;36(19):2724-2736. doi: 10.1038/onc.2016.425. Epub 2016 Dec 12.
• [2116] MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells.Oncol Rep. 2016 Nov;36(5):3051-3057. doi: 10.3892/or.2016.5063. Epub 2016 Sep 5.
• [2117] The expression profile and clinic significance of the SIX family in non-small cell lung cancer.J Hematol Oncol. 2016 Nov 8;9(1):119. doi: 10.1186/s13045-016-0339-1.
• [2118] Src kinase-associated phosphoprotein2 expression is associated with poor prognosis in non-small cell lung cancer.Anticancer Res. 2015 Apr;35(4):2411-5.
• [2119] microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18.Int J Biol Macromol. 2015 Mar;74:111-8. doi: 10.1016/j.ijbiomac.2014.12.002. Epub 2014 Dec 11.
• [2120] Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging.Mol Med Rep. 2011 Nov-Dec;4(6):1289-93. doi: 10.3892/mmr.2011.572. Epub 2011 Aug 24.
• [2121] Overexpression of miR?61?p plays an oncogenic role in human lung adenocarcinoma through the regulation of SMAD2.Int J Oncol. 2019 Jan;54(1):306-314. doi: 10.3892/ijo.2018.4602. Epub 2018 Oct 23.
• [2122] Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer.Cancer Med. 2018 Jun;7(6):2247-2255. doi: 10.1002/cam4.1349. Epub 2018 May 9.
• [2123] Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR-19b-3p/HOXA9 axis.Onco Targets Ther. 2019 Aug 30;12:7055-7065. doi: 10.2147/OTT.S216320. eCollection 2019.
• [2124] MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.J Biol Chem. 2016 Jan 22;291(4):1877-1889. doi: 10.1074/jbc.M115.667568. Epub 2015 Nov 5.
• [2125] SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.Cell Res. 2015 Apr;25(4):445-58. doi: 10.1038/cr.2015.16. Epub 2015 Feb 6.
• [2126] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.
• [2127] PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.Pathology. 2009 Feb;41(2):118-26. doi: 10.1080/00313020802579268.
• [2128] MiR-940 inhibits TGF--induced epithelial-mesenchymal transition and cell invasion by targeting Snail in non-small cell lung cancer.J Cancer. 2019 Jun 2;10(12):2735-2744. doi: 10.7150/jca.31800. eCollection 2019.
• [2129] High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.Lung Cancer. 2013 Oct;82(1):24-30. doi: 10.1016/j.lungcan.2013.07.015. Epub 2013 Aug 9.
• [2130] SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26.Cell Death Dis. 2019 Sep 11;10(9):667. doi: 10.1038/s41419-019-1929-y.
• [2131] MiR-875 can regulate the proliferation and apoptosis of non-small cell lung cancer cells via targeting SOCS2.Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5235-5241. doi: 10.26355/eurrev_201906_18189.
• [2132] miR-1260b, mediated by YY1, activates KIT signaling by targeting SOCS6 to regulate cell proliferation and apoptosis in NSCLC.Cell Death Dis. 2019 Feb 8;10(2):112. doi: 10.1038/s41419-019-1390-y.
• [2133] microRNA-148a-3p inhibited the proliferation and epithelial-mesenchymal transition progression of non-small-cell lung cancer via modulating Ras/MAPK/Erk signaling.J Cell Physiol. 2019 Aug;234(8):12786-12799. doi: 10.1002/jcp.27899. Epub 2018 Dec 10.
• [2134] SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target.Int J Mol Med. 2018 Dec;42(6):3424-3436. doi: 10.3892/ijmm.2018.3926. Epub 2018 Oct 10.
• [2135] Epigenetic inactivation of SOX1 promotes cell migration in lung cancer.Tumour Biol. 2015 Jun;36(6):4603-10. doi: 10.1007/s13277-015-3107-x. Epub 2015 Jan 23.
• [2136] MiR-185 inhibits tumor growth and enhances chemo-resistance via targeting SRY-related high mobility group box transcription factor 13 in non-small-cell carcinoma.Am J Transl Res. 2018 Aug 15;10(8):2600-2609. eCollection 2018.
• [2137] SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.Clin Chem Lab Med. 2016 Aug 1;54(8):1385-93. doi: 10.1515/cclm-2015-0776.
• [2138] Influence of miR-7a and miR-24-3p on the SOX18 transcript in lung adenocarcinoma.Oncol Rep. 2018 Jan;39(1):201-208. doi: 10.3892/or.2017.6077. Epub 2017 Nov 6.
• [2139] SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients.Respir Res. 2018 Dec 4;19(1):241. doi: 10.1186/s12931-018-0952-3.
• [2140] MiR-1269a acts as an onco-miRNA in non-small cell lung cancer via down-regulating SOX6. Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4888-4897.
• [2141] miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer.Int J Clin Exp Pathol. 2014 Sep 15;7(10):6534-42. eCollection 2014.
• [2142] The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.Mol Cell Biol. 2020 Jan 3;40(2):e00307-19. doi: 10.1128/MCB.00307-19. Print 2020 Jan 3.
• [2143] Long noncoding RNA LINC00961 inhibits cell invasion and metastasis in human non-small cell lung cancer.Biomed Pharmacother. 2018 Jan;97:1311-1318. doi: 10.1016/j.biopha.2017.11.062. Epub 2017 Dec 14.
• [2144] MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer.Biochem Biophys Res Commun. 2018 Sep 26;504(1):164-170. doi: 10.1016/j.bbrc.2018.08.149. Epub 2018 Sep 1.
• [2145] Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer.Lung Cancer. 2013 Aug;81(2):266-72. doi: 10.1016/j.lungcan.2013.04.021. Epub 2013 May 24.
• [2146] A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer.Oncotarget. 2017 Jul 4;8(39):65469-65480. doi: 10.18632/oncotarget.18971. eCollection 2017 Sep 12.
• [2147] SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival.Biomed Pharmacother. 2018 Apr;100:233-239. doi: 10.1016/j.biopha.2018.02.015. Epub 2018 Feb 16.
• [2148] miR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1.Mol Ther Nucleic Acids. 2018 Dec 7;13:154-163. doi: 10.1016/j.omtn.2018.08.020. Epub 2018 Sep 1.
• [2149] SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis.Oncol Lett. 2019 Dec;18(6):6899-6908. doi: 10.3892/ol.2019.11005. Epub 2019 Oct 18.
• [2150] Novel Role for -Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).J Biol Chem. 2015 Jun 19;290(25):15610-15620. doi: 10.1074/jbc.M114.631820. Epub 2015 Apr 29.
• [2151] STYK1 promotes tumor growth and metastasis by reducing SPINT2/HAI-2 expression in non-small cell lung cancer.Cell Death Dis. 2019 Jun 4;10(6):435. doi: 10.1038/s41419-019-1659-1.
• [2152] Critical role of Spns2, a sphingosine-1-phosphate transporter, in lung cancer cell survival and migration.PLoS One. 2014 Oct 20;9(10):e110119. doi: 10.1371/journal.pone.0110119. eCollection 2014.
• [2153] MiR-520b promotes the progression of non-small cell lung cancer through activating Hedgehog pathway.J Cell Mol Med. 2019 Jan;23(1):205-215. doi: 10.1111/jcmm.13909. Epub 2018 Nov 8.
• [2154] K-homology splicing regulatory protein (KSRP) promotes post-transcriptional destabilization of Spry4 transcripts in non-small cell lung cancer.J Biol Chem. 2017 May 5;292(18):7423-7434. doi: 10.1074/jbc.M116.757906. Epub 2017 Mar 8.
• [2155] Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.Eur J Cardiothorac Surg. 2013 Mar;43(3):628-33; discussion 633-4. doi: 10.1093/ejcts/ezs337. Epub 2012 Nov 14.
• [2156] Downregulation of Mitochondrial Single Stranded DNA Binding Protein (SSBP1) Induces Mitochondrial Dysfunction and Increases the Radiosensitivity in Non-Small Cell Lung Cancer Cells.J Cancer. 2017 May 12;8(8):1400-1409. doi: 10.7150/jca.18170. eCollection 2017.
• [2157] EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.Yonsei Med J. 2012 Nov 1;53(6):1128-35. doi: 10.3349/ymj.2012.53.6.1128.
• [2158] Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth.Mol Carcinog. 2017 Mar;56(3):1182-1188. doi: 10.1002/mc.22550. Epub 2016 Sep 22.
• [2159] Modification of 2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.Int J Cancer. 2018 Nov 1;143(9):2319-2330. doi: 10.1002/ijc.31737. Epub 2018 Sep 7.
• [2160] Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion.Neoplasia. 2019 May;21(5):482-493. doi: 10.1016/j.neo.2019.03.009. Epub 2019 Apr 9.
• [2161] Knockdown of STIM1 expression inhibits non-small-cell lung cancer cell proliferation in vitro and in nude mouse xenografts.Bioengineered. 2019 Dec;10(1):425-436. doi: 10.1080/21655979.2019.1669518.
• [2162] Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas.BMC Cancer. 2014 Feb 17;14:100. doi: 10.1186/1471-2407-14-100.
• [2163] miR-29b inhibits non-small cell lung cancer progression by targeting STRN4.Hum Cell. 2020 Jan;33(1):220-231. doi: 10.1007/s13577-019-00305-w. Epub 2019 Dec 7.
• [2164] The E3 Ligase CHIP Mediates p21 Degradation to Maintain Radioresistance.Mol Cancer Res. 2017 Jun;15(6):651-659. doi: 10.1158/1541-7786.MCR-16-0466. Epub 2017 Feb 23.
• [2165] Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion via preventing the PI3K/AKT against STXBP5 expression in non-small-cell lung carcinoma.J Cell Biochem. 2019 May;120(5):7489-7498. doi: 10.1002/jcb.28023. Epub 2018 Nov 18.
• [2166] KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway.Cancer Sci. 2018 Apr;109(4):1055-1065. doi: 10.1111/cas.13539. Epub 2018 Mar 25.
• [2167] Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis.J Transl Med. 2017 Jun 17;15(1):138. doi: 10.1186/s12967-017-1241-5.
• [2168] LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9939-9946. doi: 10.26355/eurrev_201911_19560.
• [2169] Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells.Pathol Int. 2012 Apr;62(4):232-45. doi: 10.1111/j.1440-1827.2011.02781.x. Epub 2012 Jan 13.
• [2170] Synaptotagmin 7 in twist-related protein 1-mediated epithelial - Mesenchymal transition of non-small cell lung cancer.EBioMedicine. 2019 Aug;46:42-53. doi: 10.1016/j.ebiom.2019.07.071. Epub 2019 Aug 6.
• [2171] icroRNA?89 plays a suppressive role in cell proliferation and invasion by directly targeting TAB1 in nonsmall cell lung cancer.Mol Med Rep. 2019 Jul;20(1):261-269. doi: 10.3892/mmr.2019.10245. Epub 2019 May 15.
• [2172] Overexpression of Alteration/Deficiency in Activation 3 correlates with poor prognosis in non-small cell lung cancer.Pathol Res Pract. 2019 Jun;215(6):152408. doi: 10.1016/j.prp.2019.03.036. Epub 2019 Apr 2.
• [2173] Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.Oncoimmunology. 2017 Jan 3;6(2):e1274476. doi: 10.1080/2162402X.2016.1274476. eCollection 2017.
• [2174] Expression of TARBP1 protein in human non-small-cell lung cancer and its prognostic significance.Oncol Lett. 2018 May;15(5):7182-7190. doi: 10.3892/ol.2018.8202. Epub 2018 Mar 7.
• [2175] Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.Apoptosis. 2018 Feb;23(2):132-142. doi: 10.1007/s10495-018-1443-1.
• [2176] High TBX2 expression predicts poor prognosis in non-small cell lung cancer.Neoplasma. 2014;61(4):476-80.
• [2177] T-box 3 overexpression is associated with poor prognosis of non-small cell lung cancer.Oncol Lett. 2017 May;13(5):3335-3341. doi: 10.3892/ol.2017.5855. Epub 2017 Mar 13.
• [2178] Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5251-5256. doi: 10.1007/s11033-019-04982-6. Epub 2019 Jul 18.
• [2179] Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer.J Cell Commun Signal. 2018 Jun;12(2):423-432. doi: 10.1007/s12079-017-0418-2. Epub 2017 Oct 30.
• [2180] Hsa-miR-337 inhibits non-small cell lung cancer cell invasion and migration by targeting TCF7.Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6548-6553. doi: 10.26355/eurrev_201908_18540.
• [2181] Vitamin B12 and its binding proteins in patients with non-small cell lung cancer referred to fast-track diagnostic work-up for lung cancer.Scand J Clin Lab Invest. 2020 Feb;80(1):14-19. doi: 10.1080/00365513.2019.1692232. Epub 2019 Nov 18.
• [2182] MiR-1256 suppresses proliferation and migration of non-small cell lung cancer via regulating TCTN1.Oncol Lett. 2018 Aug;16(2):1708-1714. doi: 10.3892/ol.2018.8794. Epub 2018 May 24.
• [2183] Soy isoflavones augment radiation effect by inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer.J Thorac Oncol. 2011 Apr;6(4):688-98. doi: 10.1097/JTO.0b013e31821034ae.
• [2184] Testin is a tumor suppressor in non-small cell lung cancer.Oncol Rep. 2017 Feb;37(2):1027-1035. doi: 10.3892/or.2016.5316. Epub 2016 Dec 14.
• [2185] Tescalcin/c-Src/IGF1R-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1.Sci Rep. 2018 Jul 16;8(1):10711. doi: 10.1038/s41598-018-29142-x.
• [2186] Expression of tesmin (MTL5) in nonsmall cell lung cancer: A preliminary study.Oncol Rep. 2019 Jul;42(1):253-262. doi: 10.3892/or.2019.7145. Epub 2019 May 2.
• [2187] Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.Cancer Gene Ther. 2017 Sep;24(9):373-380. doi: 10.1038/cgt.2017.26. Epub 2017 Aug 4.
• [2188] Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK/p38MAPK signaling and reducing cellular bioenergetics.Oncotarget. 2016 Mar 8;7(10):11609-24. doi: 10.18632/oncotarget.7018.
• [2189] TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling.Mol Cancer. 2014 Apr 26;13:89. doi: 10.1186/1476-4598-13-89.
• [2190] Genetic Analysis Reveals AMPK Is Required to Support Tumor Growth in Murine Kras-Dependent Lung Cancer Models.Cell Metab. 2019 Feb 5;29(2):285-302.e7. doi: 10.1016/j.cmet.2018.10.005. Epub 2018 Nov 8.
• [2191] Increased expression of transcription factor EB (TFEB) is associated with autophagy, migratory phenotype and poor prognosis in non-small cell lung cancer.Lung Cancer. 2015 Oct;90(1):98-105. doi: 10.1016/j.lungcan.2015.07.008. Epub 2015 Jul 26.
• [2192] STIP overexpression confers oncogenic potential to human non-small cell lung cancer cells by regulating cell cycle and apoptosis.J Cell Mol Med. 2015 Dec;19(12):2806-17. doi: 10.1111/jcmm.12670. Epub 2015 Sep 10.
• [2193] Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8.
• [2194] Anti-EGFR Peptide-Conjugated Triangular Gold Nanoplates for Computed Tomography/Photoacoustic Imaging-Guided Photothermal Therapy of Non-Small Cell Lung Cancer.ACS Appl Mater Interfaces. 2018 May 23;10(20):16992-17003. doi: 10.1021/acsami.7b19013. Epub 2018 May 14.
• [2195] Transforming growth factor -induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer.Oncotarget. 2019 Jan 25;10(8):810-824. doi: 10.18632/oncotarget.26574. eCollection 2019 Jan 25.
• [2196] HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.Nature. 2014 Jan 9;505(7482):212-7. doi: 10.1038/nature12785. Epub 2013 Dec 4.
• [2197] TGF induced factor homeobox 1 promotes colorectal cancer development through activating Wnt/-catenin signaling.Oncotarget. 2017 Jul 26;8(41):70214-70225. doi: 10.18632/oncotarget.19603. eCollection 2017 Sep 19.
• [2198] Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis.Thorac Cancer. 2020 Feb;11(2):264-276. doi: 10.1111/1759-7714.13245. Epub 2019 Dec 3.
• [2199] Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer.Biosci Rep. 2019 Jul 25;39(7):BSR20190476. doi: 10.1042/BSR20190476. Print 2019 Jul 31.
• [2200] TIAM2 enhances non-small cell lung cancer cell invasion and motility.Asian Pac J Cancer Prev. 2013;14(11):6305-9. doi: 10.7314/apjcp.2013.14.11.6305.
• [2201] Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer.Mol Cancer. 2018 May 12;17(1):88. doi: 10.1186/s12943-018-0839-4.
• [2202] TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner.Br J Cancer. 2015 Nov 17;113(10):1484-92. doi: 10.1038/bjc.2015.323. Epub 2015 Oct 29.
• [2203] LncRNA FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2 axis.Biomed Pharmacother. 2019 Oct;118:109309. doi: 10.1016/j.biopha.2019.109309. Epub 2019 Aug 28.
• [2204] A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.J Mol Diagn. 2019 Mar;21(2):186-197. doi: 10.1016/j.jmoldx.2018.10.001. Epub 2019 Feb 13.
• [2205] Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.Int J Oncol. 2017 Feb;50(2):545-554. doi: 10.3892/ijo.2017.3841. Epub 2017 Jan 5.
• [2206] Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.Int J Clin Exp Pathol. 2013 Nov 15;6(12):2887-95. eCollection 2013.
• [2207] Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis.Respir Res. 2019 May 29;20(1):106. doi: 10.1186/s12931-019-1071-5.
• [2208] Osteopontin production by TM4SF4 signaling drives a positive feedback autocrine loop with the STAT3 pathway to maintain cancer stem cell-like properties in lung cancer cells.Oncotarget. 2017 Sep 18;8(60):101284-101297. doi: 10.18632/oncotarget.21021. eCollection 2017 Nov 24.
• [2209] Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.Lung Cancer. 2015 Oct;90(1):22-31. doi: 10.1016/j.lungcan.2015.06.023. Epub 2015 Jul 2.
• [2210] Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer.Mol Cells. 2012 Aug;34(2):171-6. doi: 10.1007/s10059-012-0083-5. Epub 2012 Jul 18.
• [2211] Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.Lung Cancer. 2015 Jun;88(3):352-4. doi: 10.1016/j.lungcan.2015.03.014. Epub 2015 Mar 21.
• [2212] Elevation of circular RNA circ_0003645 forecasts unfavorable prognosis and facilitates cell progression via miR-1179/TMEM14A pathway in non-small cell lung cancer.Biochem Biophys Res Commun. 2019 Apr 16;511(4):921-925. doi: 10.1016/j.bbrc.2019.03.011. Epub 2019 Mar 8.
• [2213] TMEM17 depresses invasion and metastasis in lung cancer cells via ERK signaling pathway.Oncotarget. 2017 Aug 7;8(41):70685-70694. doi: 10.18632/oncotarget.19977. eCollection 2017 Sep 19.
• [2214] TMEM206 promotes the malignancy of colorectal cancer cells by interacting with AKT and extracellular signal-regulated kinase signaling pathways.J Cell Physiol. 2019 Jul;234(7):10888-10898. doi: 10.1002/jcp.27751. Epub 2018 Nov 11.
• [2215] Prognostic significance and biological function of Lamina-associated polypeptide 2 in non-small-cell lung cancer.Onco Targets Ther. 2019 May 16;12:3817-3827. doi: 10.2147/OTT.S179870. eCollection 2019.
• [2216] Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.Cancer Lett. 2019 Jul 1;453:21-33. doi: 10.1016/j.canlet.2019.03.013. Epub 2019 Mar 21.
• [2217] MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7.Oncotarget. 2015 Sep 8;6(26):21802-15. doi: 10.18632/oncotarget.5224.
• [2218] TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.BMC Cancer. 2018 Mar 6;18(1):260. doi: 10.1186/s12885-018-4177-0.
• [2219] CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer.Med Oncol. 2015 Mar;32(3):44. doi: 10.1007/s12032-015-0499-9. Epub 2015 Jan 29.
• [2220] Troponin-I enhances and is required for oncogenic overgrowth.Oncotarget. 2016 Aug 16;7(33):52631-52642. doi: 10.18632/oncotarget.10616.
• [2221] Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway.Anticancer Drugs. 2017 Sep;28(8):861-868. doi: 10.1097/CAD.0000000000000527.
• [2222] Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer.J Exp Clin Cancer Res. 2009 Feb 19;28(1):22. doi: 10.1186/1756-9966-28-22.
• [2223] Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP.Oncol Rep. 2012 Jul;28(1):133-40. doi: 10.3892/or.2012.1778. Epub 2012 Apr 23.
• [2224] TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.Lung Cancer. 2016 Jul;97:48-50. doi: 10.1016/j.lungcan.2016.04.013. Epub 2016 Apr 22.
• [2225] Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.Thorac Cancer. 2018 Feb;9(2):324-327. doi: 10.1111/1759-7714.12578. Epub 2017 Dec 18.
• [2226] TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/ Twist1 Pathway in Non-Small-Cell Lung Carcinoma.Cell Physiol Biochem. 2018;50(5):2004-2016. doi: 10.1159/000494892. Epub 2018 Nov 7.
• [2227] miR-335 inhibited cell proliferation of lung cancer cells by target Tra2.Cancer Sci. 2018 Feb;109(2):289-296. doi: 10.1111/cas.13452. Epub 2017 Dec 15.
• [2228] TNF receptor-associated factor 1 as a biomarker for assessment of non-small cell lung cancer metastasis and overall survival.Clin Respir J. 2018 Jul;12(7):2197-2203. doi: 10.1111/crj.12789. Epub 2018 Mar 24.
• [2229] MicroRNA-647 promotes the therapeutic effectiveness of argon-helium cryoablation and inhibits cell proliferation through targeting TRAF2 via the NF-B signaling pathway in non-small cell lung cancer.Onco Targets Ther. 2018 Oct 10;11:6777-6784. doi: 10.2147/OTT.S159337. eCollection 2018.
• [2230] MicroRNA-370 inhibits the progression of non-small cell lung cancer by downregulating oncogene TRAF4.Oncol Rep. 2015 Jul;34(1):461-8. doi: 10.3892/or.2015.3978. Epub 2015 May 13.
• [2231] Increased Inhibition Effect of Antrodin C from the Stout Camphor Medicinal Mushroom, Taiwanofungus camphoratus (Agaricomycetes), on A549 through Crosstalk between Apoptosis and Autophagy.Int J Med Mushrooms. 2019;21(6):595-610. doi: 10.1615/IntJMedMushrooms.2019025901.
• [2232] Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.Cell Death Dis. 2017 Apr 13;8(4):e2746. doi: 10.1038/cddis.2016.409.
• [2233] Knockdown of TRB3 induces apoptosis in human lung adenocarcinoma cells through regulation of Notch 1 expression.Mol Med Rep. 2013 Jul;8(1):47-52. doi: 10.3892/mmr.2013.1453. Epub 2013 Apr 30.
• [2234] TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung Cancer.Sci Rep. 2017 Jan 6;7:39692. doi: 10.1038/srep39692.
• [2235] Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.Oncol Res. 2018 Aug 23;26(7):1005-1014. doi: 10.3727/096504017X15144755633680. Epub 2018 Jan 2.
• [2236] TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3/-catenin signaling in non-small cell lung cancer.Oncotarget. 2017 Jul 1;8(37):62069-62080. doi: 10.18632/oncotarget.18911. eCollection 2017 Sep 22.
• [2237] Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression.J Cell Physiol. 2019 Dec;234(12):22321-22330. doi: 10.1002/jcp.28798. Epub 2019 May 17.
• [2238] TRIM32 overexpression improves chemoresistance through regulation of mitochondrial function in non-small-cell lung cancers.Onco Targets Ther. 2018 Nov 5;11:7841-7852. doi: 10.2147/OTT.S176689. eCollection 2018.
• [2239] Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF--induced epithelial-mesenchymal transition and metastasis by controlling TIF1 in non-small cell lung cancer.Mol Cancer. 2018 Sep 27;17(1):140. doi: 10.1186/s12943-018-0889-7.
• [2240] (TRIM36 hypermethylation is involved in polycyclic aromatic hydrocarbons-induced cell transformation).Environ Pollut. 2017 Jun;225:93-103. doi: 10.1016/j.envpol.2017.03.001. Epub 2017 Mar 27.
• [2241] TRIM45 Suppresses the Development of Non-small Cell Lung Cancer.Curr Mol Med. 2020;20(4):299-306. doi: 10.2174/1566524019666191017143833.
• [2242] TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.Oncotarget. 2017 Apr 4;8(14):22730-22740. doi: 10.18632/oncotarget.15188.
• [2243] Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.Cell Death Dis. 2019 Jun 3;10(6):429. doi: 10.1038/s41419-019-1660-8.
• [2244] The genomic landscape of nonsmall cell lung carcinoma in never smokers.Int J Cancer. 2020 Jun 1;146(11):3207-3218. doi: 10.1002/ijc.32797. Epub 2019 Dec 10.
• [2245] TSPAN12 is overexpressed in NSCLC via p53 inhibition and promotes NSCLC cell growth in vitro and in vivo.Onco Targets Ther. 2018 Mar 1;11:1095-1103. doi: 10.2147/OTT.S155620. eCollection 2018.
• [2246] Overexpression of TSPAN8 Promotes Tumor Cell Viability and Proliferation in Nonsmall Cell Lung Cancer.Cancer Biother Radiopharm. 2016 Dec;31(10):353-359. doi: 10.1089/cbr.2016.2108.
• [2247] Bone Marrow and Tumor Radiomics at (18)F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer.Radiology. 2019 Nov;293(2):451-459. doi: 10.1148/radiol.2019190357. Epub 2019 Sep 17.
• [2248] Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.Clin Cancer Res. 2014 Aug 1;20(15):4154-66. doi: 10.1158/1078-0432.CCR-13-3292. Epub 2014 Jun 6.
• [2249] Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer.PLoS One. 2008 May 14;3(5):e2162. doi: 10.1371/journal.pone.0002162.
• [2250] Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients.Anticancer Res. 2006 Mar-Apr;26(2B):1567-75.
• [2251] Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.Mol Immunol. 2008 Jan;45(1):169-79. doi: 10.1016/j.molimm.2007.04.025. Epub 2007 Jun 4.
• [2252] Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer.J Clin Oncol. 2009 Dec 1;27(34):5823-9. doi: 10.1200/JCO.2009.23.1738. Epub 2009 Oct 13.
• [2253] Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.PLoS One. 2010 Jul 2;5(7):e11418. doi: 10.1371/journal.pone.0011418.
• [2254] Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy.Cancer Res. 2007 Jul 1;67(13):6293-303. doi: 10.1158/0008-5472.CAN-06-3884.
• [2255] Role of DMP1 and its future in lung cancer diagnostics.Expert Rev Mol Diagn. 2008 Jul;8(4):435-47. doi: 10.1586/14737159.8.4.435.
• [2256] Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.Ann Thorac Surg. 2006 Jul;82(1):243-8. doi: 10.1016/j.athoracsur.2006.01.049.
• [2257] Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells.Clin Lung Cancer. 2008 Nov;9(6):367-74. doi: 10.3816/CLC.2008.n.053.
• [2258] MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.J Thorac Oncol. 2009 Apr;4(4):472-8. doi: 10.1097/JTO.0b013e31819a5767.
• [2259] Effect of separase depletion on ionizing radiation-induced cell cycle checkpoints and survival in human lung cancer cell lines.Cell Prolif. 2008 Aug;41(4):660-70. doi: 10.1111/j.1365-2184.2008.00540.x. Epub 2008 Jun 19.
• [2260] FRMD3, a novel putative tumour suppressor in NSCLC.Oncogene. 2007 Jun 28;26(30):4464-8. doi: 10.1038/sj.onc.1210225. Epub 2007 Jan 29.
• [2261] A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.Carcinogenesis. 2008 Jun;29(6):1164-9. doi: 10.1093/carcin/bgn020. Epub 2008 Feb 6.
• [2262] Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.BMC Cancer. 2010 Aug 17;10:434. doi: 10.1186/1471-2407-10-434.
• [2263] HOXB2, an adverse prognostic indicator for stage I lung adenocarcinomas, promotes invasion by transcriptional regulation of metastasis-related genes in HOP-62 non-small cell lung cancer cells.Anticancer Res. 2008 Jul-Aug;28(4B):2121-7.
• [2264] Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro.J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S52-60. doi: 10.3346/jkms.2007.22.S.S52.
• [2265] Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer.Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6624-31. doi: 10.1158/1078-0432.CCR-07-1328.
• [2266] MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Cancer Chemother Pharmacol. 2010 Feb;65(3):437-46. doi: 10.1007/s00280-009-1046-1. Epub 2009 Jul 1.
• [2267] Human MOB1 expression in non-small-cell lung cancer.Clin Lung Cancer. 2007 Jan;8(4):273-6. doi: 10.3816/CLC.2007.n.006.
• [2268] Prognostic significance of folate metabolism polymorphisms for lung cancer.Br J Cancer. 2007 Jul 16;97(2):247-52. doi: 10.1038/sj.bjc.6603830. Epub 2007 May 29.
• [2269] Nek4 status differentially alters sensitivity to distinct microtubule poisons.Cancer Res. 2010 Feb 1;70(3):1033-41. doi: 10.1158/0008-5472.CAN-09-2113. Epub 2010 Jan 26.
• [2270] Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC.Oncol Rep. 2009 Nov;22(5):1057-61. doi: 10.3892/or_00000536.
• [2271] Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer.PLoS Med. 2007 Mar 27;4(3):e108. doi: 10.1371/journal.pmed.0040108.
• [2272] LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.Lung Cancer. 2009 Jun;64(3):257-62. doi: 10.1016/j.lungcan.2008.09.011. Epub 2008 Nov 12.
• [2273] Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma.Cancer Sci. 2009 Jul;100(7):1198-209. doi: 10.1111/j.1349-7006.2009.01156.x. Epub 2009 Mar 12.
• [2274] Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.Cancer Res. 2006 May 1;66(9):4617-26. doi: 10.1158/0008-5472.CAN-05-4437.
• [2275] Association between polymorphisms in COMT, PLCH1, and CYP17A1, and non-small-cell lung cancer risk in Chinese nonsmokers.Clin Lung Cancer. 2013 Jan;14(1):45-9. doi: 10.1016/j.cllc.2012.04.004. Epub 2012 Jun 1.
• [2276] Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.Mol Carcinog. 2005 Oct;44(2):146-50. doi: 10.1002/mc.20125.
• [2277] Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer.Lung Cancer. 2009 Mar;63(3):360-7. doi: 10.1016/j.lungcan.2008.06.014. Epub 2008 Aug 8.
• [2278] Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.Oncol Rep. 2006 May;15(5):1281-5.
• [2279] Gene amplification and associated loss of 5' regulatory sequences of CoAA in human cancers.Oncogene. 2007 Feb 8;26(6):822-35. doi: 10.1038/sj.onc.1209847. Epub 2006 Jul 31.
• [2280] Expression profiles of SV40-immortalization-associated genes upregulated in various human cancers.J Cell Biochem. 2009 Mar 1;106(4):703-13. doi: 10.1002/jcb.22063.
• [2281] Identification of genes associated with non-small-cell lung cancer promotion and progression.Lung Cancer. 2010 Feb;67(2):151-9. doi: 10.1016/j.lungcan.2009.04.010. Epub 2009 May 26.
• [2282] Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.Ann Surg Oncol. 2008 Mar;15(3):889-99. doi: 10.1245/s10434-007-9755-3. Epub 2008 Jan 8.
• [2283] Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.Cancer Sci. 2010 Jan;101(1):46-53. doi: 10.1111/j.1349-7006.2009.01351.x. Epub 2009 Sep 9.
• [2284] Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Oncotarget. 2015 Feb 20;6(5):3335-45. doi: 10.18632/oncotarget.2793.
• [2285] Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer.Lung Cancer. 2009 Jul;65(1):34-40. doi: 10.1016/j.lungcan.2008.10.023. Epub 2008 Dec 6.
• [2286] Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women.Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2590-7. doi: 10.1158/1055-9965.EPI-10-0332. Epub 2010 Aug 27.
• [2287] Seizure 6-like (SEZ6L) gene and risk for lung cancer.Cancer Res. 2007 Sep 1;67(17):8406-11. doi: 10.1158/0008-5472.CAN-06-4784.
• [2288] Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.Mol Cancer Res. 2007 May;5(5):509-20. doi: 10.1158/1541-7786.MCR-06-0273.
• [2289] Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis.Genes Chromosomes Cancer. 2010 Apr;49(4):353-67. doi: 10.1002/gcc.20747.
• [2290] EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.Lung Cancer. 2008 Aug;61(2):163-9. doi: 10.1016/j.lungcan.2007.12.013. Epub 2008 Feb 1.
• [2291] Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents.Comput Biol Chem. 2018 Jun;74:294-303. doi: 10.1016/j.compbiolchem.2018.04.006. Epub 2018 Apr 10.
• [2292] Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.Hum Gene Ther. 2007 Jan;18(1):39-50. doi: 10.1089/hum.2006.111.
• [2293] TRIM44 promotes proliferation and metastasis in nonsmall cell lung cancer via mTOR signaling pathway.Oncotarget. 2016 May 24;7(21):30479-91. doi: 10.18632/oncotarget.8586.